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Provide a 256-character (including spaces) summary of the “take home” message of your paper, which can be 
used to publicise your study via social media 
A positive EarlyCDT, followed by CT scans significantly reduced the numbers of late stage 
cancers: performance of the blood test should be assessed further in a screening study 




The EarlyCDT-Lung test is a high specificity blood-based autoantibody biomarker that 
could contribute to predicting lung cancer risk. Here we report on the results of a phase IV 
biomarker evaluation of whether using the EarlyCDT-Lung test and any subsequent CT 
scanning to identify those at high risk of lung cancer reduces the incidence of patients with 
stage III/IV/Unspecified lung cancer at diagnosis, compared with the standard clinical 
practice at the time the study began. 
 
ECLS was a randomised controlled trial of 12,208 participants at risk of developing lung 
cancer in Scotland. The intervention arm received the EarlyCDT-Lung test and, if test 
positive, low-dose CT scanning six-monthly for up to two years. EarlyCDT-Lung test 
negative and control arm participants received standard clinical care. Outcomes were 
assessed at two years post-randomisation using validated data on cancer occurrence, 
cancer staging, mortality and comorbidities.  
 
At two years, 127 lung cancers were detected in the study population (1.0%).  
In the intervention arm, 33/56 (58.9%) lung cancers were diagnosed at stage III/IV 
compared to 52/71 (73.2%) in the control arm. The hazard ratio for stage III/IV 
presentation was 0.64 (95% confidence interval 0.41, 0.99). There were non-significant 
differences in lung cancer and all-cause mortality after two years.  
 
ECLS compared EarlyCDT-Lung plus CT screening to standard clinical care (symptomatic 
presentation), and was not designed to assess the incremental contribution of the 
EarlyCDT-Lung test. The observation of a stage-shift towards earlier-stage lung cancer 
diagnosis merits further investigations to evaluate whether the EarlyCDT-Lung test adds 
anything to the emerging standard of LDCT.  
 
Registration: ClinicalTrials.Gov registration number NCT01925625. 
 
Funding Source: Scottish Government Health and Social Care Directorate, and 




Five-year lung cancer mortality rates of 80-90% remain unacceptably high, and the UK‘s 
survival rate is poor by international comparisons.[1] To improve the poor prognosis, 
methods that detect lung cancer at an earlier stage, when it is more likely to be treated 
with curative intent, are needed. Several clinical trials have reported that low-dose 
computed tomography (LDCT) screening can reduce lung cancer mortality by around 
20%.[2–5] Most recently, the NELSON trial reported a 24% reduction in lung cancer 
mortality from screening after 10-years of follow-up of 13,131 men.[4] However, no 
difference in all-cause mortality was demonstrated in NELSON, nor in other large trials to 
date with follow-up >5 years, including NLST.[3–9] That LDCT screening can reduce lung 
cancer mortality has provided impetus to consider National screening programmes for the 
early detection of lung cancer. However, the widespread adoption of LDCT screening will 
likely remain limited by resource constraints and concerns about overdiagnosis.[10] Cost-
effective national screening programmes in the UK are likely to have to take a more 
targeted approach to LDCT. A biomarker test could potentially play a role in identifying 
those most at risk and who have most to gain from a targeted approach.[11] 
 
The EarlyCDT-Lung test is an enzyme-linked immunosorbent assay (ELISA) that 
measures seven autoantibodies (AABs), each with individual specificity for the following 
tumour-associated antigens (TAA): p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and 
SOX2. AABs can be detected in peripheral blood in patients with solid tumours up to 3-4 
years before symptomatic presentation, although it is not yet clear how long AABs 
continue to be present once triggered.[12, 13] In clinical studies of symptomatic lung 
cancer and a high risk cohort study, the EarlyCDT-Lung test has demonstrated a 
specificity of 91% and sensitivity ranging between 37-41% respectively.[14, 15] The ECLS 
trial was a phase IV (prospective screening) biomarker evaluation that addressed the 
question: ‗Does using the EarlyCDT-Lung Test to identify those at high risk of lung cancer 
and any subsequent CT scanning reduce the incidence of patients with late-stage lung 
cancer (III & IV) or unclassified presentation (U) at diagnosis, compared with standard 
clinical practice?‘.  
 
The EarlyCDT-Lung test, an enzyme-linked immunosorbent assay (ELISA) that measures 
seven autoantibodies (AABs), each with individual specificity for the following tumour-
associated antigens (TAA): p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2. 
AABs can be detected in peripheral blood in patients with solid tumours up to 3-4 years 
before symptomatic presentation, although it is not yet clear how long AABs continue to be 
present once triggered.[12, 13] In cohort studies, the EarlyCDT-Lung test has 
demonstrated a specificity of 91% and sensitivity ranging between 37-41%.[14, 15] The 
ECLS trial was a phase 4 (prospective screening) biomarker evaluation that addressed the 
question: ‗Does using the EarlyCDT-Lung Test to identify those at high risk of lung cancer 
and any subsequent CT scanning reduce the incidence of patients with late-stage lung 





ECLS was a pragmatic randomised controlled trial involving 12,208 participants recruited 
through General Practices and community-based recruitment strategies in Scotland.[16] 
Recruitment occurred between April 2013 and July 2016, and follow-up was undertaken 
for 24 months after randomisation for each participant. Adults age 50–75 at increased risk 
of developing lung cancer compared to the general population were eligible to participate. 
These were defined as current or former cigarette or tobacco smokers with at least 20 
pack-years, or with a history of smoking of less than 20 pack-years plus immediate family 
history (mother, father, sibling, child) of lung cancer. Potential trial participants were 
identified from the electronic medical records of General Practices that were located in the 
most socioeconomically deprived areas in Scotland, or they self-referred in response to a 
range of advertising methods. Trial participants had no symptoms suggestive of current 
malignancy, terminal illness or immunosuppressant therapy, and had an Eastern 
Cooperative Oncology Group (ECOG) performance status of 0-2 at recruitment.  
 
The study was conducted in accordance with the principles of Good Clinical Practice and 
the UK National Research Governance Framework.[17] The University of Dundee and 
Tayside Health Board co-sponsored the trial, which was registered with ClinicalTrials.Gov 
(ID NCT01925625). Institutional Review Board approval was provided by the East of 
Scotland Research Ethics Committee (REC Number 13/ES/0024). Funding for the trial 
was obtained from the Scottish Government and the test manufacturer Oncimmune Ltd. 
The trial was conducted in accordance with the protocol [16]; the protocol and the 
statistical analysis plan are available in Appendix 1 & 2. An independent Trial Steering 
Committee provided trial oversight. The report herein adheres to the CONSORT 
Statement and Aarhus guidelines for the reporting of clinical trials on early cancer 
diagnosis.[18, 19] 
 
Randomisation and masking  
All participants who gave informed consent provided a blood sample prior to 
randomisation. Participants were then individually randomised, stratified by recruitment 
site (Tayside, Glasgow, Lanarkshire) and minimized by age, sex and smoking status. 
Smoking cessation advice was offered in keeping with NHS Scotland advice. Participants 
allocated to the intervention arm were tested with the EarlyCDT-Lung test. If this was 
positive, they received a baseline chest X-ray (in order to prioritise access to CT for 
patients with positive findings on CXR) and chest LDCT-scan followed by 6-monthly LDCT 
scans up to 24 months post randomisation (Supplementary Table 1). Images from test-
positive participants were reviewed by a panel of experienced thoracic radiologists and 
respiratory physicians. Test positive participants were followed-up within the study or via 
the NHS care pathway (following the prevailing Fleischner society guidelines): whichever 
was most intensive.[20] Participants allocated to the control arm, and those who were test 
negative, received standard clinical care in the NHS in Scotland following National 
guidelines for identification and management of symptoms suggestive of lung cancer with 
no further study investigations.[21] 
 
Blood samples were processed according to the Protocol (Appendix 1) and Standard 
Operating Procedures, consistent with relevant UK and US guidelines. The EarlyCDT-
Lung test was performed on 0.5ml plasma samples. All test positive, and a random sample 
of test negative and control arm participants recruited between December 2013 and April 
2015, were invited to complete study questionnaires measuring psychological and 
smoking outcomes, EQ5D, and health service use (Supplementary Table 2). Invitation to 
complete the study questionnaires was done at one, three, six and 12 months for the test 
negative and control arms, with additional questionnaire testing at 18 and 24 months for 
participants in the test positive group. These results are reported elsewhere.[22, 23] 
 
With participant consent, validated data on cancer occurrence, mortality and comorbidities 
were obtained from National Services Scotland, which is a high-quality health services 
data repository. These were linked and analysed in the Dundee Health Informatics Centre 
Safe Haven.  
 
Pathology and tumour staging reports were prepared by independent assessors who were 
blinded to the allocation status of participants. Staging data were taken from the Scottish 
Cancer Registry (SMR06).[24] The primary outcome variable extracted from SMR06 was 
the first occurrence of all diagnoses starting with the International Statistical Classification 
of Diseases and Related Health Problems 10th Revision codes (ICD-10) C33 (primary 
malignant neoplasm of trachea) and C34 (bronchus or lung). Where more than one lung 
cancer tumour was present at diagnosis, the most advanced tumour was used for 
classification of disease. To determine staging, reported clinical and pathological ―T, N, M‖ 
were used with pathological staging taking precedence when present by data analysts 
blinded to allocation status. Lung tumour histology was coded in accordance with the Third 
Edition International Classification of Diseases for Oncology and lung cancer staging was 
determined using TNM 7th Edition.[25] 
 
Sample size 
During study planning, the background rate of lung cancer was 187/100,000 per year for 
people aged 50-75 in Scotland. Those in the most deprived quintile were associated with 
an increased risk of 1.8 times compared to the middle quintile of deprivation.[26, 27] The 
ECLS study population was selected using similar entry criteria as the Mayo screening 
study.[26] The precise baseline rate of stage III/IV presentation for the high-risk population 
envisaged in this study was uncertain, as was the size of the reduction in stage III/IV 
presentation likely to be achieved through use of EarlyCDT-Lung test. Based on the 
literature and expert opinion, we estimated a stage III/IV presentation rate of 1200/100,000 
per year in the control group, resulting in an estimated 2.4% prevalence rate over the two-
year follow-up period. Using this estimate, and 85% power at 5% significance (two-sided), 
we wanted to be able to detect a 35% reduction in the rate of stage III/IV presentation in 
the intervention arm. Based on discussion with a range of stakeholders, this was 
considered likely to be sufficiently clinically significant to influence practice. Taken 
together, we estimated the event rate over the two years of follow-up at 120 events in the 
control arm and 78 events in the intervention arm, and required a sample size of n=5,000 
per arm. 
 
The protocol allowed for the sample size to be modified if the observed event rate proved 
to be markedly different from the modelled estimates. The sample size was revised to 
12,000 in 2015, after recruitment of approximately 8600 participants, when it appeared 
that, while still meeting trial eligibility criteria, our initial assumption of the rate of stage 
III/IV presentation had been overestimated. The increase in sample size was achieved by 
adding an extra recruitment centre (Lanarkshire) and extending the recruitment period. 
The revised power was 85% at 5% significance (two-sided) to detect a 35% reduction in 
stage III/IV lung cancer, based on a rate of 600/100,000 with a 3-year recruitment period, 
and two years follow-up, with no loss to follow-up anticipated. 
 
Statistical Analysis  
The primary analysis compared the rate of stage III/IV lung cancer within two years of 
randomisation between the intervention and control arms. The analyses followed the 
intention to treat principle. Cox proportional hazards models were used to estimate the 
hazard ratio. One participant who withdrew consent for use of their data was excluded 
from analysis. The models were adjusted for age, gender, smoking history, socioeconomic 
status and General Practice.  
 
Similar methodology was used to analyse the secondary outcomes of mortality rates. 
Further analysis compared the outcomes of those in the intervention arm with a positive 
test, those with a negative test, and those in the control arm. Comparisons of proportions 
were carried out using Fisher‘s exact test due to the small number of events. Poisson 
regression models, (adjusting for follow-up time when necessary) were used to investigate 
other clinical outcomes. Specificity and sensitivity were calculated but these are estimated 
values as the true figures are not estimable for early-stage and late-stage separately. This 
is because the test positives received a more intensive intervention than the negatives, 
and in a prospective study cancer status is unknown most of the time. The full statistical 
analysis plan can be found in Appendix 2. 
 
A within trial model-based cost-effectiveness analysis (CEA) was conducted estimating the 
cost per stage I/II lung cancer case detected comparing the intervention to the control arm. 
Diagnostic costs were included for all groups. A model-based approach was taken for two 
reasons: (1) prevalence of lung cancer during the trial was different between arms; our 
model assumed the same prevalence in both arms, and (2) data about resource use for 
detection was only available for test positive participants (n=598) during the trial, therefore 
resource use was modelled. Full assumptions and parameters used in the model are 
presented in Appendix 3. Briefly, detection resources comprised the EarlyCDT-Lung test, 
monitoring tests and confirmatory diagnostic tests. The outcome was number of stage I/II 
lung cancers detected within the two-year follow-up. Treatment costs are not included in 




Characteristics of the participants 
A total of 77,077 invitation letters were sent to people fulfilling the medical record search 
criteria from 166 General Practices, and 16,268 responded. An additional 2389 potential 
participants self-referred in response to advertising. 12,241 were invited to an in-person 
screening appointment, and 12,215 were randomised. The recruitment rate of people 
identified as potential study participants from General Practice records was 13.4% 
(10,352/77,077). Six participants were excluded post-randomisation but prior to receiving 
imaging because of ineligibility. One participant who withdrew consent for use of their data 
was excluded from analysis leaving 12,208 participants. Participant characteristics were 
balanced between arms (Table 1). 51.8% of participants lived in the two most deprived 
quintiles, the mean age at recruitment was 60.5 years (S.D. 6.58), and the mean pack 
years smoked was 38.2 (S.D. 18.58). The incidence rate of lung cancer in the trial 
population, as determined from cancer registry data, was 520 per 100,000 per annum 
(0.52%). 
 
Adherence to protocol 
We accessed the records of 99.9% of the study population and the CONSORT flowchart 
(Figure 1) presents the end-point ascertainment in the intervention and control arms. The 
CONSORT statement is available in Appendix 4.  
 
Follow-up was performed using a national, closed administrative data system for 24 
months after individual randomisation or to death if within the follow-up period. We also 
checked national prescribing, and inpatient and outpatient data systems for activity relating 
to trial participants in the two-year post-randomisation follow-up period. We confirmed 
health service contacts in the two-year follow-up for 10,973 (89.9%) of the participants; 
5489 in the intervention arm, and 5484 in the control arm. When the 1235 patients who did 
not record health service contacts during this period were removed from the analysis, the 
key findings were unchanged (Supplementary Data Pack 2). 
 
Results of testing 
The results of the primary analysis are presented in Table 2 and Figure 2. 9.8% 
(598/6087) of participants in the intervention arm had a positive EarlyCDT-Lung test and 
3.0% (n=18) of these had a confirmed case of lung cancer within two years. In the test 
negative arm, 0.7% (n=38) had confirmed lung cancers. For the intervention group as a 
whole, 0.92% (n=56) had confirmed lung cancer within two years. In the control arm, 
1.16% (n=71) had confirmed lung cancer within two years. The percentage of stage 
III/IV/unspecified lung cancer diagnosis in the intervention and control arm was 0.5% 
(33/6087) and 0.8% (52/6121), respectively. The absolute risk reduction in stage 
III/IV/unspecified lung cancer diagnosis was 0.3% (95% CI = 0.01 to 0.6). The number of 
participants to be screened to prevent one stage III/IV/unspecified lung cancer diagnosis 
was 325 (95% CI 13 to 637) and the hazard ratio for stage III/IV presentation was 0.64 
(95% CI 0.41 to 0.99; P=0.0432) (Supplementary Data Pack 2).  
 
Although we did not perform an LDCT on all study subjects, the estimated test 
performance characteristics, using cancer registry data after two years follow up as the 
reference standard are described in Table 3. The EarlyCDT-Lung test had an estimated 
sensitivity of 52.2% (95% CI = 30.6 to 73.2) for stage I/II disease and 18.2% (95% CI = 7.0 
to35.5) for stage III/IV disease, and specificity of 90.3% (stage I/II; 95% CI = 89.6 to 91.1) 
and 90.2% (stage III/IV; 95% CI = 89.4 to 91.0). The positive predictive value was 2.0% for 
stage I/II disease (95% CI = 1.0 to 3.5) and 1.0% for stage III/IV disease (95% CI = 0.4 to 
2.2), and the negative predictive value was 99.8% (stage I/II; 95% CI = 99.6 to 99.9) and 
99.5% (stage III/IV; 95% CI = 99.3 to 99.7) in the population studied.  
 
Figure 3 shows the secondary outcomes of lung cancer and all-cause mortality at two 
years and demonstrates divergence after the first year of follow-up. In the intervention arm, 
there were fewer events than the control arm for all-cause mortality. There were non-
significant differences in lung cancer mortality (intervention arm: 17/6082 (0.28%) vs. 
control arm: 24/6121 (0.39%)) and all-cause mortality (intervention arm: 87/6082 (1.43%) 
vs. control arm: 108/6121 (1.76%)) after two years. Participants in the intervention arm 
were diagnosed with lung cancer on average 87.3 days earlier (mean: 303.0 days, 95% CI 
214.9 to 364.0) compared to the control arm (mean: 390.3 days, 95% CI 340.6 to 440.1) 
(Supplementary Data Pack 3). 
 
The cost per early case (stage I/II) detected after two years was £116,000, with the 95% 
CI ranging from £54,900 to dominated (i.e. screening using the EarlyCDT-Lung test would 
be more costly and less effective than the control arm) (Supplementary Table 3). 
Sensitivity analyses were conducted varying prevalence and test costs; results indicate 
that cost effectiveness was most affected by changes in prevalence. More detailed 
analyses are planned to extrapolate the cost per case detected to a full  lifetime cost per 
quality-adjusted life year (QALY) gained analysis, including stage specific treatment costs 
(Appendix 5). As not all required data are available at the time of writing this manuscript, 
comprehensive cost-effectiveness analyses will be presented in a subsequent article. 
 
Adverse events 
Five adverse events, as defined in the protocol as being directly related to the intervention 
(collection of blood sample), were reported and all were considered minor. For those in the 
intervention arm, there was one injection site haematoma, one panic attack, and one pre-




This is the first trial conducted as a phase IV evaluation of a blood-based biomarker panel 
for lung cancer. The results show a significant decrease in the incidence of advanced 
stage disease, thereby meeting the primary endpoint of the study. In the study population 
as a whole, the absolute risk reduction in stage III/IV lung cancer diagnosis for those in the 
intervention arm was 0.3%. For those participants given a lung cancer diagnosis in the 
study period, there was a 14.3% absolute risk reduction (33/56 vs 52/71) in stage III/IV 
lung cancer presentation in the intervention arm. After the short follow-up period of two 
years, there were non-significant reductions in lung cancer mortality - 29.2% relative risk 
(control: 24, intervention: 17), and 19.4% in all-cause mortality (control: 108, intervention: 
87).  
 
Community-based trials like ECLS are more likely to produce generalizable results than 
those conducted in academic health centres, which often recruit from a more tightly 
selected population.[28] Strengths of our trial include community recruitment with a high 
proportion of participants recruited by their General Practitioners from the two most 
socioeconomically deprived quintiles (51.8%) of the Scottish population; integration with a 
national health care system providing whole population care; a high end-point 
ascertainment rate (>99.9%); and the intention to treat analysis.  
 
The lung cancer diagnosis rate (1%) was lower than we anticipated when planning the 
study and lower than might be expected from other studies using LDCT. This approach 
therefore, in contrast to LDCT, may have missed early stage lung cancers. Our follow up 
period of two years was short and cases will continue to emerge as the study final results 
become available. Another potential contributor to the lower rate of diagnosis may be the 
―healthy volunteer‖ effect, which may have led to a higher rate of recruitment of the 
healthiest among the at-risk population meeting our inclusion criteria.[31] It is worth noting 
that even with a lower rate of lung cancer, those in the intervention arm were at a 
statistically significant and clinically important reduced risk of stage III/IV presentation. The 
results of this study are not directly comparable to those using a validated questionnaire 
before LDCT.[32] A direct comparison of both methods would need to be undertaken to 
determine how a biomarker test compares to a questionnaire followed by LDCT. A control 
arm involving CT screening would have provided evidence comparing the United States 
Preventive Task Force (USPTF) guidelines against a ‗biomarker first‘ approach, but CT 
screening was not available when the ECLS trial started, and remains unavailable in many 
health systems, including the UK.  
 
The finding that there were more lung cancers in the control arm (71 compared to 56 in the 
intervention arm) was also unexpected as CT screening trials usually report more cancers 
diagnosed in the intervention arm. We consider that there are four potential reasons for 
this. Firstly, as discussed above, we may have not diagnosed all cases of lung cancer. 
Secondly, although treatment arms were well balanced due to randomisation there may be 
differences between arms in unmeasured risk factors, such as asbestos exposure.[29] 
False reassurance in the test negative arm (leading to risk-reduction behaviours in those 
receiving the EarlyCDT test) may also be a potential explanation. A recent systematic 
review found that negative test results are unlikely to cause false reassurance, anxiety or a 
change in health-related behaviours, hence we consider it unlikely that false reassurance 
had a substantial impact on lung cancer presentation in those with negative test 
results.[30] Finally, the observed numerical difference is not statistically significant and 
could be due to chance (p=0.2) 
 
We have presented a short-term within-trial analysis of cost effectiveness data. A recent 
study has suggested that the use of an autoantibody test in patients with pulmonary 
nodules is a cost-effective use of healthcare resources.[33] The base case cost per QALY 
of £116K is a within-trial estimate and does not include long-term costs of treatment and 
survival beyond the trial. Longer-term analyses will employ a model to link the short-term 
outcomes measured within the trial to longer-term health impacts (e.g. morbidity, 
mortality), and will consider the longer-term impact of early detection and treatment on the 
cost-per QALY gained in the context of more effective and expensive therapies. 
 
The seven autoantibodies to the TAA panel of the EarlyCDT-Lung test demonstrated high 
specificity (90.3%), and moderate sensitivity at 32.1% for detecting lung cancer at two 
years. The moderate sensitivity of the test at two years may be due to tumour-induced 
suppression of immune responses that lead to less autoantibody production and 
detection.[34] The study measured the EarlyCDT-Lung test only once at baseline and so 
does not address the frequency at which the test might be repeated. A previous report 
showed that in patients with lung nodules the EarlyCDT-Lung test enhanced the positive 
predictive power of nodule-based risk assessment for the detection of lung cancer.[35] The 
high specificity of the EarlyCDT-Lung test could be used in combination with LDCT, which 
demonstrates high sensitivity, to ensure a high detection rate of stage I/II lung cancer 
cases. Recent developments in the use of Artificial Intelligence in imaging and other 
biomarkers are also likely to be important.[36] 
 
In conclusion, ECLS demonstrates that blood-based biomarker panels, such as the 
EarlyCDT-Lung test, followed by LDCT, can detect stage I/II lung cancer. Follow-up 
analyses will be performed after 5 and 10 years, although we recognise that the absolute 
lung cancer incidence would be higher than that detected due to deaths from other 
causes. Further investigation in large, community-based studies will be required to 
determine the long-term impact of performing the EarlyCDT-Lung test with LDCT on 
mortality, cost-effectiveness, the level of risk that should be targeted, the time interval 





1.  Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, 
Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo e 
Silva G, Chen W-QQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods 
RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP, CONCORD Working 
Group CW, Bouzbid S, Hamdi-Chérif M, Zaidi Z, Meguenni K, Regagba D, 
Bayo S, et al. Global surveillance of trends in cancer survival 2000-14 
(CONCORD-3): analysis of individual records for 37 513 025 patients 
diagnosed with one of 18 cancers from 322 population-based registries in 71 
countries. Lancet [Internet] NIH Public Access; 2018 [cited 2019 Jul 23]; 391: 
1023–1075Available from: http://www.ncbi.nlm.nih.gov/pubmed/29395269. 
2.  National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg 
CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus 
PM, Sicks JD. Reduced Lung-Cancer Mortality with Low-Dose Computed 
Tomographic Screening. N. Engl. J. Med. [Internet] 2011 [cited 2019 Jul 23]; 
365: 395–409Available from: http://www.ncbi.nlm.nih.gov/pubmed/21714641. 
3.  The National Lung Screening Trial Research Team. Lung Cancer Incidence 
and Mortality with Extended Follow-up in the National Lung Screening Trial. J. 
Thorac. Oncol. Elsevier Inc; 2019; 14: 1732–1742. 
4.  de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, 
Heuvelmans MA, Lammers J-WJ, Weenink C, Yousaf-Khan U, Horeweg N, 
van‘t Westeinde S, Prokop M, Mali W, Mohamed Hoesein F, van Ooijen PM, 
Aerts J, den Bakker M, Thunnissen E, Verschakelen J, Vliegenthart R, Walter 
J, ten Haaf K, Groen HJM, Oudkerk M. Reduced Lung-Cancer Mortality with 
Volume CT Screening in a Randomized Trial. N. Engl. J. Med. 2020; : 1–11. 
5.  Infante M, Cavuto S, Lutman F, Passera E, Chiarenza M, Chiesa. Long-Term 
Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer 
Screening with Spiral Computed Tomography. Ann. Oncol. Oxford University 
Press; 2019; 30: 1162–1169. 
6.  Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, Sverzellati N, 
Sozzi G, Corrao G, Marchianò A. Prolonged Lung Cancer Screening Reduced 
10-year Mortality in the MILD Trial. Ann. Oncol. [Internet] 2019; Available from: 
https://academic.oup.com/annonc/advance-
article/doi/10.1093/annonc/mdz117/5425325. 
7.  Huang KL, Wang SY, Lu WC, Chang YH, Su J, Lu YT. Effects of low-dose 
computed tomography on lung cancer screening: A systematic review, meta-
analysis, and trial sequential analysis. BMC Pulm. Med. [Internet] BioMed 
Central Ltd.; 2019 [cited 2020 Feb 24]; 19: 126Available from: 
https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-019-0883-x. 
8.  Becker N, Motsch E, Trotter A, Heussel CP, Dienemann H, Schnabel PA, 
Kauczor HU, Maldonado SG, Miller AB, Kaaks R, Delorme S. Lung cancer 
mortality reduction by LDCT screening—Results from the randomized German 
LUSI trial. Int. J. Cancer 2019; 1513: 1503–1513. 
9.  Wille MMW, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, 
Clementsen PF, Hansen H, Larsen KR, Mortensen J, Rasmussen JF, 
 
Seersholm N, Skov BG, Thomsen LH, Tønnesen P, Pedersen JH. Results of 
the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk 
Profiling. Am. J. Respir. Crit. Care Med. [Internet] American Thoracic Society; 
2016 [cited 2019 Jul 2]; 193: 542–551Available from: 
http://www.atsjournals.org/doi/10.1164/rccm.201505-1040OC. 
10.  Han D, Heuvelmans MA, Vliegenthart R, Rook M, Dorrius MD, Oudkerk M. An 
update on the European lung cancer screening trials and comparison of lung 
cancer screening recommendations in Europe. J. Thorac. Imaging Lippincott 
Williams and Wilkins; 2019. p. 65–71. 
11.  Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, 
Bastarrika G, Sverzellati N, Mascalchi M, Delorme S, Baldwin DR, Callister 
ME, Becker N, Heuvelmans MA, Rzyman W, Infante M V., Pastorino U, 
Pedersen JH, Paci E, Duffy SW, de Koning H, Field JK. European position 
statement on lung cancer screening. Lancet Oncol. Elsevier Ltd; 2017; 18: 
e754–e766. 
12.  Li Y, Karjalainen A, Koskinen H, Hemminki K, Vainio H, Shnaidman M, Ying Z, 
Pukkala E, Brandt-Rauf PW. P53 Autoantibodies Predict Subsequent 
Development of Cancer. Int. J. Cancer [Internet] 2005 [cited 2020 Jan 22]; 
114: 157–160Available from: http://doi.wiley.com/10.1002/ijc.20715. 
13.  Robertson JFR, Chapman C, Cheung K-L, Murray A, Pinder SE, Price MR, 
Graves RL. Autoantibodies in early breast cancer. J. Clin. Oncol. American 
Society of Clinical Oncology (ASCO); 2005; 23: 549–549. 
14.  Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, 
Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, MacDonald IK, Jewell W, 
Maddison P, Robertson JFRR. EarlyCDT®-Lung test: Improved clinical utility 
through additional autoantibody assays. Tumor Biol. [Internet] 2012 [cited 2019 
May 28]; 33: 1319–1326Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460172/pdf/13277_2012_Artic
le_379.pdf. 
15.  Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JFR. Audit 
of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of 
its performance in routine clinical practice. Lung Cancer [Internet] 2014 [cited 
2019 May 28]; 83: 51–55Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0169500213004522. 
16.  Sullivan FM, Farmer E, Mair FS, Treweek S, Kendrick D, Jackson C, 
Robertson C, Briggs A, Mccowan C, Bedford L, Young B, Vedhara K, Gallant 
S, Littleford R, Robertson J, Sewell H, Dorward A, Sarvesvaran J, Schembri S. 
Detection in blood of autoantibodies to tumour antigens as a case-finding 
method in lung cancer using the EarlyCDT®-Lung Test (ECLS): Study protocol 
for a randomized controlled trial. BMC Cancer [Internet] 2017 [cited 2017 Jun 
7]; 17Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346215/pdf/12885_2017_Artic
le_3175.pdf. 
17.  UK Policy Framework for Health and Social Care Research - Health Research 




18.  Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, Campbell C, 
Andersen RS, Hamilton W, Olesen F, Rose P, Nafees S, van Rijswijk E, Hiom 
S, Muth C, Beyer M, Neal RD. The Aarhus statement: improving design and 
reporting of studies on early cancer diagnosis. Br. J. Cancer [Internet] 2012 
[cited 2019 Jul 23]; 106: 1262–1267Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/22415239. 
19.  Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 
statement: updated guidelines for reporting parallel group randomised trials. 
BMJ [Internet] British Medical Journal Publishing Group; 2010 [cited 2019 Jul 
23]; 340: c332Available from: http://www.ncbi.nlm.nih.gov/pubmed/20332509. 
20.  MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, Mehta AC, 
Ohno Y, Powell CA, Prokop M, Rubin GD, Schaefer-Prokop CM, Travis WD, 
Van Schil PE, Bankier AA. Guidelines for Management of Incidental 
Pulmonary Nodules Detected on CT Images: From the Fleischner Society 
2017. Radiology [Internet]  Radiological Society of North America ; 2017 [cited 
2019 Jul 23]; 284: 228–243Available from: 
http://pubs.rsna.org/doi/10.1148/radiol.2017161659. 
21.  National Institute for Health and Care Excellence (NICE). Overview | 
Suspected cancer: recognition and referral | Guidance | NICE [Internet]. 
NICE;Available from: https://www.nice.org.uk/guidance/ng12. 
22.  Young B, Vedhara K, Kendrick D, Littleford R, Robertson JFR, Sullivan FM, 
Schembri S, Das Nair R. Determinants of motivation to quit in smokers 
screened for the early detection of lung cancer: a qualitative study. BMC Public 
Health [Internet] 2018 [cited 2020 Jan 20]; 18: 1276Available from: 
https://doi.org/10.1186/s12889-018-6211-1. 
23.  Clark ME, Bedford LE, Young B, Robertson JFR, Das Nair R, Vedhara K, 
Littleford R, Sullivan FM, Mair FS, Schembri S, Rauchhaus P, Kendrick D. 
Lung cancer CT screening: Psychological responses in the presence and 
absence of pulmonary nodules. Lung Cancer [Internet] 2018 [cited 2020 Feb 
7]; 124: 160–167Available from: https://doi.org/10.1016/j.lungcan.2018.08.001. 
24.  National Data Catalogue | Information Services Division Scotland | SMR06 
[Internet]. [cited 2019 Nov 19].Available from: 
https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=8. 
25.  WHO | International Classification of Diseases for Oncology, 3rd Edition (ICD-
O-3). WHO [Internet] World Health Organization; 2015 [cited 2019 Jul 23]; 
Available from: 
https://www.who.int/classifications/icd/adaptations/oncology/en/. 
26.  Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, 
Sykes A-M, Aughenbaugh GL, Bungum AO, Allen KL. CT Screening for Lung 
Cancer: Five-year Prospective Experience. Radiology [Internet] 2005 [cited 
2019 Jul 24]; 235: 259–265Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15695622. 
27.  Sharpe KH, McMahon AD, Raab GM, Brewster DH, Conway DI. Association 
between Socioeconomic Factors and Cancer Risk: A Population Cohort Study 
in Scotland (1991-2006). Behrens T, editor. PLoS One [Internet] Public Library 
of Science; 2014 [cited 2019 Sep 26]; 9: e89513Available from: 
 
http://dx.plos.org/10.1371/journal.pone.0089513. 
28.  Kinsinger LS, Anderson C, Kim J, Larson M, Chan SH, King HA, Rice KL, 
Slatore CG, Tanner NT, Pittman K, Monte RJ, McNeil RB, Grubber JM, Kelley 
MJ, Provenzale D, Datta SK, Sperber NS, Barnes LK, Abbott DH, Sims KJ, 
Whitley RL, Wu RR, Jackson GL. Implementation of Lung Cancer Screening in 
the Veterans Health Administration. JAMA Intern. Med. [Internet] American 
Medical Association; 2017 [cited 2017 Jun 19]; 177: 399Available from: 
http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.201
6.9022. 
29.  Schreuder A, Schaefer-Prokop CM, Scholten ET, Jacobs C, Prokop M, Van 
Ginneken B. Lung cancer risk to personalise annual and biennial follow-up 
computed tomography screening. Thorax 2018; 73: 626–633. 
30.  Cooper GC, Harvie MN, French DP. Do negative screening test results cause 
false reassurance? A systematic review. Br. J. Health Psychol. [Internet] 2017 
[cited 2019 Sep 4]; 22: 958–977Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28895257. 
31.  Pinsky P, Miller A, Kramer B, Church T, Reding D, Prorok P, Gelmann E, 
Schoen R, Buys S, Hayes R, Berg C. Evidence of a Healthy Volunteer Effect in 
the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am. J. 
Epidemiol. [Internet] 2007 [cited 2019 Jul 24]; 165: 874–881Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17244633. 
32.  Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, 
Chaturvedi AK, Silvestri GA, Riley TL, Commins J, Berg CD. Selection criteria 
for lung-cancer screening. N. Engl. J. Med. 2013; 368: 728–736. 
33.  Edelsberg J, Weycker D, Atwood M, Hamilton-Fairley G, Jett JR. Cost-
effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early 
diagnosis of lung cancer in patients with incidentally detected pulmonary 
nodules. PLoS One [Internet] Public Library of Science; 2018 [cited 2019 May 
28]; 13: e0197826Available from: 
https://doi.org/10.1371/journal.pone.0197826. 
34.  Zaenker P, Gray ES, Ziman MR. Autoantibody Production in Cancer—The 
Humoral Immune Response toward Autologous Antigens in Cancer Patients. 
Autoimmun. Rev. [Internet] 2016 [cited 2019 Jul 23]; 15: 477–483Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/26827909. 
35.  Massion PP, Healey GF, Peek LJ, Fredericks L, Sewell HF, Murray A, 
Robertson JFRR. Autoantibody Signature Enhances the Positive Predictive 
Power of Computed Tomography and Nodule-Based Risk Models for 
Detection of Lung Cancer. [Internet]. J Thorac Ocol NIH Public Access; 2017 
MarAvailable from: http://dx.doi.org/10.1016/j.jtho.2016.08.143. 
36.  McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, 
Back T, Chesus M, Corrado GC, Darzi A, Etemadi M, Garcia-Vicente F, Gilbert 
FJ, Halling-Brown M, Hassabis D, Jansen S, Karthikesalingam A, Kelly CJ, 
King D, Ledsam JR, Melnick D, Mostofi H, Peng L, Reicher JJ, Romera-
Paredes B, Sidebottom R, Suleyman M, Tse D, Young KC, De Fauw J, et al. 
International evaluation of an AI system for breast cancer screening. Nature 
Nature Research; 2020; 577: 89–94. 
 
37.  Balata H, Evison M, Sharman A, Crosbie P, Booton R. CT screening for lung 
cancer: Are we ready to implement in Europe? Lung Cancer [Internet] Elsevier; 





Tables and Figures.  
  
 
Table 1. Selected Baseline Characteristics of the Trial Participants. 
 
 
Intervention  Control  
EarlyCDT-Lung Test Standard Clinical Care 
(N=6088) (N=6121) 
 Characteristic number (percent) 
Age at randomisation 
50-54 yrs 1393 (22.9) 1409 (23.0) 
55-59 yrs 1562 (25.7) 1531 (25.0) 
60-64 yrs 1300 (21.4) 1318 (21.5) 
65-69 yrs 1179 (19.4) 1203 (19.7) 
70-75 yrs 654 (10.7) 660 (10.8) 
Sex 
Male 3095 (50.8) 3129 (51.1) 
Female 2993 (49.2) 2992 (48.9) 
SIMD quintiles (1= most deprived) 
Quintile 1 1751 (28.8) 1726 (28.2) 
Quintile 2 1431 (23.5) 1420 (23.2) 
Quintile 3 1108 (18.2) 1121 (18.3) 
Quintile 4 966 (15.9) 1002 (16.4) 
Quintile 5 782 (12.8) 792 (12.9) 
No information 50 (0.8) 60 (1.0) 
Smoking status 
Current 3199 (52.5) 3178 (51.9) 
Former 2889 (47.5) 2943 (48.1) 
Quit  ≥ 1 week 2207 (36.3) 2283 (37.3) 
Quit ≥ 6 months 1998 (32.8) 2083 (34.0) 
Mean pack years ± SD 38.4 ± 18.7 38.0 ± 18.5 
Family history 1550 (25.5) 1614 (26.4) 
Comorbidity 
COPD 306 (5.0) 287 (4.7) 
 
 
Legend: SIMD- Scottish Index of Multiple Deprivation; SD- standard deviation; COPD- 




























§ Primary care (n=10352)
§ Self-referral (n=1889)
Not proceeding (n=26)
Allocated to intervention (n=6088)
Randomised (n=12208)
Requesting contact (n=18657) Not proceeding (n=6416)
§ No further contact (n=2202)
§ Not eligible (n=2963)
§ Declined (n=1251)
Primary care invitations (n=77077)
Self-referral (n=2389)              
Excluded (n=6)
§ Ineligible error (n=1)
§ Randomisation error (n=1)
§ Duplicate records (n=4)
No response (n=60809)








Allocated to control (n=6121)
Test negative (n=5489)








Table 2. Stage of Lung Cancer at Diagnosis in the Intervention and Control Arms. 
 
 
Intervention  Control  
Test positive Test negative Standard Clinical Care 
(N=598) (N=5489) (N=6121) 
 Stage number (percent) number (percent) 
I 10 (1.7) 7 (0.1) 9 (0.1) 
II 2 (0.3) 4 (0.1) 10 (0.2) 
III 3 (0.5) 12 (0.2) 17 (0.3) 
IV 3 (0.5) 15 (0.3) 28 (0.5) 
Unspecified 0 (0.0) 0 (0.0) 7 (0.1) 





































Figure 2. Primary Outcome: Diagnosis of Stage III/IV/Unspecified Lung Cancer Two 
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Table 3. Estimated EarlyCDT-Lung Test Performance Characteristics Six Months, One Year, and Two Years After Randomisation. 
 







% value (95% CI) 
Specificity 
% value (95% CI) 
PPV 
% value (95% CI) 
NPV 
% value (95% CI) 
Six Months After Randomisation (post-hoc) 
I & II 7 (1.2) 2 (0.0) 77.8 (40.0, 97.2) 90.3 (89.5, 91.0) 1.2 (0.5, 2.4) 100.0 (99.9, 100.0) 
III & IV 5 (0.8) 8 (0.2) 38.5 (13.9, 68.4) 90.2 (89.5, 91.0) 0.8 (0.3, 1.9) 99.9 (99.7, 99.9) 
I - IV 12 (2.0) 10 (0.2) 54.6 (32.2, 75.6) 90.3 (89.6, 91.1) 2.0 (1.0, 3.5) 99.8 (99.7, 99.9) 
One Year After Randomisation (post-hoc) 
I & II 9 (1.5) 4 (0.1) 69.2 (38.6, 90.9) 90.3 (89.5, 91.0) 1.5 (0.7, 2.8) 99.9 (99.8, 100.0) 
III & IV 6 (1.0) 14 (0.2) 30.0 (11.9, 54.3) 90.2 (89.5, 91.0) 1.0 (0.4, 2.2) 99.7 (99.6, 99.9) 
I - IV 15 (2.5) 18 (0.3) 45.5 (28.1, 63.6) 90.4 (89.6, 91.1) 2.5 (1.4, 4.1) 99.7 (99.5, 99.8) 
Two Years After Randomisation 
I & II 12 (2.0) 11 (0.2) 52.2 (30.6, 73.2) 90.3 (89.6, 91.1) 2.0 (1.0, 3.5) 99.8 (99.6, 99.9) 
III & IV 6 (1.0) 27 (0.5) 18.2 (7.0, 35.5) 90.2 (89.4, 91.0) 1.0 (0.4, 2.2) 99.5 (99.3, 99.7) 
I - IV 18 (3.0) 38 (0.7) 32.1 (20.3, 46.0) 90.4 (89.6, 91.1) 3.0 (1.8, 4.7) 99.3 (99.1, 99.5) 
 
 
Legend: PPV- positive predictive value; NPV- negative predictive value; CI- confidence interval. 
 
Note: Absolute risk reduction of late-stage lung cancer diagnosis 2 years after randomisation was 0.31%. The number needed to screen to 
prevent one late-stage lung cancer diagnosis 2 years after randomisation was 325 (95% CI: 13, 637). 
 
 
Figure 3. Secondary Outcomes: Mortality Two Years After Randomisation in the 
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Primary and secondary objectives and outcomes: summary 
 
 Objectives Outcomes 
Primary to assess the effectiveness of 
EarlyCDT-Lung test in reducing the 
incidence of patients with late-stage 
lung cancer at diagnosis, compared 
with standard clinical practice; 
difference at 24 months after randomisation, 
between the number of patients with stage 3, 4 
or unclassified lung cancer at diagnosis in the 
intervention arm, and those in the control arm; 
Secondary 
1 
to assess the effectiveness of 
EarlyCDT-Lung test in improving the 
diagnosis of early-stage lung cancers; 
numbers, at 24months after randomisation, in 
the different stages at diagnosis (3/ 4/ U/ other) 
in the intervention arm and the control arm; 
2 to undertake a cost-effectiveness 
analysis  of EarlyCDT-Lung test as a 
primary screening method in 
comparison to standard clinical 
practice; 
difference, after 2 years, in the costs and 
outcomes between the intervention arm and the 
control arm; cost-effectiveness of the 
intervention compared to standard clinical 
practice 
3a to compare lung-cancer mortality, all-
cause mortality and cancer-specific 
mortality in high-risk groups provided 
with EarlyCDT-Lung test, compared 
with standard practice; 
estimates, after 2 years, of lung cancer 
mortality, all-cause mortality and cancer-specific 
mortality in the intervention arm and in the 
control arm; assessment of significance of 
differences; 
3b to compare long-term future 
mortality in high-risk groups provided 
with EarlyCDT-Lung test, compared 
with standard practice; 
estimates, after 5 and 10 years of long-term 
future mortality in the intervention arm and in 
the control arm; assessment of significance of 
differences; 
4 to obtain refined estimates of the 
sensitivity, specificity, positive 
predictive value and negative 
predictive value of EarlyCDT-Lung 
test; 
estimates, after 2 years of (i) the number of 
patients with stage 3, 4 or unclassified lung 
cancer at diagnosis in the EarlyCDT-Lung test-
positive group and those in the EarlyCDT-Lung 
test-negative group and (ii) stage at diagnosis in 
the EarlyCDT-Lung test-positive and EarlyCDT-
Lung test-negative group; 
 
5 to assess behavioural outcomes 
including smoking, psychological 
outcomes including cancer worry, 
anxiety, depression, distress specific 
to clinical investigations; 
scores at baseline, and follow-up on EQ5D, 
Hospital Anxiety and Depression Scale (HADS), 
Positive and Negative Affect Schedule (PANAS), 
Revised Illness Perception Questionnaire – Lung 
Cancer (IPQ-LC), Lung cancer risk perception, 
Health anxiety subscale of Health Orientation 
Scale (HOS) and the Lung Cancer Worry Scale 
(LCWS), Medication, smoking behaviour, 
demographic details. Follow-up questionnaires 
include same items, plus Impact of Events Scale 
(intervention group only), healthcare utilisation 
and dates and results of follow-up investigations 
for lung cancer (test positive group only). The 
HADS is not included in follow- up 
questionnaires. Follow-up questionnaires are 
administered between 1 and 24 months to 
subsets of the control arm and intervention arm; 
(all participants in the EarlyCDT-positive group 
will be approached with the recruitment aim of 
300 from this group collected at 1,3,6,12,18 and 
24 months. The EarlyCDT-negative and control 
groups will be recruited at the same rate as the 
EarlyCDT-positive group with the recruitment 
aim of 300 from each group collected at 1,3,6 
and 12 months). 
6 to assess the effectiveness of 
EarlyCDT-Lung test on other clinical 
outcomes such as CVD, COPD, other 
cancers, hospital stays and outcomes 
identified though SMR linkage, etc.; 
Incidence of  other clinical outcomes such as 
CVD, COPD, other cancers, hospital stays, 
identified through SMR linkage, measured at 24 
months, 5 and 10  
years in the intervention arm and in the control 
arm; assessment of significance of differences; 
7 to assess uptake of subsequent 
investigations such as CXR, CT, 
bronchoscopy, etc. 
numbers in Tayside group (EarlyCDT-Lung  
test-positive, EarlyCDT-Lung test-negative, 
control) undertaking subsequent investigations 
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QUESTION / RATIONALE 
Lung cancer is the most common cause of cancer-related death worldwide. The majority of cases are 
detected at a late stage when prognosis is poor. Lung cancer remains the fourth least likely cancer to be 
picked up early by GPs. Low dose computed tomography (CT) scanning of high risk individuals can reduce 
lung cancer mortality by 20% but it is expensive and, despite scanning, late stage diagnosis results in 
substantial morbidity.  
 
The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and 
detection in the earliest stages of the disease. Survival rates are much higher when cancer is diagnosed 
early but because lung cancer is often diagnosed symptomatically, most cases are discovered after the 
disease has spread. In these cases, the 5-year survival rate is less than 10%. By testing patients who are at a 
high risk for developing lung cancer before symptoms appear, the EarlyCDT-Lung test could help diagnose 
lung cancer sooner, when treatment options are more likely to be successful. The EarlyCDT-Lung test 
detects autoantibodies, which are a patient’s immune response to antigens produced by solid-tumor cells. 
Because these autoantibodies are produced by healthy individuals at lower levels, the EarlyCDT-Lung test 
enables physicians to identify those patients producing autoantibodies at higher levels and who are at an 
increased lung cancer risk or who are already in the early stages of lung cancer. 
 
The EarlyCDT-Lung test can potentially identify those at high risk of lung cancer in whom the benefit/risk 
ratio for CT scanning is likely to be more favourable. The primary research question is therefore: 
Does using the EarlyCDT-Lung test to identify those at high risk of lung cancer and any subsequent CT 
scanning reduce the incidence of patients with late-stage lung cancer (3 & 4) or unclassified presentation 




Secondary questions include, but are not limited to: 
i) Is the use of the EarlyCDT-Lung test cost-effective compared to standard clinical practice? 
ii) What is the short and long term emotional and behavioural impact of the EarlyCDT-lung test? 
iii) Does the EarlyCDT-Lung test improve clinical outcomes including but not limited to cardiovascular 
disease (CVD), COPD, hospital stays and outcomes identified through SMR linkage? 
 
HYPOTHESIS 
In a high risk population the EarlyCDT-Lung test reduces the incidence of late stage tumours; 3 / 4 / 
Unclassified (U) at diagnosis compared to normal clinical practice. 
 
AIMS 
to assess the effectiveness of EarlyCDT-Lung test in increasing early stage lung cancer detection, thereby 
reducing the rate of late stage (3 / 4 / U) presentation, compared to normal clinical practice; 
to assess the cost-effectiveness of EarlyCDT-Lung test compared to normal clinical practice;  
to assess the effectiveness of EarlyCDT-Lung test in reducing adverse outcomes including potential 
psychological and behavioural consequences. 
 
DESIGN 
 We propose a randomised controlled trial of 12,000 participants. Cancer screening programmes should be 
based on the high quality evidence which trials provide that they reduce cancer specific mortality. People 
should be invited to participate in population screening programmes on the basis of firm evidence that the 
overall balance between potential benefits and harms is favourable. Where screening programmes have 
relied upon observational data, for example in breast and prostate cancer screening programmes have 
remained controversial for many years. Eventually in the case of breast cancer large trials have been 
undertaken to determine the place of the screening method in national programmes. In contrast where 
large trials have preceded regional and national roll-out of cancer screening programmes e.g. in bowel 
cancer, the programmes have been more evidence based (for example, population based trials of faecal 
 
occult blood testing have consistently demonstrated significant reductions in colorectal cancer mortality 
and are summarised in a meta-analysis that indicates a reduction of 16% overall and 25% when adjusted for 
screening uptake). In the case of lung cancer we have observational data to suggest that the Early CDT-Lung 
test may be effective and it is now necessary to undertake a trial to determine whether this potential 
benefit outweighs potential harms and whether the test would be a cost effective use of NHS resources. 
 
SETTING 
To recruit participants via  general practices, predominately within the lowest quintile of deprivation 
measured using the Scottish Index of Multiple Deprivation in NHS Tayside, NHS Greater Glasgow & Clyde 
(GG&C) and NHS Lanarkshire (recruitment in NHS Tayside is now complete.) However, it is anticipated that 
a number of potential participants will contact the study team in response to the initial media interest 
surrounding the launch of the study and via family and friends of randomised participants. All interested 
individuals outwith the GP recruitment strategy will be assessed in relation to inclusion/exclusion criteria 
including residing within the selected geographical post codes. These participants will be screened at either 
their participating GP practice or at the local Clinical Research Facility/Centre.  
 
PARTICIPANTS 
Adults aged 50 to 75 who are at risk of lung cancer will be eligible to participate. These are defined as those 
who are current or former cigarette smokers with at least 20 pack-years, or have a history of cigarette 
smoking less than 20 pack-years plus a family history (mother, father, brother, sister) of lung cancer which 
gives an individual a personal risk similar to a smoking history of 20 pack years. Participants should be 
healthy enough to undergo pulmonary resection or stereotactic radiotherapy.  
 
INTERVENTION 




Standard practice of awaiting clinical presentation of symptoms suggestive of lung cancer then 




Primary   
The difference, at 24 months after randomisation, between the rates of patients with stage 3, 4 or 
unclassified lung cancer at diagnosis in the intervention arm, and those in the control arm; 
 
Secondary  
(1) numbers at 24 months after randomisation, in the different stages at diagnosis (3/ 4/ U/ other) in the 
intervention arm and the control arm; 
(2) difference, after 2 years, between costs and outcomes in the intervention arm and in the control 
arm, cost-effectiveness of EarlyCDT-Lung test compared to normal clinical practice; 
(3a) estimates, after 2 years, of lung cancer mortality, all-cause mortality and cancer-specific mortality 
rates in the intervention arm and in the control arm ; assessment of significance of differences; 
(3b) estimates, after 5 years and 10 years, of long-term future mortality rates in the intervention arm and 
in the control arm; assessment of significance of differences; 
(4) estimates, after 2 years of, provided by (i) the number of patients with stage 3, 4 or unclassified lung 
cancer at diagnosis in the EarlyCDT-Lung test-positive group and those in the EarlyCDT-Lung test-
negative group and (ii) stage at diagnosis in the EarlyCDT-Lung test-positive and EarlyCDT-Lung test-
negative group;  
(5) scores at baseline, and follow-up on in a survey administered prior to treatment allocation, including 
EQ5D, Hospital Anxiety and Depression Scale (HADS), Positive and Negative Affect Schedule (PANAS), 
Revised Illness Perception Questionnaire – Lung Cancer (IPQ-LC), Lung cancer risk perception, Health 
anxiety subscale of Health Orientation Scale (HOS) and the Lung Cancer Worry Scale (LCWS), 
 
Medication, smoking behaviour, demographic details. Follow-up questionnaires include same items, 
plus Impact of Events Scale (intervention group only) and healthcare utilisation. The HADS is not 
included in follow- up questionnaires. Follow-up questionnaires are EQ-5D, cancer worry, positive 
and negative mood, smoking behaviour including cessation intentions and attempts; scores in 
additional questionnaires administered at between 1 and 24 months to subsets of the control arm 
and intervention arm; (all participants in the EarlyCDT-positive group will be approached with the 
recruitment aim of 300 from this group collected at 1,3,6,12,18 and 24 months. The EarlyCDT-
negative and control groups will be recruited at the same rate as the EarlyCDT-positive group with 
the recruitment aim of 300 from each group collected at 1,3,6 and 12 months). 
Three qualitative sub-studies will enquire via interview (telephone or face-to-face) to; 1) Investigate 
the experiences of individuals who choose not to have the EarlyCDT-Lung test rationale for not 
responding to a lung cancer screening, 2) Enquire how patients perceive the EarlyCDT-lung test and 
what do they understand about their test results and 3) Examine changes in smoking behaviour 
following EarlyCDT-Lung testing.  
The recruitment and methodologies for these sub-studies are outlined in detail in Appendix 2.  
(6) incidence at 24 months, and after 5 years and 10 years, in other clinical measures such as CVD, 
COPD, hospital stays, and outcomes identified through SMR linkage, etc. in the intervention arm and 
in the control arm; assessment of significance of differences; 
(7) numbers in Tayside group (EarlyCDT-Lung test-positive, EarlyCDT-Lung test-negative, control) 
undertaking subsequent investigations such as CXR, CT, bronchoscopy, etc.  Statistical modelling will 
be used to generate sample data for the Glasgow and Lanarkshire groups. 
 
METHODS 
Based on the test’s 93% specificity and 41% sensitivity we anticipate that approximately 640 participants in 
the intervention arm will have a positive test result. These will be offered a chest X-ray.  Those with a 
negative or indeterminate X-ray will be referred for a study CT scan.  If the initial CT is negative then 
subsequent CTs will be offered 6 monthly for 24 months. Those individuals with  monitorable abnormalities 
 
as classified by the radiology/respiratory physician’s study panel on baseline CT scan or subsequent CT will 
be followed up over the study period or referred for NHS clinical care as appropriate. All individuals 
entering the study will be flagged and followed up via the Scottish Cancer Registry. Participants who 
develop lung cancer will be individually followed-up via electronic record-linkage to assess both time to 
diagnosis and stage of disease at diagnosis. If no histological stage is available, stage will be assessed blind 
to allocation status from chest X-rays or CT, or, if no imaging is available a medical assessment of stage will 
be carried out.  
 
HOW THE RESULTS OF THIS RESEARCH WILL BE USED 
The study will assess the EarlyCDT-Lung test’s clinical and cost effectiveness and suitability for a large-scale, 
accredited screening service for early lung cancer detection.  It will also assess potential morbidity arising 
from the test and potential harms and benefits of a negative EarlyCDT-Lung test result. 
 
DATES AND DURATION OF TRIAL 
01/04/2013 –31-07-16 - End of recruitment (12k) 




1.1. BACKGROUND TO THE RESEARCH 
Lung cancer is the world’s leading cause of cancer related mortality and a major source of morbidity. 85% 
of patients with lung cancer remain undiagnosed until the disease is symptomatic and has reached an 
advanced stage. Moreover, Scotland has had one of the highest rates of lung cancer in the world. Around 
2,460 men and 2,340 women are diagnosed with lung cancer in Scotland every year, which is 16% of the 
total UK lung cancer cases, despite Scotland having 8% of the UK’s population. Survival from lung cancer is 
poor with less than 9% of patients still alive at five years after diagnosis, due primarily to late stage of 
presentation. 
 
Early detection and diagnosis of cancer improves prognosis - the current 5-year survival rate is 
approximately 60% for stage I lung cancer but is only 1% for those with stage IV disease. The potential of 
early detection of lung cancer to improve outcomes was highlighted by the National Cancer Institute (NCI) 
National Lung Screening Trial (NLST) which recently reported that CT screening reduced lung cancer 
mortality by 20%. However as a primary screening modality CT is expensive and leads to substantial 
morbidity in a significant percentage of individuals whose tests are false positives. The EarlyCDT-Lung test is 
an innovative diagnostic test for early detection of lung cancer. The test can stratify individuals by risk of 
developing future lung cancer; those with a positive test are invited for a chest X-ray then, if that is normal, 
a CT scan.  This targeted approach to CT scanning for early lung cancer detection is likely to be a more cost-
effective and potentially less harmful approach to population screening than a blanket CT-scanning 
program of all people considered at high risk of future lung cancer. 
 
A substantial body of published research has documented autoantibody (AAB) responses against various 
tumour derived/associated antigens (TAA) in patients with a wide range of solid tumours, including lung 
cancer. The serum proteome provides an attractive source of potential biomarkers and because serum 
collection is minimally invasive it can be repeatedly surveyed for cancer biomarkers.  AABs have been 
detected months to years before clinical diagnosis of breast and lung cancers, supporting the hypothesis 
 
that AABs could be incorporated into an early detection assay. Subsequent research studies have 
confirmed AABs to TAAs in patients with early stage lung cancer.  AABs have been reported in lung cancer 
subjects up to 5 years before clinical diagnosis even where annual screening spiral CTs were being 
performed.  
 
A serum assay has been developed and validated called Early Cancer Detection Test-Lung (EarlyCDT-Lung) 
that can detect 40% of lung cancers with a specificity of 90% by measuring autoantibodies to a panel of 
cancer antigens (p53, NY-ESO-1, CAGE, GBU4-5, Annexin1, & SOX2). Further confirmation of this sensitivity 
and specificity of the test for lung cancer using four new, independent sample sets has recently been 
published. A study of patient demographics showed no difference in autoantibodies based on age, gender 
and ethnicity. This autoantibody technology is different from CT scanning which in a prevalence screening 
test has a sensitivity of 67% for lung cancers developing over the following 12 months but with a low 
specificity of only around 49%. Indeed a prevalence CT screen will detect approximately 36% of the lung 
cancers which will develop in the next three years. If the EarlyCDT-Lung test has a three year ‘look forward’, 
as clinical data suggests, then the test will detect 40% of lung cancers which develop over this three year 
time period but with seven times fewer false positives than CT scanning. Two new autoantibodies (AAbs) 
have recently been added to the panel (and one removed) and the test now measures seven; p53, NY-ESO-
1, CAGE, GBU4-5, HuD, MAGE A4 & SOX2 and identifies 41% of lung cancers with an increased specificity of 
93% (Chapman et al; 2012). The 7-AAbs panel will be utilised in this study and all statistical calculations are 
based on the 41% sensitivity and 93% specificity of the Early CDT-Lung test.   
 
EarlyCDT-Lung detects lung cancer at all stages – i.e. it detects early stage lung cancer as well as advanced 
disease - which means autoantibodies are present at all stages of disease.  In a large group of patients with 
newly diagnosed lung cancers there was no difference  in positivity rate for EarlyCDT-Lung in early or late 
stage disease lung cancers – whether this was looking at all lung cancers, only non small-cell (NSC) lung 
cancer, NSC lung cancer, or only small-cell lung cancer (SCLC). Thus, while autoantibodies are present in 
early stage they are not a biomarker of only early stage disease. An audit, (presented July 2011 at the 
 
International Association for The Study of Lung Cancer) of the first 1000 patients to take the EarlyCDT-Lung 
test commercially, further confirms that the test works in clinical practice. These data are promising but an 
insufficient basis for introducing a national lung cancer screening program in the UK. 
 
1.2. RESEARCH QUESTIONS 
The primary research question is: 
Does using the EarlyCDT-Lung test to identify those at high risk of lung cancer and any subsequent CT 
scanning reduce the incidence of patients with late-stage lung cancer (3 & 4) or unclassified presentation 
(U) at diagnosis, compared with standard practice? 
 
Secondary questions include, but are not limited to: 
i) is the use of the EarlyCDT-Lung test cost-effective compared to standard clinical practice? 
ii) what is the emotional and behavioural impact of the EarlyCDT-lung test? 
iii) does the EarlyCDT-Lung test improve clinical outcomes including but not limited to CVD, COPD, 
other cancers, hospital stays, outcomes identified through SMR linkage, etc.? 
 
1.3. RATIONALE FOR STUDY 
Lung cancer is the most common cause of cancer related death worldwide. The majority of cases are 
detected at a late stage when prognosis is poor. 
 
CT scanning can reduce lung cancer mortality by 20%, but there are too many false positives leading to a 
large number of individuals without cancer being exposed to repeated unnecessary radiation. 
 
A disproportionate amount of patients are given cause for concern when between 35%-75%  of patients 
screened by CT are treated as positive (with resultant increased anxiety) but only 2%-3% will have a true 
cancer. 
 
Active interventions (e.g. trans-thoracic biopsy, surgical resection) as the result of positive CT scans give rise 
to significant side effects and complications in a percentage of individuals. 
 
The cost of screening with CT is expensive and unlikely to meet the thresholds for cost-effectiveness (£20k - 
£30k/QALY) usually used within the UK by bodies such as NICE.  
 
Background to the study: pre-trial qualitative work 
 
Four focus group sessions (Ethical approval by I-WHO, University of Nottingham, Appendix 1) were held 
with smokers aged 50 and over living in some of Glasgow and Dundee’s most deprived areas in order to 
explore recruitment preferences and likely willingness to participate in the forthcoming EarlyCDT Lung 
Cancer Scotland (ECLS) Study.  
 
The work was carried out throughout June and July 2012 in four areas of Scotland: Castlemilk, Darnley, 
Charleston and Douglas.  A total of 32 people aged 50 – 75 took part in the work, including 14 men and 18 
women.  All but one were current smokers, and most had smoked for 40 years or more, smoking one pack 
or more per day. 
 
The findings from the work enabled the formation of a number of recommendations for both the main trial 
recruitment strategy and materials, including: 
 
1.3.1 Recruitment Strategy 
• Adopting a personal approach to invitations, sent from GPs and followed up in writing;   
• Setting deadlines for people to respond to invitations to maximise likely response rates, bolstered 
by local radio and newspaper coverage of the study;  
• Providing early summary information which emphasises that the study is not focussed on trying to 
encourage people to stop smoking; 
 
• Telling people which group they are in after taking their blood in order to minimise attrition during 
initial appointments but also emphasising the value of being in the ‘non-test group’ for the benefit 
of wider research and public health; and 
• Offering flexible appointments that are close to people’s homes. 
 
1.3.2 Recruitment Materials 
• Making sure that all documents explicitly say that the trial relates solely to lung cancer;  
• Explaining the reasoning for the study design (including control and intervention groups) and 
setting out clearly what the inclusion/exclusion criteria are, and why these criteria apply; 
• Explaining the purpose of randomisation, and ensuring early on that people know when they will 
be notified of which group they are in.  This includes offering assurances that random means 
random and that being placed in the test group is not an indicator of risk; 
• Acknowledging that not only smokers can be affected by lung cancer; and    
• Offering sufficient information on the issue of making blood available to other researchers, and 
what this might entail, to allow fully informed consent to be given. 
 
Trial documents have been developed based on the learning to emerge from these groups which will 
hopefully maximise participation in the upcoming trial and forearm those involved in its delivery as to the 




To assess the effectiveness of EarlyCDT-Lung test in reducing the incidence of patients with late-stage lung 




1) to assess the effectiveness of EarlyCDT-Lung test in improving the diagnosis of early-stage lung 
cancers; 
2) to undertake a cost-effectiveness analysis of EarlyCDT-Lung test as a primary screening method 
compared to standard clinical practice; 
3a) to compare lung-cancer mortality, all-cause mortality and cancer-specific mortality in high-risk groups 
provided with EarlyCDT-Lung test, compared with standard practice; 
3b) to compare long-term future mortality in high-risk groups provided with EarlyCDT-Lung test, compared 
with standard practice; 
4) to obtain refined estimates of the sensitivity, specificity, positive predictive value and negative 
predictive value of EarlyCDT-Lung test; 
5) to assess behavioural outcomes including smoking, psychological outcomes including cancer worry, 
anxiety, depression, distress specific to clinical investigations; 
6) to assess the effectiveness of EarlyCDT-Lung test on other clinical outcomes; 




The difference, at 24 months after randomisation, between the number of patients with stage 3, 4 or 
unclassified lung cancer at diagnosis in the intervention arm, and those in the control arm; 
 
Secondary Outcomes 
1) numbers, at 24 months after randomisation, in the different stages at diagnosis (3/ 4/ U/ other) in the 
intervention arm and the control arm; 
2) difference, after 2 years, between costs and outcomes in the intervention arm and in the control arm, 
cost-effectiveness of EarlyCDT-Lung test compared to normal clinical practice; 
 
3a) estimates, after 2 years, of lung cancer mortality, all-cause mortality and cancer-specific mortality 
rates in the intervention arm and in the control arm; assessment of significance of differences; 
3b) estimates, after 5 years and 10 years of long-term future mortality rates in the intervention arm and in 
the control arm; assessment of significance of differences; 
4) estimates, after 2 years of  (i) the number of patients with stage 3, 4 or unclassified lung cancer at 
diagnosis in the EarlyCDT-Lung test-positive group and those in the EarlyCDT-Lung test-negative group 
and (ii) stage at diagnosis in the EarlyCDT-Lung test-positive and EarlyCDT-Lung test-negative group;  
5) scores at baseline, and follow-up on in a survey administered prior to treatment allocation, including 
EQ5D, Positive and Negative Affect Schedule (PANAS), Revised Illness Perception Questionnaire – Lung 
Cancer (IPQ-LC), Lung cancer risk perception, Health anxiety subscale of Health Orientation Scale (HOS) 
and the Lung Cancer Worry Scale (LCWS), Medication, smoking behaviour, demographic details. 
Follow-up questionnaires include same items, plus Impact of Events Scale (intervention group only), 
healthcare utilisation and dates and results of follow-up investigations for lung cancer (test positive 
group only). The HADS is not included in follow- up questionnaires. Follow-up questionnaires are EQ-
5D, cancer worry, positive and negative mood, smoking behaviour including cessation intentions and 
attempts; scores in additional questionnaires administered at between 1 and 24 months to subsets of 
the control arm and intervention arm; (all participants in the EarlyCDT-positive group will be 
approached with the recruitment aim of 300 from this group collected at 1,3,6,12,18 and 24 months. 
The EarlyCDT-negative and control groups will be recruited at the same rate as the EarlyCDT-positive 
group with the recruitment aim of 300 from each group collected at 1,3,6 and 12 months). 
6) incidence at baseline, 24 months, and after 5 years and 10 years, in other clinical measures such as 
CVD, COPD, other cancers, hospital stays, and outcomes identified through SMR linkage, etc. in the 
intervention arm and in the control arm; assessment of significance of differences; 
7) numbers in Tayside group(EarlyCDT-Lung test-positive, EarlyCDT-Lung test-negative, control) 
undertaking subsequent investigations such as CXR, CT, bronchoscopy, etc. Statistical modelling will be 
used to generate sample data for the Glasgow and Lanarkshire groups. 
 
 
2. STUDY DESIGN 
2.1. STUDY DESCRIPTION 
A randomised controlled trial involving 12,000 participants recruited through primary care and community 
based recruitment strategies in Scotland.  
 
2.1.1. Setting 
General practices in the lowest quintile of deprivation in Scotland as measured by the quintiles of the 
Scottish Index of Multiple Deprivation (SIMD 2012). Subsequent recruitment will be attained through 
adverts, posters, flyers and community based interactions. Potential participants can either be seen at their 
participating GP practice or at the local clinical research centre, or other appropriate clinical location.  
 
2.1.2. Participants 
Adults aged 50 to 75 who are at risk of lung cancer will be eligible to participate. These are defined as those 
who are, current or former cigarette smokers with at least 20 pack-years, or have a history of cigarette 
smoking less than 20 pack-years plus an immediate family history (mother, father, brother, sister, child) of 
lung cancer which gives an individual a personal risk similar to a smoking history of 20 pack years.  




2.2. STUDY FLOWCHART  
2.3. STUDY ASSESSMENT AND NOTIFICATIONS 
Table 1. Overview of Study Assessments/Notifications.  
ASSESSMENT/PROCEDURES         TIMELINE* ( ± 2 weeks) 
 Visit 1 (~30 -45mins)  Visit 2*(~30mns) 
➢ *EarlyCDT Positive Test 
Participants may visit or call. 
➢ EARLY CDT Negative Test 
Participants may attend for 
further information/advice only.  
Informed Consent  X   
Inclusion/Exclusion Criteria X   
• Review/Record only Relevant Medical History relating to 
IC/EC 
X   
• Review/Record Relevant Medications  
• Relating to IC/EC 
X   
Blood Sample X   
Baseline Questionnaire X   
Thank you letter to Control Group  X  
EarlyCDT- Lung Test Result Letter   X  
GP Results Letter & ICF copy (negative)  X  
Result Discussion/ Imaging Schedule    X 
Provide PIS 2    X 
GP Result Letter & ICF copy (positive)   X  
EARLYCDT – Lung Test  Positive Result Participants – Imaging Schedule 
 
 TIMELINE( ± 4 weeks) (±12 weeks for CT prior to study entry) 
 0 6 months 12 months 18 months 24 months 
CXR X     
CT Scan* X X X X X 
*Scheduled every 6 months, if participant enters NHS clinical care 
pathway, subsequent study CT scans will be cancelled. 
 Research team member will call 2-4 days before each scheduled CT 




3. STUDY POPULATION 
3.1. NUMBER OF PARTICIPANTS 
Twelve thousand participants from general practices in the most deprived quintile of the population 
Scotland (as measured by the quintiles of the Scottish Index of Multiple Deprivation (SIMD) 2012 - 
version 2. In this second phase of recruitment, from 10,000 to 12,000 only participants from NHS 
Greater Glasgow and Clyde and NHS Lanarkshire will be invited as recruitment in NHS Tayside is now 
complete.  
 
3.2. INCLUSION CRITERIA 
1. Participant is willing and able to give informed consent for participation in the study 
2. Male or female aged 50 years to 75 years 
3. Current or Ex-smoker with at least 20 year pack history 
4. or Less than 20 year pack history but with family history of lung cancer in a 1st degree 
relative (mother, father, sister, brother, child) 
5. ECOG Status: 0, 1 and 2 (Eastern Co-operative Oncology Group) 
 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. 





6. Geographical postal sectors of:  
NHS Geographical Area  Eligible Postcodes 
Tayside DD1 - DD11, PH1–PH3 , PH6-PH8, PH10, PH11, PH13, PH15 & 
PH16, KY13 
Greater Glasgow & Clyde G1-G5, G11 –G15, G20-G22, G31-34, G40 –G46,  
G51- G53, G60-G62 &G64, G66 & G69, G72 & G73,   
G76-G78, G81-G83 
PA1–PA8 (except PA6), PA11-PA16 & PA19  
Lanarkshire G33, G65, G67, G69, G71-75, ML1-12 
 
3.3. EXCLUSION CRITERIA 
1. History of any cancer other than non-melanomatous skin cancer, cervical cancer in situ.  
2.  Symptoms suggestive of lung cancer within past 6 months (haemoptysis, unintentional 
weight loss (at least 5% in preceding 6 months). 
3.  Patients for whom the GP considers invitation to the study would cause undue distress. 
4. Patients with other terminal disease. 
5. Patients on (> 3months) of Cyclophosphamide .  Note: Other prolonged / continuous use 
(>3months) of cytotoxic/ immuno-suppressant drugs eg: Methotrexate, Azathioprine, 
Rapamycin, Mycophenolate, Rituximab and anti-immunophilins such as Ciclosporin, 
Tacrolimus,and  Monotherapy using glucocorticoids/ steroids eg prednisolone are  NOT 
exclusion criteria. 
 
4. PARTICIPANT SELECTION AND ENROLMENT 
4.1. IDENTIFYING PARTICIPANTS 
Potentially eligible individuals will be identified from GP medical records by an electronic medical 
record search undertaken by the Scottish Primary Care Research Network. Potential participants will 
be recruited via their General Practitioner (through SPCRN) using a range of methods including: 
a. postal invitation letter including a Participant Information Brochure; 
and where necessary or appropriate: 
b. invitation letter including a summary of the study Participant Information Sheet on collection 
of repeat prescription; 
c. invitation during consultation with GP / Practice Nurse / Health Care Assistant at the 
practice; 
d. invitation to those eligible on registered research volunteer databases  
e. poster present in the GP’s waiting room; 
f. other recruitment strategies may be employed including; Media campaign involving: local 
and national newspapers; BBC Scotland; local radio,  
Celebrity endorsement 
g. Publicity campaign using posters/leaflets etc….including: 
Football/Bingo halls/ Bowling      
Smoking Cessation Clinics 
Hospital main entrances/ hospital clinics  
Shopping Centres/Supermarkets/Pubs/etc. 
Benefits offices/Post offices etc. 
Sheltered Housing /Housing Associations 
Community and charitable outreach programs 
Mobile screening clinic 
Pharmacist approach through practices. 
 
 
The potential impact of the presentation of the PIB on recruitment (rather than understanding) 
is unclear and is being evaluated by the embedded MRC START study 
(http://www.medicine.manchester.ac.uk/mrcstart/about/).  ECLS has l included an embedded 
methodological substudy (substudy 4) of two, ethically-approved PIB presentations as part of 
the START study.  The full protocol of sub-study 4 is given in Appendix 3. (The START (sub-study 
4) now completed). 
 
For this sub-study, potential participants received one of two versions – the original version 
(ECLS PIB) or a revised version (START PIB), which has had both its language and its design 
modified after consultation with groups of the public selected to be similar to the ECLS target 
population. The content (i.e. the topics covered) remains the same in the both versions of the 
Participant Information Brochure. The allocation of brochure sheet version to each participant 
was decided randomly. The main outcome of interest here is the proportion of participants 
receiving each version of the sheet who go on to take part in the ECLS trial.  When a participant 
is consented to the ECLS Study they will indicate that they have read and understood either the 
ECLS PIB or the START PIB.   A sample size of approximately 2000 participants was involved in 
MRC START in ECLS, split equally between the two versions of the PIB and GP Invitation Letters.   
Sub study 5 is the work of an MRC funded PhD studentship at the University of Glasgow.  The 
proposal adds two new aspects to the psychological sub-studies.  Firstly looking at people who 
decide not to take part after showing interest by either cancelling or not attending their 
appointment, and exploring why they change their mind.  Secondly exploring any differences 
between the people taking part who self refer for the study as opposed to reply to a GP 
invitation.  Full details of the sub-study can be found in Appendix 4. 
The study invitation letter will include a slip for participants to either express interest in finding 
out more about the study, provide their contact details or to request no further contact about 
 
the study. Those returning an expression of interest will be telephoned, more than 24 hours 
after anticipated receipt of the Participant Information Brochure, by a member of the research 
team. Additionally, the participant is given the opportunity to call or email the study team. The 
call (instigated by participant or study team) will allow a discussion of the study, to answer any 
questions the potential participant may have, do a preliminary assessment of eligibility and if 
they agree, to make an appointment for a recruitment visit (hereafter referred to as the 
eligibility assessment phone contact).  An appointment letter/email will be sent out to confirm 
appointment.  
 
A reminder call/email or text, whichever is preferable to the participant, will be carried out up to 
2 days prior to the screening appointment. A reminder process decreases non-attendance.  
Non-responders to the GP postal invite will be approached again using a reminder letter or 
postcard. Those participants who have not responded after the first reminder will be viewed as 
non-responder and eligible for the first qualitative sub-study (See Appendix 2). This study will 
investigate the experiences of individuals who choose not to respond to lung cancer screening. If 
GPs agree, a member of the ECLS research team will attend the practice and call non-responders 
as per the eligible SPCRN list. This process has proven to be a successful reminder methodology 
in previous primacy care research conducted by the CI. A member of the research team will 
undertake the eligibility assessment phone contact for those expressing interest in the 
consultation or by returning the expression of interest form at a later date.  
 
The recommended study visit order (findings from focus groups) is: 
➢ obtain consent 
➢ take bloods from all consented participants (in the unlikely event; a blood sample is 
unobtainable or the blood sample blood sample from a participant in the test group is lost 
during transportation the participant will be contacted to arrange a subsequent sample.)   
 
➢ complete survey questionnaire 
➢ randomise to treatment arm 
 
After randomisation group allocation is known all participates will be asked if they continue to 
be happy for their bloods to be used for the Early CDT- Lung Test  
(lung cancer test group) and for future cancer related research for those  who agreed by  
initialling the relevant box on the consent form.  
 
For participants randomised to the intervention arm the EarlyCDT-Lung test will be performed 
and patients followed up according to their result. 
 
At Visit 1 participants are advised that those with a positive EarlyCDT-Lung test result will be invited 
to a follow-up visit to interpret the test results and explain the progress on study thereafter. Those 
with a negative EarlyCDT-Lung test result will be written to, explaining the test results and will be 
offered a follow-up visit or a telephone call if they wish. They will be advised of symptoms to watch 
for including persistent cough, coughing up blood, shortness of breath, weight loss or loss of 
appetite. They will be counselled to carry on having tests for other types of cancer if they are offered 
(e.g. bowel cancer test, mammograms, cervical smears). In less than 1% of cases an Early CDTLung 
test is deemed invalid. The test panel for the participant shows a characteristic indicative of some 
interfering nonspecific immunoreactive component. This result is deemed neither positive nor 
negative and it is not recommended that the test is repeated as the result will remain invalid. On 
those very rare cases that this occurs a participant will be informed by a telephone call and a follow-
up results letter. Those in the control arm will be written to and thanked for their contribution to the 
study and advised and counselled identically to those with a negative test result. 
 
 
All participants who agreed to donate blood for future will be advised that it will be used in cancer 
related research.  
 
A patient specific section of the study website (www.eclsstudy.org) containing Participant 
Information Sheets and research staff contact details will be available for participants to view.  
 
4.2. CONSENTING PARTICIPANTS 
All individuals taking informed consent will have received training in Good Clinical Practice (GCP). It 
will be explained to patients that they are under no obligation to enter the trial and that they can 
withdraw at any time during the trial, without having to give a reason. A copy of the signed Informed 
Consent Form (ICF) will be given /or posted out to the study participant. A copy of the signed 
consent form will be given or sent to the GP with a letter outlining the study and patient pathway. 
The letter will notify the GP of their patients’ group allocation, relevant Early CDT-Lung test result, 
and any notable findings found at the screening visit, namely, the request to give up smoking or 
relevant clinical information that requires further clinical judgement.  The original copy of the ICF is 
to be retained at the study site (ISF or TMF, as appropriate.). If any notable findings are found at the 
screening visit an anonymised copy of the GP letter will be filed in the participant’s study file.  If new 
safety information results in significant changes to the study risk–benefit assessment, the Protocol, 
Participant Information Sheet and/or consent form will be reviewed, updated and amended as 
necessary. All participants will be informed of the new information, given a copy of the revised 
consent form and asked to re-consent if they choose to continue in the study. 
 
4.3. SCREENING FOR ELIGIBILITY 
SPCRN staff will visit practices to undertake searches of the GP computerised records. The resulting 
list of potentially eligible participants will be checked by a GP at the practice to ensure that those for 
whom study participation would cause undue distress and those with a terminal disease are not sent 
 
study invitations. Telephone screening of potentially eligible participants who have returned an 
expression of interest will be undertaken by a member of the research team at the eligibility 
assessment phone contact. This will include assessment of age, smoking history, family history of 
lung cancer, previous cancer, ECOG status and eligible postcode. 
 
4.4. INELIGIBLE AND NON-RECRUITED PARTICIPANTS  
The reason(s) for ineligibility will be explained to the patients and any questions they have will be 
answered. They will be thanked for their interest in the trial and any relevant clinical information will 
be communicated to their GP where the patient has given consent. 
 
4.5. RANDOMISATION 
Participants will be allocated to intervention or comparison group during the recruitment visit (Visit 
1) using a web-based randomisation system; TRuST, provided by Tayside Clinical Trials Unit (TCTU).  
Set-up of the randomisation system will be by TCTU staff under the supervision of a TCTU 
statistician.  Randomisation will be stratified by site and minimised by age, sex and smoking history. 
 
4.6. ADMINISTRATION OF THE TEST 
Individuals at higher risk will be identified from GP medical records or community based recruitment 
as described above. Consenting individuals will be randomised to either receive an EarlyCDT-Lung 
test or standard care.  
 
4.7. MANAGEMENT OF THE VISITS 
Based on the test’s 93% specificity and 41% sensitivity we anticipate that approximately 640 
participants in the intervention arm will have a positive test result. These will be offered a chest X-
ray.  Those with a negative or indeterminate X-ray will be referred for a CT scan.  If the initial CT is 
negative then subsequent CTs will be offered 6 monthly for 24 months.  
 
 
If a participant has had a chest X-ray in the previous 1 month, or a CT scan in the previous 3 months 
to a scheduled study CT scan, these can be reviewed as part of the study. This will reduce the need 
to expose participants to unnecessary radiation. With the participants consent chest X-rays or CT 
scans prior to study entry will be retrospectively coded as per ECLS Radiology Schema. The 
participant will proceed to have the series of 5 CTs if clinically appropriate.   
 
Participants will receive appointments via mail/email (as preferred). Participants will be called 2-4 
days before each CT-scan appointment. By calling, this allows the participant to ask any questions, 
check health status, arrange transport (if required) and increase participant retention. Individuals 
with monitorable abnormalities as classified by the radiology/respiratory physician’s study panel on 
baseline CT scan or subsequent CT will be followed up over the study period or referred for NHS 
clinical care as appropriate. All individuals entering the study will be flagged and followed-up via the 
Scottish Cancer Registry. Participants who develop lung cancer will be individually followed-up via 
their medical records to assess both time to diagnosis and stage of disease at diagnosis. If no 
histological stage is available, stage will be assessed by a panel of three respiratory physicians blind 
to allocation status of the study subjects from chest X-rays or CT, or, if no imaging is available, 
medical assessment of stage will be carried out. 
 
Prior to sending CT scan appointments participant deaths will be check using the SMR to ensure 
sensitivity is maintained. All participants in the EarlyCDT- Positive test groups known to have died 
will be removed from the CT scan appointment schedule register.  If patients (EarlyCDT-Positive test) 
fail to attend for any imaging assessment during the study, they will receive two reminders (one 
letter, one phone call). On the third non-attendance, a letter will be sent to the participant’s GP to 
inform them of non-attendance.  An appointment window of ± 4 weeks will be initiated for each 
scheduled CT scan.   
 
 
Participants will receive results letters in relation to their initial CXR and CT scan and subsequent CT 
scans. Any clinical intervention/treatment will be arranged by the study team.   
Two additional sub- studies 6 and 7 (Appendix 5 & 6, respectively) have been added to establish 
difference in the emotional, cognitive and behavioral response to a positive EarlyCDT test if 
pulmonary nodules are present on a chest computed tomography compared to a normal chest 
computed tomography? 
 
This study will utilise anonymised data from study participants in the EarlyCDT-positive group who 
participated in the emotional and behavioural outcomes study and completed the baseline 
questionnaire and at least one follow-up questionnaire at one, three or six months post recruitment 
(Qualitative Sub-Studies, Appendix 2). Participants will not require to be contacted for this sub-
study. Full proposal is described in Appendix 5.  
 
Sub- study &:  Living with lung nodules: what information would patients find helpful? 
 
The aim of this sub-study study is to explore the ECLS study participant response following receipt of 
a letter informing them that their CT scan showed a pulmonary nodule.   
 
The letter currently used in the trial is based on that used in routine clinical care. It is important to 
explore patient’s experiences following receipt of the letter to inform any roll out of lung cancer 
screening as a national programme.  Through the use of focus groups the existing letter will be 
reviewed and, if deemed appropriate, modifications will be made with a view to improving how 
these test results are communicated.  
 
 
The objectives of this study will be achieved through the use of four different focus groups.  Groups 
1 and 2 will focus on the current experiences of the ECLS trial participants receiving notification of a 
lung nodule while Groups 3 and 4 will seek to address what the participant response would be to a 
modified information letter which would be developed (if changes are required) from the comments 
from focus Groups 1 and 2.. A full outline of the project is outlined in Appendix 6.  
 
4.8. WITHDRAWAL AND STUDY TERMINATION PROCEDURES 
No circumstances are anticipated for the withdrawal of patients from the trial initiated by the clinical 
team or trial investigators. Patients may choose to withdraw from the trial at any time, without 
giving a reason, and without compromising their future treatment.  
 
If the study should be terminated early, for whatever reason, all participants with a positive Early 
CDT-Lung test will continue to be seen by the PI (lung specialist) and will continue to undergo any 




5. STUDY AND SAFETY ASSESSMENTS STUDY ASSESSMENTS 
 
The main study assessment is the test result.  
Other assessments include; 
i. diagnosis 
ii. costs associated with intervention including any follow up/confirmatory tests and subsequent 
treatment 
iii. costs associated with routine clinical management of patients  
iv. health utility data  
v. mortality (various) 
vi. measures of psychological outcomes and health behaviour 
vii. other clinical outcomes uptake of subsequent investigations  
 
5.1. SAFETY ASSESSMENTS 
As the study does not employ an Investigational Medicinal Product, Adverse Events (AE) or Serious 
Adverse Events (SAE) will be recorded but not reported in the Annual Report.  A number of factors 
affecting the trial population suggest that we would expect to observe a larger than normal 
incidence of episodes of ill-health due to both the age and co-morbidities of the study population.  
All known disease progressions and co-morbidities will be regarded as outcomes including 
complications arising from investigations which result in a hospital stay which will be captured in 
outcome 6 and all medical treatment or interventions will be predicated upon normal clinical care 
and not related to the study protocol.  All CXR and CT scan incidental findings (incidentaloma) will be 
recorded in the CRF as an incidental findings as per Radiological reporting Schema and Study 
Operations Manual.   Bespoke letters to GPs and/or specialist referrals will be completed by study 
 
physicians as required.   Participants will be informed of any incidental findings and any action 
required by a study physicians via letter or phone call if appropriate.  
  
 
6. DATA COLLECTION & MANAGEMENT 
6.1. DATA COLLECTION 
It is the CI and PIs responsibility to ensure the accuracy of all data entered and recorded in the 
CRF/eCRFs and the database. The Delegation of Responsibilities Log will identify all trial personnel 
responsible for data collection, entry, handling and managing the database. 
 
The data will be collected by the RN and/or the PI directly onto a paper CRF with subsequent 
transcription to the eCRF. Where there is electronic storage of non-identifiable data this will be on a 
password protected device and/or database.  A plan for data quality control will be developed by the 
data management staff at Tayside Clinical Trials Unit and the trial management team.  
 
All research blood samples (anonymised using barcodes) will be labelled and packaged according to 
IATA regulations using Royal Mail Safeboxes or INTELSIUS or equivalent transport box systems to be 
transported to the University of Nottingham for processing, transporting and storage of samples for 
future research.  All samples will be stored under custodianship as per UK Biobank guidelines. 
Sample Analysis and Chain of Custody Plans will be documented in the Study Operations Manual.   
 
The participant’s medical notes (GP and hospital) paper or electronic will act as source data for 
relevant past medical history, subsequent medical conditions, hospital admissions and diagnostic 
reports. 
 
Psychological and behavioural data relating to smoking, psychological outcomes including cancer 
worry, anxiety, depression and distress will be collected on all 12,000 participants through a baseline 
questionnaire administered during Visit 1. If required the RN can assist the participant with the 
completion of the questionnaire. Follow-up data will be collected between 1 and 24 months on 
subsets of the intervention and control groups. All participants in the EarlyCDT-positive group will be 
 
approached with the recruitment aim of 300 from this group collected at 1,3,6,12,18 and 24 months. 
The EarlyCDT-negative and control groups will be approached at the same rate as the EarlyCDT-
positive group with the recruitment aim of 300 from each group, collected at 1,3,6 and 12 months.. 
A web-based tool will be used weekly to randomly sample patients from the EarlyCDT-negative and 
control groups, stratified by the two study centres. It is anticipated an average of 8 individuals (4 
from each of the two study centres) will be randomly sampled and invited to complete follow-up 
questionnaires from each of the EarlyCDT-negative and control groups per week (based on a 10 
month recruitment period and an anticipated response rate of 67%). Response rates will be 
monitored and if they are lower than 67%, the number randomly sampled at each centre will be 
increased to achieve a minimum of 200 responses. Participants will be sent a £5 gift voucher for use 
in a range of stores for each questionnaire to be completed.  A Cochrane review found the use of 
small monetary incentives significantly increases response rates to postal questionnaires (Edwards 
et al., 2009). There are precedents in trials and other UK studies where small monetary incentives 
have been used. 
 
Two methods will be used for the initial period of recruitment: 50% of the sample will receive the 
questionnaire with the voucher and 50% will receive the voucher once they have returned their 
questionnaire. An assessment will be carried out to determine which of the two methods is more 
effective in maximising recruitment rate and will then be employed for the remainder of the study. 
A phone number will be provided for participants to call the research team for assistance in 
completing questionnaires.  Occasionally the research team may call participants to check on postal 
delivery and offer assistance with completion to increase return rate.  Participants who develop lung 
cancer during the 24 month follow-up period will not be sent further study questionnaires.  
For those participants who have agreed to further contact will be eligible for qualitative sub-study 2 
and 3 as outlined in Appendix 2.  
 
Follow up questionnaire sampling to achieve 300 participants in control, negative and positive 
groups is now complete. No participants will be actively recruited to these sub-studies. However, 
those participants in the positive group will be invited to continue to complete the follow-up 
questionnaires to 24 months post randomisation.  
 
6.2. DATA MANAGEMENT SYSTEM 
Tayside Clinical Trials Unit (TCTU) will provide a data management system using OpenClinica 
(https://www.openclinica.com/), its standard GCP-compliant data management system. Case Report 
Forms (CRF) will be developed together with the trial management team, statistician and data 
manager to ensure that the data management system supports the research aims of the study. The 
data management system will be fully validated, including the provision of test data and supporting 
documentation. Data entry will be coordinated by TCTU.  Data will be stored on servers controlled 
through the Tayside Medical Science Centre and housed within the Health Informatics Centre and 
the University of Dundee.  Backup and disaster recovery will be provided by TCTU according to its 
standard operating procedures. 
 
The Statistical Analysis Plan will specify dummy tables linked to primary and secondary outcomes 
and the data management system will be designed to export directly to the dummy table formats for 
analysis.   
  
 
7. STATISTICS AND DATA ANALYSIS 
7.1. SAMPLE SIZE CALCULATION 
The rate of lung cancer is 187/100,000 per year for patients aged 50-74 in Scotland 2008 (ISD cancer 
statistics). Deprivation is associated with a higher risk of lung cancer. Those in the most deprived 
quintile are associated with an increased risk of 1.8 times compared to the middle quintile of 
deprivation. (ISD cancer statistics) this gives an estimated annual lung cancer rate of 336/100,000 
among the practices taking part in the study. A high risk group within this population will be selected 
using similar entry criteria (outlined above) as the Mayo screening study which had a 2% prevalence 
rate of lung cancer and a further 2% incidence rate over the following 5 years (Swensson 2005). The 
baseline rate of late stage presentation for the particular high risk population envisaged in this study 
is uncertain, as is the size of the reduction in late stage presentation likely to be achieved through 
use of EarlyCDT-Lung. Using an estimated late stage presentation rate of 1,200/100,000 per year in 
the control group i.e. 2.4% over the two-year follow-up period, we require 85% power at 5% 
significance (two-sided) to detect an estimated reduction of 35% in presentation rate in the test 
group i.e. as low as 780/100,000 per year or 1.56% over the two-year follow-up period. This 
corresponds to an estimated event rate over the two years of follow-up of 120 events in the control 
group and 78 events in the test group and implies a required sample size of n=5,000 per group i.e. 
10,000 altogether. 
 
The anticipated 35% reduction in event rate between the control group and the test group is 
justified by current estimates of the capability of the EarlyCDT-Lung test to identify cases (41% 
sensitivity, 93% specificity) together with current estimates of the specificity of CT scanning (67%). 
The sample size calculations are based upon standard methods for time to event data using the 
cpower function in R and stpower exponential procedure in Stata and assuming exponential survival. 
They were also confirmed using standard approaches for detecting a change in binomial 
 
probabilities, and confirmed using approaches to detect a change in Poisson rates (with essentially 
identical results as loss to follow up is expected to be low). 
 
The study aims for a short recruitment period and so no allowance has been made for accrual. With 
such an allowance, say to 1 year, the power will increase to 91% to identify a 35% reduction 
provided the minimum follow up period of 2 years is observed.  
 
The initial assumptions of the rate of late stage presentation rate of 1,200/100,000 per year among 
the study participants was too optimistic and in January to May 2015 investigations were carried out 
to inform an increase in the sample size.  Baseline information on the 8639 participants recruited to 
March 2015 (18 months from first randomisation) was used to derive an estimate of lung cancer risk 
based upon the Spitz Model (25).  A number of variables in this model were not recorded in the 
study data base and low risk values were used in the risk calculation implying that the risk estimates 
should be underestimates.  This suggested that the with 10,000 participants the rate of lung cancer 
would be expected to be around 680/100,000 and  540/100,000 for stage T3/T4/Unknown lung 
cancer using ISD cancer statistics figures of 80% lung cancers in Scotland are late stage.  A sensitivity 
analysis around the missing data assumptions suggests that a late stage rate of around 600/100,000 
may not be unreasonable, though is likely to be at the upper limit. 
 
Using an assumption of 600/100,000 for late stage lung cancer and acknowledging that recruitment 
is over a 2 year period the study has a power of 80% to detect a 35% reduction associated with the 
use of the EarlyCDT-Lung test to identify cases, provided that analysis takes place after all 
randomised patients have been followed up for 2 years.  While an 80% power is at the lower end of 
acceptable powers this is the power level which has been used in a number of lung cancer screening 
trials. 
 
The power of the study is sensitive to the assumptions about the rate of late stage cancer and the 
recruitment rate, see Table 2.  A power in excess of 90% could only realistically be achieved by 
recruiting 15,000 patients or by changing the primary endpoint to 3 years post randomisation for all 
patients.  It the recruitment phase extends past 2 years to 2.5 years to recruit 12,000 participants 
then the power will increase slightly to 83%. 
 
Table 2.  Powers for a 35% reduction in the rate of T3/T4/Unknown lung cancer using a log rank test 
at the 5% significance level for various underlying rates in the control group, total sample sizes, and 




For the follow-up analysis of behavioural and psychological outcomes, 200 participants in each group 
will allow a mean difference of 3.00 (SD 15.04 (unpublished data from the ProtecT prostate cancer 
study) in the Impact of Events Scale with 80% power and 2-sided 5% significance level. We will, 
however, collect data from 300 patients in each group to allow for attrition. Assuming 80% 
participants are current smokers, we will obtain 80% power at 5% significance level to detect a 
reduction in smoking from 80% to 67% i.e. 13% points difference assuming follow up on 200 
participants. 
 
7.2. PROPOSED ANALYSES 
Characteristics of participants will be compared informally between treatment arms at baseline. The 
main analysis of the primary outcome will be intention-to-treat. Cox proportional hazards models 
will be used to estimate the hazard ratio of the rate of late stage lung cancer in the intervention arm 
compared to the control arm.  Participants who are lost to follow up will be censored.  The models 
will adjust for age, gender smoking history and practice.  If appropriate, random cluster effects will 
be included rather than fixed effects for practices. A similar methodology will be used for the 
secondary outcomes of comparisons of mortality rates (secondary outcomes 3a and 3b). A 
subsequent analysis will compare the outcomes of those with EarlyCDT positive in comparison to 
those in the intervention group with EarlyCDT negative (primary contrast for this analysis) and those 
in the control group (secondary analysis 1).  Comparisons of proportions (secondary analyses 1 and 
4) will be carried out using chi square tests.  Fishers exact test will be used if the numbers of events 
are small. 
 
The analyses of the questionnaire responses (secondary analysis 5) will be carried out using the 
appropriate 2 sample t tests and regression methods at baseline.  Non parametric tests will be used 
if there is evidence of non-normal scores.  Multilevel models will be used to analyse the repeated 
scores during follow up. 
 
Poisson regression models, adjusting for follow up time if necessary, will be used to investigate the 
other clinical measures (secondary outcomes 6 and 7). 
 
7.2.1. Cost effective analysis 
The short-term within-trial analysis will compare the costs and outcomes associated with the 
intervention group to those of the comparison group at 24 months.  A longer term analysis will 
employ a decision analytic model to link the short term outcomes measured within the trial to 
 
potential longer term impacts on health (for example in terms of impacts on the development of 
cardiovascular disease, diabetes etc.). Both analyses will utilise the NHS and personal social service 
perspective favoured by NICE. 
 
7.3. MISSING DATA 
The extent of missing data will be examined and, if necessary, methods such as multiple imputation 
will be implemented to provide robust results, assuming data are missing at random (MAR). 
 
7.4. TRANSFER OF DATA  
Transfer of Data will be achieved according to standard TCTU SOPs (Study Operations Manual). 
 
7.5. PREGNANCY 
The female age group in this study (50 to 75 years) are unlikely to be pregnant. However, 
assessment of risk is established when all women are asked about the possibility of pregnancy prior 
to any imaging investigations as per usual NHS risk assessment protocols. 
  
 
8. TRIAL MANAGEMENT AND OVERSIGHT ARRANGEMENTS 
8.1. TRIAL MANAGEMENT GROUP 
The trial will be overseen by a Trial Steering Committee (TSC) and a Trial Management Group (TMG) 
consisting of the CI and co-investigators, trial managers and with representation for research nurses 
and SPCRN. Day-to-day management of delivery of the trial will be achieved through the Trial 
Operations Group chaired by the Assistant Director of TCTU and comprising project and trial 
managers, data managers, statistician and software developers. 
 
8.2. TRIAL MANAGEMENT 
The Senior Trial Manager and Trial Manager will oversee the study and will be accountable to the CI. 
The Senior Trial Manager will be responsible for other trial processes hosted within the TCTU. 
However, this remains the overall responsibility of the CI. Any queries will be resolved by the CI or 
delegated member of the trial team. 
 
A study-specific Delegation Log will be prepared for each site, detailing the responsibilities of each 
member of staff working on the trial.  
 
8.3. TRIAL STEERING COMMITTEE 
The committee will be a TSC with an integrated data monitoring committee. It will be a mixture of 
lung cancer investigators and independent members.  The TSC will be chaired by an independent, 
expert in cancer research and clinical trials.  Other independent members will include a statistician.  
The TSC will meet bi-annually, with the first meeting being shortly after the start of the project. The 
terms of reference of the TSC and the draft template for reporting will be detailed in the ECLS TSC 
Terms of Reference.  
 
8.4. INSPECTION OF RECORDS 
The CI, PIs and all institutions involved in the study will permit trial related monitoring, audits, REC 
review, and regulatory inspection(s). In the event of an audit, the CI agrees to allow the Sponsor, 
representatives of the Sponsor or regulatory authorities direct access to all study records and source 
documentation. 
 
8.5. RISK ASSESSMENT 
A pre-Sponsorship study risk assessment was carried out by the TASC Research Governance Manager 
prior to Sponsorship approval being granted. 
 
8.6. STUDY MONITORING 
The Sponsor will determine the appropriate extent and nature of monitoring for the study and will 
appoint appropriately qualified and trained monitors. 
 
8.6.1 Potential Risks 
 
8.6.2 Blood sampling 
Veins and arteries vary in size from one patient to another and from one side of the body to the 
other. Obtaining a blood sample from some people may be more difficult than from others. Risks 
associated with having blood drawn are slight but may include: 
➢ Excessive bleeding  
➢ Fainting or feeling light-headed  
➢ Hematoma (blood accumulating under the skin)  
➢ Infection (a slight risk any time the skin is broken) 
All research nursing staff will be highly trained and experienced in venipuncture thereby minimizing 
risk.  
 
8.6.3 Test results 
False positives and false negatives are explained as follows: 
No medical test is completely accurate. This blood test is expected to pick up about 40 in 100 cases 
of lung cancer and detect the cancer at an early stage. However this means it doesn’t pick up all 
cases of lung cancer. So even if your test is negative, or if you are in the non-test group, it is 
important that you see your GP if you are unwell in any way that could be due to lung cancer. This 
includes persistent cough, coughing up blood, shortness of breath, weight loss or loss of appetite.  
As no medical test is completely accurate, the blood test will be positive in some people who do not 
have early lung cancer (false positive). These people will be offered a chest X-ray and lung scans to 
see if they have lung cancer. We expect this to happen to 8 out of every 9 people who have a 
positive test result.   
 
8.6.4 Radiography 
Risks relating to chest X-ray and CT scan are explained as follows:  
Chest X-rays and lung scans use radiation. People can develop cancer because of this radiation, but 
this is very rare. The amount of radiation you get from a chest X-ray is very small. About 1 million 
people would need to have a chest X-ray for one extra person to develop cancer because of the 
chest X-ray. A CT lung scan gives about 600 times as much radiation as a chest X-ray. 1500 people 
would need to have a CT lung scan for one extra person to develop cancer because of the scan. 
These risks are very small compared to the one in four chance we each have of developing cancer in 
our lifetime. Only about 640 people in this study are expected to have a positive blood test and will, 
therefore, need chest X-rays and scans. The chances of radiation affecting anyone in this study in this 
way are therefore very small. 
 
8.6.5 Minimising Risk 
All associated risks are well understood and have established procedures for management.  
 
9. GOOD CLINICAL PRACTICE 
9.1. ETHICAL CONDUCT OF THE STUDY 
The study will be conducted in accordance with the principles of good clinical practice (GCP) and the 
Research Governance Framework Scotland. 
 
In addition to Sponsorship approval, a favorable ethical opinion will be obtained from an appropriate 
REC and appropriate NHS R&D approval(s) will be obtained prior to commencement of the study. 
 
9.1.1. Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner 
designed to maintain participant confidentiality. All records will be kept in a secure storage area with 
limited access to study staff only. Clinical information will not be released without the written 
permission of the participant, except as necessary for monitoring and auditing by the Sponsor, its 
designee or Regulatory Authorities. The CI and study staff involved with this study will not disclose or 
use for any purpose other than performance of the study, any data, record, or other unpublished, 
confidential information disclosed to those individuals for the purpose of the study. Prior written 
agreement from the Sponsor or its designee will be obtained for the disclosure of any said 
confidential information to other parties. 
 
9.1.2. Data Protection 
The CI and study staff involved with this study will comply with the requirements of the Data 
Protection Act 1998 and subsequent General Data Protection Regulation updates, with regard to the 
collection, storage, processing and disclosure of personal information and will uphold the Act’s core 
principles. The CI and study staff will also adhere, if appropriate, to the current version of the NHS 
Scotland Code of Practice on Protecting Patient Confidentiality.  Access to collated participant data 
will be restricted to the CI and appropriate study staff. 
 
Computers used to collate the data will have limited access measures via user names and passwords. 
Published results will not contain any personal data that could allow identification of individual 
participants. 
 
9.1.3. Insurance and Indemnity 
The University of Dundee and Tayside Health Board are Co-Sponsoring the study. 
Insurance. –The University of Dundee will obtain and hold Professional Negligence Clinical Trials 
Insurance cover for legal liabilities arising from the study. 
 
Tayside Health Board will maintain its membership of the Clinical Negligence and Other Risks 
Insurance Scheme (“CNORIS”) which covers the legal liability of Tayside in relation to the study. 
Where the study involves University of Dundee staff undertaking clinical research on NHS patients, 
such staff will hold honorary contracts with Tayside Health Board which means they will have cover 
under Tayside’s membership of the CNORIS scheme. 
 
Indemnity. The Co-Sponsors do not provide study participants with indemnity in relation to 
participation in the Study but have insurance for legal liability as described above. 
  
 
10. STUDY CONDUCT RESPONSIBILITIES 
10.1. PROTOCOL AMENDMENTS, DEVIATIONS AND BREACHES 
The CI will seek approval for any amendments to the Protocol or other study documents from the 
Sponsor, REC and NHS R&D Office(s). Amendments to the protocol or other study docs will not be 
implemented without these approvals.  
 
In the event that a CI needs to deviate from the protocol, the nature of and reasons for the deviation 
will be recorded in a Protocol Deviation & Breach Log and Protocol Deviation & Breach Report (if 
required) and submitted to the Sponsor (if required). If this necessitates a subsequent protocol 
amendment, this will be submitted to the Sponsor for approval and then to the appropriate REC and 
lead NHS R&D Office for review and approval.  
 
In the event that a serious breach of GCP is suspected, this will be reported to the Sponsor 
immediately using the form “Notification to Sponsor of Serious Breach or Serious Deviation”.  
 
10.2. STUDY RECORD RETENTION 
To enable evaluations and/or audits from regulatory authorities, the investigators agree to keep 
records, including the identity of all participating patients (sufficient information to link records, all 
signed informed consent forms, source documents, and group allocation to intervention and 
control). The records should be retained by the study site coordinators and investigator according to 
TASC SOP or local NHS Board regulations, or as specified in the Clinical Study Agreement, whichever 
is longer. 
 
If the CI, PI or a study site coordinator relocates, retires, or for any reason withdraws from the trial, 
the University of Dundee should be prospectively notified. The trial records must be transferred to 
an acceptable designee. The study site coordinator must comply with the TASC SOP on archiving and 
 
obtain written permission from the Sponsor before disposing of any records, even if retention 
requirements have been met. 
 
10.3. END OF STUDY 
The end of study is defined as last patient last visit scan (LPLV) plus 24 M. The Sponsor, CI and/or the 
TSC have the right at any time to terminate the study for clinical or administrative reasons. 
End of follow-up. 
 
The end of the study will be reported to the Sponsor, REC and NHS R&D Offices within 90 days, or 15 
days if the study is terminated prematurely. The CI will ensure that any appropriate follow up is 
arranged for all participants. 
 
A summary report of the study will be provided to the Sponsor and REC within 1year of the end of 
the study. 
 
10.4.  CONTINUATION OF TREATMENT FOLLOWING THE END OF STUDY 
All participants will enter the standard NHS care pathway after their last scan; for further 
investigations or treatment if: a positive scan, classified nodules or incidental finding or if a non-




11. REPORTING, PUBLICATIONS AND NOTIFICATION OF RESULTS 
11.1.  AUTHORSHIP POLICY 
Ownership of the data arising from this study resides with the study team. On completion of the 
study, the study data will be analysed and tabulated, and a clinical study report will be prepared. 
Authorship eligibility for each manuscript arising from this study will be determined according to the 
criteria laid out in the Working Practice Document on Authorship filed in the Study Operations 
Manual. 
 
11.2.  PUBLICATION 
The clinical study report will be used for publication and presentation at scientific meetings. Trial 
Investigators have the right to publish orally or in writing the results of the study. 
Summaries of results will also be made available to trial Investigators for dissemination within their 
clinical areas (where appropriate and according to their discretion). 
 
11.3.  PEER REVIEW 
This trial has undergone peer review by the Sponsorship Committee.  The trial design and results will 
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Maximising recruitment in early cancer detection trials: The lung cancer trial 
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Background 
Approximately two thirds of trials fail to reach their recruitment target or have to extend their 
recruitment period (1,2). Failing to fulfil recruitment targets rates leads to underpowered studies, 
reduced generalisability, increased costs and delays in the implementation of effective interventions. 
Maximising recruitment is thus key to a trial’s success. 
 
Funding has been obtained for a large trial of the effectiveness and cost effectiveness of early cancer 
detection test in lung cancer, which is to be evaluated in individuals at high risk of lung cancer. The 
trial will be undertaken in general practices from disadvantaged areas in Glasgow and Dundee, 
commencing October 2012. Recruitment to trials amongst disadvantaged populations can be 
particularly challenging due to a lack of trust, limited knowledge of research and low literacy 
amongst potential participants (3). Previous research has demonstrated that qualitative methods 
 
can be used to inform recruitment strategies by tailoring recruitment to the trial population. For 
example, the ProtecT feasibility study, for prostate specific antigen testing for prostate cancer, 
explored men’s views of trial participation, interpretation of study information, understanding and 
acceptance of randomisation and treatment. Findings fed into recruitment strategies and this 
resulted in the proportion of men consenting to randomisation increasing from 49% to 70% (4).  
 
The current research has been designed to deliver tailored recruitment strategies and materials for 
the population to be targeted in the forthcoming early lung cancer detection trial. We propose to 
achieve this be addressing the following aims: 
 
Aims 
1. To explore potential trial participant views on: 
(a) issues likely to influence recruitment into the trial and willingness to be randomised (e.g., 
recruitment strategies; understanding of risk information; clinical equipoise and randomisation) 
(b) recruitment and study documentation (e.g., invitation letter, questionnaires); 
(c) factors which facilitate and hinder trial participation.  
2. To develop recruitment processes and materials for use in this, and subsequent trials. 
3. To contribute to the literature on methods for enhancing trial recruitment  
 
Methods 
We will be working with a local research company based in Scotland (KSO Research Limited) who will 
identify eligible participants; undertake the focus groups and complete the transcribing and analysis 
of material obtained through focus group discussions. As the clinical trial will recruit patients from 
both Glasgow and Dundee, we will be seeking to conduct 2 focus groups in each city, with up to 10 
participants in each group. 
 
Participants: The population to be targeted in the trial will be individuals at high risk of developing 
lung cancer aged between 50-75 years i.e., individuals who self-identify as current or former 
cigarette smokers with at least 20 pack-years, or a history of cigarette smoking plus family history of 
lung cancer which gives an individual a personal risk similar to a smoking history of 20 pack years).  
 
Recruitment: KSO Research limited will use ‘on-street’ recruitment methods to recruit participants 
into the focus groups. This will involve a trained recruiter working in each of the two areas. The 
recruiter will target local amenities where eligible participants may be found, for example, smoking 
areas outside of recreational facilities, at local train or bus stations, etc.  Recruitment will take place 
at different times/days over one week.  The company have used this kind of ‘on-street’ recruitment 
before with considerable success. They have observed that finding people who agree ‘at random’ to 
participate are often more likely to show genuine commitment to participation than those who 
respond to press advertisements. Furthermore, meeting the recruiter face-to-face encourages an 
early relationship and opportunity for participants to ask any questions that they have about 
participation on the spot before agreeing to take part. This approach also has the advantage of being 
cheaper than a press advertisement with no risk of over-subscription. In accordance with usual 
practice, the local police will be notified of the recruiters’ on-street presence and will be done with 
their support. 
 
Individuals will be approached on the street at random, although efforts will be made to recruit a 
mix of genders in each area and to fill quotas in three separate age bands (50-59, 60-69, 70-75 
years). The recruiter will first introduce themselves; provide a brief verbal introduction to the 
research and will enquire whether the individual would be willing to discuss a research project about 
a new blood test for lung cancer involving people who currently smoke or who have smoked 
previously (see recruitment questionnaire). Those who consent to further conversation will be asked 
first about their smoking status and family history of lung cancer to establish eligibility. Those who 
 
are not eligible will be thanked for their time and will only be given further information about the 
research should this be requested. Those who are eligible will be asked additional brief screening 
questions regarding age and working status. Individuals who agree to participate immediately will 
receive a participant cover letter and information sheet (enclosed) and will be asked to provide 
contact information so that they can be re-contacted and reminded of the date, time and location of 
the focus group. Participants who wish to consider the invitation first, will be provided with contact 
details for the research team and a participant information sheet. Individuals will be advised that 
they will receive £30 cash to thank them for their time and to cover their out of pocket and travel 
expenses. Anonymised data will be provided to the research team on: 
1. The number of recruitment sessions undertaken 
2. The number of people approached 
3. The number of those approached who were eligible to participate and reasons for ineligibility 
4. The number of those eligible who agreed to take par 
5. The reasons why people chose not to take part 
6. Characteristics of those who were eligible who did and did not agree to take part and the 
reasons for non participation (in an EXCEL spreadsheet) 
7. The number of those agreeing to take part who attended each focus group 
 
Procedure: Written informed consent (enclosed) will be obtained from all participants prior to 
commencing the focus groups. Participants will be reminded that the discussions of the group are to 
be audio-taped and transcribed verbatim, but that they will not be identified in the recordings and, 
as such, their contributions to the discussions will remain anonymous. Participants will be asked to 
discuss issues related to the aims outlined in 1a-c above, with discussions structured according to a 
topic guide (enclosed). Participants will receive £30 at the end of the focus group to thank them for 
their time and to cover out of pocket and travel expenses and will be asked to sign a receipt for this.  
 
Analysis: Audio recordings of focus groups will be transcribed verbatim and a thematic analysis will 
be undertaken to provide a rich and detailed account of the data (5). Strategies for ensuring quality 
assurance of credibility, transferability, dependability, and confirmability of analysis will be followed 
(6). The information from this analysis will be used to further refine the recruitment strategy and 
materials for the main trial. All original data files will be confidentially destroyed and written data 
stored anonymously.   
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APPENDIX 2: ECLS STUDY: QUALITATIVE SUB-STUDIES 
 
(Version 1, 11-09-13) 
 
Study background information and rationale 
 
Three qualitative sub-studies have been developed to explore a number of aspects of participant s’ 
attitudes and experiences of EarlyCDT-Lung testing and changes in smoking behaviour:  
 
Sub-study one: Investigating the experiences of individuals who choose not to have the EarlyCDT-
Lung test (Ben Young) 
In order to maximise the effectiveness of a screening test in a population, uptake must be high. 
Those at highest risk of a disease are often least likely to attend for screening1 and rates of uptake 
can vary according to the type of screening2, 3. Furthermore, lung cancer screening trial participants 
have previously displayed gaps in essential knowledge, suggesting that the goal of informed choice 
in lung cancer screening may be difficult to achieve4. Quantitative research suggests screening 
uptake may be related to demographic factors, health status and attendance at previous screening 
tests3, 5, 6. The acceptability of a screening method is also a recurring factor in decisions to attend2. 
 
Lung cancer screening differs from other cancer screening because it targets a higher risk subgroup 
of the population characterised predominantly by smoking status. Barriers to uptake of lung cancer 
screening may include the absence of symptoms, lack of knowledge about the test and stigma 
associated with lung cancer4, 7, 8. Smokers may be more likely to perceive early detection and 
intervention to be of limited use9. It is important to develop an in depth understanding of the 
reasons some people decide not to have the EarlyCDT-Lung test in order to promote future uptake 
in those most at risk of lung cancer. 
 
Objectives: 
1. To explore decisions to not respond to ECLS Study invitations, reasons for not responding 
and the perceived barriers to attending for the ECLS Study visit. 
2. To assess non-responders’ understanding and knowledge of the information communicated 
to them about the EarlyCDT-Lung test. 
3. To identify theory-based methods which could increase recruitment in a future trial or 
screening programme for early lung cancer detection. 
 
Sub-study two: How do participant s perceive the EarlyCDT-lung test and what do they understand 
about their test results? (Laura Bedford & Gozde Ozakinci) 
 
As the EarlyCDT-lung test is a different type of screening test for lung cancer it is important to 
examine participant s’ beliefs and expectations about the test. Qualitative research has highlighted 
different aspects of screening tests that individuals can hold beliefs about, for example, beliefs about 
the accuracy (sensitivity) of the test, the nature of the test, risks and side effects associated with the 
test, and type of result obtained using the test. Together, each of these beliefs can make up an 
individual’s overall perception of a screening test. Relatively limited research to date has found that 
screening test beliefs are one of several factors that can influence screening uptake8 and predict 
emotional and behavioural responses to screening test results10-12. As there is currently no method 
to quantitatively assess screening test beliefs, qualitative work in this area will be valuable as it will 
inform the development of a measure to capture participant s’ beliefs about screening tests. 
Furthermore, findings will inform how information on the EarlyCDT-lung test is presented to 
participant s.  
 
A participant’s understanding of their test result also has the potential to influence psychological 
outcomes following screening. For example, research has shown that a lack of understanding of the 
 
correct meaning of a positive screening test result can predict emotional distress following receipt of 
screening test results13, 14. Misunderstanding of a negative or normal screening test result has been 
found to lead to false reassurance, where an individual incorrectly understands a negative screening 
test result to mean that they are at no risk of developing the condition being screened for15, 16. In 
addition to understanding of test results, dissatisfaction with information provided on test results 
has also been found to predict adverse emotional outcomes, such as high levels of anxiety and 
worry15-17.  
 
It is therefore important to explore what participant s understand about their EarlyCDT-lung test 
result and identify what information they need about their result as this will help to inform future 
communication of EarlyCDT-lung test results. Furthermore, the majority of work exploring 
understanding of screening test results and satisfaction with test result information has used 
quantitative methodology, so it would be valuable to conduct qualitative research in this area so 
that these factors can be explored in more depth.  
 
Objectives: 
1. To examine participants’ understanding of, and satisfaction with, the information they 
received about the test 
2. To explore participants’ beliefs about the EarlyCDT-lung test  
3. To examine participants’ understanding of their test result 
4. To find out how satisfied participants were with the information provided on their test 
result. 
 




Smokers who attend lung cancer screening may be more motivated to stop smoking than other 
smokers18-20 and they may experience a 'teachable moment' for smoking cessation, a brief period in 
which motivation to stop smoking is enhanced21. However, evidence of changes in smoking 
behaviour in lung cancer screening participant s is inconclusive and long term changes in smoking 
prevalence in screened groups have not generally been observed22, 23. Increased cessation rates have 
been observed in participants receiving abnormal results21, 24. The ECLS Study will measure smoking 
behaviour and attitudes to smoking in a sample of participants over 12 months and this sub-study 
aims to provide an in depth exploration of those individuals’ experiences in relation to smoking 
during the study. 
 
Perceived barriers to smoking cessation can include current smoking behaviour, motivation to quit, 
past quit attempts, preferences for cessation support and fear of withdrawal symptoms, or of being 
judged or failing25, 26. Facilitators to cessation can include concerns about health, cost and the views 
of others27, as well as support services which are perceived to be personalised, accessible and 
effective25. The implementation of smoking cessation interventions as part of lung cancer screening 
programmes is being advocated28, creating a need for an evidence based approach to the integration 
of cessation interventions in such programmes. An exploration of the perceived barriers and 
facilitators to smoking behaviour change in ECLS Study participants can inform the development of 
relevant and acceptable cessation support in the lung cancer screening context. 
 
Objectives: 
8. To identify and explore decisions made regarding smoking cessation, reasons for those decisions 
and perceived barriers and facilitators to smoking cessation in screened ECLS Study participants. 
9. To compare differences in thoughts and experiences regarding smoking cessation between: 
a. Those who are successful in stopping smoking (i.e. reporting a change in smoking status from 
smoker to non-smoker), those who are unsuccessful (i.e. reporting a cessation attempt but 
 
no change in smoking status) and those who do not attempt to stop smoking (i.e. reporting 
no cessation attempt). 




1. Study management 
The studies will be conducted by Laura Bedford and Ben Young (PhD students) under the supervision 
of academic supervisors Kavita Vedhara (Professor of Health Psychology), Denise Kendrick (Professor 
of Primary Care Research) and John Robertson (Professor of Surgery), three ECLS study Principal 
Investigators based at the University of Nottingham, a research partner. In addition, Roshan das Nair 
(Consultant Clinical Psychologist and Honorary Associate Professor) will assist. Dr Gozde Ozakinci 
(University of St Andrews) will conduct analysis of Sub-study 2 data.  
 
2. Duration 
Sub-studies will take place between September 2013 – September 2015. 
 
3. Selection of participants 
Sub-study one – Investigating the experiences of individuals who choose not to have the EarlyCDT-
Lung test (Ben Young) 
One recruitment strategy for the main ECLS study is identifying potential participants via SPCRN from 
primary care. Each GP list is screened by the GP to ensure eligibility and suitability. Invitation letters 
are sent via the Health Informatics Centre. These individual’s details are not know to the study team. 
Individuals who respond positively either by returning the reply slip or calling/emailing the study 
team directly will be registered on the Recruitment Tracker. The recruitment tracker is held within 
the HIC safehaven and ensures participant confidentiality and data security as per HIC information 
 
governance Standard Operating Procedures. The contact details of these individuals are released by 
HIC to the study team to allow further contact. Invited individuals who respond indicating they 
would like no further contact are registered on the recruitment tracker as a negative response. The 
specific details of these individuals are not visible to the study team, merely documented as a 
number of negative responses. The group which responded neither positively nor negatively are 
termed non-responders. This group can often be over 80% of the invited population. As per the 
study protocol these individuals will be sent a reminder letter/postcard.  
 
Participants unable to speak English will not be eligible for any of the three sub-studies as they 
involve with telephone or face to face interview. A surrogate marker for sub-studies 2 & 3 will be 
eligibility into the main ECLS study. For sub-study 1, eligibility will be assessed at the beginning of the 
telephone interview.  
 
For sub-study 1, eligible participants will be those within the non-responder group and who would 
have been eligible for the main ELCS study had they responded and can confirm they remember 
receiving the invitation and that they intentionally did not respond. 
 
Non-responders will be identified periodically and sampled purposively from both the Glasgow and 
Dundee areas as recruitment to ECLS Study progresses. Consent will be obtained to participant in 
sub-study 1.  
Participants in the main ECLS study are invited to give consent to be contact for further contact. Only 
those participants who have given permission will be contacted with regard to sub-studies 2 & 3. 
Participants who have withdrawn from the main study or have received a diagnosis of lung cancer 
will not be eligible for sub-studies 2 &3.  
For all sub-studies one reminder will be sent. If the invited participant does not reply to either the 
initial invitation or the reminder they will not be contacted again for the sub-study participation.  
 
 
Sub-study 2: How do participants perceive the EarlyCDT-lung test and what do they understand 
about their test results? (Laura Bedford and Gozde Ozakinci) 
Eligible participants will be: 
• Willing and able to give informed consent for participation in the study 
• In the EarlyCDT-negative group or the EarlyCDT-positive group 
• Have received their screening test result within the past eight weeks.  
 
The aim is to recruit a diverse sample. This can be achieved through a maximum variation sampling 
strategy, which is recommended for qualitative studies.29 A sample obtained using maximum 
variation is not a representative sample but a purposive sample recruited to tap a variety of different 
views on a subject. This requires a strategy for sampling people who are different on a wide range of 
demographics. In this study, age, gender, ethnicity, level of deprivation (from the Scottish Index of 
Multiple Deprivation) and education level will be considered as variation factors. Roughly equal 
numbers of participants from Glasgow and Dundee will be recruited. Maximum variation sampling is 
an iterative process, whereby the first few participants sampled will direct who is sampled next.30  
 
It is expected that the final sample will consist of 30 participants, 15 from the EarlyCDT-positive 
group and 15 from the EarlyCDT-negative group. It is expected that saturation will be achieved with 
this sample; however, up to two participants from each group may be further recruited if saturation 
is not achieved. Both groups of participants will be recruited at the same rate. The sampling of 
participants will be dictated by the overall number required for this study. As previously stated, it is 
anticipated that 15 participants will be sampled per group over the 10-month study period. 
Therefore, approximately six participants will be approached per month per group with the aim of 
recruiting two participants from each group (33% response rate). A review will be carried out after 
two months of recruitment, and if response rates are low, then the number of participants 
 
approached each month will be increased. The order of selecting participants will be based on 
maximum variation as described above.   
 
Sub-study 3 - An examination of changes in smoking behaviour following EarlyCDT-Lung testing 
(Ben Young) 
Eligible participants will have been: i) allocated to the ECLS Study screened group; ii) selected for 
follow up questionnaires; iii) have been a self-reported smoker at baseline. Participants reporting 
either successful or unsuccessful cessation attempts, or no attempt, will be sampled from groups 
receiving a positive test result and a negative test result, making six distinct groups for this sub-
study. 
• A smoker at baseline will be defined as a ‘YES’ response to the question: “Have you smoked 
any cigarettes or tobacco in the last seven days/week?” 
• A cessation attempt will be identified as a ‘YES’ response to the question at 3 months: “In the 
LAST 2 MONTHS have you tried to stop smoking?” 
• A successful cessation attempt will be defined as a smoker at baseline and a ‘NO’ response to 
the following question at 3 months: “Have you smoked any cigarettes or tobacco in the last 
seven days/week?” 
 
Individuals will be periodically sampled from participants in the RCT and approached in advance of 
planned researcher visits to Scotland. They will be sampled in a stratified quota manner with the 
objective of 15 negative test and 15 positive test participants and the aim of a 5-5-5 smoking 
behaviour split in each group. It is anticipated that 150 individuals will be approached with a 
recruitment rate of 20%, however the number of people sampled will be adjusted depending on 
response rates, the number of participants becoming eligible in each group and the available time in 







4. Participant recruitment 
 
Sub-study 1 
Eligible participants will be mailed an invitation letter, information sheet and consent and contact 
forms requesting a contact telephone number and convenient times to call, to be returned in a 
prepaid envelope. This process will be carried out via HIC as the contact details of ECLS study non-
responders are not known to the study team. The replies will be returned to HIC and any positive 
responses will be uploaded onto the recruitment tracker. The researcher’s telephone number and 
ECLS study team details will be provided for any queries. If a participant’s telephone number is 
available, a follow up call will be made by the researcher to confirm receipt of the mailing and 
answer any questions. If there is no answer, a voicemail message may be left or one further call 
attempt made at a different time. 
On receipt of a completed consent form and contact form participants will be telephoned by the 
researcher at a time they have indicated as being convenient. Verbal consent will be confirmed at 
the beginning of the call. Eligibility for the study will be confirmed and any questions from the 
participant will be answered. Should an individual indicate that they now wish to take part in the 
ELCS Study following contact regarding the sub-study, they will become ineligible for the sub-study 
and they will instead be telephoned by the ECLS Study research team as described in the main 
protocol. 
 
Sub-studies 2 & 3 
 
The researcher will send potential participants an invitation letter and a participant information 
sheet. The invitation letter will include a seven-day response deadline to ensure that the interview 
will take place as soon as possible of receipt of test result. Potential participants will be invited to 
indicate their interest in the research by completing a short form and posting it back to the 
researcher in the freepost envelope provided, or contacting the researcher by e-mail or phone. Once 
a response is received from a participant, the researcher will contact the participant by phone to 
arrange a date and time for their interview. During this phone call, the researcher will explain the 
details of the study and answer any questions that the participant has concerning study 
participation. An appointment letter or e-mail will be sent to the participant to confirm the date and 
time of their interview. The day before the interview, the participant will be contacted by phone, 
text, or e-mail as a reminder. If the participant is unable to attend the interview, but would still like 
to take part, then another interview will be arranged. 
 
[Please note: in order to maximise comprehension of study materials, readability of all participant 
documents has been tested using a readability programme. The participant information sheet layout 
and format was informed by the results of a study that applied the user testing method to improve 
the readability of a participant information sheet31. The participant information sheet (PIS) for study 
two was also piloted with three participants who matched those who will be eligible for recruitment 




5.1. Obtaining informed consent 
Sub-study 1. Potential participants will be sent PIS and informed consent form (ICF) with their letter 
of invitation. Contact numbers are given to contact the study team to answer any questions they 
may have. They are invited to send their reply and completed consent form in the prepaid envelope 
 
(to HIC). A copy of the ICF be kept by the participant and the original filed the study ISF. Prior to the 
telephone interview they will be asked to confirm their verbal consent. One consent form will be 
kept by the participant and the other kept by the researcher and filed in the ISF. 
 
Sub-studies 2&3.  At the start of each face-to face interview, participants will be provided with a 
copy of the PIS and informed consent form. They will be asked if they have any further questions 
concerning their involvement in the study and asked to sign the ICF.  If the interview is to be 
conducted by telephone, the ICF will have been sent in advance of the interview and the participant 
will be asked to return to the study team using the prepaid envelope. Prior to conducting the 
telephone interview verbal consent will be confirmed. The process for obtaining consent will be in 
accordance with the REC guidance and Good Clinical Practice (GCP). Two consent forms will be 
signed and dated by the participant and the researcher. A copy of the ICF be kept by the participant 
and the original filed the study ISF.  
 
5.2. Interview procedure 
It is estimated that each interview will take no more than an hour. All interview questions have been 
structured around the aims of each sub-study (see interview schedules below).  
 
Sub-study one 
Participants will take part in a semi-structured interview by telephone which will be digitally 
recorded. There is a precedent for using this method for the study of non-responders to cancer 
screening trials in previous research in the UK8, 32, 33. It is anticipated telephone interviews will be 
more acceptable and convenient than face-to-face interviews in a population of non-responders and 
this method has been used successfully in similar studies8, 32. An initial interview schedule can be 
found in the appendices and these questions will be developed further by the findings of additional 
pilot work and a qualitative meta-synthesis currently being undertaken. Approximately 20 interviews 
 
will be conducted, however recruitment will continue until no new themes emerge from the 
interviews. 
 
Sub-studies two and three 
The participant will be interviewed in a one-to-one semi-structured interview at their local facility 
(CRC/CRF, GP practice) or if required their home. They can also take part in the interview over the 
phone. The interview will be conducted in a location where it cannot be overheard. Only the 
researcher and the participant will be present at the interview, however, the participant will have 
the option to have someone with them if they would prefer. If the participant would prefer a home 
visit, where possible a study nurse will also attend but will not present at the interview unless invited 
by the participant. All interviews will be carried out by the researcher who will adhere to local 
policies of research fieldwork. Participants will be offered taxi transport or travel expenses to attend 
face-to-face interviews.  
 
5.3. Incentives 
Participants in all three sub-studies will be given a £5 gift voucher for use in a range of stores to 
thank them for their time. If they request it, participants will receive a lay summary of the findings of 
the study when it is complete. 
 
5.4. Withdrawal from each sub-study 
Participants may be withdrawn from each study either at their own request or at the discretion of 
the researcher. The participants will be made aware that they do not have to give a reason for 
withdrawing from the study and withdrawing will not affect their future care. Participants will be 




Interviews for all three sub-studies will be audio recorded, transcribed verbatim and analysed using 
thematic analysis. The process of thematic analysis will be informed by the following phases outlined 
by Braun and Clarke34 in their step-by-step guide to doing thematic analysis:  
1) Familiarising oneself with the data (i.e., transcribing and re-reading the data),  
2) Generation of codes (i.e., developing codes that identify key features of the data. This will be 
done using NVivo software),  
3) Searching for themes (i.e., sorting the codes into themes and gathering all the data relevant to 
each theme. Consideration will be given to how codes can be combined to form an overall theme) 
4) Reviewing of themes (i.e., checking the extracts for each theme, ensuring that they form a clear 
pattern, and developing a thematic map), and  
5) Defining and naming themes. 
 
An initial analysis of the data will be conducted by both researchers [LB & BY]. They will discuss the 
results of each analysis and a final thematic framework will agreed upon. A third researcher [RdN] 
will review the framework and results of both analyses. This procedure will enable a validation of the 
themes and provide an in-depth interpretation of the data.  The 18 and 24 month psychological data 
will be analysed by the forth researcher [MC]. 
 
7. Adverse events 
The occurrence of adverse events as a result of participation within these studies is not expected.  
However, the researchers are aware that certain questions will be of a sensitive nature, which 
participants might find distressing. Participants will be made aware that they do not have to answer 
all of the questions if they do not want to. The researchers will remind participants that they can 
withdraw from the study at any time without giving a reason. In the unlikely event the participant 
feels distressed by the interview; they will be signposted to local services for further support if 
required and to the ECLS study research team.  
 
 
8. Records and record retention 
All data will be stored in compliance with the Data Protection Act 1998 and in accordance with 
University of Dundee, Health Informatics Standard operating Procedures and the Universities of 
Nottingham and St Andrews Code of Research Conduct and Research Ethics (non-identifiable study 
management information only, dates of interviews etc). The researchers [LB, BY, MC & GO] will be 
responsible for maintaining all documents concerning the study. The database will be stored on a 
University of Nottingham password protected computer in a locked office at Queens Medical Centre 
and will only be accessible by the research team and a University of St Andrews password protected 
computer in a locked office (e.g., the researchers and research supervisors).  
 
Each participant will be assigned a unique study identity code number for use on their interview 
transcript. Transcripts and signed consent forms will be treated as confidential documents and held 
securely in accordance with regulations. Each transcript document will be password protected and 
will be stored on a password protected file on University of Nottingham server. Only members of the 
research team (e.g., the researchers and the research supervisors) will have access to interview 
transcripts. Audio recordings will be stored on an audio recorder in a locked filing cabinet. Once 
audio recordings have been transcribed, the recording will be deleted off the audio recorder. Signed 
consent forms will be kept in the study ISF in a locked filing cabinet in a locked office at Queens 
Medical Centre. In line with the University of Nottingham Code of Research Conduct and Research 
Ethics, data will be stored for seven years from the date of any publication that is based upon them.  
 
9. Data protection 
All members of the research team will adhere to the Data Protection Act, 1998. Study documents 
will contain only the minimum required information for the purposes of the study.  
 
 
10. Publication and Dissemination 
The results of the sub-studies will be used for publications in peer reviewed scientific journals, 
conference presentations and a PhD thesis. Participants will not be identified in any publications. 
 
11. Funding source 
The sub-studies are funded by Oncimmune Ltd, University of Nottingham and the Dundee Cancer 
Centre. 
 
Sub-study 1: Telephone Interview Schedule 
Please note: This is an interview guide. The questions posed will relate to this guide, but the exact 
questions will be formulated based on the individual’s responses to previous questions during the 
interview and on the basis of the preceding interviews with other participants. This iterative process 
is required when using qualitative methods to explore themes fully. 
 
It will have been established in the pre-interview screening call that the participant remembers 
receiving the ECLS Study invitation mailing and made a conscious decision to not respond to it. 
Preliminary data gathering tool 
 
At the start of the interview the researcher will ask the following structured questions as a 
preliminary data gathering tool. 
1. What is your age? 
2. Are you married/single/cohabiting? 
3. What is your current work situation? 
4. How would you describe your current health? Prompts: 
• Do you have any problems getting around? 
• Are you taking any medication? 
 
5. Have you ever been tested for any diseases, called a ‘screening test’? 
• For lung cancer? 
• For other cancers? 
• For other diseases? 
• If yes, why did you have the test(s)? 
• If no, why not? 
6. Are you a smoker? 
• If yes, how many cigarettes do you smoke per day on average and for how many years have 
you smoked? 
• If no, have you ever smoked? 
7. Do you have any family history of lung cancer? Or other cancers? 
• If yes, prompt to elaborate. 
 
Topic Guide for semi-structured interview 
Aim: To find out how the participant reacted to receiving the ECLS Study invitation letter/reminder 
1. When people receive a letter like this they often have many different thoughts and feelings. 
Please describe your thoughts and feelings when you received the mailing? When you received the 
invitation mailing for the Early Lung Cancer Detection Study, please describe how you felt about it? 
 
Prompts: 
a. Thoughts and feelings might be about the mailing itself, the screening test, the research 
study, lung cancer, your health in general or other information you read in the mailing 
b. They might be positive or negative thoughts or feelings 
c. They might be prolonged or brief thoughts or feelings 
d. How did you feel when you received the mailing? Why did you feel like that? 
 
e. What thoughts did you have when you read the letter? How did those thoughts make you 
feel? 
f. How did you feel 5 minutes after reading the letter and leaflet? Were you still thinking about 
it? If so, what were you thinking? 
g. How did you feel 24 hours after reading the letter and leaflet? Were you still thinking about 
it? If so, what were you thinking? 
h. How much of the letter did you read? 
i. How much of the leaflet did you read? 
j. Where did you put them? 
k. Did you show them to anyone else? 
i. What did they say about them? 
ii. How did this influence you? 
l. Did you discuss them with anyone else? 
i. What did they say about it? 
ii. How did this influence you? 
m. Did you try to find out any more information about the study? 
n. At what point did you decide you wouldn’t respond to the letter? What were your thoughts 
and feelings at that stage? 
o. What were your reasons for not replying to the letter? 
i. Too busy/unable to attend/could not read the letter? 
 ii. Worries about the test e.g. fear of needles? 
iii. Worries about lung cancer e.g. fear of the test being positive? 
iv. Invitation materials not good enough? 
v. Advice from others e.g. discussion with family or friends? 
vi. Previous experience of screening tests? 





Sub-study 2: Telephone Interview Schedule 
Aim: To explore understanding and knowledge of the information communicated in the ECLS 
Study invitation mailing 
2. The blood test offered to you is a new test. It can sometimes be difficult to understand what 
a test like this does and what the result means. It is important for us to see what people understood 
from the information they read. Please tell me everything you understand about the test you were 
offered. Tell me as much as you can and if you don’t know or you are unsure, it’s fine to say so. 
 
Prompts: 
a) What do you understand about what the test does? 
b) What do you understand about how the test is done? 
c) What do you understand about how good is the test at finding lung cancer? 
d) What do you understand about the risks of having the test? In other words, any bad things 
that could happen? 
e) What is your understanding of what it means if somebody gets a positive test result? 
 
Aim: To explore thoughts about how the ECLS Study invitation materials could be improved. 
3. If you were in charge of writing to people to ask them to have the test, what would you think 
was important to put in the letter and leaflet? What would you change about the way you were 
invited and the invitation letter? 
4. Is there anything else you would like to tell me about what we have talked about? 
  
 
Sub-study 3: Telephone Interview Schedule  
Please note: This is an interview guide. The questions posed will relate to this guide, but the exact 
questions will be formulated based on the individual’s responses to previous questions during the 
interview and on the basis of the preceding interviews with other participants. This iterative process 
is required when using qualitative methods to explore themes fully. 
 
Aim: To explore changes in attitudes to smoking 
1) Before you joined the Early Lung Cancer Detection Study, how did you think and feel about 
smoking? 
2) Had you ever tried to stop smoking before you joined the study? If so, how did you find it? 
Prompts: 
a) How easy or difficult did you find it? 
b) Did you use a stop smoking support service or ask for any help to stop smoking? 
c) How long did you stop smoking for and how did you feel about that? 
3) How do you feel about smoking now? 
Prompt: 
a) If different from Q.1 – Why do you think your feelings have changed? 
 
Aim: To establish the decisions made regarding smoking cessation during the ECLS Study, the success 
of those decisions and explore the reasons for those decisions and the perceived barriers and 
facilitators to cessation. 
 
Questions are worded differently depending on whether the participant was successful at stopping 
smoking (‘Stopped’), unsuccessful at stopping smoking (‘Tried’) or made no attempt to stop smoking 
(‘No attempt’). 
 
4) Stopped: You told us you have stopped smoking since you had the lung blood test. Is this 
correct? 
Tried: You told us you have tried to stop smoking since you had the lung blood test but you didn’t 
manage to stop smoking. Is this correct? 
No attempt: Some smokers try to stop smoking and other people choose to carry on smoking 
without trying to stop. You told us you have not tried to stop smoking since you had the lung blood 
test and you are still a smoker. Is this correct? 
a) If not correct, clarify the decisions made to stop smoking and the success of those decisions 
i.e. stopped/relapsed/tried but didn’t stop. 
5) Stopped & Tried: Can you tell me about your decision to try/stop smoking? 
Prompts: 
a) Which method(s) did you use to try to stop smoking? 
b) How easy or difficult was it for you to try to stop smoking after the lung cancer blood test? 
c) What do you feel helped you to try to stop smoking?  
d) Which things did you feel did not help you to try to stop smoking? 
No attempt: What thoughts and feelings did you have about smoking after your lung cancer blood 
test? 
Prompts: 
a) Did the lung cancer blood test change your thoughts and feelings about smoking? If so, 
how? 
b) We know that some people find that having a lung cancer blood test makes them want to 
stop smoking but other people find that it doesn’t. It is important for us to understand why this is. 
Based on your experience of having a lung cancer blood test, why do you think this is? 
 
Aim: To explore thoughts and feelings about smoking cessation advice for lung cancer screening 
patients. 
 
6) Imagine you are having a lung cancer blood test for the first time, but this time everybody 
who has the test is given special advice and support about stopping smoking. How would this make 
you feel about smoking? 
Prompts:  
a) Would it make you think or feel differently about having the lung cancer blood test if you 
knew this was going to happen? If so, how? 
b) Would it make you think or feel differently about stopping smoking? If so, how? 
c) Would it change how confident you felt about being able to stop smoking? If so, how? 
d) Would it change your plans to stop or carry on smoking? If so, how? 
e) Would it make you more likely or less likely to have a repeat lung cancer blood test in the 
future e.g. five years time? And why? 
7) What type of special advice & support would you find most helpful, if it was given to you 
during a visit for a lung cancer blood test? 
8) Is there anything else you would like to tell me about the things we have talked about? 
Please note: This is an interview guide. The questions posed will relate to this guide but the exact 
questions will be formulated based on the individual’s responses to previous questions during the 
interview, and on the basis of the preceding interviews with other participants. This iterative process 
is required when using qualitative methods to explore themes fully.   
 
1. Since your lung cancer blood test, have you had any other tests for lung cancer? 
 
2. Before you had the lung cancer blood test, what were you told about it? 
 
3. How satisfied were you with the information you received about the test? 
 
 
4. Since you have had other tests for lung cancer, how has your understanding about this lung 
cancer blood test changed? (Question 4 is for participants in the EarlyCDT-positive group who have 
had further tests for lung cancer). 
 
5. If somebody asked you what having the lung cancer blood test was like, how would you describe it 
to them based on your experience?  
 
6. How do you think lung cancer is found in the blood? 
 
7. If somebody asked you to tell them about the letter you got about your lung cancer blood test 
result, how would you describe it to them? How satisfied were you with this letter, in terms of giving 
you the information you needed to understand the test results. (Question 7 is for participants in the 
EarlyCDT-negative group) 
 
8. If somebody asked you to tell them about the appointment when you were given your lung cancer 
blood test result, how would you describe it to them based on your experience? (Question 8 is for 
participants in the EarlyCDT-positive group) 
 
9. Your lung cancer blood test result was negative. What does a negative blood test result mean to 
you? (Question 9 is for participants in the EarlyCDT-negative group) 
 
10. Your lung cancer blood test result was positive. What does a positive blood test result mean to 
you? (Question 10 is for participants who received a positive test result but have not yet had further 
tests for lung cancer) 
 
 
11. Since you have had other tests for lung cancer, how have your thoughts about your lung cancer 
blood test result changed? (Question 11 is for participants who received a positive test result and 
have had further tests for lung cancer) 
 
End of interview 
 
• We have now come to the end of the interview. Before I switch off the recorder, is there 
anything else that you would like to tell me?  
 
General prompts to use throughout interview: 
 
- Can you please tell me more about that … 
- How has that changed … 
- Can you give me an example of … 
- What is your understanding of … 
  
 
APPENDIX 3: ECLS STUDY: START RECRUITMENT SUBSTUDY (Version 1, 6/1/2014) 
 
MRC START in ECLS: What are the effects of a re-written and re-designed Participant Information 
Sheet?  
 
NB: This sub-study was implemented when the recruitment target was 10,000 from NHS Tayside and 
NHS Glasgow. This study is now complete.  
1. Background 
In the UK, the NIHR vision sees ‘more patients and health professionals participating in health 
research’ *1+. Fundamental to health research is the testing of interventions through Randomised 
Controlled Trials (RCTs). Achieving high participation in RCTs has traditionally been difficult. 
Published data show that a minority of RCTs recruit successfully [2,3]. Recruitment problems reduce 
the total recruited sample (limiting internal validity), and the proportion of eligible participants who 
are recruited (limiting external validity). They can increase the cost of the study and delay the 
results. In extreme cases, poor recruitment can result in the cancellation of a trial. 
 
Clearly, there is a need to develop and test interventions to improve recruitment, and one method is 
to ‘nest’ trials of recruitment interventions in ongoing RCTs. Given the consensus among the 
research community concerning the challenge of recruitment, it is surprising that nested trials of 
recruitment interventions are so rare. Two recent reviews identified only 14 nested studies in real 
trials [4] and 27 overall [5]. Recruitment for science is not underpinned by a science of recruitment.  
 
The MRC START study is designed to develop the conceptual, methodological and logistical 
framework for nested studies, and to assess their feasibility. At the completion of MRC START, we 
will have rigorously tested two potential interventions for adoption in to routine practice (improved 
participant information sheets (PIS), and a multimedia decision aid), and provided the framework to 
 
make delivery of nested recruitment RCTs a routine activity. This will assist the rapid development of 
recruitment to meet policy goals [12].  
The Early Cancer Detection Test – Lung Cancer Scotland (ECLS) is acting as a host trial to test an MRC 
START recruitment intervention. This protocol details the work that will be undertaken for the ‘MRC 
START in ECLS’ sub-study. 
 
2. The intervention – Participant information sheets 
Research has reported patients’ rather patchy understanding at the end of a trial, such as one in five 
participants not knowing the name of the medicine being tested [6] and similar proportions not 
knowing that they could withdraw at any time [7]. These findings are confirmed by a systematic 
review of consent in cancer trials [8] in which aspects such as treatment risks and benefits and the 
right to withdraw consent, were found to be not well understood. The review concluded that 
“patients do not appear to be adequately informed” (p.304). A lack of participant knowledge might 
result from the difficulty in understanding complex information, such as randomisation [9], or 
because of the way the Participant Information Sheet (PIS) is written. The level of literacy required 
to understand a study PIS is often higher than that found within the general population [10], and 
poor information provision may particularly affect older or less educated patients [11].   
One promising approach to improving the quality of the written information provided is to develop 
the PIS through formal User Testing. In this process people in the target group for the trial read the 
PIS and are then asked to find and show an understanding of key information contained in the sheet. 
Any identified problems are rectified by the use of clear writing and by changing the way the PIS is 
laid out and designed. Further User Testing then tests whether the changes have led to 
improvements to the way the PIS performs. Three small, recent studies suggest that a combination 
of re-writing, design and testing results in a PIS that works much better to inform potential trial 
participants and which they prefer [13, 14, 15]. These studies have involved hypothetical settings, 
with participants being asked to imagine themselves being recruited to a trial, and what remains 
 
unknown is the effect of such changes to the PIS in actual trials. In particular, does an improved PIS 
impact on either of the quality of informed consent and the rate of recruitment? 
 
3. Host study details 
The ECLS trial will evaluate a new test (Early CDT) for lung cancer as part of a potential Scottish lung 
cancer screening program. The ECLS Trial needs to recruit at least 10,000 participants, chiefly from 
around Glasgow and Dundee.  A key recruitment route will be through postal invitation, which opens 
up the possibility of using the trial to test MRC START user tested patient information. 
 
The trial is being managed by Tayside Clinical Trials Unit (TCTU) and the trial management team at 
TCTU has developed a PIS presented in booklet form and referred to in this trial as a participant 
information brochure PIB.  Recruitment consists of the following steps: 
1. Potential participants are identified by SPCRN staff from practice lists.  
2. Potential participants are sent a GP letter of invitation and a PIB 
3. Those responding positively to the invitation (via reply slip, text, email or phone) are then 
screened for eligibility for the study. Those eligible and consenting are recruited. 
 
ECLS, along with the TCTU PIB, has received ethical approval from the East of Scotland Research 
Ethics Service REC 1, reference 13/ES/0024.   
A revised PIB and GP covering letter will be developed by the MRC START team (Dr Peter Knapp) 
through User Testing. The content of the original PIB will be retained but it will be re-written and re-
designed based on the outcomes of the User Testing process.  
Potential participants to the ECLS trial will be randomised to receive either the original or the user-
tested PIB and GP invitation letter. It would be useful to know if the revised PIB and covering letter 
impact on rate of recruitment in comparison with the original PIB. A nested RCT would be the best 
approach to evaluate its effects.  
 
4. Research Objectives 
1. To measure differences in those expressing an interest in participating in the ECLS study as a 
result of receiving a participant information brochure and covering letter 
2. To establish if the number of patients recruited in to ECLS is improved by the use of a 
participant information brochure and covering letter developed through User Testing, 




The proposed study will use an RCT design. Patients identified from GP lists will be randomly 
allocated to one of two conditions:  
a) Control PIB: the original ECLS participant information brochure and covering letter (approved in 
13/ES/0024 on 16/4/2013);  
b) Intervention PIB: the user tested participant information brochure and covering letter (approved 
on [Date] by EoSREC REC 1).  
 
5.2 Inclusion / exclusion criteria 
All individuals approached by the ECLS host trial are eligible for this nested recruitment intervention 
study. 
 
5.3 Recruitment and Randomisation 
SPCRN will search practice lists for patients eligible for invitation to participate in the ECLS study. 
Potential participants identified from GP lists as eligible will be randomly allocated to receive the 
control or intervention PIB and covering letter in a 1:1 ratio.  The randomisation will use a list of 
random numbers from http://www.random.org/sequences/ with management of random allocation 
being done by SPCRN staff.   
 
Each potential participant will be allocated a cohort number (from the central patient management 
system). 
Potential participants can express and interest in the ECLS study in a number of ways: 
• By returning a reply paid slip to the central patient management system who notify the 
research team 
• By email to the research team 
• By text (to the research team) 
• By phone to the research team 
In each instance the patient cohort number will be recorded.  
Anonymised data on numbers of respondents and PIS version will be sent to the MRC START team. 
 
5.4 Control 
The control PIS is not a plain text document but is formatted in a more attractive way.  It was not, 
however, developed in a systematic way but relies on the experience of TCTU staff. One of the MRC 
START investigators, Shaun Treweek did proof-read the content of the control PIS in his former roles 
as Assistant Director of TCTU and co-investigator on ECLS.  None of the other MRC START 
investigators were involved in the development of the original PIS. This PIS is 32 pages in length and 
was approved by The East of Scotland Research Ethics Committee REC1 on 16th April 2013, reference 
13/ES/0024, as part of the application to conduct the ECLS study. 
 
5.5 Intervention 
The revised PIS will contain the same content as the original version but will differ in the way that 
the information is laid out, written and presented. It will be developed through User Testing with 
members of the public selected to reflect the target patients for the PIB, who will read and then be 
asked to find and show an understanding of key facts contained in the PIB. The testing will be 
undertaken in several rounds: the first round testing the original PIB; then several rounds with 
 
different iterations of the revised PIB until we were confident that the PIB could perform well to 
inform potential trial participants. 
 
5.6 Outcome measures 
The primary outcome will be the number of patients recruited to the ECLS trial from each of the PIB 
arms.  
Secondary outcomes will be:  
1. The proportion of patients expressing an interest in participating in the ECLS study in 
response to each version of the PIB and covering letter 
2. The proportion of recruited patients who complete the ECLS screening process from 
each of the PIB arms. 
 
6. Statistical considerations 
6.1 Sample size 
MRC START in ECLS is powered to detect a significant improvement in recruitment rate, defined as 
an absolute increase of five per cent above baseline.  Baseline response rates for the first five ECLS 
practices are around 20% (2/12/2013).  Ineligibility, difficulties contacting people etc reduces the 
20% response rate to a recruitment rate of around 14%.  The recruitment rate is the key rate for the 
MRC START project.  A range of samples sizes at 80% power and alpha 0.05 for a 5% minimum 







Response rate (%)  Recruitment (%) 
TCTU PIB START PIB 
Sample size 
(per arm) TCTU PIB START PIB 
Sample size 
(per arm) 
17 22 1970 (985) 11 16 1466 (733) 
20 25 2188 (1094) 14 19 1728 (864) 
23 28 2384 (1192) 17 22 1970 (985) 
 
Based on this table, we will have a sample size of 2000 invitations.  
 
6.2 Analysis 
Anonymised and aggregated recruitment data (ie. the number of potential participants sent each PIB 
and covering letter,  the numbers expressing an interest in participation, recruited to ECLS and 
completing the screening from each group) from ECLS will be sent to the MRC START team in 
accordance with the MRC START data sharing agreement (see Section 12). 
The proportion of participants who express an interest in the study, who are recruited in to the 
study and who complete the screening process will be calculated for the two groups (control and 
intervention PIB). The difference between the two proportions will be calculated along with the 
corresponding 95% confidence interval.  
 
Results from this trial will ultimately be combined in a meta-analysis with response rate data from 
other host trials participating in the MRC START programme. 
 
7. Ethical issues 
Patients will not have the opportunity to give informed consent to enter into the nested recruitment 
study. This has been approved by NRES Committee Yorkshire and the Humber – South Yorkshire 
 
(REC Reference 11/YH/0271) on the basis that the nested study is not withholding information – just 
changing the way it is presented. 
The nested study (MRC START in ECLS) will be registered by the ECLS trial as a sub-study on 
Clinicaltrials.gov 
 
8. Financial and Insurance Issues 
The user testing for the nested trial is funded as part of MRC START which is sponsored by the 
University of Manchester. It forms a sub-study to the ECLS study, which is co-sponsored by the 
University of Dundee and Tayside Health Board. Normal NHS indemnity procedures will apply. 
 
9. Project Timetable 
Date  Action 
Jun 2013 Documentation for the nested study agreed & signed off 
Jun/July 2013 User Testing of original PIB and development and testing of revised PIB 
Jan 2014 Submission to REC of application for substantive amendment  
Feb/Mar 2014 Recruitment to the nested trial begins 
May/Jun 2014 Recruitment to the nested trial ends  
Jun/Jul 2014 Data cleaning and submission of data set to MRC START team 
Jul 2014 Collation of results and analysis, begin write up of trial level paper 
 
10. Dissemination of research 
The results of this nested sub-study will be published in a peer-reviewed journal to further improve 
the evidence base regarding effective recruitment strategies in trials. This publication will be led by 
 
the ECLS team. In addition the data will be included in a meta analysis of all studies recruited to the 
MRC START programme led by the MRC START team. Dissemination of research findings will be 
conducted in line with the MRC START authorship arrangements (see Section 13). 
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12. MRC START Data Sharing Agreement 
 
 
MRC START Data sharing agreement 
This document specifies the data management and data sharing agreement between the MRC START 
study and the ECLS study.  
In this document, the ‘START research team’ refers to researchers named on the protocol. ‘START 




MRC START roles and responsibilities 
ECLS team agrees to: 
(a) Randomly allocate a proportion of patients participating in ECLS to receive either the 
standard participant information brochure or the user tested patient information brochure. 
Both baseline response rates and baseline recruitment are uncertain at this point. A range of 
samples sizes at 80% power and alpha 0.05 for a 5% minimum important difference between 
the Tayside Clinical Trials Unit (TCTU) PIB and the MRC START PIB have been calculated and 
the final sample size for the MRC START sub-study will be determined by the response rate 
achieved in the early stages of the ECLS recruitment as per the MRC START in ECLS protocol. 
(b) Randomise patients to either the recruitment intervention using random number generation 
within the SQL software used for the ECLS patient management system. 
(c) Collect data on the numbers of patients approached using each recruitment method, and 
data on the numbers recruited to the trial, and the number retained at each follow up point 
as follows: 
a. Expressing interest (responding to either PIB) 
b. Attending screening 
c. Being consented in to the trial 
d. Completing the trial 
(d) Provide collected data in an anonymised form (labelled data set in SPSS or a data base 
suitable for import to SPSS) to the START research team for analysis by [target date for data 
collection tbc] 
(e) Not introduce the recruitment intervention in a non-randomised fashion during MRC START 
(f) Seek permission from the MRC START research team to introduce them after the end of the 
MRC START study period. 
It is possible that host trials may wish to withdraw from MRC START before the end of the study. In 
this case, data collected up to that point would still be provided to the MRC START research team. 
 
Data Protection and publication issues in the START study 
The University of Manchester has strict guidelines for data storage, access to study data and 
adherence to the principles of data protection (including the Data Protection Act 1998). The link to 




Data Transfer Policy 
Datasets will be accepted from MRC START collaborators in electronic format (the University of 
Manchester can translate datasets in various formats through Stat Transfer). In addition, MRC START 
collaborators will provide written details of the coding of variables in the dataset to allow consistent 
analysis (see study protocol).  
All datasets will be anonymised by MRC START collaborators before transfer to the University of 
Manchester, removing all identifiable patient information such as names and addresses. Data may 
be encrypted before transmission to ensure security.  
 
Data storage 
Datasets from MRC START collaborators will be transferred to a combined database on a secure 
server at the Health Sciences Research Group, University of Manchester. All data received will be 
treated in the strictest confidence. Analysis of the data will take place by Professor Peter Bower and 
Professor Sandra Eldridge. Professor Bower will act as custodian for the combined dataset. The 
combined dataset will be stored by the University of Manchester in a secure location. Data from 






The NIHR School for Primary Care Research 
(http://www.haps.bham.ac.uk/primarycare/nspcr/index.shtml) comprises the leading academic 
centres for primary care research in England, with a focus on research to improve everyday practice 
in primary care. The MRC START research project is led by the Centre for Primary Care, Institute of 
Population Health, the University of Manchester (http://www.population-
health.manchester.ac.uk/research/primarycare/)  
 
13 MRC START Authorship Arrangements 
 
 
MRC START publications & authorship arrangements  
MRC START has the potential to generate a large number of publishable datasets, which will include 
nested trials of MRC START interventions run in single trials (‘single datasets’), and the combined 
datasets of MRC START interventions run in multiple trials (‘combined datasets’).   
This document describes the ground rules for publishing and authorship for applicants and 
researchers on the MRC START grant (‘START research team’) and researchers providing ‘host’ trials 
for the study (‘START collaborators’). 
 
Core Principles 
The core principle governing authorship are:  clear communication; no surprises; no waiting to 






1. All publications arising from the ‘combined datasets’ will include the START research team and 
representatives from START collaborators (normally host trial PI).  
a) Where START collaborators request more than one representative, nominations for 
authorship will be discussed among the START research team.  
b) Requirements for authorship are those of the International Committee of Medical 
Journal Editors (http://www.icmje.org/).  
c) If author numbers become excessive, papers may be authored under a collaborative 
name or a combination of named authors (START research team) and a group 
collaborative name (START collaborators) 
(http://www.councilscienceeditors.org/i4a/pages/index.cfm?pageid=3373).  
2. The START research team are keen to encourage publication from single datasets where 
possible. 
a) Publication of the final MRC START data takes precedence – we cannot delay 
publication, for example, to allow single datasets to be published first. 
b) We would expect that START collaborators would look for opportunities to involve 
members of the START research team as authors in publications arising from individual 
datasets, either as individuals or under a collective name.  
c) The START research team will be able to provide materials for papers on the 
development of the interventions, as well as general background and criteria for 
reporting standards in nested trials developed as part for the MRC START project. 
3. All other publications arising from MRC START (ie not based on the combined datasets) remain 
in the authorship of the START research team 
4. START collaborators need to sign up to the MRC START authorship arrangements. 
 
5. We will appoint an independent adviser to whom the START research team or START 
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APPENDIX 4: Sub Study 5: University Of Glasgow Mrc Phd Studentship.  
Exploring public perceptions of lung cancer screening  
Researcher: Hannah Scobie 
Supervisors: Dr Katie Robb, Dr Sara MacDonald, Professor Sally Wyke, Dr Stephen Harrow. University 
of Glasgow 




Lung cancer kills more people than any other cancer, with approximately 5,000 people dying from 
lung cancer every year in Scotland. This is often because there are few symptoms until the cancer is 
at an advanced stage when the chance of cure is low. Lung screening offers the potential to detect 
lung cancers at an earlier stage when they are easier to treat. A recent trial in the US found that lung 
cancer mortality decreased by 20% among those receiving low dose computed tomography 
screening (Aberle, Adams, Berg, Black, Clapp & Fagerstrom, 2011). However, the benefits of cancer 
screening are only realised if people are willing to participate. Cancer screening participation rates 
remain suboptimal (Audit Scotland, 2012), and may be particularly challenging in the case of lung 
screening. Smokers are disproportionately represented among people living in more deprived areas 
who also have lower uptake of other cancer screening programmes (Scottish Household Survey, 
2013). This means that the potential lung screening target population could be particularly hard-to-
reach. 
   
1.2 Proposed research 
The proposed research consists of two further sub-studies within the Early Cancer detection test – 
Lung cancer Scotland (ECLS) Trial.  The first sub-study will qualitatively investigate why individuals 
decided not to take part in the ECLS Trial, after showing initial interest. This study (Study 1) will 
 
involve interviewing ECLS Trial ‘non-attenders’ – those who initially expressed an interest in having 
the test, were appointed to be screened, but later decided not to participate. It is intended that up 
to a total of 20 men and women non-attenders in the ECLS trial will be interviewed. The sample will 
be drawn from the NHS Greater Glasgow and Clyde and NHS Lanarkshire Health Boards. 
 
The second proposed sub-study (Study 2) will be a quantitative analysis of ECLS Trial attenders 
examining potential demographic and psychosocial differences by recruitment type. Participants in 
the ECLS Trial were recruited by two strategies: i) those who were invited to take part via their 
General Practice (GP) or; ii) those who ‘self-selected’ after seeing community advertisement/media 
releases or responded as a result of word of mouth. This study will examine potential differences in 
the demographic characteristics, beliefs about lung cancer and lung cancer screening, subjective 
health and risk perceptions among these two groups.  
 
The proposed studies will complement the embedded psychological sub-studies currently being 
conducted by researchers at the University of Nottingham including: emotional and behavioural 
responses following screening; exploring why people declined to participate; understanding of 
screening results; and smoking cessation in participants of the lung screening Trial.  The proposed 
work therefore adds two new aspects to the ECLS Trial research by considering; i) why people 
change their mind about participating in the Trial; and ii) exploring any potential differences 
between participants recruited through GPs and ‘self-selecters’.   
 
2. STUDY 1 
2.1 Background & Literature Review 
While it is noted that participating in a screening Trial is not the same as participating in a screening 
programme, it is useful to draw from the literature on cancer screening programme participation in 
helping to understand screening behavior.  When participants make an appointment for cancer 
 
screening, it suggests they are motivated and intend to go to the screening appointment. However, 
this intention to attend does not always translate into action (i.e. attending the appointment) and 
‘did not attend’ (DNA) and cancellations are frequent outcomes at screening clinics (Sheeran, 2002). 
Within the psychological literature. Orbell & Sheeran (1998) used the term inclined abstainers. To 
describe people with positive intentions who fail to act. 
 
In the context of the present study, participants who initially make an appointment (positive 
intention), but go on to cancel or do not attend their appointment would be considered to be 
inclined abstainers. It is this group who are the primary interest of Study 1.  
 
Among the small number of studies on psychosocial barriers to lung cancer screening, cancer 
fatalism appears to play a significant role in uptake. A qualitative study in England exploring 
attitudes towards participation in lung cancer screening found themes of fatalism, worry, and 
avoidance in those who declined to be screened (Patel, Akporobora, Chinyanganya, Hackshaw, 
Seale, Spiro, & Griffiths, 2012).  This conclusion was also supported by a quantitative study in the US, 
where participants who had fatalistic beliefs about lung cancer were less likely to undergo screening 
(Jonnalagadda, Bergamo, Lin, Lurslurchachai, Diefenbach, Smith, Nelson & Wisnivesky, 2012). Other 
barriers to lung cancer screening included: denial of risk, shame about smoking, fears about 
screening and embarrassment (Walton, McNeil, Stevens, Murray, Lewis, Aitken & Garrett, 2013). 
 
Understanding the socio-demographic characteristics of attenders and non-attenders of cancer 
screening is crucial to ensure the introduction of a screening programme does not exacerbate health 
inequalities. For example, those from more deprived groups may be less likely to attend cancer 
screening (Weller & Campbell, 2009; Moser, Patnick & Beral (2009), but have a higher risk of cancer 
due to e.g. smoking, unhealthy diet, sedentary lifestyle. Other socio-demographic characteristics 
that may play a role in cancer screening attendance include age and gender.  
 
 
2.2 Potential Risks & Benefits 
Risks - This study is low risk, however there are a few areas to consider as potentially problematic.  
Study 1 (invitation Strategy 2) will involve writing to potential participants in some cases 6 months or 
more after they did not attend their appointment.  It is possible that individual circumstances may 
have changed within this time. In some circumstances it is possible participants may have passed 
away or become unwell.  As a result, Health Informatics (HIC) University of Dundee will check against 
the patients CHI number through NHS health records to see if participants are still alive. In addition, 
the Study 1, Strategy 2 invitation letter will include the sentence:  ‘We apologise if this letter arrives 
at a particularly difficult time for you.’ 
 
Another potential area of risk could be the topic of the study. We are discussing a health issue and 
cancer in particular, which might upset some participants. This will be avoided by reminding the 
participant that they are under no obligation to answer all of the questions and may stop the 
discussion at any point. Moreover, the interview will be flexible enough to allow participants to 
introduce information that they feel comfortable with. If the participant appears hesitant or in doubt 
about responding, the interviewer will give them some time to proceed, alter the question or move 
on.  Finally, we will provide the telephone number and email address of the researcher at the end of 
the interview in case participants wish to talk about any of the issues raised in the interview. If 
necessary the researcher will refer participants to one of the project supervisors to provided further 
information or support.  If required, the supervisor will provide details for professional organisations 
for people who feel they need to discuss issues further. 
 
Benefits –There are few potential benefits to research participants although in the past some 
participants in similar studies have reported enjoying the opportunity to take part in research. Those 
who participate in the interviews will be offered a £20 voucher as a token of appreciation for their 
 
participation (Appendix A). Participants will be required to sign for the voucher received at the end 
of the interview. If the participant wishes to withdraw from the interview at any point during the 
interview, the participant will still receive the voucher. 
 
2.3 Aim 
The aim of Study 1 is to explore the beliefs and perceptions about lung cancer and lung screening 
among people who initially expressed an interest in screening, were appointed to be screened, but 




2.4 Inclusion Criteria 
Participants are required to have been invited and subsequently been eligible to participate in the 
ECLS Trial. Further, participants will have shown initial interest in the study, but at a later time, 
declined to participate. See Table 1 for further details. 
 
2.5 Exclusion Criteria 
Participants who were invited to take part in the ECLS trial, and completed the study. Also, inability 
to speak, read or write English. The study involves understanding a Participant Information Sheet, 
completing a consent form and taking part in an interview in English. People who are unable to 
speak, read or write English will therefore be excluded most likely because they will not have 
responded to the initial invite to take part in the Trial.  See Table 1 for further details. 
Table 1: Study 1 Inclusion / Exclusion Criteria 
Inclusion Exclusion 
Invited to take part in the ECLS trial Inability to speak, read or write English 
 
Eligible to take part in ECLS trial on 
reassessment 
Individuals who contacted the team for 
information, but did not make an appointment 
Participants who made an appointment, but 
subsequently cancelled or DNA 
Individuals whose eligibility to take part in the 
ECLS trial was not established 
 
Participants who cancelled or DNA, but 
rescheduled another appointment for a later 
date and attended. 
 
2.6 Study Design 
Interviews will be conducted face-to-face in the participants’ own homes or at the University of 
Glasgow, or over the telephone, whichever is most convenient to the participant. Participants’ travel 
expenses will be reimbursed if they choose to come to the University of Glasgow. It is recognised 
that the researcher will be working alone. As a result, the University of Glasgow’s policy on lone 
working will be followed to ensure the safety of the researcher and participant. 
 
Participants will receive the Participant Information Leaflet and informed consent form with their 
letter of invitation by post before the interview is conducted. Contact numbers are given to contact 
the study team to answer any questions they may have. In the case of telephone interviews being 
the preferred interview format, participants are invited to send their reply and completed consent 
form in the prepaid envelope. Prior to the telephone interview they will be asked to confirm their 
verbal consent.  Participants will be offered the opportunity to ask any questions about the study 
before informed consent is taken by the researcher. The researcher will seek consent in the first 
instance. Interviews will last approximately 1 hour and will be based on a topic guide (Appendix B) 
developed from the existing screening literature with a particular focus on barriers to cancer 
screening. To avoid post-hoc rationalisations of their screening behaviour we will ask participants to 
 
discuss their general views on screening first before moving on to their personal experience. With 
the permission of the interviewee, interviews will be audio-recorded and transcribed verbatim. If the 
participant does not consent to be recorded, the participant can continue with the interview with 
the researcher taking detailed notes instead. Data from interviews will be anonymised during the 
transcription process. Thereafter paper copies of the transcripts will be stored in locked filing 
cabinets at General Practice & Primary Care, University of Glasgow. Interview transcripts will be 
assigned unique identifiers and any quotations that may be used with publications or reports will use 
the unique identifier. As such individual participants will not be identified.  
 
2.7 Researcher Effects 
Researcher effects will be kept to a minimum by using a topic guide to ensure participants are asked 
the same questions.  However, due to the nature of qualitative research, supplementary questions 
may vary depending on the responses of the participants. 
 
2.8 Duration of Participation 
Participants will be asked to take part in one qualitative interview lasting approximately one hour. 
The research team will not contact the participant again, although study results will be disseminated 
to the individual following completion of the study if requested. If participant request the study 
results, their name and address will be noted. Participants requesting the results will be mailed a 
summary of the main findings. The study results will also be disseminated through the normal 
academic channels, including, publications and conference presentations. 
 
2.9 Criteria for Discontinuation 
Study 1 involves a one off interview and this will be the only contact with the research team. If 
informed consent is taken at the time of interview and the participant completes the interview, the 
research team will have no further contact with the research participant. If a participant decides part 
 
way through the interview to withdraw from this study the data collected would be retained if 
permission is given. If no permission is given, the data will be withdrawn. 
 
If participants make an appointment with the researcher, and cancel or DNA the researcher will 
attempt to make contact again. Appointments will be rearranged up to three times. If a participant is 
unable to make the interview after the third attempt of rearranging an appointment they will be 
removed from the invitation list. 
 
2.10 Procedure for collecting data 
This will be a difficult group to engage, as a result, three recruitment strategies will be used:  
1a. It is normal practice that the ECLS study team call participants the day before their appointment 
as a reminder in an attempt to reduce the number of DNAs. If during this call a potential participant 
states they wish to withdraw from the Trial the study team will ask the participant if they would be 
interested in taking part in a research project for people who decide not to attend their 
appointment.  
If participants express an interest they will be asked if they agree for a member of the research team 
to contact them directly to provide more information about the research. The participant will be 
reassured if they wish to decline and no further contact will be made by the research team.  
 
1b. Within the ECLS Trial protocol, if a participant DNA, the study team will call the participant to 
offer a new appointment time.  If during this call the participant states they wish to withdraw from 
the Trial, the study team will ask the participant if they would be interested in taking part in a 
research project and the procedure would be as described in 1a.   
 
2) We will retrospectively identify and contact people who booked an appointment, accepted an 
appointment, but cancelled or DNA initially within the previous 12  months (i.e. 1 year from the 
 
commencement of the sub-study). If insufficient participants respond, we will contact people from 
the beginning of the Trial in Glasgow.  Participants will be identified from the Patient Management 
System used by the ECLS Trial. Eligible participants will be identified by the researcher, searching the 
additional text related to each case for key words such as, ‘cancelled’, ‘did not attend’ or ‘DNA’. 
Once participants have been identified, the Health Informatics Centre (HIC at Dundee University) will 
extract the names and addresses of those eligible. 
 
Participants will be contacted by post after they have been identified as a suitable candidate via HIC.  
Invitation letters will be sent out via a mail merge at HIC and those identified by HIC as having died 
will be excluded. Participants will be given a reply slip to return if they would like the researcher to 
contact them. Alternatively they can contact the researcher by telephone or email. The researcher 
will not know the identity of the participant until the reply slip stating that they wish to participate is 
returned. 
 
2.11 Data Protection 
When potential participants express an interest, contact details will be stored in a locked filing 
cabinet at the University of Glasgow.  Consent forms will similarly be stored in locked filing cabinets. 
Data from interviews will be digitally recorded and recordings will be uploaded to password 
protected university computers.  The recordings will be assigned a unique ID number rather than the 
participant name. Thereafter paper copies of transcripts will also be stored in locked filing cabinets 
at the University of Glasgow. Any direct quotations that may be used with publications or reports 
will use the unique identifier. As such individual participants will not be identified. Data will be 







2.12 Sample Size 
We will undertake interviews with a sample of approximately 20 ECLS Trial non-attenders. Based on 
previous literature, this is the likely number required to reach 'saturation' in terms of identification 
of new themes/ideas/issues. Based on previous experience, in order to obtain a sample of 20 
participants, around 400 people may need to be contacted although this may be less depending on 
the success of Strategies 1a and b. The study aims to interview a mix of males and females.  If 
possible a sampling frame will be used so the balance of gender reflects the ratio of men to women 
among the DNA group overall.  However, we anticipate that it will be challenging to obtain 20 
participants so this may not be possible.  
 
2.13 Method of Analysis  
The data will be analysed using the `framework approach´, a type of thematic analysis. Thematic 
analysis is a method for identifying, analysing, and reporting recurring patterns within data, which 
can then be reported in a detailed way.  The demographic characteristics of the participants 
including age, gender and Scottish Index of Multiple Deprivation score will also be described.  
 
3. STUDY 2 
3.1 Background & literature review 
The ECLS trial recruits participants in two distinct ways: i) invitation via GP or; ii) through community 
advertisement/ media releases/word of mouth and website review. As a result, it may be possible 
that there are sociodemographic and psychosocial differences between the participants who were 
invited by their GP and those who self-selected to participate. 
 
 
Previous research in lung cancer screening indicates that there are significant differences between 
participants who are invited to take part, and those who self-select. Participants in the US National 
Lung Screening Trial, who were recruited by the media, appeared to be younger, higher educated 
and less likely to be current smokers (NLST, 2010). Similarly, in the Dutch–Belgian Lung Cancer 
Screening Trial (NELSON trial), respondents to the initial invitation were somewhat younger, and less 
likely to be current smokers (van der Aalst et al., 2012).  
 
Similar results can also be found outside lung cancer screening trials. In the Oslo Health Study, 
respondents to community and media advertisement were associated with older age, higher 
education levels, 
Thelle, 2004). A secondary analysis of the Malmo Diet and Cancer Study concurs with the results of 
ns and personal 
invitations, Manjer et al. (2002) found that community respondents were older, and more often 
females, than participants recruited using personal invitations. Furthermore, participants recruited 
through community advertisement had a comparably more favourable situation with regard to 
sociodemographic and lifestyle factors. They also had a lower frequency of prevalent disease, lower 
incidence of cancer and lower mortality (Manjer, Elmsta, Janzon&Berglund, 2002).   
 
The present ECLS study will examine potential differences between the two invitation groups of the 
ECLS trial. This will assist with the future development of more efficient invitation strategies that will 
target the most high risk groups.  
 
3.2 Aim 
The primary aim of Study 2 is to explore if there are any sociodemographic or psychosocial 
differences as assessed by a baseline questionnaire between participants of the ECLS study who 
were invited by GP or self-selected through community advertising. 
 
Methodology 
3.3 Inclusion Criteria 
In order to be included within the statistical analyses, participants are required to have taken part in 
the ECLS trial, and completed the baseline study questionnaire.   
 
3.4 Exclusion Criteria 
Participants who took part in the ECLS trial, but did not complete the study questionnaire will be 
excluded from the analysis. 
 
3.5 Procedure for identifying participants 
Participants will be identified from the patient management system (PMS) used by the ECLS trial. 
Eligible participants for the analyses will be identified by their invitation type group (GP or self-
select). Once cases have been identified, the anonymised data required including demographic 
characteristics (age, gender, Scottish Index of Multiple Deprivation) and the responses to the 
psychosocial questionnaire will be extracted from OpenClinica.  Data will be extracted using 
participants’ cohort ID. 
 
3.6 Study Design 
The required anonymized data will be extracted from study data base; Open Clinica in order to 
complete the analysis. Data will be analysed at the University of Glasgow. The data will be 
transferred and stored as per the Data Sharing Agreement. The data will be analysed using Microsoft 
Excel 2010 and IBM SPSS version 21, provided by the University of Glasgow. 
Statistical Considerations 
 
3.7 Sample Size 
This sub study will analyse the data from all attenders of the ECLS Trial. 
 
3.8 Method of Analysis 
Statistical analysis will be conducted using IBM SPSS. Participants’ base-line data will be compared 
for the two groups of interest – GP invitation and self-selected. This will include demographic 
characteristics, beliefs about lung cancer and lung cancer screening, perception of general health 
and risk perception obtained from the baseline questionnaire.  
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APPENDIX 4A: ECLS Non-Attenders Interview Schedule (version 1, May 2015) 
 
Study Title: Understanding why people who are initially interested in lung screening fail to 
participate. 
1) General views about cancer screening 
What do they think about it, what do they feel about it 
How do they think people make decisions about whether to do screening –‘know’ as 
soon as invited/think it over/don’t know  
 
2) Beliefs about cancer in general and lung cancer 
Are they aware of spouse/family/friends taking part in screening? 
What comes to mind when you think about: 
i. Cancer? 
ii. Lung cancer? 
 
Following elicitation of participants’ beliefs about, ask how fearful participants are of cancer 
in general and lung cancer and whether they believe they (lung or other types) can be 
successfully treated (if these have not come up in response to the first questions). 
 
3) Understanding of the lung screening test 
What comes to mind when you think about lung cancer screening? 
Following the elicitation of image, ask them to explain how they would explain this  image 
and why they had it.  
What is their understanding of what the test involves?  
What is their understanding of the purpose of the test – detection/prevention? 
 
 
4) Personal decision about lung cancer screening participation (show example invitation 
letters and leaflets to prompt memory) 
Do they remember receiving an invitation for the screening test? 
As best they can remember, when invitation letter arrived in the post how did they think, 
how did they feel? 
How did they decide what to do next?  (e.g. Knew right away what they’d do/thought it 
over/don’t know/remember) 
What did they do next?  (e.g. Acted immediately, acted after a reminder, forgot, changed 
mind, didn’t get round to it.....) 
Did other things happening in life at the time influence decision?   
What did they think when decided not to attend the lung screening appointment?  How did 
they feel about it?  Were other things happening in their life that influenced their decision?  
 
5) Feelings of risk lung cancer 
What do they feel about their chances of getting lung cancer?  Do they feel equally at 
risk/not at risk/higher risk for lung cancer compared to other types of cancer? Do they feel 
their chances of getting lung cancer is the same or different for other types of cancer? Why?  
Who do they think would be at high risk of getting lung cancer and why? 
 
Conclusion 
Thank participant for time 
Is there anything else you would like to add that we might have missed out? 
  
 
APPENDIX 5. Sub-Study 6: Is there a difference in the emotional, cognitive and behavioural 
response to a positive earlyCDT test if pulmonary nodules are present on a chest computed 
tomography compared to a normal chest computed tomography?  
 
Researchers  
Dr. Marcia Clark (Primary Care, University of Nottingham) 
Prof. Denise Kendrick (Primary Care, University of Nottingham) 
Prof. Kavita Vedhara (Primary Care, University of Nottingham) 
 
Background:  
In the United States, it is estimated that every year hundreds of thousands of pulmonary nodules are 
detected following computed tomography (CT) examination of the chest [1].  With the increasing use 
of CT scanning for high risk individuals, the often incidental finding of pulmonary nodules is only 
going to rise.  Indeed, it is thought that pulmonary nodules are detected in 20-50 % of individuals 
who undergo CT screening [2].  In the United States, the National Lung Screening Trial showed that 
the incidence of pulmonary nodules was 25.9 % in participants with a pack year history of at least 30 
years [3].  Whilst the vast majority of pulmonary nodules are benign, the National Lung Screening 
Research Team found that in 1.1 % of cases they were cancerous [3].   
 
The Early Cancer Detection Test - Lung Cancer Scotland Study (ECLS study), is currently assessing the 
effectiveness of using a blood test, which detects autoantibodies to tumour antigens (EarlyCDT-Lung 
test), in high risk individuals.  Those with a positive EarlyCDT-Lung test undergo 6-monthly serial CT 
scans of their chest.  Since it is only those with a positive test that have a subsequent CT scan, this 
test will potentially reduce the number of high risk individuals who undergo CT scanning.  Despite 
this it is probable that a significant number of individuals will be found have to incidental pulmonary 
nodules following their CT scan.   
 
 
Previous studies, although limited, have found that a diagnosis of pulmonary nodules can have a 
negative impact [4-7].  Slatore and colleagues assessed the psychosocial effect that an incidental 
finding of pulmonary nodules had on a group of veterans from Portland, Oregon [4, 5].  They 
employed qualitative interview methods and found that the presence of pulmonary nodules was 
associated with distress [4, 5].  Although this distress decreased with time, some veterans were 
noted to have increased levels at the time of their follow-up CT scans (1 and 2 years after their 
original diagnosis) [4, 5].  Their findings are supported by work completed by Weiner, who found 
through the use of focus groups (participants were undergoing pulmonary nodule surveillance with a 
median time since diagnosis of 10 months), that a diagnosis of pulmonary nodules results in 
frustration and fear [7].  The participants’ fear was related to their perceived risk of cancer and 
whilst in some this fear diminished with time, there were participants (particularly those with a 
family history of cancer) who continued to experience a negative emotional response [7].  
 
To the investigators best knowledge, there have not been any studies investigating the emotional, 
cognitive and behavioural effect of a diagnosis of pulmonary nodules following a CT scan within a 
United Kingdom population.  In addition, the majority of studies are qualitative in nature.  This study 
aims to address this knowledge gap through the use of validated quantitative health outcome 
measures.  Based on previous studies, the investigators hypothesise that participants of the ECLS 
study who are diagnosed with pulmonary nodules, will have adverse emotional, cognitive and 
behavioural responses compared to those who have a normal CT scan.        
 
Objective: 
To determine whether the short and long term emotional, cognitive and behavioural response to 
having a positive early CDT test differs between participants diagnosed with pulmonary nodules on 




Participants and Procedure 
Study participants will be taken from the EarlyCDT-positive group who participated in the emotional 
and behavioural outcomes study and completed the baseline questionnaire and at least one follow-
up questionnaire at one, three or six months post recruitment.  It is estimated that approximately 
150 participants in this group have had a chest CT that shows the presence of pulmonary nodules 
that are 8 mm or less in diameter (coded 1b on the ECLS Radiology Schema).  A comparison group 
will comprise the remaining participants in the EarlyCDT-positive group with a normal chest CT 
(coded 1a on the ECLS Radiology Schema).  Data collected from the questionnaire study will be 
compared between the pulmonary nodule and normal chest CT groups at baseline, 1, 3 and 6 
months.  The emotional outcomes of interest will be EQ5D, positive and negative affect schedule 
(PANAS), health anxiety subscale of health orientation scale (HOS), lung cancer worry scale (LCWS) 
and impact of events scale.  The revised illness perception questionnaire - lung cancer (IPQ-LC) and 
lung cancer risk perception will be used to determine the cognitive response.  Differences in 
behavioural response will be assessed using smoking behaviour and health utilisation data.  
 
Analysis 
Continuous data will be described using means and standard deviations or medians and interquartile 
ranges, depending on the distribution.  Box and whisker plots will also be used to graphically display 
the differences between the pulmonary nodule and normal chest CT groups.  Histograms will be 
used to illustrate discrete data.   
 
Baseline characteristics of participants with and without nodules will be compared using 2-sample t-
tests or Mann Whitney U tests as appropriate for continuous data and chi-squared tests for 
categorical data.  Outcomes at 1, 3 and 6 months will be compared between participants with and 
 
without nodules using multilevel linear (for continuous outcomes) or logistic (for binary outcomes) 
regression.   
 
Two-level models will be used with observations at level one and participants at level two.  Analyses 
will:  
(a)  Adjust for baseline values of outcome variables.  
(b)  Adjust for baseline values of outcome variables, plus variables used in the minimisation for 
the ECLS trial (age, sex, smoking history, socio-economic status and practice).  If appropriate, 
practice will be adjusted for as a random effect rather than as a fixed effect. 
(c) Adjust for baseline values of outcome variables, plus minimisation variables, plus a prior 
defined confounder (educational level, family history of lung cancer, taking antidepressants) 
and variable imbalances at baseline. 
 
All data will be stored in compliance with the Data Protection Act 1998 and in accordance with 
University of Dundee, Health Informatics and TCTU Standard Operating Procedures and the 
University of Nottingham Code of Research Conduct and Research Ethics (non-identifiable study 
management information only, dates of interviews etc.). The researchers will be responsible for 
maintaining all documents concerning the study. The extracted data will be stored on a University of 
Nottingham on a password protected computer in a locked office at Queens Medical Centre and will 
only be accessible by the research team (e.g., the researchers and research supervisors).  
 
Each participant will be assigned a unique study identity code number for use on their interview 
transcript. Transcripts and signed consent forms will be treated as confidential documents and held 
securely in accordance with regulations. Each transcript document will be password protected and 
will be stored on a password protected file on University of Nottingham server. Only members of the 
research team (e.g., the researchers and the research supervisors) will have access to interview 
 
transcripts. Audio recordings will be stored on an audio recorder in a locked filing cabinet. Once 
audio recordings have been transcribed, the recording will be deleted off the audio recorder. Signed 
consent forms will be kept in the study ISF in a locked filing cabinet in a locked office at Queens 
Medical Centre. In line with the University of Nottingham Code of Research Conduct and Research 
Ethics, data will be stored for seven years from the date of any publication that is based upon them.  
 
Data protection 
All members of the research team will adhere to the Data Protection Act, 1998. Study documents 
will contain only the minimum required information for the purposes of the study. 
The results of this study will be disseminated at conferences and published in peer-reviewed 
journals.  A summary of our findings and recommendations will be produced for dissemination to 
clinicians, professional bodies and the UK National Screening Committee. A plain English summary of 
our findings will be published on the ECLS study website for participants to access.  This will also be 
made available to relevant lung cancer charities.          
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APPENDIX 6. Living with lung nodules: what information would patients find helpful? 
 
Investigators: 
Dr. Marcia Clark (Primary Care, University of Nottingham) 
Prof. Denise Kendrick (Primary Care, University of Nottingham) 
Prof. Kavita Vedhara (Primary Care, University of Nottingham) 
Prof. Roshan das Nair (Rehabilitation & Ageing, University of Nottingham) 




Pulmonary nodules are widely defined as round lesions within the lung that are less than 3 cm in 
diameter and entirely surrounded by normal lung tissue [1, 2].  It is estimated in the United States, 
that every year at least 150,000 individuals with pulmonary nodules are detected following 
computed tomography (CT) examination of the chest [3].  Pulmonary nodules are found in 20-50 % 
of high risk individuals who undergo CT screening [1].  It is anticipated that the UK incidence of 
pulmonary nodules is going to increase in light of the possibility of lung cancer screening for high risk 
individuals.   
 
The Early Cancer Detection Test - Lung Cancer Scotland Study (ECLS study), is currently assessing the 
effectiveness of using a blood test (EarlyCDT-Lung test), which detects autoantibodies to tumour 
antigens in high risk individuals.  Those with a positive EarlyCDT-Lung test will then undergo 6-
monthly serial CT scans of their chest for two years.  The resultant CT scans are reviewed and coded 
according to the ECLS Radiology Schema.  Participants of the study who are found to have 
pulmonary nodules less than 8 mm in diameter (coded 1b) are sent a letter informing them of this 
result and are advised to contact the study team should they wish to discuss their result further.     
 
 
Previous studies, although limited, have found that a diagnosis of pulmonary nodules can have a 
negative impact, causing distress, frustration, fear and reduced health-related quality of life [4-7].  A 
systematic review by Hagerty showed that amongst cancer patients the manner and quality in which 
their diagnoses are communicated impacts on the patient’s subsequent emotional and behavioural 
response [8].  For physicians, communicating an incidental finding of pulmonary nodules to 
individuals can also be challenging. This is especially in light of the fact that a study by Golden and 
colleagues found that primary care physicians in America felt that they did not have adequate 
information from their respiratory colleagues to communicate the incidental finding effectively to 
their patients [9].  It has been shown for breast cancer screening that women who receive their 
results by letter have a lower level of understanding and satisfaction than those who receive their 
result in person or over the telephone [10].  Despite this, screening results of screening programmes 
(e.g. breast, cervical, colorectal cancer screening) in the United Kingdom are communicated in 
writing in a manner similar to the ECLS study.  It is therefore imperative that the results letter sent 
provides adequate information in order to minimise any negative impact that a diagnosis of 
pulmonary nodules could potentially have. 
 
The aim of the study is to explore the ECLS study participant response following receipt of a letter 
informing them that their CT scan showed a pulmonary nodule.  The letter currently used in the trial 
is based on that used in routine clinical care.  It is important to explore patient’s experiences 
following receipt of the letter to inform any roll out of lung cancer screening as a national 
programme.  Through the use of focus groups the existing letter will be reviewed and, if deemed 








1) Develop an understanding of the current participant experience following receipt of the 
letter informing them that they have a diagnosis of pulmonary nodules.  This will be 
achieved by answering the following questions: 
a. What was the participant’s emotional response on receipt of the letter? 
b. What was the participant’s initial and subsequent behavioural response to receipt of 
the letter? 
c. What is the participant’s understanding of pulmonary nodules and their relationship 
to lung cancer? 
2) How can the provision of information following a diagnosis of pulmonary nodules be 
optimised? 
3) What is the participant response to the modified information letter?  
 
Methods: 
The objectives of this study will be achieved through the use of four different focus groups.  Groups 
1 and 2 will focus on the current experiences of the ECLS trial participants and will seek to address 
objectives 1 and 2.  Groups 3 and 4 will seek to address the third objective.  Each focus group will 
have a maximum of 8 participants; this number has been chosen to balance the ability of managing 
the group with the production of high quality data [11].  It is anticipated through the use of focus 
groups that data will be generated that reflects a variety of opinions, whilst respecting what could 
potentially be a sensitive topic [12, 13].   
  
Focus Group Participants 
Eligible participants will be: 
 
 Recruited to the ECLS trial and given consent to be contacted for future research. 
 In the EarlyCDT-positive group and have been informed by letter that they have lung nodules 
on their study CT.  A range of participants will be selected with different times since 
diagnosis of their lung nodules. 
 Able and willing to give informed consent for participation in the study. 
 
Focus Group Recruitment 
It is intended that a diverse range of participants are recruited with different demographic 
backgrounds in order to obtain a good variation of views and experiences.  Maximum variation 
sampling will therefore be employed with the demographics of the participants in focus group 1 
analysed prior to recruiting the second.  This process will be repeated for focus groups 3 and 4.  The 
demographic factors considered relevant to this study include age, gender, smoking history, GP 
practice location, level of deprivation (from the Scottish Index of Multiple Deprivation), educational 
level and time since diagnosis of a pulmonary nodule. 
 
Participants that fit the eligibility criteria will be identified from the ECLS study databases (baseline 
questionnaire and CT result).  Letters will be sent to eligible participants who have previously agreed 
to be contacted for future research, with a participant information leaflet, consent form and a 
response slip indicating their interest and availability for participating in the study.  On receipt of 
their response slip a researcher will contact the participant by telephone, and describe the study to 
them, answer any questions they may have and ask if they are still happy to participate in the study.  
If they are, they will be advised of the date, time and venue of the focus group.  In addition, they will 
be asked demographic information including their marital status, work situation and smoking 
history.  Non-responders will be sent a reminder letter 14 days after the initial letter.  Further letters 
will be sent to potential participants until an adequate number have been recruited.  Participants 
will be reminded of the focus group one day prior to the date by a phone call from a researcher.   
 
 
Focus Group Logistics 
There will be four focus groups in total.  Focus groups 1 and 3 will be conducted in Glasgow.  Focus 
groups 2 and 4 will be conducted in Dundee.  Glasgow and Dundee have been chosen as the ECLS 
study recruited participants from these two locations.  It is anticipated that community venues will 
be used, with each focus group being facilitated by two researchers; one will act as the moderator 
facilitating the group and the other as observer taking notes.  Refreshments will be provided. 
 
Procedure 
Prior to the focus groups commencing, written informed consent will be obtained from each 
participant.  A copy will be sent to the participant after the event, a copy to their GP (with consent) 
and one filed in the ISF. They will be advised that the session will be audio recorded, with a verbatim 
transcript generated of the discussion held, which will be anonymised.  The basis of each focus group 
will be centred on the relevant objectives as outlined above and structured according to the focus 
group guide (see below).  At the end of each of the focus groups participants will offered reasonable 
travel expenses and issued as per local policy and procedure and be given a £5 voucher to thank 
them for their contribution. They will also be advised that on their request they can be sent a plain 
English summary of the findings of the study which will be documented at time of consent. At any 
stage of the study participants can request to be withdrawn.  Participants do not need to give a 
reason for this and doing so will not impact on their future care.  They will be informed that they can 
withdraw their data up to 24 hours after the focus group.  After this time, the data will have been 
transcribed and anonymised and therefore, cannot be withdrawn. 
 
It is anticipated that participation in the focus groups will not result in the occurrence of any form of 
adverse events.  However, the researchers are aware that discussion during the focus group may be 
sensitive and potentially distressing.  Should any undue distress occur, participants will be supported 
 
should they wish to withdraw from the focus group and study.  They will be advised to seek help 
from the Principal Investigator, Research Nurse at their site or consult with their general 
practitioner.  
Study documentation and digital audio recorders will be security stored in a lockable box/brief case 
after each focus group prior to transportation and secure storage at the University of Nottingham.  
 
Analysis 
Each of the focus groups will be recorded using audio equipment, transcribed verbatim and analysed 
using the framework method.  This involves the researchers familiarising themselves with the 
transcription, coding the data, developing a working analytical framework, applying this framework 
and charting the data into the framework matrix [14].  The information obtained from focus groups 
1 and 2 will be used to optimise the participant information following a pulmonary nodule diagnosis, 
with further refinements made following focus groups 3 and 4.  Although direct quotes and extracts 
from the focus groups may be presented in the research outputs, they will be anonymised to ensure 
that participants cannot be identified through the data.  Participants will be assigned pseudonyms to 
protect their identities.  
 
All data will be stored in compliance with the Data Protection Act 1998 and in accordance the 
University of Nottingham Code of Research Conduct and Research Ethics (non-identifiable study 
management information only, dates of interviews etc.). The researchers will be responsible for 
maintaining all documents concerning the study. The data will be stored on a University of 
Nottingham on a password protected computer in a locked office at Queens Medical Centre and will 
only be accessible by the research team (e.g., the researchers and research supervisors).  
 
Each participant will be assigned a unique study identity code number for use on their interview 
transcript. Transcripts and signed consent forms will be treated as confidential documents and held 
 
securely in accordance with regulations. Each transcript document will be password protected and 
will be stored on a password protected file on University of Nottingham server. Only members of the 
research team (e.g., the researchers and the research supervisors) will have access to interview 
transcripts. Audio recordings will be stored on an audio recorder in a locked filing cabinet. Once 
audio recordings have been transcribed, the recording will be deleted off the audio recorder. Signed 
consent forms will be kept in the study ISF in a locked filing cabinet in a locked office at Queens 
Medical Centre. In line with the University of Nottingham Code of Research Conduct and Research 
Ethics, data will be stored for seven years from the date of any publication that is based upon them.  
 
The results of this study will be disseminated at conferences and published in peer-reviewed 
journals.  A summary of our findings and recommendations will be produced for dissemination to 
clinicians, professional bodies and the UK National Screening Committee.   A plain English summary 
of our findings will be published on the ECLS study website for participants to access.  This will also 
be made available to relevant lung cancer charities.          
 
Alternative Data Collection 
Should it prove too difficult to organise the focus groups as outlined above, semi-structured 
interviews will be used as an alternative means of data collection.  There will be two different 
interview types.  The first will cover the first and second objectives.  The second will cover the third 
objective.  Participants for the interview covering the third objective (what is the participants’ 
response to the modified information letter?) will be sent the modified letter at least one week prior 
to the interview, to allow time for reading the modified letter.  Questions asked in the interview will 
be the same as those within the focus group guide.  Participants will be recruited using the same 
criteria as that for the focus groups.  Written consent will be obtained, with the interviews held face-
to-face or over the telephone dependent upon participant preference.  Where interviews are 
conducted by telephone consent forms will be posted to potential participants and interviews will 
 
only be conducted once completed forms have been returned.  The interview will be audio recorded, 
with a verbatim transcript generated of the discussion held, which will be anonymised.  Data will be 
analysed as described above for the focus groups.  Interviews will be continued until data saturation 
is reached.     
 
Focus Group/Interview Guides: 
The questions within this guide are designed to act as a participant prompt and as a means of 
steering participant discussion in order to achieve the objectives of the study.  They are intended to 
facilitate discussion and debate amongst participants, rather than a question and answer session 
between participant and facilitator. 
 
Prior to commencement of all the focus groups participants will complete both consent and 
demographic forms.  Before starting the recording equipment ground rules will be established, 
including the need for confidentiality amongst participants.  Each focus group will start with an 
introduction advising the participants that it is their thoughts and opinions that are being sought and 
that there are no right or wrong answers. 
 
Focus Groups 1 and 2 
Following the general introduction the participants will be provided with a copy of the ECLS trial 
pulmonary results letter. 
1) Participant feelings on receipt of the pulmonary nodule results letter 
 What happened when you first received the letter? 
 What was your initial reaction to the letter? 
 What was your understanding of what the letter was trying to inform you of? 
 What was your understanding of the future plan following diagnosis of a nodule? 
 How did you feel about finding out this result in the form of a letter? 
 
2) Participant response following receipt of the pulmonary nodule results letter 
 Did you seek any advice or further information after you received the letter?  If so 
how did you do this?  
 How do you now feel about having a nodule within your lungs? 
 How have your feelings about the nodule changed since you received the letter? 
 How often do you think about your lung nodule? 
 What do you find most difficult about living with a lung nodule? 
 Has the finding of a nodule within your lungs changed your lifestyle?  Ask specifically 
about smoking behaviour if not discussed. 
3) Understanding of pulmonary nodules 
 What do you think a lung nodule is? 
 How likely do you think it is that the nodule will become cancer?  
 How often and for how long do you think you will be followed up for as a result of 
having a lung nodule? 
 Do you think that your nodule is causing you to have symptoms?  If so which ones?    
 If you wanted to explain the presence of nodules in your lungs to your family or 
friends, what would you say to them?  
4) Improvement to information provision 
At this stage participants will be given a short explanation of lung nodules. 
 Do you think that the results letter could be improved? If so how? Consider 
including a definition of a lung nodule, images, the risk of lung cancer, details of a 
follow-up plan and symptoms that should trigger a visit to their GP. 
 Knowing what you know now, are there things it would have been helpful to know 
at the time you were told you had a lung nodule? 
 What would be your preferred method of receiving news that you had a lung 
nodule?  Why would you prefer that method? Consider the provision of results in 
 
person, over the telephone, a link to online information or a link to a YouTube video 
of a physician explaining a diagnosis of lung nodules. 
 
Focus Groups 3 and 4 
Participants will be given copies of both the original nodule result letter and the modified nodule 
result letter and information. 
1) Response to modified information provision 
 How would your initial feelings differ if you were to receive the modified letter? 
 How would this letter change what you did after being told you had a lung nodule?  
How might it affect you looking for information elsewhere?  How might it affect 
where you looked for information.  How might it affect the sort of information you 
looked for? (e.g. about what lung nodules are , risk of cancer, follow-up scans, affect 
of lifestyle on reducing the chance on progressing to cancer). 
 Has your understanding of lung nodules changed since reading the modified letter? 
 How does the modified nodule result letter compare to the original letter? 
 Are there any other ways the letter could be improved? 
 
All focus groups will close by asking whether there is anything else that the participants would like to 
share with the group and thanking the participants for their time. 
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Abbreviations and Definitions 
AAB Autoantibody 
AE Adverse event 
CRF Care Report Form  
CI Chief Investigator 
CNORIS clinical negligence and other risks scheme 
CT scan  Computerised Tomography Scan 
CXR Chest X-Ray 
eCRF Electronic case report form 
EarlyCDT – Lung Test  Early Cancer Detection Test- Lung Test  
ECLS Study  Early Cancer Detection Test – Lung Cancer Scotland Study 
GG&C Greater Glasgow & Clyde 
GCP Good Clinical Practice 
HEAP Health Economics Analysis Plan 
HIC Health Informatics Centre 
ICF Informed Consent Form 
ISF Investigator Site File 
MAR Missing at random 
SCR Scottish Cancer Register 
SIMD Scottish Index of Multiple Deprivation 
SMR Scottish Morbidity Record  
SOP Standard Operating Procedure 
TASC Tayside Medical Science Centre  
TCTU Tayside Clinical Trials Unit  
TAA Tumour Derived/Associated Antigens 
TMF Trial Master File 
TMN Tumour, Node, Metastases 




The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment 
and detection in the earliest stages of the disease. Survival rates are much higher when cancer is 
diagnosed early but because lung cancer is often diagnosed symptomatically, most cases are 
discovered after the disease has spread. In these cases, the 5-year survival rate is less than 10%. By 
testing patients who are at a high risk for developing lung cancer before symptoms appear, the 
EarlyCDT-Lung test could help diagnose lung cancer sooner, when treatment options are more likely 
to be successful. The EarlyCDT-Lung test detects autoantibodies, which are a patient’s immune 
response to antigens produced by solid-tumor cells. Because these autoantibodies are produced by 
healthy individuals at lower levels, the EarlyCDT-Lung test enables physicians to identify those 
patients producing autoantibodies at higher levels and who are at an increased lung cancer risk or 
who are already in the early stages of lung cancer. 
Purpose of the analyses 
 
The analyses proposed in this SAP will be part of the final study report and assess the outcomes 
described below.  
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To assess the effectiveness of EarlyCDT-Lung test in reducing the incidence of patients with late-




1) to assess the effectiveness of EarlyCDT-Lung test in improving the diagnosis of early-stage lung 
cancers; 
2) to undertake a cost-effectiveness analysis of EarlyCDT-Lung test as a primary screening method 
compared to standard clinical practice; 
3a) to compare lung-cancer mortality, all-cause mortality and cancer-specific mortality in high-risk 
groups provided with EarlyCDT-Lung test, compared with standard practice; 
3b) to compare long-term future mortality in high-risk groups provided with EarlyCDT-Lung test, 
compared with standard practice; 
4) to obtain refined estimates of the sensitivity, specificity, positive predictive value and negative 
predictive value of EarlyCDT-Lung test; 
5) to assess behavioural outcomes including smoking, psychological outcomes including cancer 
worry, anxiety, depression, distress specific to clinical investigations; 
6) to assess the effectiveness of EarlyCDT-Lung test on other clinical outcomes as CVD, COPD, 
other cancers, hospital stays and outcomes identified though SMR linkage 
7) to assess uptake of subsequent investigations such as CXR, CT, bronchoscopy and biopsies. 




The difference, at 24 months after randomisation, between the number1 of patients with stage 3, 4 
or unclassified lung cancer at diagnosis in the intervention arm, and those in the control arm; 
 
Secondary Outcomes 
1) The numbers, at 24 months after randomisation, in the different stages at diagnosis (3/ 4/ U/ 
other) in the intervention arm and the control arm; 
2) The difference, after 2 years, in the costs and outcomes between the intervention arm and the 
control arm; cost-effectiveness of the intervention compared to standard clinical practice; 
3a) The estimates, after 2 years, of lung cancer mortality, all-cause mortality and cancer-specific 
mortality rates in the intervention arm and in the control arm; assessment of significance of 
differences; 
3b) The estimates, after 5 years and 10 years of long-term mortality rates in the intervention arm 
and in the control arm; assessment of significance of differences; 
4) The estimates, after 2 years of  (i) the number of patients with stage 3, 4 or unclassified lung 
cancer at diagnosis in the EarlyCDT-Lung test-positive group and those in the EarlyCDT-Lung 
test-negative group and (ii) stage at diagnosis in the EarlyCDT-Lung test-positive and EarlyCDT-
Lung test-negative group;  
5) The scores at baseline, and follow-up on in a survey administered prior to treatment allocation, 
including EQ5D, Positive and Negative Affect Schedule (PANAS), Revised Illness Perception 
Questionnaire – Lung Cancer (IPQ-LC), Lung cancer risk perception, Health anxiety subscale of 
                                                          
1 The Protocol contains Primary Outcome inconsistencies.  For clarity and consistency the SAP will 
adopt the clinicaltrials.gov published text – incidence and number; however incidence, number and 
rate will be reported. 
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Health Orientation Scale (HOS) and the Lung Cancer Worry Scale (LCWS), Medication, smoking 
behaviour, demographic details. Follow-up questionnaires include same items, plus Impact of 
Events Scale (intervention group only), healthcare utilisation and dates and results of follow-up 
investigations for lung cancer (test positive group only). The HADS is not included in follow- up 
questionnaires. Follow-up questionnaires are EQ-5D, cancer worry, positive and negative mood, 
smoking behaviour including cessation intentions and attempts; scores in additional 
questionnaires administered at between 1 and 24 months to subsets of the control arm and 
intervention arm; (all participants in the EarlyCDT-positive group will be approached with the 
recruitment aim of 300 from this group collected at 1,3,6,12,18 and 24 months. The EarlyCDT-
negative and control groups will be recruited at the same rate as the EarlyCDT-positive group 
with the recruitment aim of 300 from each group collected at 1,3,6 and 12 months). 
6) The incidence of  other clinical outcomes such as CVD, COPD, other cancers, hospital stays, 
identified through SMR linkage, measured at 24 months, 5 and 10 years in the intervention arm 
and in the control arm; assessment of significance of differences; 
7) The numbers in Tayside group (EarlyCDT-Lung test-positive, EarlyCDT-Lung test-negative, 
control) undertaking subsequent investigations such as CXR, CT, bronchoscopy and biopsies. 
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3. Study Methods 
 
General Study Design and Plan 
This trial is a randomised controlled parallel-arm trial involving 12,000 participants recruited through 
primary care and community based recruitment strategies in Scotland.  
Initially ten thousand participants from general practices in the most deprived quintile of the 
population Scotland (as measured by the quintiles of the Scottish Index of Multiple Deprivation 
(SIMD) 2012 - version 2) were recruited. In the second phase of recruitment, following from a 
sample size recalculation, an additional 2,000 participants from NHS Greater Glasgow and Clyde and 
NHS Lanarkshire only were invited as recruitment in NHS Tayside was complete. 
For a separate sub-study, all participants in the EarlyCDT-positive group were approached with the 
recruitment aim of 300 from this group collected at 1,3,6,12,18 and 24 months. The EarlyCDT-
negative and control groups were recruited at the same rate as the EarlyCDT-positive group with the 
recruitment aim of 300 from each group collected at 1,3,6 and 12 months. Sub-study analysis was 
done separately and is not addressed in this SAP (See Appendix 1) 
 
Randomisation 
Participants were allocated to intervention or comparison group during the recruitment visit (Visit 1) 
using a web-based randomisation system; TRuST, provided by Tayside Clinical Trials Unit (TCTU).  
Set-up of the randomisation system was performed by TCTU staff under the supervision of a TCTU 
statistician.  Randomisation was stratified by site and minimised by age, sex and smoking history. 
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4. Sample Size  
 
Original sample size calculation 
The rate of lung cancer is 187/100,000 per year for patients aged 50-74 in Scotland 2008 (ISD cancer 
statistics). Deprivation is associated with a higher risk of lung cancer. Those in the most deprived 
quintile are associated with an increased risk of 1.8 times compared to the middle quintile of 
deprivation (ISD cancer statistics). This gives an estimated annual lung cancer rate of 336/100,000 
among the practices taking part in the study. A high risk group within this population will be selected 
using similar entry criteria as the Mayo screening study which had a 2% prevalence rate of lung 
cancer and a further 2% incidence rate over the following 5 years (Swensson 2005). The baseline 
rate of late stage presentation for the particular high risk population envisaged in this study is 
uncertain, as is the size of the reduction in late stage presentation likely to be achieved through use 
of EarlyCDT-Lung. Using an estimated late stage presentation rate of 1,200/100,000 per year in the 
control group i.e. 2.4% over the two-year follow-up period, we require 85% power at 5% significance 
(two-sided) to detect an estimated reduction of 35% in presentation rate in the test group, i.e. as 
low as 780/100,000 per year or 1.56% over the two-year follow-up period. This corresponds to an 
estimated event rate over the two years of follow-up of 120 events in the control group and 78 
events in the test group and implies a required sample size of n=5,000 per group i.e. 10,000 
altogether. 
 
The anticipated 35% reduction in event rate between the control group and the test group is 
justified by current estimates of the capability of the EarlyCDT-Lung test to identify cases (41% 
sensitivity, 93% specificity) together with current estimates of the specificity of CT scanning (67%). 
The sample size calculations are based upon standard methods for time to event data using the 
cpower function in R and stpower exponential procedure in Stata and assuming exponential survival.  
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They were also confirmed using standard approaches for detecting a change in binomial 
probabilities, and confirmed using approaches to detect a change in Poisson rates (with essentially 
identical results as loss to follow up is expected to be low). 
 
The study aims for a short recruitment period and so no allowance has been made for accrual. With 
such an allowance, say to 1 year, the power will increase to 91% to identify a 35% reduction 
provided the minimum follow up period of 2 years is observed.  
 
Revised sample size calculation 
The initial assumptions of the rate of late stage presentation of 1,200/100,000 per year among the 
study participants was too optimistic and in January to May 2015 investigations were carried out to 
inform an increase in the sample size.  Baseline information on the 8,639 participants recruited to 
March 2015 (18 months from first randomisation) was used to derive an estimate of lung cancer risk 
based upon the Spitz Model.  A number of variables in this model were not recorded in the study 
data base and low risk values were used in the risk calculation implying that the risk estimates 
should be underestimates.  This suggested that the with 10,000 participants the rate of lung cancer 
would be expected to be around 680/100,000 and 540/100,000 for stage T3/T4/Unknown lung 
cancer using ISD cancer statistics figures of 80% lung cancers in Scotland are late stage.  A sensitivity 
analysis around the missing data assumptions suggests that a late stage rate of around 600/100,000 
may not be unreasonable, though is likely to be at the upper limit. 
 
Using an assumption of 600/100,000 for late stage lung cancer and acknowledging that recruitment 
is over a 2 year period the study has a power of 80% to detect a 35% reduction associated with the 
use of the EarlyCDT-Lung test to identify cases, provided that analysis takes place after all 
randomised patients have been followed up for 2 years.  While an 80% power is at the lower end of 
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acceptable powers this is the power level which has been used in a number of lung cancer screening 
trials. 
 
The power of the study is sensitive to the assumptions about the rate of late stage cancer and the 
recruitment rate, see Table 2.  A power in excess of 90% could only realistically be achieved by 
recruiting 15,000 patients or by changing the primary endpoint to 3 years post randomisation for all 
patients.  It the recruitment phase extends past 2 years to 2.5 years to recruit 12,000 participants 
then the power will increase slightly to 83%. 
 
Table 2.  Powers for a 35% reduction in the rate of T3/T4/Unknown lung cancer using a log rank test 
at the 5% significance level for various underlying rates in the control group, total sample sizes, and 
differing lengths of recruitment periods and follow up periods. 
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5. General Considerations 
 
Timing of Analyses 
The analysis for the primary outcome and any outcomes for 2-year follow-up will be performed 
using data up to 2 years after the last patient randomised, after all data have been entered and the 
clinical database has been locked.  
 
Scotland-wide follow-up data will be requested from eData Research & Innovation Service (eDRIS), 
to allow derivation of study outcomes. 
 
Analysis for the 5- and 10-year outcomes will be performed using data up to 5 and 10 years 
respectively after the last patient randomised. 
 
Analysis Populations 




The extent of missing data will be examined and multiple imputation will be implemented for 
missing baseline data to provide robust results, assuming data are missing at random (MAR). It is 
assumed that there will be no missing data for randomised group as the patients are randomised 
centrally. It is likewise assumed that there are no missing data in the primary outcome as the data is 
extracted from Scotland-wide data.  
 
Multiple imputation will be performed using a Markov chain Monte Carlo method with multiple 
chains over 1000 imputations.  
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6. Summary of Study Data 
All continuous variables will be summarised using the following descriptive statistics: n (non-missing 
sample size), number of missing records, mean, standard deviation, median, maximum and 
minimum.  
The frequency and percentages (based on the non-missing sample size) of observed levels will be 
reported for all categorical measures. Number of missing records will also be reported. 
 
In general, all data will be listed, sorted by subject and treatment and where appropriate by visit 
number within subject. 
 
All summary tables will be structured with a column for each treatment in the order (Positive 
assessment, Negative assessment, Control) and an additional column for the total population 
relevant to that table/treatment, including any missing observations. 
 
Demographic and Baseline Variables 
Baseline characteristics for patients are: GP Practice, age, gender, current smoking status, Pack year 
history, marital status, employment status, housing status, SIMD at recruitment and ethnicity. 
 
7. Efficacy Analyses 
Characteristics of participants will be compared informally between treatment arms at baseline. Cox 
proportional hazards models will be used to estimate the hazard ratio of the rate of late stage lung 
cancer in the intervention arm compared to the control arm. Participants who are lost to follow up 
will be censored. The models will adjust for age, gender, smoking history, and practice. Random 
cluster effects will be included rather than fixed effects for practices. A similar methodology will be 
used for the secondary outcomes of comparisons of mortality rates (secondary outcomes 3a and 
3b). A subsequent analysis will compare the outcomes of those with EarlyCDT positive in comparison 
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to those in the intervention group with EarlyCDT negative (primary contrast for this analysis) and 
those in the control group (secondary analysis 1). Comparisons of proportions (secondary analyses 1 
and 4) will be carried out using chi square tests. Fisher’s Exact test will be used if the numbers of 
events are small. 
 
Poisson regression models, adjusting for age, gender, smoking history, practice and follow up time if 
necessary, will be used to investigate the other clinical measures (secondary outcomes 6 and 7). 
  
Primary Efficacy Analysis 
The primary outcome is to assess the difference, up to 24 months after randomisation, in the 
incidence of stage 3, 4 or unclassified lung cancer at diagnosis, between the intervention arm, and 
the control arm. The data will be taken from the SMR06 Scottish cancer registry data. The outcome 
variable is the first occurrence (as defined by the field “DATE OF INCIDENCE”) of the field “SITE 
ICD10” and include all diagnosis starting with C33 and C34. Where more than one tumour is present 
at diagnosis, the most advanced tumour will be used for classification of disease. 
 
To determine staging, the fields “CLINICAL T, N, M” and “PATHOLOGICAL T, N, M” will be used. 
Where both fields are present, Pathological staging will be used for greater accuracy. Staging is 
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 classified as:  




Lung Cancer TNM Status was changed during the trial from version 7 to version 8. This change was 
performed in Tayside on 01/01/2018, in Glasgow and Greater Clyde in January 2017 and Lanarkshire 
on 01/02/2017. As the TNM status maps to the Lung Cancer staging in the same way for both TNM 
versions, and patients were recruited on a 1:1 basis, TNM status from the original data will be used 
to map to Staging. 
 
A Cox proportional hazards model will be used to estimate the hazard ratio of the rate of late stage 
lung cancer in the intervention arm compared to the control arm. Participants who are lost to follow 
up will be censored, with lost to follow-up being defined as participants no longer present on the CHI 
register. The model will adjust for age, gender, smoking history, and practice. Random cluster effects 
will be included rather than fixed effects for practices. 
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 Secondary Efficacy Analyses 
1) numbers, at 24 months after randomisation, in the different stages at diagnosis (3/ 4/ U/ other) 
in the intervention arm and the control arm. The data will be taken from the SMR06 Scottish 
cancer registry data with the same criteria as the primary outcome. Comparisons of proportions 
will be carried out using chi square tests. If the number of diagnoses is small, Fisher's Exact test 
will be used instead. 
 
2) Outcome 2 (The difference, after 2 years, in the costs and outcomes between the intervention 
arm and the control arm; cost-effectiveness of the intervention compared to standard clinical 
practice) will be assessed by the health economics team and is not described in the SAP. For 
details of the analysis see the Health Economics Analysis Plan (HEAP) 
 
3a) estimates, after 2 years, of lung cancer mortality, all-cause mortality and cancer-specific 
mortality rates in the intervention arm and in the control arm; assessment of significance of 
differences. Date and cause of death will be extracted from the NRS death dataset for all-cause 
mortality. The field to be used is “PRIMARY CAUSE OF DEATH”. For lung cancer mortality, ICD10 
codes C33 and C34 will be used. For cancer specific mortality, all ICD codes from C00 to C97 will 
be used. All cause mortality will use all records and ICD10 codes in this field. 
 
These outcomes will be assessed in the same way as the primary outcome. 
 
3b) estimates, after 5 years and 10 years of long-term future mortality rates in the intervention arm 
and in the control arm; assessment of significance of differences. These outcomes will be 
defined and assessed in the same way as outcome 3a. 
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4) estimates, after 2 years of (i) the number of patients with stage 3, 4 or unclassified lung cancer 
at diagnosis in the EarlyCDT-Lung test-positive group and those in the EarlyCDT-Lung test-
negative group and (ii) stage at diagnosis in the EarlyCDT-Lung test-positive and EarlyCDT-Lung 
test-negative group. These outcomes will be assessed as described in secondary outcome 1. 
 
5)  For analysis of outcome 5 see section 4.2.2. 
 
6) The incidence of other clinical outcomes such as CVD, COPD, other cancers, hospital stays, 
identified through SMR linkage, measured at 24 months, 5 and 10 years in the intervention arm 
and in the control arm; assessment of significance of differences.  
 
Data will be extracted from the Scottish dataset SMR01 (Inpatient visits). The date of admission, the 
main reason for admission and up to 3 additional reasons will be extracted.  
 
In the primary analysis, only the field “MAIN CONDITION” will be used, in a secondary analysis, all 4 
fields will be used. The following ICD10 codes will be extracted: CVD will be defined as all codes from 
I20 to I25. COPD is defined as all ICD10 codes from J40 to J44. Other cancers will include all ICD10 
codes from C00 to C97. No other conditions will be assessed. Hospital stays will be extracted from 
SMR01 field “LENGTH OF STAY” and used in the economic analysis. 
 
This outcome will be assessed using Poisson regression models, adjusting for age, gender, smoking 
history, practice and follow up time if necessary. 
 
7) numbers in Tayside group (EarlyCDT-Lung test-positive, EarlyCDT-Lung test-negative, control) 
undertaking the following subsequent investigations: CXR, CT, bronchoscopy .  
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Examinations are not part of the public datasets. For Tayside patients, HIC (Health Informatics 
Centre) will provide a dataset including all examinations of CXR, CT and bronchoscopy and biopsies. 
No data will be available for participants from the other health Boards.  
 
8. Safety Analyses 
 
Adverse Events 
Adverse events were only collected in the positive group and relate to clinical investigations 
performed in this group. All other participants were referred to standard clinical practice and had no 
additional parameters assessed. 
 
Adverse events (AE) will be coded with MedDRA 18.1. Where more than one diagnosis is present in 
the AE description, the AE will be split with all the descriptors kept the same for all diagnosis. 
Adverse events will be reported by primary System Organ Class (SOC) and Preferred Term (PT). 
Subjects will be counted only once when calculating the incidence of AEs. An overview table will be 
created counting the number of adverse events by system organ class and preferred term. 
Descriptors for Adverse events will be tabulated separately as described for categorical variables in 
section 8. The total number of AEs will be used as basis for tabulation. 
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9. Reporting Conventions 
P-values ≥0.001 will be reported to 3 decimal places; p-values less than 0.001 will be reported as 
“<0.001”. The mean, standard deviation, and any other statistics other than quantiles, will be 
reported to one decimal place greater than the original data. Quantiles, such as median, or minimum 
and maximum will use the same number of decimal places as the original data. Estimated 
parameters, not on the same scale as raw observations (e.g. regression coefficients) will be reported 
to 3 significant figures.  
 
10. Technical Details 
All analysis will be performed using SAS 9.3. All data, analysis programs and output will be kept on 
the TCTU Server and backed up according to the internal IT SOPs.  
Analysis programs will be required to run without errors or warnings. The analysis programs for 
outcomes will be reviewed by a second statistician, and any irregularities within the programs will be 
investigated and fixed and date of finalised analysis programs will be signed and recorded. 
 
11. Example tables 
Example tables will be created on a subset of 1000 patients on a blinded basis and will be reviewed 
and signed off by the Chief Investigator. Prior to the final analysis the Trial Steering Committee 
statistician will receive example tables for information. 
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Appendix 1: List of Sub studies 
Study Investigator Group Sample size Timepoints 
Sub-Study 1. Investigating the experiences of 
individuals who choose not to have the EarlyCDT-
Lung test 
Ben Young Non-Responders 20 Participants Periodically 
Sub-Study 2. How do participants perceive the 
EarlyCDT-Lung test and what do they understand 
about their test results? 
Laura Bedford (Dr Gozde 




Positive  n= 15 
Negative n= 15 
10 month study period  
Sub-Study 3. An examination of changes in 




Positive  n= 15 
Negative n= 15 
Over a 12 month period 
Sub-Study 4. MRC START in ECLS - This study 
assessed the potential impact of the presentation 




All Participants Recruitment 
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Sub- Study 5.1 Exploring Public Perceptions of Lung 
Cancer Screening - Qualitatively investigate why 
individuals decided not to take part in the ECLS 
Trial, after showing initial interest 





Sub- Study 5.2 Exploring Public Perceptions of Lung 
Cancer Screening - Exploring differences between 
the people taking part who self refer for the study 





All participants  
Sub-Study 6. Is there a difference in the emotional, 
cognitive and behavioural response to a positive 
EarlyCDT test if pulmonary nodules are present on 
a chest computed tomography compared to a 
normal chest computed tomography?  
Marcia Clarke Positive 300 Participants Baseline, 1, 3 and 6 months 
Sub-Study 7. Living with lung nodules: what 
information would patients find helpful? 
Marcia Clarke Positive 32 Participants Varying timepoints 
Supplementary Appendices: ECLS Appendix 2: ECLS Statistical Analysis Plan Version 1.0 
Questionnaire Study  
Ben Young will analyse 
behavioural outcomes. 







Follow-up questionnaires will 
be given to participants at 
the time-points already 
specified in the research 
protocol:                                                                                                                                                                                         
• 1-2 weeks following ELCD 
test results (all groups; n = 
300 in each group): to 
examine emotional 
consequences following 
receipt of results from the 
ELCD test. 
• 3, 6 and 12 months 
(patients who receive a 
negative ELCD test result (n = 
300) and the control group (n 
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= 300)): to examine long-
term emotional 
consequences of receiving a 
negative ELCD test result or 
standard care. 
• 3, 6, 12, 18 and 24 months 
(patients who receive a 
positive ELCD test result (n = 
300)): to examine the long-
term emotional 
consequences of receiving a 
positive ELCD test result and 
the imaging investigations 
required (chest x-ray and CT 
scan followed by 6 monthly 
CT scans for 24 months).  
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Appendix 3. Within-trial model-based cost effectiveness analysis: assumptions and parameters. 
The within trial model utilised a combination of trial data and assumptions extracted from expert 
knowledge, assumptions made in the model are presented below: 
 Lung cancer prevalence was the same in both arms 
 Prevalence was calculated as the proportion of participating patients developing lung cancer 
during the two-year within trial period. 
 6 monthly non-contrast thoracic CT scans in the test positive arm detected all cases of lung 
cancer in that arm (100% accuracy over two years) 
 Trial resource use data for test positive participants were utilised in the model: initial x-ray 
and non-contrast thoracic CT scans  
 Expert opinion was used to estimate the resource use associated with a diagnosis 
(confirmatory diagnostic) – whether as a result of a suspicious 6 monthly non-contrast 
thoracic CT scan in the test positive arm or as a result of participants becoming symptomatic 
or presenting at A&E in the test negative and control arms 
 Confirmatory diagnostic resource use was applied to all participants with a diagnosis of lung 
cancer during the trial follow-up irrespective of randomisation group 
 Confirmatory diagnostic tests consisted of: x-ray, contrast CT scan and a bronchoscopy or CT 
guided biopsy 
 The cost for the bronchoscopy/ CT guided biopsy was calculated by applying the average 
cost of these tests 
 The distribution of lung cancer stage is assumed to be conditional on screened detection (i.e. 
a positive EarlyCDT®-Lung Test result) vs. symptomatic presentation 
 Deterministic sensitivity analysis was conducted by varying the cost of the blood test and 
prevalence of lung cancer, roughly halving and doubling the original parameters 
 Trial parameters are presented in Tables 1 and 2. 
 Unit costs are presented in Table 3. 
 
Table 1. Model parameters 
Parameter Description 
Probabilities: 
% LC Proportion of patients developing lung cancer within two years from 
randomisation. The same proportion is assumed for the screening and 
no screening arms. 
Sens Sensitivity of the EarlyCDT-Lung test. Computed as the ratio of the 
number of patients diagnosed with lung cancer and positive test result 
over the total number of patients diagnosed with lung cancer. 
Spec Specificity of the EarlyCDT-Lung test. Computed as the ratio of the 
number of patients without lung cancer and negative test result over the 
total number of patients without lung cancer. 
% Late LC Proportion of LCs diagnosed at late stage (III, IV or U). Estimated 
separately for true positive patients in the screening arm, on the one 
hand, and false negative in the screening arm jointly with patients in the 
Supplementary Appendices: ECLS Appendix 2: ECLS Statistical Analysis Plan Version 1.0 
 
no-screening arm, on the other hand. 
% Early LC Proportion of LCs diagnosed at early stage (I or II). Estimated separately 
for true positive patients in the screening arm, on the one hand, and 
false negative in the screening arm jointly with patients in the no-
screening arm, on the other hand. 
% CT+ Proportion of patients with positive result after CT scans follow-up 
screening. Assumed to be 100% (0%) for those with(out) lung cancer. 
% CT- Proportion of patients with negative result after CT scans follow-up 
screening. Assumed to be 0% (100%) for those with(out) lung cancer. 
Costs: 
C_test Cost of blood test - EarlyCDT®-Lung Test plus cost of 15 minutes of nurse 
at a GP practice 
C_i Investigation costs: contrast CT scans; Chest X-ray; contrast enhanced 
staging CT. 
 
Table 2. Parameters values   
Parameter Mean SE Distribution 
% LC 0.0104  Beta(127, 12081) 
Sens 0.3214  Beta(18, 38) 
Spec 0.9038  Beta(5451, 580) 
% Late LC (True positive) 0.6667  Beta(12, 6) 
% Early LC (True positive) 0.3333  Beta(6, 12) 
% Late LC (False negative) 0.2970  Beta(30, 71) 
% Early LC (False negative) 0.7030  Beta(71, 30) 
% Late LC (No screening 
arm) 0.2970 
 Beta(30, 71) 
% Early LC (No screening 
arm) 0.7030 
 Beta(71, 30) 
C_test £105.50   
C_i (True positive) £1343.54 28.18 Gamma(1282.77, 28.18) 
C_i (False negative) £1,162.77   
C_i (False positive) £473.26 4.22 Gamma(478.8, 4.23) 
C_i (True negative) £0.00   
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C_i (No screening LC) £1,162.77   
C_i (No screening No LC) £0.00   
 
Table 3: Unit costs and sources 
Unit of resource £ Source Details 
Per blood test 95.00 Oncimmune $124 per kit 
Per blood test 10.50 PSSRU 2017/18 15 minutes of nurse time (GP surgery) 
Per scan 90.00 NHS reference costs 2017/18 CT of one area, no contrast RD20A in diagnostic 
imaging tab, outpatient 
Per scan 107.00 NHS reference costs 2017/18 CT scan of two areas with contrast (chest and 
abdomen) RD24Z, diagnostic imaging tab, 
outpatient 
Per x-ray 60.77 ISD costs 2017/18  Other radiology R120X  
Bronchoscopy 728.00 NHS reference costs 2017/18 Diagnostic bronch DZ69A day case 
CT guided 
biopsy 
1,245.00 NHS reference costs 2017/18 DZ63C major thoracic procedures, 19 years and 
over, with CC score 0-2 
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Supplementary Table 1. Assessment Schedule for Participants in the Intervention Group 
 
Procedure Visit 1 
≤ 2 
weeks 
















    
CT Scan * 
 
x x x x x 
 
* Study CT scan follow-up was carried out only if the EarlyCDT-Blood test result was 
positive. If a participant entered NHS Clinical Care pathway, then their subsequent study 














   
Supplementary Table 2. Baseline Questionnaires for Participants 
 
Baseline Questionnaire V (Part A) 
Hospital Anxiety and Depression Scale (HADS) (Part B) 
Positive and Negative Affect Schedule (PANAS) (Part C) 
Views about Lung Cancer (Part D, E) 
Views about Health (Part F) 
Medical History (G) 
Smoking Behaviour (Part H) 
   
 







Initials:                            
 
 
Please tell us 
the date you 






This participant  





                
       NO TEST 
 










  Participant Questionnaire 
                     
D D M M Y Y Y Y 
   ECLS  
   
  
   
PART A 
 
By placing a tick in one box in each group below, please indicate which statements 





I have no problems in walking about  
I have some problems in walking about 
I am confined to bed
 
Self-Care  
I have no problems with self-care  
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
 
Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities 
I am unable to perform my usual activities  
 
Pain/Discomfort  
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression  
I am not anxious or depressed  
I am moderately anxious or depressed 









   
To help people say how good or bad a health state is, we have drawn a scale (rather 
like a thermometer) on which the best state you can imagine is marked 100 and the 
worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or bad your own health is 
today, in your opinion. Please do this by drawing a line from the box below to 








































   
PART B 
 
This questionnaire is designed to help us know how you feel. Read each item and 
place a tick opposite the reply which comes closest to how you have been feeling 
in the past week. 
 
Don’t take too long over your replies: your immediate reaction to each item will 
probably be more accurate than a long thought-out response. Tick only one answer 





I feel tense or „wound up‟:   I feel as if I am slowed down:  
Most of the time    Nearly all the time  
A lot of the time   Very often  
Time to time, Occasionally   Sometimes  
Not at all   Not at all  
I still enjoy the things I used to 
enjoy: 
  I get a sort of frightened feeling like 
"butterflies" in the stomach: 
 
Definitely as much   Not at all  
Not quite so much   Occasionally  
Only a little   Quite often  
Hardly at all   Very often  
I get a sort of frightened 
feeling as if something awful 
is about to happen: 
  
I have lost interest in my appearance: 
 
Very definitely and quite badly   Definitely  
Yes, but not too badly   I don’t take as much care as I should  
A little, but it doesn’t worry me   I may not take quite as much care  
Not at all   I take just as much care as ever  
I can laugh and see the funny 
side of things: 
  I feel restless as if I have to be on  
the move: 
 
As much as I always could   Very much indeed  
Not quite so much now   Quite a lot  
Definitely not so much now   Not very much  
Not at all    Not at all  









Worrying thoughts go through 
my mind: 
 I look forward with enjoyment to things:  
A great deal of the time  As much as I ever did  
A lot of the time  Rather less than I used to  
From time to time but not too often  Definitely less than I used to  
Only occasionally   Hardly at all  
I feel cheerful: 
 
I get sudden feelings of panic: 
 
Not at all  Very often indeed  
Not often  Quite often  
Sometimes  Not very often  
Most of the time  Not at all  
I can sit at ease and feel relaxed: 
 
I can enjoy a good book or radio or TV 
programme: 
 
Definitely  Often   
Usually  Sometimes  
Not often  Not often  
Not at all  Very seldom  
   
PART C 
 
This questionnaire lists a number of words that people often use to describe different 
feelings and emotions.  Read each item and then tick the appropriate answer in the 





or not at all 
A little Moderately Quite a bit Extremely 
1) Interested      
2) Distressed      
3) Excited      
4) Upset      
5) Strong      
6) Guilty      
7) Scared      
8) Hostile      
9) Enthusiastic      
10) Proud      
11) Irritable      
12) Alert      
13) Ashamed      
14) Inspired      
15) Nervous      
16) Determined      
17) Attentive      
18) Jittery      
19) Active      
20) Afraid      
 
 
From "Development and validation of brief measures of positive and negative affect:  The PANAS scales," by D. Watson, L. A. 
Clark, and A. Tellegen, 1988, Journal of Personality and Social Psychology, 54, 1063-1070. Copyright © 1988 by the American 
Psychological Association.  Reproduced with permission.  No further reproduction or distribution is permitted without written 
permission from the American Psychological Association. 
  
   
PART D 
 
We are interested in your personal views about lung cancer.  
 
Please indicate how much you agree or disagree with the statements below by 
ticking the box that best describes your views.  
 




Agree Neutral Disagree Strongly 
disagree 
1 What I do can affect my risk of 
getting lung cancer 
 
     
2 When I think about my risk of 
getting lung cancer I get upset 
     
3 I do not know how likely it is that 
I might get lung cancer 
     
4 Finding lung cancer early can 
improve my chances of survival 
 
     
5 Lung cancer would have a big 
impact on my life 
     
6 Lung cancer lasts for a long time      
7 A blood screening test can 
accurately detect lung cancer 




Please list in rank-order the three most important factors that you believe cause lung 
cancer.  
 









   
PART E 
 
1. What are the chances that you will develop lung cancer over the next five years? 
(Please tick one box) 
 
Approximately 1 in 1000 (0.1%) 
 
Approximately 1 in 500 (0.2%) 
 
Approximately 1 in 250 (0.4%) 
 
Approximately 1 in 100 (1%)  
 
Approximately 1 in 20 (5%)  
 





2. Compared to other people of your age and sex, how likely are you to develop 
lung cancer over the next 5 years? (Please tick one box) 
 
A lot less likely than other people   
 
Less likely than other people 
 
About as likely as other people    
 
More likely than other people  
 
Much more likely than other people 
 
Don’t know 




   
PART F 
 
Please read the following statements carefully and decide to what extent it is a 
characteristic of you at the moment. Please tick one of the responses to each 
question. 
 
  Not at all Slightly Somewhat Moderately      Very 
1) I feel anxious when I 
think about my health 
     
2) I rarely become 
discouraged about my 
health 
     
3) I am pleased with how 
well and healthy I feel 
     
4) I have positive feeling 
about my health 
     
5) I feel that I have handled 
my health very well 
     
 
 
Below are four questions asking you about how worried you are about lung cancer 
at the moment. Please tick one of the responses to each question.   
 
PART G 
How worried are you about 
getting lung cancer someday? 
 How much does your worry affect your 
mood? 
 
Not at all worried  Not at all  
Rarely worried  A little  
Sometimes worried  Somewhat  
Often worried  A lot  
Worried almost all the time  Almost all the time  
How much does your worry 
affect your ability to perform 




What is your current level of anxiety about 
the results of future tests/treatments? 
 
Not at all  Not at all anxious  
A little  A little anxious  
Sometimes  Somewhat anxious  
A lot  Anxious a lot  
Almost all the time  Anxious almost all the time  
   
 
Below are some questions about medications and OTHER treatments you may be 
receiving.   
 
1) Have you been prescribed any medications to help you with low mood (e.g., 
anxiety, depression) in the last 3 months? 
 
Yes  No 
If YES, please go to Question 1a) 
If NO, please go to Question 2 
 
1 a) If YES, please state the name of the medication:_______________________ 
 
 2) Are you currently taking any medications to help you with low mood (e.g., 
anxiety, depression)? 
 
Yes  No 
If YES, please go to Question  2 a) 
If NO, please go to Question  3 
 
 2 a) If YES, please state the name of the 
medication:_______________________ 
 
 3) Are you currently being investigated for any other conditions? 
 
Yes  No 
If YES, please answer  questions 3 a) and 3 b)  
If NO, please go to PART H 
 









Not at all worried   
A little worried  
Quite worried  




   
 
This study is not about trying to encourage people to stop smoking but we are still 
interested in your smoking behaviour and your views about smoking. 
 
1) Not counting the last week, have you smoked any cigarettes or tobacco in 
the last 6 months? 
 




2)  Have you smoked any cigarettes or tobacco in the last seven days / week? 
 
Yes  No 
 
If YES, please go to Question 3 
If NO, please go to PART I 
 
 
3) How soon after you wake up do you smoke your first cigarette or tobacco? 
(Tick one box) 
 
After 60 minutes   
 
31 to 60 minutes 
 
6 to 30 minutes   
 









   
5) Do you have any intention of giving up smoking in the next four weeks? 
(Tick one box) 
 
Yes, definitely   
 
Yes, probably   
 
Don’t know    
 
Probably not    
 
Definitely not    
 
 
6) How sure or confident are you that if you tried, you could give up smoking 
for good? (Tick one box) 
 
Very certain    
 
Fairly certain    
 
Don’t know    
 
Fairly uncertain   
 
Very uncertain  
 
 
7) Which one of these statements do you most strongly agree with? 
(Tick one box)     
 
I would like to keep on smoking     
 
I don’t really want to stop smoking    
 
I don’t know whether I want to  
stop smoking or not  
 
I don’t really want to carry on smoking    
 
I would like to stop smoking     
 
   
8) Which one of these statements do you most strongly agree with? 
(Tick one box) 
 
I never think about stopping smoking   
 
One day I will need to think about  
stopping smoking  
 
I should stop smoking but I don’t think  
I’m ready  
 
I am starting to think about how I can  
smoke less  
 
I am trying to stop smoking    
 
 
9) How strongly do you agree or disagree with the statement “My health will 
improve if I stop smoking.” (Tick one box) 
 
Disagree strongly  
 
Disagree   
 
Don’t know   
 
Agree    
 
Agree strongly  
 
 
10) How strongly do you agree or disagree with the statement “People who are 
important to me want me to stop smoking.” (Tick one box) 
 
Disagree strongly  
 
Disagree   
 
Don’t know   
 
Agree    
 






11) In the LAST 6 MONTHS have you tried to cut down the number of 
cigarettes  
you smoke? 
   
 




12) In the LAST 6 MONTHS have you tried to stop smoking? 
 





Please continue to the next page.
   
PART I  
 
Please tell us a little more about yourself. Your answers to these questions will be 
very helpful to us and will be stored using a unique study code from which you 
cannot be identified. 
 
1) Date of birth 
 
 




3) Marital Status:   
 
Single      Widowed  
 
In a relationship    Separated  
 




4) Which best describes your work situation? 
 
In paid employment      
 
Unable to work due to illness or disability 
 
Unemployed and looking for work    
 
At home and not looking for work    
 
Retired      
 




 5) Do you own or rent your home? 
 
Rented   
 
Owned or mortgaged  
 
Other (Please say what)                 ___________________________________ 
 

















   
 6) The total number of people (adults + children) living in my home is: 
 




 7) The total number of rooms (excluding halls, landings, toilets and 
bathrooms) in my home is 
 




8) How many cars or vans are available for use by one or more members of 
your household? 
 
None    
 




 9) Ethnic Origin:   
 
I would describe my ethnic origin as: 
 





Any other Asian 
background 
 










White & Asian 
White & Black African 
White & Black Caribbean 






Other White British 
Irish 




Other Ethnic Group 
 
Chinese  
Any other ethnic  




I do not wish to  












   
Supplementary Table 3. Estimation of Cost Per Early Stage Lung Cancer Case Detected Per One Thousand Participants Screened. 
 
 Screening 
Mean (95% CI) 
No screening 
Mean (95% CI) 
Difference 
Mean (95% CI) 
Base case analysis 
Costs (£) 163,000 (159,000 – 167,000) 12,100 (9990 – 14,400) 151,000 (148,000 – 155,000) 
Early stage LCs detected 4.19 (3.02, 5.62) 2.89 (1.91, 4.09) 1.3 (-0.15, 2.77) 
ICER   116 000 (54 900, dominated) 
Deterministic sensitivity analysis 
Prevalence (0.5%) 
Costs (£) 157,000  5810  151,000  
Early stage LCs detected 2.01  1.39  0.6  
ICER   242,000  
Prevalence (2%) 
Costs (£) 175,000  23,300  151,000  
Early stage LCs detected 8.06  5.56  2.5  
ICER   60,500  
EarlyCDT cost (£58.00) 
Costs (£) 116,000  12,100 104,000  
Early stage LCs detected 4.19  2.89 1.3  
ICER   79 700  
EarlyCDT cost (£200.50)    
Costs (£) 258,000  12,100  246,000  
Early stage LCs detected 4.19  2.89  1.3  
ICER   189,000  
 
 
Legend: ICER- Incremental cost effectiveness ratio; LC- Lung cancer; CI- Confidence interval. 
 
Note: Dominated is when the intervention arm is more costly and less effective than the control arm
   
Supplementary Data Pack 1:  
Primary Outcome Analysis: Diagnosis of Stage III/IV/Unspecified Lung Cancer Two 




First incidence of late stage lung cancer in the 2 years since randomisation 
 No Test Test Total 
Variable N (%) N (%) N (%) 
No 6069 (99.2%) 6054 (99.5%) 12123 (99.3%) 
Yes 52 (0.8%) 33 (0.5%) 85 (0.7%) 
Total 6121 (100.0%) 6087 (100.0%) 12208 (100.0%) 
 
Lung cancer staging (numeric) 
 No Test Test Total 
Variable N (%) N (%) N (%) 
No cancer 6069 (99.2%) 6054 (99.5%) 12123 (99.3%) 
Unspecified 7 (0.1%) 0 (0.0%) 7 (0.1%) 
Stage 3 17 (0.3%) 15 (0.2%) 32 (0.3%) 
Stage 4 28 (0.5%) 18 (0.3%) 46 (0.4%) 






Statistic Value p-Value 
Chi-Square 4.1710 0.0411 
0 200 400 600 800
















With 95% Confidence Limits
   
Chi-Square Statistics 
Statistic Value p-Value 
Continuity Adj. Chi-Square 3.7382 0.0532 
Likelihood Ratio Chi-Square 4.2070 0.0403 
Mantel-Haenszel Chi-Square 4.1706 0.0411 
 
Fisher's Exact Test 
Left-sided Pr <= F 0.0263 
Right-sided Pr >= F 0.9846 
Table Probability (P) 0.0108 
Two-sided Pr <= P 0.0495 
 
Analysis of Maximum Likelihood Estimates 





Error Chi-Square p-value 
Group allocation Test -0.450 0.223 4.0856 0.0432 
 
 Confidence Interval 
Parameter Hazard Ratio lower upper 
Group allocation Test 0.638 0.412 0.986 
 
Analysis of Maximum Likelihood Estimates 





Error Chi-Square p-value 
Age [years] 0.112 0.018 39.4211 <.0001 
Pack year history 0.013 0.003 18.8157 <.0001 
Gender Male 0.144 0.226 0.4050 0.5245 
Smoking status  
Ex-smoker 
-0.479 0.223 4.6020 0.0319 
Group allocation Test -0.440 0.223 3.9039 0.0482 
 
 Confidence Interval 
Parameter Hazard Ratio lower upper 
Age [years] 1.119 1.080 1.159 
Pack year history 1.013 1.007 1.019 
Gender Male 1.155 0.741 1.800 
Smoking status Ex-smoker 0.619 0.400 0.959 





Supplementary Data Pack 2:  
   
Analysis of Primary Outcome for Participants with Records in the Last Two Years of 




First incidence of late stage lung cancer in the 2 years since randomisation 
 No Test Test Total 
Variable N (%) N (%) N (%) 
No 5432 (99.1%) 5456 (99.4%) 10888 (99.2%) 
Yes 52 (0.9%) 33 (0.6%) 85 (0.8%) 
Total 5484 (100.0%) 5489 (100.0%) 10973 (100.0%) 
 
Lung cancer staging (numeric) 
 No Test Test Total 
Variable N (%) N (%) N (%) 
No cancer 5432 (99.1%) 5456 (99.4%) 10888 (99.2%) 
Unspecified 7 (0.1%) 0 (0.0%) 7 (0.1%) 
Stage 3 17 (0.3%) 15 (0.3%) 32 (0.3%) 
Stage 4 28 (0.5%) 18 (0.3%) 46 (0.4%) 







Statistic Value p-Value 
Chi-Square 4.2977 0.0382 
0 200 400 600 800
















With 95% Confidence Limits
   
Chi-Square Statistics 
Statistic Value p-Value 
Continuity Adj. Chi-Square 3.8581 0.0495 
Likelihood Ratio Chi-Square 4.3338 0.0374 
Mantel-Haenszel Chi-Square 4.2973 0.0382 
 
Fisher's Exact Test 
Left-sided Pr <= F 0.0244 
Right-sided Pr >= F 0.9857 
Table Probability (P) 0.0102 
Two-sided Pr <= P 0.0390 
 
Analysis of Maximum Likelihood Estimates 





Error Chi-Square p-value 
Group allocation Test -0.456 0.223 4.2061 0.0403 
 
 Confidence Interval 
Parameter Hazard Ratio lower upper 
Group allocation Test 0.634 0.410 0.980 
 
Analysis of Maximum Likelihood Estimates 





Error Chi-Square p-value 
Age [years] 0.108 0.018 36.2773 <.0001 
Pack year history 0.015 0.004 16.1504 <.0001 
Gender Male 0.154 0.228 0.4550 0.5000 
Smoking status  
Ex-smoker 
-0.443 0.225 3.8986 0.0483 
Group allocation Test -0.472 0.223 4.4963 0.0340 
 
 Confidence Interval 
Parameter Hazard Ratio lower upper 
Age [years] 1.114 1.076 1.154 
Pack year history 1.016 1.008 1.023 
Gender Male 1.166 0.746 1.822 
Smoking status Ex-smoker 0.642 0.413 0.997 





Supplementary Data Pack 3:  
   





Lung cancer death reported in the 2 years since randomisation? 
 No Test Test Total 
Variable N (%) N (%) N (%) 
No 6097 (99.6%) 6070 (99.7%) 12167 (99.7%) 
Yes 24 (0.4%) 17 (0.3%) 41 (0.3%) 
Total 6121 (100.0%) 6087 (100.0%) 12208 (100.0%) 
 
Chi-Square Statistics 
Statistic Value p-Value 
Chi-Square 1.1604 0.2814 
Continuity Adj. Chi-Square 0.8478 0.3572 
Likelihood Ratio Chi-Square 1.1662 0.2802 
Mantel-Haenszel Chi-Square 1.1603 0.2814 
 
Fisher's Exact Test 
Left-sided Pr <= F 0.1787 
Right-sided Pr >= F 0.8916 
Table Probability (P) 0.0703 
Two-sided Pr <= P 0.3482 
 
0 200 400 600 800














With 95% Confidence Limits
   
Analysis of Maximum Likelihood Estimates 





Error Chi-Square p-value 
Group allocation 
Test 
-0.340 0.317 1.1509 0.2834 
 
 Confidence Interval 
Parameter Hazard Ratio lower upper 
Group allocation Test 0.712 0.382 1.325 
 
Analysis of Maximum Likelihood Estimates 










Age [years] 0.127 0.026 23.1273 <.0001 <.0001 
Pack year history 0.016 0.004 21.5281 <.0001 <.0001 
Random Factor 
Practice 
  2.5531  0.3744 
Gender Male 0.121 0.329 0.1358 0.7125 0.7122 
Smoking status  
Ex-smoker 
-0.924 0.340 7.3666 0.0066 0.0066 
Group allocation Test -0.330 0.318 1.0805 0.2986 0.2985 
 
 Confidence Interval 
Parameter Hazard Ratio lower upper 
Age [years] 1.135 1.078 1.195 
Pack year history 1.016 1.009 1.023 
Random Factor Practice    
Gender Male 1.129 0.592 2.154 
Smoking status Ex-smoker 0.397 0.204 0.774 
















   




Any cancer death reported in the 2 years since randomisation? 
 No Test Test Total 
Variable N (%) N (%) N (%) 
No 6076 (99.3%) 6050 (99.4%) 12126 (99.3%) 
Yes 45 (0.7%) 37 (0.6%) 82 (0.7%) 
Total 6121 (100.0%) 6087 (100.0%) 12208 (100.0%) 
 
Chi-Square Statistics 
Statistic Value p-Value 
Chi-Square 0.7415 0.3892 
Continuity Adj. Chi-Square 0.5630 0.4531 
Likelihood Ratio Chi-Square 0.7428 0.3888 
Mantel-Haenszel Chi-Square 0.7415 0.3892 
 
Fisher's Exact Test 
Left-sided Pr <= F 0.2266 
Right-sided Pr >= F 0.8344 
Table Probability (P) 0.0611 
Two-sided Pr <= P 0.4383 
 
0 200 400 600 800
















With 95% Confidence Limits
   
Analysis of Maximum Likelihood Estimates 





Error Chi-Square p-value 
Group allocation Test -0.191 0.222 0.7400 0.3897 
 
 Confidence Interval 
Parameter Hazard Ratio lower upper 
Group allocation Test 0.826 0.535 1.276 
 
Analysis of Maximum Likelihood Estimates 





Error Chi-Square p-value 
Age [years] 0.098 0.018 30.4475 <.0001 
Pack year history 0.011 0.004 10.0361 0.0015 
Gender Male 0.286 0.232 1.5111 0.2190 
Smoking status  
Ex-smoker 
-0.859 0.240 12.7782 0.0004 
Group allocation Test -0.191 0.222 0.7366 0.3907 
 
 Confidence Interval 
Parameter Hazard Ratio lower upper 
Age [years] 1.103 1.065 1.142 
Pack year history 1.011 1.004 1.019 
Gender Male 1.331 0.844 2.099 
Smoking status Ex-smoker 0.424 0.265 0.679 





















Secondary Outcome Analysis 3: All-Cause Mortality Two Years After Randomisation 




Any cause death reported in the 2 years since randomisation? 
 No Test Test Total 
Variable N (%) N (%) N (%) 
No 6013 (98.2%) 6000 (98.6%) 12013 (98.4%) 
Yes 108 (1.8%) 87 (1.4%) 195 (1.6%) 
Total 6121 (100.0%) 6087 (100.0%) 12208 (100.0%) 
 
Chi-Square Statistics 
Statistic Value p-Value 
Chi-Square 2.1809 0.1397 
Continuity Adj. Chi-Square 1.9729 0.1601 
Likelihood Ratio Chi-Square 2.1853 0.1393 
Mantel-Haenszel Chi-Square 2.1808 0.1397 
 
Fisher's Exact Test 
Left-sided Pr <= F 0.0800 
Right-sided Pr >= F 0.9394 
Table Probability (P) 0.0194 
Two-sided Pr <= P 0.1489 
 
0 200 400 600 800















With 95% Confidence Limits
   
Analysis of Maximum Likelihood Estimates 





Error Chi-Square p-value 
Group allocation Test -0.212 0.144 2.1735 0.1404 
 
 Confidence Interval 
Parameter Hazard Ratio lower upper 
Group allocation Test 0.809 0.610 1.072 
 
Analysis of Maximum Likelihood Estimates 





Error Chi-Square p-value 
adjusted  
p-value 
Age [years] 0.070 0.011 38.4582 <.0001 <.0001 
Pack year history 0.010 0.003 14.9175 0.0001 0.0001 
Random Factor 
Practice 
  14.3637  0.3422 
Gender Male 0.486 0.154 10.0249 0.0015 0.0015 
Smoking status  
Ex-smoker 
-0.679 0.153 19.6351 <.0001 <.0001 
Group allocation Test -0.212 0.144 2.1549 0.1421 0.1420 
 
 Confidence Interval 
Parameter Hazard Ratio lower upper 
Age [years] 1.072 1.049 1.096 
Pack year history 1.010 1.005 1.015 
Random Factor Practice    
Gender Male 1.626 1.203 2.197 
Smoking status Ex-smoker 0.507 0.375 0.685 
Group allocation Test 0.809 0.610 1.073 
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 Objectives Outcomes 
Primary to assess the effectiveness of 
EarlyCDT-Lung test in reducing 
the incidence of patients with late-
stage lung cancer at diagnosis, 
compared with standard clinical 
practice; 
difference at 24 months after randomisation, 
between the number of patients with stage 
3, 4 or unclassified lung cancer at diagnosis 




to assess the effectiveness of 
EarlyCDT-Lung test in improving 
the diagnosis of early-stage lung 
cancers; 
numbers, at 24months after randomisation, 
in the different stages at diagnosis (3/ 4/ U/ 
other) in the intervention arm and the control 
arm; 
2 to undertake a cost-effectiveness 
analysis  of EarlyCDT-Lung test 
as a primary screening method in 
comparison to standard clinical 
practice; 
difference, after 2 years, in the costs and 
outcomes between the intervention arm and 
the control arm; cost-effectiveness of the 
intervention compared to standard clinical 
practice 
3a to compare lung-cancer mortality, 
all-cause mortality and cancer-
specific mortality in high-risk 
groups provided with EarlyCDT-
Lung test, compared with standard 
practice; 
estimates, after 2 years, of lung cancer 
mortality, all-cause mortality and cancer-
specific mortality in the intervention arm and 
in the control arm; assessment of 
significance of differences; 
3b to compare long-term future 
mortality in high-risk groups 
provided with EarlyCDT-Lung test, 
compared with standard practice; 
estimates, after 5 and 10 years of long-term 
future mortality in the intervention arm and in 
the control arm; assessment of significance 
of differences; 
4 to obtain refined estimates of the 
sensitivity, specificity, positive 
predictive value and negative 
predictive value of EarlyCDT-Lung 
test; 
estimates, after 2 years of (i) the number of 
patients with stage 3, 4 or unclassified lung 
cancer at diagnosis in the EarlyCDT-Lung 
test-positive group and those in the 
EarlyCDT-Lung test-negative group and (ii) 
stage at diagnosis in the EarlyCDT-Lung 
test-positive and EarlyCDT-Lung test-
negative group; 
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5 to assess behavioural outcomes 
including smoking, psychological 
outcomes including cancer worry, 
anxiety, depression, distress 
specific to clinical investigations; 
scores at baseline, and follow-up on EQ5D, 
Hospital Anxiety and Depression Scale 
(HADS), Positive and Negative Affect 
Schedule (PANAS), Revised Illness 
Perception Questionnaire – Lung Cancer 
(IPQ-LC), Lung cancer risk perception, 
Health anxiety subscale of Health 
Orientation Scale (HOS) and the Lung 
Cancer Worry Scale (LCWS), Medication, 
smoking behaviour, demographic details. 
Follow-up questionnaires include same 
items, plus Impact of Events Scale 
(intervention group only), healthcare 
utilisation and dates and results of follow-up 
investigations for lung cancer (test positive 
group only). The HADS is not included in 
follow- up questionnaires. Follow-up 
questionnaires are administered between 1 
and 24 months to subsets of the control arm 
and intervention arm; (all participants in the 
EarlyCDT-positive group will be approached 
with the recruitment aim of 300 from this 
group collected at 1,3,6,12,18 and 24 
months. The EarlyCDT-negative and control 
groups will be recruited at the same rate as 
the EarlyCDT-positive group with the 
recruitment aim of 300 from each group 
collected at 1,3,6 and 12 months). 
6 to assess the effectiveness of 
EarlyCDT-Lung test on other 
clinical outcomes such as CVD, 
COPD, other cancers, hospital 
stays and outcomes identified 
though SMR linkage, etc.; 
Incidence of  other clinical outcomes such as 
CVD, COPD, other cancers, hospital stays, 
identified through SMR linkage, measured at 
24 months, 5 and 10  
years in the intervention arm and in the 
control arm; assessment of significance of 
differences; 
7 to assess uptake of subsequent 
investigations such as CXR, CT, 
bronchoscopy, etc. 
numbers in Taysidegroup (EarlyCDT-Lung  
test-positive, EarlyCDT-Lung test-negative, 
control) undertaking subsequent 
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QUESTION / RATIONALE 
Lung cancer is the most common cause of cancer-related death worldwide. The majority of cases 
are detected at a late stage when prognosis is poor. Lung cancer remains the fourth least likely 
cancer to be picked up early by GPs. Low dose computed tomography (CT) scanning of high risk 
individuals can reduce lung cancer mortality by 20% but it is expensive and, despite scanning, late 
stage diagnosis results in substantial morbidity.  
The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk 
assessment and detection in the earliest stages of the disease. Survival rates are much higher 
when cancer is diagnosed early but because lung cancer is often diagnosed symptomatically, most 
cases are discovered after the disease has spread. In these cases, the 5-year survival rate is less 
than 10%. By testing patients who are at a high risk for developing lung cancer before symptoms 
appear, the EarlyCDT-Lung test could help diagnose lung cancer sooner, when treatment options 
are more likely to be successful. The EarlyCDT-Lung test detects autoantibodies, which are a 
patient’s immune response to antigens produced by solid-tumor cells. Because these 
autoantibodies are produced by healthy individuals at lower levels, the EarlyCDT-Lung test 
enables physicians to identify those patients producing autoantibodies at higher levels and who are 
at an increased lung cancer risk or who are already in the early stages of lung cancer. 
The EarlyCDT-Lung test can potentially identify those at high risk of lung cancer in whom the 
benefit/risk ratio for CT scanning is likely to be more favourable. The primary research question is 
therefore: 
Does using the EarlyCDT-Lung test to identify those at high risk of lung cancer and any 
subsequent CT scanning reduce the incidence of patients with late-stage lung cancer (3 & 4) or 
unclassified presentation (U) at diagnosis, compared with standard practice? 
 
Secondary questions include, but are not limited to: 
Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer 
using the EarlyCDT-Lung test 
Version 8 23-05-2018 
23-05-2018 
i) Is the use of the EarlyCDT-Lung test cost-effective compared to standard clinical practice? 
ii) What is the short and long term emotional and behavioural impact of the EarlyCDT-lung 
test? 
iii) Does the EarlyCDT-Lung test improve clinical outcomes including but not limited to 
cardiovascular disease (CVD), COPD, hospital stays and outcomes identified through SMR 
linkage? 
HYPOTHESIS 
In a high risk population the EarlyCDT-Lung test reduces the incidence of late stage tumours; 3 / 4 
/ Unclassified (U) at diagnosis compared to normal clinical practice. 
AIMS 
to assess the effectiveness of EarlyCDT-Lung test in increasing early stage lung cancer detection, 
thereby reducing the rate of late stage (3 / 4 / U) presentation, compared to normal clinical 
practice; 
to assess the cost-effectiveness of EarlyCDT-Lung test compared to normal clinical practice;  
to assess the effectiveness of EarlyCDT-Lung test in reducing adverse outcomes including 
potential psychological and behavioural consequences. 
DESIGN 
 We propose a randomised controlled trial of 12,000 participants. Cancer screening programmes 
should be based on the high quality evidence which trials provide that they reduce cancer specific 
mortality. People should be invited to participate in population screening programmes on the basis 
of firm evidence that the overall balance between potential benefits and harms is favourable. 
Where screening programmes have relied upon observational data, for example in breast and 
prostate cancer screening programmes have remained controversial for many years. Eventually in 
the case of breast cancer large trials have been undertaken to determine the place of the 
screening method in national programmes. In contrast where large trials have preceded regional 
and national roll-out of cancer screening programmes e.g. in bowel cancer, the programmes have 
been more evidence based (for example, population based trials of faecal occult blood testing 
Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer 
using the EarlyCDT-Lung test 
Version 8 23-05-2018 
23-05-2018 
have consistently demonstrated significant reductions in colorectal cancer mortality and are 
summarised in a meta-analysis that indicates a reduction of 16% overall and 25% when adjusted 
for screening uptake). In the case of lung cancer we have observational data to suggest that the 
Early CDT-Lung test may be effective and it is now necessary to undertake a trial to determine 
whether this potential benefit outweighs potential harms and whether the test would be a cost 
effective use of NHS resources. 
SETTING 
To recruit participants via  general practices, predominately within the lowest quintile of deprivation 
measured using the Scottish Index of Multiple Deprivation in NHS Tayside, NHS Greater Glasgow 
& Clyde (GG&C) and NHS Lanarkshire (recruitment in NHS Tayside is now complete.) However, it 
is anticipated that a number of potential participants will contact the study team in response to the 
initial media interest surrounding the launch of the study and via family and friends of randomised 
participants. All interested individuals outwith the GP recruitment strategy will be assessed in 
relation to inclusion/exclusion criteria including residing within the selected geographical post 
codes. These participants will be screened at either their participating GP practice or at the local 
Clinical Research Facility/Centre.  
PARTICIPANTS 
Adults aged 50 to 75 who are at risk of lung cancer will be eligible to participate. These are defined 
as those who are current or former cigarette smokers with at least 20 pack-years, or have a history 
of cigarette smoking less than 20 pack-years plus a family history (mother, father, brother, sister) 
of lung cancer which gives an individual a personal risk similar to a smoking history of 20 pack 
years. Participants should be healthy enough to undergo pulmonary resection or stereotactic 
radiotherapy.  
INTERVENTION 
EarlyCDT-Lung test followed by imaging studies in those with a positive result. 
COMPARATOR 
Standard practice of awaiting clinical presentation of symptoms suggestive of lung cancer then 
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investigation by the standard NHS pathway involving chest X-ray, CT scan and bronchoscopy as 
clinically necessary. 
OUTCOMES  
Primary   
The difference, at 24 months after randomisation, between the rates of patients with stage 3, 4 or 
unclassified lung cancer at diagnosis in the intervention arm, and those in the control arm; 
Secondary  
(1) numbers at 24 months after randomisation, in the different stages at diagnosis (3/ 4/ U/ other) 
in the intervention arm and the control arm; 
(2) difference, after 2 years, between costs and outcomes in the intervention arm and in the control 
arm, cost-effectiveness of EarlyCDT-Lung test compared to normal clinical practice; 
(3a) estimates, after 2 years, of lung cancer mortality, all-cause mortality and cancer-specific 
mortality rates in the intervention arm and in the control arm ; assessment of significance of 
differences; 
(3b) estimates, after 5 years and 10 years, of long-term future mortality rates in the intervention 
arm and in the control arm; assessment of significance of differences; 
(4) estimates, after 2 years of, provided by (i) the number of patients with stage 3, 4 or unclassified 
lung cancer at diagnosis in the EarlyCDT-Lung test-positive group and those in the EarlyCDT-Lung 
test-negative group and (ii) stage at diagnosis in the EarlyCDT-Lung test-positive and EarlyCDT-
Lung test-negative group;  
(5)  scores at baseline, and follow-up on in a survey administered prior to treatment allocation, 
including EQ5D, Hospital Anxiety and Depression Scale (HADS), Positive and Negative Affect 
Schedule (PANAS), Revised Illness Perception Questionnaire – Lung Cancer (IPQ-LC), Lung 
cancer risk perception, Health anxiety subscale of Health Orientation Scale (HOS) and the Lung 
Cancer Worry Scale (LCWS), Medication, smoking behaviour, demographic details. Follow-up 
questionnaires include same items, plus Impact of Events Scale (intervention group only) and 
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healthcare utilisation. The HADS is not included in follow- up questionnaires. Follow-up 
questionnaires are EQ-5D, cancer worry, positive and negative mood, smoking behaviour including 
cessation intentions and attempts; scores in additional questionnaires administered at between 1 
and 24 months to subsets of the control arm and intervention arm; (all participants in the 
EarlyCDT-positive group will be approached with the recruitment aim of 300 from this group 
collected at 1,3,6,12,18 and 24 months. The EarlyCDT-negative and control groups will be 
recruited at the same rate as the EarlyCDT-positive group with the recruitment aim of 300 from 
each group collected at 1,3,6 and 12 months). 
Three qualitative sub-studies will enquire via interview (telephone or face-to-face) to; 1) Investigate 
the experiences of individuals who choose not to have the EarlyCDT-Lung test rationale for not 
responding to a lung cancer screening, 2) Enquire how patients perceive the EarlyCDT-lung test 
and what do they understand about their test results and 3) Examine changes in smoking 
behaviour following EarlyCDT-Lung testing.  
The recruitment and methodologies for these sub-studies are outlined in detail in Appendix 2.  
(6) incidence at 24 months, and after 5 years and 10 years, in other clinical measures such as 
CVD, COPD, hospital stays, and outcomes identified through SMR linkage, etc. in the intervention 
arm and in the control arm; assessment of significance of differences; 
(7) numbers in Tayside group (EarlyCDT-Lung test-positive, EarlyCDT-Lung test-negative, control) 
undertaking subsequent investigations such as CXR, CT, bronchoscopy, etc.  Statistical modelling 
will be used to generate sample data for the Glasgow and Lanarkshire groups. 
METHODS 
Based on the test’s 93% specificity and 41% sensitivity we anticipate that approximately 640 
participants in the intervention arm will have a positive test result. These will be offered a chest X-
ray.  Those with a negative or indeterminate X-ray will be referred for a study CT scan.  If the initial 
CT is negative then subsequent CTs will be offered 6 monthly for 24 months. Those individuals 
with  monitorable abnormalities as classified by the radiology/respiratory physician’s study panel 
on baseline CT scan or subsequent CT will be followed up over the study period or referred for 
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NHS clinical care as appropriate. All individuals entering the study will be flagged and followed up 
via the Scottish Cancer Registry. Participants who develop lung cancer will be individually 
followed-up via electronic record-linkage to assess both time to diagnosis and stage of disease at 
diagnosis. If no histological stage is available, stage will be assessed blind to allocation status from 
chest X-rays or CT, or, if no imaging is available a medical assessment of stage will be carried out.  
 
HOW THE RESULTS OF THIS RESEARCH WILL BE USED 
The study will assess the EarlyCDT-Lung test’s clinical and cost effectiveness and suitability for a 
large-scale, accredited screening service for early lung cancer detection.  It will also assess 
potential morbidity arising from the test and potential harms and benefits of a negative EarlyCDT-
Lung test result. 
DATES AND DURATION OF TRIAL 
01/04/2013 –31-07-16 - End of recruitment (12k) 
End of 24 month follow-up - 31/07/18 (+/- 4 weeks)  
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1. INTRODUCTION 
1.1. BACKGROUND TO THE RESEARCH 
Lung cancer is the world’s leading cause of cancer related mortality and a major source of 
morbidity. 85% of patients with lung cancer remain undiagnosed until the disease is symptomatic 
and has reached an advanced stage. Moreover, Scotland has had one of the highest rates of lung 
cancer in the world. Around 2,460 men and 2,340 women are diagnosed with lung cancer in 
Scotland every year, which is 16% of the total UK lung cancer cases, despite Scotland having 8% 
of the UK’s population. Survival from lung cancer is poor with less than 9% of patients still alive at 
five years after diagnosis, due primarily to late stage of presentation. 
Early detection and diagnosis of cancer improves prognosis - the current 5-year survival rate is 
approximately 60% for stage I lung cancer but is only 1% for those with stage IV disease. The 
potential of early detection of lung cancer to improve outcomes was highlighted by the National 
Cancer Institute (NCI) National Lung Screening Trial (NLST) which recently reported that CT 
screening reduced lung cancer mortality by 20%. However as a primary screening modality CT is 
expensive and leads to substantial morbidity in a significant percentage of individuals whose tests 
are false positives. The EarlyCDT-Lung test is an innovative diagnostic test for early detection of 
lung cancer. The test can stratify individuals by risk of developing future lung cancer; those with a 
positive test are invited for a chest X-ray then, if that is normal, a CT scan.  This targeted approach 
to CT scanning for early lung cancer detection is likely to be a more cost-effective and potentially 
less harmful approach to population screening than a blanket CT-scanning program of all people 
considered at high risk of future lung cancer. 
A substantial body of published research has documented autoantibody (AAB) responses against 
various tumour derived/associated antigens (TAA) in patients with a wide range of solid tumours, 
including lung cancer. The serum proteome provides an attractive source of potential biomarkers 
and because serum collection is minimally invasive it can be repeatedly surveyed for cancer 
biomarkers.  AABs have been detected months to years before clinical diagnosis of breast and 
lung cancers, supporting the hypothesis that AABs could be incorporated into an early detection 
assay. Subsequent research studies have confirmed AABs to TAAs in patients with early stage 
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lung cancer.  AABs have been reported in lung cancer subjects up to 5 years before clinical 
diagnosis even where annual screening spiral CTs were being performed.  
A serum assay has been developed and validated called Early Cancer Detection Test-Lung 
(EarlyCDT-Lung) that can detect 40% of lung cancers with a specificity of 90% by measuring 
autoantibodies to a panel of cancer antigens (p53, NY-ESO-1, CAGE, GBU4-5, Annexin1, & 
SOX2). Further confirmation of this sensitivity and specificity of the test for lung cancer using four 
new, independent sample sets has recently been published. A study of patient demographics 
showed no difference in autoantibodies based on age, gender and ethnicity. This autoantibody 
technology is different from CT scanning which in a prevalence screening test has a sensitivity of 
67% for lung cancers developing over the following 12 months but with a low specificity of only 
around 49%. Indeed a prevalence CT screen will detect approximately 36% of the lung cancers 
which will develop in the next three years. If the EarlyCDT-Lung test has a three year ‘look 
forward’, as clinical data suggests, then the test will detect 40% of lung cancers which develop 
over this three year time period but with seven times fewer false positives than CT scanning. Two 
new autoantibodies (AAbs) have recently been added to the panel (and one removed) and the test 
now measures seven; p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 & SOX2 and identifies 
41% of lung cancers with an increased specificity of 93% (Chapman et al; 2012). The 7-AAbs 
panel will be utilised in this study and all statistical calculations are based on the 41% sensitivity 
and 93% specificity of the Early CDT-Lung test.   
EarlyCDT-Lung detects lung cancer at all stages – i.e. it detects early stage lung cancer as well as 
advanced disease - which means autoantibodies are present at all stages of disease.  In a large 
group of patients with newly diagnosed lung cancers there was no difference  in positivity rate for 
EarlyCDT-Lung in early or late stage disease lung cancers – whether this was looking at all lung 
cancers, only non small-cell (NSC) lung cancer, NSC lung cancer, or only small-cell lung cancer 
(SCLC). Thus, while autoantibodies are present in early stage they are not a biomarker of only 
early stage disease. An audit, (presented July 2011 at the International Association for The Study 
of Lung Cancer) of the first 1000 patients to take the EarlyCDT-Lung test commercially, further 
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confirms that the test works in clinical practice. These data are promising but an insufficient basis 
for introducing a national lung cancer screening program in the UK. 
1.2. RESEARCH QUESTIONS 
The primary research question is: 
Does using the EarlyCDT-Lung test to identify those at high risk of lung cancer and any 
subsequent CT scanning reduce the incidence of patients with late-stage lung cancer (3 & 4) or 
unclassified presentation (U) at diagnosis, compared with standard practice? 
Secondary questions include, but are not limited to: 
i) is the use of the EarlyCDT-Lung test cost-effective compared to standard clinical practice? 
ii) what is the emotional and behavioural impact of the EarlyCDT-lung test? 
iii) does the EarlyCDT-Lung test improve clinical outcomes including but not limited to CVD, 
COPD, other cancers, hospital stays, outcomes identified through SMR linkage, etc.? 
1.3. RATIONALE FOR STUDY 
Lung cancer is the most common cause of cancer related death worldwide. The majority of cases 
are detected at a late stage when prognosis is poor. 
CT scanning can reduce lung cancer mortality by 20%, but there are too many false positives 
leading to a large number of individuals without cancer being exposed to repeated unnecessary 
radiation. 
A disproportionate amount of patients are given cause for concern when between 35%-75%  of 
patients screened by CT are treated as positive (with resultant increased anxiety) but only 2%-3% 
will have a true cancer. 
Active interventions (e.g. trans-thoracic biopsy, surgical resection) as the result of positive CT 
scans give rise to significant side effects and complications in a percentage of individuals. 
The cost of screening with CT is expensive and unlikely to meet the thresholds for cost-
effectiveness (£20k - £30k/QALY) usually used within the UK by bodies such as NICE.  
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Background to the study: pre-trial qualitative work 
Four focus group sessions (Ethical approval by I-WHO, University of Nottingham, Appendix 1) were 
held with smokers aged 50 and over living in some of Glasgow and Dundee’s most deprived areas 
in order to explore recruitment preferences and likely willingness to participate in the forthcoming 
EarlyCDT Lung Cancer Scotland (ECLS) Study.  
The work was carried out throughout June and July 2012 in four areas of Scotland: Castlemilk, 
Darnley, Charleston and Douglas.  A total of 32 people aged 50 – 75 took part in the work, including 
14 men and 18 women.  All but one were current smokers, and most had smoked for 40 years or 
more, smoking one pack or more per day. 
The findings from the work enabled the formation of a number of recommendations for both the main 
trial recruitment strategy and materials, including: 
1.3.1 Recruitment Strategy 
• Adopting a personal approach to invitations, sent from GPs and followed up in writing;   
• Setting deadlines for people to respond to invitations to maximise likely response rates, 
bolstered by local radio and newspaper coverage of the study;  
• Providing early summary information which emphasises that the study is not focussed on 
trying to encourage people to stop smoking; 
• Telling people which group they are in after taking their blood in order to minimise attrition 
during initial appointments but also emphasising the value of being in the ‘non-test group’ for 
the benefit of wider research and public health; and 
• Offering flexible appointments that are close to people’s homes. 
1.3.2 Recruitment Materials 
• Making sure that all documents explicitly say that the trial relates solely to lung cancer;  
• Explaining the reasoning for the study design (including control and intervention groups) and 
setting out clearly what the inclusion/exclusion criteria are, and why these criteria apply; 
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• Explaining the purpose of randomisation, and ensuring early on that people know when they 
will be notified of which group they are in.  This includes offering assurances that random 
means random and that being placed in the test group is not an indicator of risk; 
• Acknowledging that not only smokers can be affected by lung cancer; and    
• Offering sufficient information on the issue of making blood available to other researchers, 
and what this might entail, to allow fully informed consent to be given.    
Trial documents have been developed based on the learning to emerge from these groups which 
will hopefully maximise participation in the upcoming trial and forearm those involved in its delivery 
as to the potential barriers to participation that may exist among the target population. 
1.4. OBJECTIVES 
Primary Objective 
To assess the effectiveness of EarlyCDT-Lung test in reducing the incidence of patients with late-
stage lung cancer at diagnosis compared with standard practice. 
Secondary Objectives 
1) to assess the effectiveness of EarlyCDT-Lung test in improving the diagnosis of early-stage lung 
cancers; 
2) to undertake a cost-effectiveness analysis of EarlyCDT-Lung test as a primary screening 
method compared to standard clinical practice; 
3a) to compare lung-cancer mortality, all-cause mortality and cancer-specific mortality in high-risk 
groups provided with EarlyCDT-Lung test, compared with standard practice; 
3b) to compare long-term future mortality in high-risk groups provided with EarlyCDT-Lung test, 
compared with standard practice; 
4) to obtain refined estimates of the sensitivity, specificity, positive predictive value and negative 
predictive value of EarlyCDT-Lung test; 
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5) to assess behavioural outcomes including smoking, psychological outcomes including cancer 
worry, anxiety, depression, distress specific to clinical investigations; 
6) to assess the effectiveness of EarlyCDT-Lung test on other clinical outcomes; 
7) to assess uptake of subsequent investigations. 
1.5. OUTCOMES 
Primary Outcomes 
The difference, at 24 months after randomisation, between the number of patients with stage 3, 4 
or unclassified lung cancer at diagnosis in the intervention arm, and those in the control arm; 
Secondary Outcomes 
1) numbers, at 24 months after randomisation, in the different stages at diagnosis (3/ 4/ U/ other) in 
the intervention arm and the control arm; 
2) difference, after 2 years, between costs and outcomes in the intervention arm and in the control 
arm, cost-effectiveness of EarlyCDT-Lung test compared to normal clinical practice; 
3a) estimates, after 2 years, of lung cancer mortality, all-cause mortality and cancer-specific 
mortality rates in the intervention arm and in the control arm; assessment of significance of 
differences; 
3b) estimates, after 5 years and 10 years of long-term future mortality rates in the intervention arm 
and in the control arm; assessment of significance of differences; 
4) estimates, after 2 years of  (i) the number of patients with stage 3, 4 or unclassified lung cancer 
at diagnosis in the EarlyCDT-Lung test-positive group and those in the EarlyCDT-Lung test-
negative group and (ii) stage at diagnosis in the EarlyCDT-Lung test-positive and EarlyCDT-Lung 
test-negative group;  
5) scores at baseline, and follow-up on in a survey administered prior to treatment allocation, 
including EQ5D, Positive and Negative Affect Schedule (PANAS), Revised Illness Perception 
Questionnaire – Lung Cancer (IPQ-LC), Lung cancer risk perception, Health anxiety subscale of 
Health Orientation Scale (HOS) and the Lung Cancer Worry Scale (LCWS), Medication, smoking 
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behaviour, demographic details. Follow-up questionnaires include same items, plus Impact of 
Events Scale (intervention group only), healthcare utilisation and dates and results of follow-up 
investigations for lung cancer (test positive group only). The HADS is not included in follow- up 
questionnaires. Follow-up questionnaires are EQ-5D, cancer worry, positive and negative mood, 
smoking behaviour including cessation intentions and attempts; scores in additional questionnaires 
administered at between 1 and 24 months to subsets of the control arm and intervention arm; (all 
participants in the EarlyCDT-positive group will be approached with the recruitment aim of 300 
from this group collected at 1,3,6,12,18 and 24 months. The EarlyCDT-negative and control groups 
will be recruited at the same rate as the EarlyCDT-positive group with the recruitment aim of 300 
from each group collected at 1,3,6 and 12 months). 
6) incidence at baseline, 24 months, and after 5 years and 10 years, in other clinical measures 
such as CVD, COPD, other cancers, hospital stays, and outcomes identified through SMR linkage, 
etc. in the intervention arm and in the control arm; assessment of significance of differences; 
7) numbers in Tayside group(EarlyCDT-Lung test-positive, EarlyCDT-Lung test-negative, control) 
undertaking subsequent investigations such as CXR, CT, bronchoscopy, etc. Statistical modelling 
will be used to generate sample data for the Glasgow and Lanarkshire groups. 
 
2. STUDY DESIGN 
2.1. STUDY DESCRIPTION 
A randomised controlled trial involving 12,000 participants recruited through primary care and 
community based recruitment strategies in Scotland.  
2.1.1. Setting 
General practices in the lowest quintile of deprivation in Scotland as measured by the quintiles of 
the Scottish Index of Multiple Deprivation (SIMD 2012). Subsequent recruitment will be attained 
through adverts, posters, flyers and community based interactions. Potential participants can either 
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be seen at their participating GP practice or at the local clinical research centre, or other 
appropriate clinical location.  
2.1.2. Participants 
Adults aged 50 to 75 who are at risk of lung cancer will be eligible to participate. These are defined 
as those who are, current or former cigarette smokers with at least 20 pack-years, or have a 
history of cigarette smoking less than 20 pack-years plus an immediate family history (mother, 
father, brother, sister, child) of lung cancer which gives an individual a personal risk similar to a 
smoking history of 20 pack years.  Participants should be healthy enough to undergo pulmonary 
resection or stereotactic radiotherapy.
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2.2. STUDY FLOWCHART  
2.3. STUDY ASSESSMENT AND NOTIFICATIONS 
Table 1. Overview of Study Assessments/Notifications.  
ASSESSMENT/PROCEDURES         TIMELINE* ( ± 2 weeks) 
 Visit 1 (~30 -45mins)  Visit 2*(~30mns) 
➢ *EarlyCDT Positive Test 
Participants may visit or call. 
➢ EARLY CDT Negative Test 
Participants may attend for 
further information/advice only.  
Informed Consent  X   
Inclusion/Exclusion Criteria X   
• Review/Record only Relevant Medical History relating 
to IC/EC 
X   
• Review/Record Relevant Medications  
• Relating to IC/EC 
X   
Blood Sample X   
Baseline Questionnaire X   
Thank you letter to Control Group  X  
EarlyCDT- Lung Test Result Letter   X  
GP Results Letter & ICF copy (negative)  X  
Result Discussion/ Imaging Schedule    X 
Provide PIS 2    X 
GP Result Letter & ICF copy (positive)   X  
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EARLYCDT – Lung Test  Positive Result Participants – Imaging Schedule 
 TIMELINE( ± 4 weeks) (±12 weeks for CT prior to study entry) 
 0 6 months 12 months 18 months 24 months 
CXR X     
CT Scan* X X X X X 
*Scheduled every 6 months, if participant enters NHS clinical care 
pathway, subsequent study CT scans will be cancelled. 
 Research team member will call 2-4 days before each 
scheduled CT scan to check health status and attendance.  
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3. STUDY POPULATION 
3.1. NUMBER OF PARTICIPANTS 
Twelve thousand participants from general practices in the most deprived quintile of the population 
Scotland (as measured by the quintiles of the Scottish Index of Multiple Deprivation (SIMD) 2012 - 
version 2. In this second phase of recruitment, from 10,000 to 12,000 only participants from NHS 
Greater Glasgow and Clyde and NHS Lanarkshire will be invited as recruitment in NHS Tayside is 
now complete.  
3.2. INCLUSION CRITERIA 
1. Participant is willing and able to give informed consent for participation in the study 
2. Male or female aged 50 years to 75 years 
3. Current or Ex-smoker with at least 20 year pack history 
4. or Less than 20 year pack history but with family history of lung cancer in a 1st degree 
relative (mother, father, sister, brother, child) 
5. ECOG Status: 0, 1 and 2 (Eastern Co-operative Oncology Group) 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work 
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6. Geographical postal sectors of:  
NHS Geographical Area  Eligible Postcodes 
Tayside DD1 - DD11, PH1–PH3 , PH6-PH8, PH10, PH11, PH13, 
PH15 & PH16, KY13 
Greater Glasgow & 
Clyde 
G1-G5, G11 –G15, G20-G22, G31-34, G40 –G46,  
G51- G53, G60-G62 &G64, G66 & G69, G72 & G73,   
G76-G78, G81-G83 
PA1–PA8 (except PA6), PA11-PA16 & PA19  
Lanarkshire G33, G65, G67, G69, G71-75, ML1-12 
 
3.3. EXCLUSION CRITERIA 
1. History of any cancer other than non-melanomatous skin cancer, cervical cancer in situ.  
2.  Symptoms suggestive of lung cancer within past 6 months (haemoptysis, unintentional 
weight loss (at least 5% in preceding 6 months). 
3.  Patients for whom the GP considers invitation to the study would cause undue distress. 
4. Patients with other terminal disease. 
5. Patients on (> 3months) of Cyclophosphamide .  Note: Other prolonged / continuous use 
(>3months) of cytotoxic/ immuno-suppressant drugs eg: Methotrexate, Azathioprine, 
Rapamycin, Mycophenolate, Rituximab and anti-immunophilins such as Ciclosporin, 
Tacrolimus,and  Monotherapy using glucocorticoids/ steroids eg prednisolone are  NOT 
exclusion criteria. 
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4. PARTICIPANT SELECTION AND ENROLMENT 
4.1. IDENTIFYING PARTICIPANTS 
Potentially eligible individuals will be identified from GP medical records by an electronic medical 
record search undertaken by the Scottish Primary Care Research Network. Potential participants 
will be recruited via their General Practitioner (through SPCRN) using a range of methods 
including: 
a. postal invitation letter including a Participant Information Brochure; 
and where necessary or appropriate: 
b. invitation letter including a summary of the study Participant Information Sheet on collection 
of repeat prescription; 
c. invitation during consultation with GP / Practice Nurse / Health Care Assistant at the 
practice; 
d. invitation to those eligible on registered research volunteer databases  
e. poster present in the GP’s waiting room; 
f. other recruitment strategies may be employed including; Media campaign involving: local 
and national newspapers; BBC Scotland; local radio,  
Celebrity endorsement 
g. Publicity campaign using posters/leaflets etc….including: 
Football/Bingo halls/ Bowling      
Smoking Cessation Clinics 
Hospital main entrances/ hospital clinics  
Shopping Centres/Supermarkets/Pubs/etc. 
Benefits offices/Post offices etc. 
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Sheltered Housing /Housing Associations 
Community and charitable outreach programs 
Mobile screening clinic 
Pharmacist approach through practices. 
The potential impact of the presentation of the PIB on recruitment (rather than understanding) 
is unclear and is being evaluated by the embedded MRC START study 
(http://www.medicine.manchester.ac.uk/mrcstart/about/).  ECLS has l included an embedded 
methodological substudy (substudy 4) of two, ethically-approved PIB presentations as part of 
the START study.  The full protocol of sub-study 4 is given in Appendix 3. (The START (sub-
study 4) now completed). 
For this sub-study, potential participants received one of two versions – the original version 
(ECLS PIB) or a revised version (START PIB), which has had both its language and its design 
modified after consultation with groups of the public selected to be similar to the ECLS target 
population. The content (i.e. the topics covered) remains the same in the both versions of the 
Participant Information Brochure. The allocation of brochure sheet version to each participant 
was decided randomly. The main outcome of interest here is the proportion of participants 
receiving each version of the sheet who go on to take part in the ECLS trial.  When a 
participant is consented to the ECLS Study they will indicate that they have read and 
understood either the ECLS PIB or the START PIB.   A sample size of approximately 2000 
participants was involved in MRC START in ECLS, split equally between the two versions of 
the PIB and GP Invitation Letters.   
Sub study 5 is the work of an MRC funded PhD studentship at the University of Glasgow.  The 
proposal adds two new aspects to the psychological sub-studies.  Firstly looking at people who 
decide not to take part after showing interest by either cancelling or not attending their 
appointment, and exploring why they change their mind.  Secondly exploring any differences 
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between the people taking part who self refer for the study as opposed to reply to a GP 
invitation.  Full details of the sub-study can be found in Appendix 4. 
The study invitation letter will include a slip for participants to either express interest in finding 
out more about the study, provide their contact details or to request no further contact about 
the study. Those returning an expression of interest will be telephoned, more than 24 hours 
after anticipated receipt of the Participant Information Brochure, by a member of the research 
team. Additionally, the participant is given the opportunity to call or email the study team. The 
call (instigated by participant or study team) will allow a discussion of the study, to answer any 
questions the potential participant may have, do a preliminary assessment of eligibility and if 
they agree, to make an appointment for a recruitment visit (hereafter referred to as the eligibility 
assessment phone contact).  An appointment letter/email will be sent out to confirm 
appointment.  
A reminder call/email or text, whichever is preferable to the participant, will be carried out up to 
2 days prior to the screening appointment. A reminder process decreases non-attendance.  
Non-responders to the GP postal invite will be approached again using a reminder letter or 
postcard. Those participants who have not responded after the first reminder will be viewed as 
non-responder and eligible for the first qualitative sub-study (See Appendix 2). This study will 
investigate the experiences of individuals who choose not to respond to lung cancer screening. 
If GPs agree, a member of the ECLS research team will attend the practice and call non-
responders as per the eligible SPCRN list. This process has proven to be a successful 
reminder methodology in previous primacy care research conducted by the CI. A member of 
the research team will undertake the eligibility assessment phone contact for those expressing 
interest in the consultation or by returning the expression of interest form at a later date.  
The recommended study visit order (findings from focus groups) is: 
➢ obtain consent 
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➢ take bloods from all consented participants (in the unlikely event; a blood sample is 
unobtainable or the blood sample blood sample from a participant in the test group is lost 
during transportation the participant will be contacted to arrange a subsequent sample.)   
➢ complete survey questionnaire 
➢ randomise to treatment arm 
After randomisation group allocation is known all participates will be asked if they continue to 
be happy for their bloods to be used for the Early CDT- Lung Test  
(lung cancer test group) and for future cancer related research for those  who agreed by  
initialling the relevant box on the consent form.  
For participants randomised to the intervention arm the EarlyCDT-Lung test will be performed 
and patients followed up according to their result. 
At Visit 1 participants are advised that those with a positive EarlyCDT-Lung test result will be 
invited to a follow-up visit to interpret the test results and explain the progress on study thereafter. 
Those with a negative EarlyCDT-Lung test result will be written to, explaining the test results and 
will be offered a follow-up visit or a telephone call if they wish. They will be advised of symptoms to 
watch for including persistent cough, coughing up blood, shortness of breath, weight loss or loss of 
appetite. They will be counselled to carry on having tests for other types of cancer if they are 
offered (e.g. bowel cancer test, mammograms, cervical smears). In less than 1% of cases an Early 
CDTLung test is deemed invalid. The test panel for the participant shows a characteristic indicative 
of some interfering nonspecific immunoreactive component. This result is deemed neither positive 
nor negative and it is not recommended that the test is repeated as the result will remain invalid. 
On those very rare cases that this occurs a participant will be informed by a telephone call and a 
follow-up results letter. Those in the control arm will be written to and thanked for their contribution 
to the study and advised and counselled identically to those with a negative test result. 
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All participants who agreed to donate blood for future will be advised that it will be used in cancer 
related research.  
A patient specific section of the study website (www.eclsstudy.org) containing Participant 
Information Sheets and research staff contact details will be available for participants to view.  
4.2. CONSENTING PARTICIPANTS 
All individuals taking informed consent will have received training in Good Clinical Practice (GCP). 
It will be explained to patients that they are under no obligation to enter the trial and that they can 
withdraw at any time during the trial, without having to give a reason. A copy of the signed 
Informed Consent Form (ICF) will be given /or posted out to the study participant. A copy of the 
signed consent form will be given or sent to the GP with a letter outlining the study and patient 
pathway. The letter will notify the GP of their patients’ group allocation, relevant Early CDT-Lung 
test result, and any notable findings found at the screening visit, namely, the request to give up 
smoking or relevant clinical information that requires further clinical judgement.  The original copy 
of the ICF is to be retained at the study site (ISF or TMF, as appropriate.). If any notable findings 
are found at the screening visit an anonymised copy of the GP letter will be filed in the participant’s 
study file.  If new safety information results in significant changes to the study risk–benefit 
assessment, the Protocol, Participant Information Sheet and/or consent form will be reviewed, 
updated and amended as necessary. All participants will be informed of the new information, given 
a copy of the revised consent form and asked to re-consent if they choose to continue in the study. 
4.3. SCREENING FOR ELIGIBILITY 
SPCRN staff will visit practices to undertake searches of the GP computerised records. The 
resulting list of potentially eligible participants will be checked by a GP at the practice to ensure 
that those for whom study participation would cause undue distress and those with a terminal 
disease are not sent study invitations. Telephone screening of potentially eligible participants who 
have returned an expression of interest will be undertaken by a member of the research team at 
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the eligibility assessment phone contact. This will include assessment of age, smoking history, 
family history of lung cancer, previous cancer, ECOG status and eligible postcode.   
4.4. INELIGIBLE AND NON-RECRUITED PARTICIPANTS  
The reason(s) for ineligibility will be explained to the patients and any questions they have will be 
answered. They will be thanked for their interest in the trial and any relevant clinical information will 
be communicated to their GP where the patient has given consent. 
4.5. RANDOMISATION 
Participants will be allocated to intervention or comparison group during the recruitment visit (Visit 
1) using a web-based randomisation system; TRuST, provided by Tayside Clinical Trials Unit 
(TCTU).  Set-up of the randomisation system will be by TCTU staff under the supervision of a 
TCTU statistician.  Randomisation will be stratified by site and minimised by age, sex and smoking 
history. 
4.6. ADMINISTRATION OF THE TEST 
Individuals at higher risk will be identified from GP medical records or community based 
recruitment as described above. Consenting individuals will be randomised to either receive an 
EarlyCDT-Lung test or standard care.  
4.7. MANAGEMENT OF THE VISITS 
Based on the test’s 93% specificity and 41% sensitivity we anticipate that approximately 640 
participants in the intervention arm will have a positive test result. These will be offered a chest X-
ray.  Those with a negative or indeterminate X-ray will be referred for a CT scan.  If the initial CT is 
negative then subsequent CTs will be offered 6 monthly for 24 months.  
If a participant has had a chest X-ray in the previous 1 month, or a CT scan in the previous 3 
months to a scheduled study CT scan, these can be reviewed as part of the study. This will reduce 
the need to expose participants to unnecessary radiation. With the participants consent chest X-
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rays or CT scans prior to study entry will be retrospectively coded as per ECLS Radiology 
Schema. The participant will proceed to have the series of 5 CTs if clinically appropriate.   
Participants will receive appointments via mail/email (as preferred). Participants will be called 2-4 
days before each CT-scan appointment. By calling, this allows the participant to ask any questions, 
check health status, arrange transport (if required) and increase participant retention. Individuals 
with monitorable abnormalities as classified by the radiology/respiratory physician’s study panel on 
baseline CT scan or subsequent CT will be followed up over the study period or referred for NHS 
clinical care as appropriate. All individuals entering the study will be flagged and followed-up via 
the Scottish Cancer Registry. Participants who develop lung cancer will be individually followed-up 
via their medical records to assess both time to diagnosis and stage of disease at diagnosis. If no 
histological stage is available, stage will be assessed by a panel of three respiratory physicians 
blind to allocation status of the study subjects from chest X-rays or CT, or, if no imaging is 
available, medical assessment of stage will be carried out. 
Prior to sending CT scan appointments participant deaths will be check using the SMR to ensure 
sensitivity is maintained. All participants in the EarlyCDT- Positive test groups known to have died 
will be removed from the CT scan appointment schedule register.  If patients (EarlyCDT-Positive 
test) fail to attend for any imaging assessment during the study, they will receive two reminders 
(one letter, one phone call). On the third non-attendance, a letter will be sent to the participant’s 
GP to inform them of non-attendance.  An appointment window of ± 4 weeks will be initiated for 
each scheduled CT scan.   
Participants will receive results letters in relation to their initial CXR and CT scan and subsequent 
CT scans. Any clinical intervention/treatment will be arranged by the study team.   
Two additional sub- studies 6 and 7 (Appendix 5 & 6, respectively) have been added to establish 
difference in the emotional, cognitive and behavioral response to a positive EarlyCDT test if 
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pulmonary nodules are present on a chest computed tomography compared to a normal chest 
computed tomography? 
This study will utilise anonymised data from study participants in the EarlyCDT-positive group who 
participated in the emotional and behavioural outcomes study and completed the baseline 
questionnaire and at least one follow-up questionnaire at one, three or six months post recruitment 
(Qualitative Sub-Studies, Appendix 2). Participants will not require to be contacted for this sub-
study. Full proposal is described in Appendix 5.  
Sub- study &:  Living with lung nodules: what information would patients find helpful? 
The aim of this sub-study study is to explore the ECLS study participant response following receipt 
of a letter informing them that their CT scan showed a pulmonary nodule.   
The letter currently used in the trial is based on that used in routine clinical care. It is important to 
explore patient’s experiences following receipt of the letter to inform any roll out of lung cancer 
screening as a national programme.  Through the use of focus groups the existing letter will be 
reviewed and, if deemed appropriate, modifications will be made with a view to improving how 
these test results are communicated.  
The objectives of this study will be achieved through the use of four different focus groups.  Groups 
1 and 2 will focus on the current experiences of the ECLS trial participants receiving notification of 
a lung nodule while Groups 3 and 4 will seek to address what the participant response would be to 
a modified information letter which would be developed (if changes are required) from the 
comments from focus Groups 1 and 2.. A full outline of the project is outlined in Appendix 6.  
4.8. WITHDRAWAL AND STUDY TERMINATION PROCEDURES 
No circumstances are anticipated for the withdrawal of patients from the trial initiated by the clinical 
team or trial investigators. Patients may choose to withdraw from the trial at any time, without 
giving a reason, and without compromising their future treatment.  
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If the study should be terminated early, for whatever reason, all participants with a positive Early 
CDT-Lung test will continue to be seen by the PI (lung specialist) and will continue to undergo any 
clinically relevant investigations and reviews and will be  treated (if required) according to current 
clinical practice. 
5. STUDY AND SAFETY ASSESSMENTS STUDY 
ASSESSMENTS 
The main study assessment is the test result.  
Other assessments include; 
i. diagnosis 
ii. costs associated with intervention including any follow up/confirmatory tests and subsequent 
treatment 
iii. costs associated with routine clinical management of patients  
iv. health utility data  
v. mortality (various) 
vi. measures of psychological outcomes and health behaviour 
vii. other clinical outcomes uptake of subsequent investigations  
5.1. SAFETY ASSESSMENTS 
As the study does not employ an Investigational Medicinal Product, Adverse Events (AE) or 
Serious Adverse Events (SAE) will be recorded but not reported in the Annual Report.  A number 
of factors affecting the trial population suggest that we would expect to observe a larger than 
normal incidence of episodes of ill-health due to both the age and co-morbidities of the study 
population.  All known disease progressions and co-morbidities will be regarded as outcomes 
including complications arising from investigations which result in a hospital stay which will be 
captured in outcome 6 and all medical treatment or interventions will be predicated upon normal 
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clinical care and not related to the study protocol.  All CXR and CT scan incidental findings 
(incidentaloma) will be recorded in the CRF as an incidental findings as per Radiological reporting 
Schema and Study Operations Manual.   Bespoke letters to GPs and/or specialist referrals will be 
completed by study physicians as required.   Participants will be informed of any incidental findings 
and any action required by a study physicians via letter or phone call if appropriate.  
6. DATA COLLECTION & MANAGEMENT 
6.1. DATA COLLECTION 
It is the CI and PIs responsibility to ensure the accuracy of all data entered and recorded in the 
CRF/eCRFs and the database. The Delegation of Responsibilities Log will identify all trial 
personnel responsible for data collection, entry, handling and managing the database. 
The data will be collected by the RN and/or the PI directly onto a paper CRF with subsequent 
transcription to the eCRF. Where there is electronic storage of non-identifiable data this will be on 
a password protected device and/or database.  A plan for data quality control will be developed by 
the data management staff at Tayside Clinical Trials Unit and the trial management team.  
All research blood samples (anonymised using barcodes) will be labelled and packaged according 
to IATA regulations using Royal Mail Safeboxes or INTELSIUS or equivalent transport box 
systems to be transported to the University of Nottingham for processing, transporting and storage 
of samples for future research.  All samples will be stored under custodianship as per UK Biobank 
guidelines. Sample Analysis and Chain of Custody Plans will be documented in the Study 
Operations Manual.  The participant’s medical notes (GP and hospital) paper or electronic will act 
as source data for relevant past medical history, subsequent medical conditions, hospital 
admissions and diagnostic reports. 
Psychological and behavioural data relating to smoking, psychological outcomes including cancer 
worry, anxiety, depression and distress will be collected on all 12,000 participants through a 
baseline questionnaire administered during Visit 1. If required the RN can assist the participant 
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with the completion of the questionnaire. Follow-up data will be collected between 1 and 24 
months on subsets of the intervention and control groups. All participants in the EarlyCDT-positive 
group will be approached with the recruitment aim of 300 from this group collected at 1,3,6,12,18 
and 24 months. The EarlyCDT-negative and control groups will be approached at the same rate as 
the EarlyCDT-positive group with the recruitment aim of 300 from each group, collected at 1,3,6 
and 12 months.. A web-based tool will be used weekly to randomly sample patients from the 
EarlyCDT-negative and control groups, stratified by the two study centres. It is anticipated an 
average of 8 individuals (4 from each of the two study centres) will be randomly sampled and 
invited to complete follow-up questionnaires from each of the EarlyCDT-negative and control 
groups per week (based on a 10 month recruitment period and an anticipated response rate of 
67%). Response rates will be monitored and if they are lower than 67%, the number randomly 
sampled at each centre will be increased to achieve a minimum of 200 responses. Participants will 
be sent a £5 gift voucher for use in a range of stores for each questionnaire to be completed.  A 
Cochrane review found the use of small monetary incentives significantly increases response rates 
to postal questionnaires (Edwards et al., 2009). There are precedents in trials and other UK 
studies where small monetary incentives have been used. 
Two methods will be used for the initial period of recruitment: 50% of the sample will receive the 
questionnaire with the voucher and 50% will receive the voucher once they have returned their 
questionnaire. An assessment will be carried out to determine which of the two methods is more 
effective in maximising recruitment rate and will then be employed for the remainder of the study. 
A phone number will be provided for participants to call the research team for assistance in 
completing questionnaires.  Occasionally the research team may call participants to check on 
postal delivery and offer assistance with completion to increase return rate.  Participants who 
develop lung cancer during the 24 month follow-up period will not be sent further study 
questionnaires.  
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For those participants who have agreed to further contact will be eligible for qualitative sub-study 2 
and 3 as outlined in Appendix 2.  
Follow up questionnaire sampling to achieve 300 participants in control, negative and positive 
groups is now complete. No participants will be actively recruited to these sub-studies. However, 
those participants in the positive group will be invited to continue to complete the follow-up 
questionnaires to 24 months post randomisation.  
6.2. DATA MANAGEMENT SYSTEM 
Tayside Clinical Trials Unit (TCTU) will provide a data management system using OpenClinica 
(https://www.openclinica.com/), its standard GCP-compliant data management system. Case 
Report Forms (CRF) will be developed together with the trial management team, statistician and 
data manager to ensure that the data management system supports the research aims of the 
study. The data management system will be fully validated, including the provision of test data and 
supporting documentation. Data entry will be coordinated by TCTU.  Data will be stored on servers 
controlled through the Tayside Medical Science Centre and housed within the Health Informatics 
Centre and the University of Dundee.  Backup and disaster recovery will be provided by TCTU 
according to its standard operating procedures. 
 
The Statistical Analysis Plan will specify dummy tables linked to primary and secondary outcomes 
and the data management system will be designed to export directly to the dummy table formats 
for analysis.   
 
7. STATISTICS AND DATA ANALYSIS 
7.1. SAMPLE SIZE CALCULATION 
The rate of lung cancer is 187/100,000 per year for patients aged 50-74 in Scotland 2008 (ISD 
cancer statistics). Deprivation is associated with a higher risk of lung cancer. Those in the most 
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deprived quintile are associated with an increased risk of 1.8 times compared to the middle quintile 
of deprivation. (ISD cancer statistics) this gives an estimated annual lung cancer rate of 
336/100,000 among the practices taking part in the study. A high risk group within this population 
will be selected using similar entry criteria (outlined above) as the Mayo screening study which had 
a 2% prevalence rate of lung cancer and a further 2% incidence rate over the following 5 years 
(Swensson 2005). The baseline rate of late stage presentation for the particular high risk 
population envisaged in this study is uncertain, as is the size of the reduction in late stage 
presentation likely to be achieved through use of EarlyCDT-Lung. Using an estimated late stage 
presentation rate of 1,200/100,000 per year in the control group i.e. 2.4% over the two-year follow-
up period, we require 85% power at 5% significance (two-sided) to detect an estimated reduction 
of 35% in presentation rate in the test group i.e. as low as 780/100,000 per year or 1.56% over the 
two-year follow-up period. This corresponds to an estimated event rate over the two years of 
follow-up of 120 events in the control group and 78 events in the test group and implies a required 
sample size of n=5,000 per group i.e. 10,000 altogether. 
The anticipated 35% reduction in event rate between the control group and the test group is 
justified by current estimates of the capability of the EarlyCDT-Lung test to identify cases (41% 
sensitivity, 93% specificity) together with current estimates of the specificity of CT scanning (67%). 
The sample size calculations are based upon standard methods for time to event data using the 
cpower function in R and stpower exponential procedure in Stata and assuming exponential 
survival. They were also confirmed using standard approaches for detecting a change in binomial 
probabilities, and confirmed using approaches to detect a change in Poisson rates (with essentially 
identical results as loss to follow up is expected to be low). 
The study aims for a short recruitment period and so no allowance has been made for accrual. 
With such an allowance, say to 1 year, the power will increase to 91% to identify a 35% reduction 
provided the minimum follow up period of 2 years is observed.  
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The initial assumptions of the rate of late stage presentation rate of 1,200/100,000 per year among 
the study participants was too optimistic and in January to May 2015 investigations were carried 
out to inform an increase in the sample size.  Baseline information on the 8639 participants 
recruited to March 2015 (18 months from first randomisation) was used to derive an estimate of 
lung cancer risk based upon the Spitz Model (25).  A number of variables in this model were not 
recorded in the study data base and low risk values were used in the risk calculation implying that 
the risk estimates should be underestimates.  This suggested that the with 10,000 participants the 
rate of lung cancer would be expected to be around 680/100,000 and  540/100,000 for stage 
T3/T4/Unknown lung cancer using ISD cancer statistics figures of 80% lung cancers in Scotland 
are late stage.  A sensitivity analysis around the missing data assumptions suggests that a late 
stage rate of around 600/100,000 may not be unreasonable, though is likely to be at the upper 
limit. 
Using an assumption of 600/100,000 for late stage lung cancer and acknowledging that 
recruitment is over a 2 year period the study has a power of 80% to detect a 35% reduction 
associated with the use of the EarlyCDT-Lung test to identify cases, provided that analysis takes 
place after all randomised patients have been followed up for 2 years.  While an 80% power is at 
the lower end of acceptable powers this is the power level which has been used in a number of 
lung cancer screening trials. 
The power of the study is sensitive to the assumptions about the rate of late stage cancer and the 
recruitment rate, see Table 2.  A power in excess of 90% could only realistically be achieved by 
recruiting 15,000 patients or by changing the primary endpoint to 3 years post randomisation for all 
patients.  It the recruitment phase extends past 2 years to 2.5 years to recruit 12,000 participants 
then the power will increase slightly to 83%. 
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Table 2.  Powers for a 35% reduction in the rate of T3/T4/Unknown lung cancer using a log rank 
test at the 5% significance level for various underlying rates in the control group, total sample 
sizes, and differing lengths of recruitment periods and follow up periods. 
 
For the follow-up analysis of behavioural and psychological outcomes, 200 participants in each 
group will allow a mean difference of 3.00 (SD 15.04 (unpublished data from the ProtecT prostate 
cancer study) in the Impact of Events Scale with 80% power and 2-sided 5% significance level. We 
will, however, collect data from 300 patients in each group to allow for attrition. Assuming 80% 
participants are current smokers, we will obtain 80% power at 5% significance level to detect a 
reduction in smoking from 80% to 67% i.e. 13% points difference assuming follow up on 200 
participants. 
7.2. PROPOSED ANALYSES 
Characteristics of participants will be compared informally between treatment arms at baseline. 
The main analysis of the primary outcome will be intention-to-treat. Cox proportional hazards 
models will be used to estimate the hazard ratio of the rate of late stage lung cancer in the 
intervention arm compared to the control arm.  Participants who are lost to follow up will be 
censored.  The models will adjust for age, gender smoking history and practice.  If appropriate, 
random cluster effects will be included rather than fixed effects for practices. A similar methodology 
will be used for the secondary outcomes of comparisons of mortality rates (secondary outcomes 
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3a and 3b). A subsequent analysis will compare the outcomes of those with EarlyCDT positive in 
comparison to those in the intervention group with EarlyCDT negative (primary contrast for this 
analysis) and those in the control group (secondary analysis 1).  Comparisons of proportions 
(secondary analyses 1 and 4) will be carried out using chi square tests.  Fishers exact test will be 
used if the numbers of events are small. 
The analyses of the questionnaire responses (secondary analysis 5) will be carried out using the 
appropriate 2 sample t tests and regression methods at baseline.  Non parametric tests will be 
used if there is evidence of non-normal scores.  Multilevel models will be used to analyse the 
repeated scores during follow up. 
Poisson regression models, adjusting for follow up time if necessary, will be used to investigate the 
other clinical measures (secondary outcomes 6 and 7). 
7.2.1. Cost effective analysis 
 
The short-term within-trial analysis will compare the costs and outcomes associated with the 
intervention group to those of the comparison group at 24 months.  A longer term analysis will 
employ a decision analytic model to link the short term outcomes measured within the trial to 
potential longer term impacts on health (for example in terms of impacts on the development of 
cardiovascular disease, diabetes etc.). Both analyses will utilise the NHS and personal social 
service perspective favoured by NICE. 
7.3. MISSING DATA 
The extent of missing data will be examined and, if necessary, methods such as multiple 
imputation will be implemented to provide robust results, assuming data are missing at random 
(MAR). 
7.4. TRANSFER OF DATA  
Transfer of Data will be achieved according to standard TCTU SOPs (Study Operations Manual). 
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The female age group in this study (50 to 75 years) are unlikely to be pregnant. However, 
assessment of risk is established when all women are asked about the possibility of pregnancy 
prior to any imaging investigations as per usual NHS risk assessment protocols. 
8. TRIAL MANAGEMENT AND OVERSIGHT ARRANGEMENTS 
8.1. TRIAL MANAGEMENT GROUP 
The trial will be overseen by a Trial Steering Committee (TSC) and a Trial Management Group 
(TMG) consisting of the CI and co-investigators, trial managers and with representation for 
research nurses and SPCRN. Day-to-day management of delivery of the trial will be achieved 
through the Trial Operations Group chaired by the Assistant Director of TCTU and comprising 
project and trial managers, data managers, statistician and software developers. 
8.2. TRIAL MANAGEMENT 
The Senior Trial Manager and Trial Manager will oversee the study and will be accountable to the 
CI. The Senior Trial Manager will be responsible for other trial processes hosted within the TCTU. 
However, this remains the overall responsibility of the CI. Any queries will be resolved by the CI or 
delegated member of the trial team. 
A study-specific Delegation Log will be prepared for each site, detailing the responsibilities of each 
member of staff working on the trial.  
8.3. TRIAL STEERING COMMITTEE 
The committee will be a TSC with an integrated data monitoring committee. It will be a mixture of 
lung cancer investigators and independent members.  The TSC will be chaired by an independent, 
expert in cancer research and clinical trials.  Other independent members will include a statistician.  
The TSC will meet bi-annually, with the first meeting being shortly after the start of the project. The 
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terms of reference of the TSC and the draft template for reporting will be detailed in the ECLS TSC 
Terms of Reference.  
8.4. INSPECTION OF RECORDS 
The CI, PIs and all institutions involved in the study will permit trial related monitoring, audits, REC 
review, and regulatory inspection(s). In the event of an audit, the CI agrees to allow the Sponsor, 
representatives of the Sponsor or regulatory authorities direct access to all study records and 
source documentation. 
8.5. RISK ASSESSMENT 
A pre-Sponsorship study risk assessment was carried out by the TASC Research Governance 
Manager prior to Sponsorship approval being granted. 
8.6. STUDY MONITORING 
The Sponsor will determine the appropriate extent and nature of monitoring for the study and will 
appoint appropriately qualified and trained monitors. 
8.6.1 Potential Risks 
8.6.2 Blood sampling 
Veins and arteries vary in size from one patient to another and from one side of the body to the 
other. Obtaining a blood sample from some people may be more difficult than from others. Risks 
associated with having blood drawn are slight but may include: 
➢ Excessive bleeding  
➢ Fainting or feeling light-headed  
➢ Hematoma (blood accumulating under the skin)  
➢ Infection (a slight risk any time the skin is broken) 
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All research nursing staff will be highly trained and experienced in venipuncture thereby minimizing 
risk.  
8.6.3 Test results 
False positives and false negatives are explained as follows: 
No medical test is completely accurate. This blood test is expected to pick up about 40 in 100 
cases of lung cancer and detect the cancer at an early stage. However this means it doesn’t pick 
up all cases of lung cancer. So even if your test is negative, or if you are in the non-test group, it is 
important that you see your GP if you are unwell in any way that could be due to lung cancer. This 
includes persistent cough, coughing up blood, shortness of breath, weight loss or loss of appetite.  
As no medical test is completely accurate, the blood test will be positive in some people who do 
not have early lung cancer (false positive). These people will be offered a chest X-ray and lung 
scans to see if they have lung cancer. We expect this to happen to 8 out of every 9 people who 
have a positive test result.   
 
8.6.4 Radiography 
Risks relating to chest X-ray and CT scan are explained as follows:  
Chest X-rays and lung scans use radiation. People can develop cancer because of this radiation, 
but this is very rare. The amount of radiation you get from a chest X-ray is very small. About 1 
million people would need to have a chest X-ray for one extra person to develop cancer because 
of the chest X-ray. A CT lung scan gives about 600 times as much radiation as a chest X-ray. 1500 
people would need to have a CT lung scan for one extra person to develop cancer because of the 
scan. These risks are very small compared to the one in four chance we each have of developing 
cancer in our lifetime. Only about 640 people in this study are expected to have a positive blood 
test and will, therefore, need chest X-rays and scans. The chances of radiation affecting anyone in 
this study in this way are therefore very small. 
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8.6.5 Minimising Risk 
All associated risks are well understood and have established procedures for management. 
9. GOOD CLINICAL PRACTICE 
9.1. ETHICAL CONDUCT OF THE STUDY 
The study will be conducted in accordance with the principles of good clinical practice (GCP) and 
the Research Governance Framework Scotland. 
In addition to Sponsorship approval, a favorable ethical opinion will be obtained from an 
appropriate REC and appropriate NHS R&D approval(s) will be obtained prior to commencement 
of the study. 
9.1.1. Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner 
designed to maintain participant confidentiality. All records will be kept in a secure storage area 
with limited access to study staff only. Clinical information will not be released without the written 
permission of the participant, except as necessary for monitoring and auditing by the Sponsor, its 
designee or Regulatory Authorities. The CI and study staff involved with this study will not disclose 
or use for any purpose other than performance of the study, any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the study. 
Prior written agreement from the Sponsor or its designee will be obtained for the disclosure of any 
said confidential information to other parties. 
9.1.2. Data Protection 
The CI and study staff involved with this study will comply with the requirements of the Data 
Protection Act 1998 and subsequent General Data Protection Regulation updates, with regard to 
the collection, storage, processing and disclosure of personal information and will uphold the Act’s 
core principles. The CI and study staff will also adhere, if appropriate, to the current version of the 
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NHS Scotland Code of Practice on Protecting Patient Confidentiality.  Access to collated 
participant data will be restricted to the CI and appropriate study staff. 
Computers used to collate the data will have limited access measures via user names and 
passwords. 
Published results will not contain any personal data that could allow identification of individual 
participants. 
9.1.3. Insurance and Indemnity 
The University of Dundee and Tayside Health Board are Co-Sponsoring the study. 
Insurance. –The University of Dundee will obtain and hold Professional Negligence Clinical Trials 
Insurance cover for legal liabilities arising from the study. 
Tayside Health Board will maintain its membership of the Clinical Negligence and Other Risks 
Insurance Scheme (“CNORIS”) which covers the legal liability of Tayside in relation to the study. 
Where the study involves University of Dundee staff undertaking clinical research on NHS patients, 
such staff will hold honorary contracts with Tayside Health Board which means they will have cover 
under Tayside’s membership of the CNORIS scheme. 
Indemnity. The Co-Sponsors do not provide study participants with indemnity in relation to 
participation in the Study but have insurance for legal liability as described above. 
10. STUDY CONDUCT RESPONSIBILITIES 
10.1. PROTOCOL AMENDMENTS, DEVIATIONS AND BREACHES 
The CI will seek approval for any amendments to the Protocol or other study documents from the 
Sponsor, REC and NHS R&D Office(s). Amendments to the protocol or other study docs will not be 
implemented without these approvals.  
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In the event that a CI needs to deviate from the protocol, the nature of and reasons for the 
deviation will be recorded in a Protocol Deviation & Breach Log and Protocol Deviation & Breach 
Report (if required) and submitted to the Sponsor (if required). If this necessitates a subsequent 
protocol amendment, this will be submitted to the Sponsor for approval and then to the appropriate 
REC and lead NHS R&D Office for review and approval.  
In the event that a serious breach of GCP is suspected, this will be reported to the Sponsor 
immediately using the form “Notification to Sponsor of Serious Breach or Serious Deviation”.  
10.2. STUDY RECORD RETENTION 
To enable evaluations and/or audits from regulatory authorities, the investigators agree to keep 
records, including the identity of all participating patients (sufficient information to link records, all 
signed informed consent forms, source documents, and group allocation to intervention and 
control). The records should be retained by the study site coordinators and investigator according 
to TASC SOP or local NHS Board regulations, or as specified in the Clinical Study Agreement, 
whichever is longer. 
If the CI, PI or a study site coordinator relocates, retires, or for any reason withdraws from the trial, 
the University of Dundee should be prospectively notified. The trial records must be transferred to 
an acceptable designee. The study site coordinator must comply with the TASC SOP on archiving 
and obtain written permission from the Sponsor before disposing of any records, even if retention 
requirements have been met.   
10.3. END OF STUDY 
The end of study is defined as last patient last visit scan (LPLV) plus 24 M. The Sponsor, CI and/or 
the TSC have the right at any time to terminate the study for clinical or administrative reasons. 
End of follow-up. 
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The end of the study will be reported to the Sponsor, REC and NHS R&D Offices within 90 days, 
or 15 days if the study is terminated prematurely. The CI will ensure that any appropriate follow up 
is arranged for all participants. 
A summary report of the study will be provided to the Sponsor and REC within 1year of the end of 
the study. 
10.4. CONTINUATION OF TREATMENT FOLLOWING THE END OF 
STUDY 
All participants will enter the standard NHS care pathway after their last scan; for further 
investigations or treatment if: a positive scan, classified nodules or incidental finding or if a non-
referable scan is determined they will be monitored by their GP if they become symptomatic for 
lung cancer.  
11. REPORTING, PUBLICATIONS AND NOTIFICATION OF 
RESULTS 
11.1. AUTHORSHIP POLICY 
Ownership of the data arising from this study resides with the study team. On completion of the 
study, the study data will be analysed and tabulated, and a clinical study report will be prepared. 
Authorship eligibility for each manuscript arising from this study will be determined according to the 
criteria laid out in the Working Practice Document on Authorship filed in the Study Operations 
Manual. 
11.2. PUBLICATION 
The clinical study report will be used for publication and presentation at scientific meetings. Trial 
Investigators have the right to publish orally or in writing the results of the study. 
Summaries of results will also be made available to trial Investigators for dissemination within their 
clinical areas (where appropriate and according to their discretion). 
Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer 
using the EarlyCDT-Lung test 
Version 8 23-05-2018 
23-05-2018 
11.3. PEER REVIEW 
This trial has undergone peer review by the Sponsorship Committee.  The trial design and results 
will be reviewed in publications by the referees of the journal to which the paper (and its protocol) 
will be submitted. 
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Maximising recruitment in early cancer detection trials: The lung cancer trial 
Version 1: 30/4/12 
Investigators: 
Professor Kavita Vedhara (IWHO, University of Nottingham) 
Professor Denise Kendrick (Primary Care, University of Nottingham) 
Professor John Robertson (Division of Breast Surgery, University of Nottingham) 
Dr Roshan Das Nair (NUH NHS Trust & University of Nottingham) 
Dr Kate Skellington-Orr (KSO Research Limited, Glasgow) 
Professor Frank Sullivan (Population Health Sciences, University of Dundee) 
 
Background 
Approximately two thirds of trials fail to reach their recruitment target or have to extend their 
recruitment period (1,2). Failing to fulfil recruitment targets rates leads to underpowered studies, 
reduced generalisability, increased costs and delays in the implementation of effective 
interventions. Maximising recruitment is thus key to a trial’s success. 
Funding has been obtained for a large trial of the effectiveness and cost effectiveness of 
early cancer detection test in lung cancer, which is to be evaluated in individuals at high risk of 
lung cancer. The trial will be undertaken in general practices from disadvantaged areas in Glasgow 
and Dundee, commencing October 2012. Recruitment to trials amongst disadvantaged populations 
can be particularly challenging due to a lack of trust, limited knowledge of research and low literacy 
amongst potential participants (3). Previous research has demonstrated that qualitative methods 
can be used to inform recruitment strategies by tailoring recruitment to the trial population. For 
example, the ProtecT feasibility study, for prostate specific antigen testing for prostate cancer, 
explored men’s views of trial participation, interpretation of study information, understanding and 
acceptance of randomisation and treatment. Findings fed into recruitment strategies and this 
resulted in the proportion of men consenting to randomisation increasing from 49% to 70% (4).  
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The current research has been designed to deliver tailored recruitment strategies and 
materials for the population to be targeted in the forthcoming early lung cancer detection trial. We 
propose to achieve this be addressing the following aims: 
 
Aims 
1. To explore potential trial participant views on: 
(a) issues likely to influence recruitment into the trial and willingness to be randomised (e.g., 
recruitment strategies; understanding of risk information; clinical equipoise and randomisation) 
(b) recruitment and study documentation (e.g., invitation letter, questionnaires); 
(c) factors which facilitate and hinder trial participation.  
2. To develop recruitment processes and materials for use in this, and subsequent trials. 
3. To contribute to the literature on methods for enhancing trial recruitment  
 
Methods 
We will be working with a local research company based in Scotland (KSO Research Limited) who 
will identify eligible participants; undertake the focus groups and complete the transcribing and 
analysis of material obtained through focus group discussions. As the clinical trial will recruit 
patients from both Glasgow and Dundee, we will be seeking to conduct 2 focus groups in each 
city, with up to 10 participants in each group. 
Participants: The population to be targeted in the trial will be individuals at high risk of developing 
lung cancer aged between 50-75 years i.e., individuals who self-identify as current or former 
cigarette smokers with at least 20 pack-years, or a history of cigarette smoking plus family history 
of lung cancer which gives an individual a personal risk similar to a smoking history of 20 pack 
years).  
Recruitment: KSO Research limited will use ‘on-street’ recruitment methods to recruit participants 
into the focus groups. This will involve a trained recruiter working in each of the two areas. The 
recruiter will target local amenities where eligible participants may be found, for example, smoking 
areas outside of recreational facilities, at local train or bus stations, etc.  Recruitment will take 
place at different times/days over one week.  The company have used this kind of ‘on-street’ 
recruitment before with considerable success. They have observed that finding people who agree 
‘at random’ to participate are often more likely to show genuine commitment to participation than 
those who respond to press advertisements. Furthermore, meeting the recruiter face-to-face 
encourages an early relationship and opportunity for participants to ask any questions that they 
have about participation on the spot before agreeing to take part. This approach also has the 
advantage of being cheaper than a press advertisement with no risk of over-subscription. In 
accordance with usual practice, the local police will be notified of the recruiters’ on-street presence 
and will be done with their support. 
Individuals will be approached on the street at random, although efforts will be made to 
recruit a mix of genders in each area and to fill quotas in three separate age bands (50-59, 60-69, 
70-75 years). The recruiter will first introduce themselves; provide a brief verbal introduction to the 
research and will enquire whether the individual would be willing to discuss a research project 
about a new blood test for lung cancer involving people who currently smoke or who have smoked 
previously (see recruitment questionnaire). Those who consent to further conversation will be 
asked first about their smoking status and family history of lung cancer to establish eligibility. 
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Those who are not eligible will be thanked for their time and will only be given further information 
about the research should this be requested. Those who are eligible will be asked additional brief 
screening questions regarding age and working status. Individuals who agree to participate 
immediately will receive a participant cover letter and information sheet (enclosed) and will be 
asked to provide contact information so that they can be re-contacted and reminded of the date, 
time and location of the focus group. Participants who wish to consider the invitation first, will be 
provided with contact details for the research team and a participant information sheet. Individuals 
will be advised that they will receive £30 cash to thank them for their time and to cover their out of 
pocket and travel expenses. Anonymised data will be provided to the research team on: 
1. The number of recruitment sessions undertaken 
2. The number of people approached 
3. The number of those approached who were eligible to participate and reasons for ineligibility 
4. The number of those eligible who agreed to take par 
5. The reasons why people chose not to take part 
6. Characteristics of those who were eligible who did and did not agree to take part and the 
reasons for non participation (in an EXCEL spreadsheet) 
7. The number of those agreeing to take part who attended each focus group 
 
Procedure: Written informed consent (enclosed) will be obtained from all participants prior to 
commencing the focus groups. Participants will be reminded that the discussions of the group are 
to be audio-taped and transcribed verbatim, but that they will not be identified in the recordings 
and, as such, their contributions to the discussions will remain anonymous. Participants will be 
asked to discuss issues related to the aims outlined in 1a-c above, with discussions structured 
according to a topic guide (enclosed). Participants will receive £30 at the end of the focus group to 
thank them for their time and to cover out of pocket and travel expenses and will be asked to sign 
a receipt for this.  
Analysis: Audio recordings of focus groups will be transcribed verbatim and a thematic analysis will 
be undertaken to provide a rich and detailed account of the data (5). Strategies for ensuring quality 
assurance of credibility, transferability, dependability, and confirmability of analysis will be followed 
(6). The information from this analysis will be used to further refine the recruitment strategy and 
materials for the main trial. All original data files will be confidentially destroyed and written data 
stored anonymously.   
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SEPARATE DOCUMENT (attached)  
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APPENDIX 2: ECLS STUDY: QUALITATIVE SUB-STUDIES 
(Version 1, 11-09-13) 
    
Study background information and rationale 
 
Three qualitative sub-studies have been developed to explore a number of aspects of participant s’ 
attitudes and experiences of EarlyCDT-Lung testing and changes in smoking behaviour:  
 
Sub-study one: Investigating the experiences of individuals who choose not to have the EarlyCDT-
Lung test (Ben Young) 
In order to maximise the effectiveness of a screening test in a population, uptake must be high. 
Those at highest risk of a disease are often least likely to attend for screening1 and rates of uptake 
can vary according to the type of screening2, 3. Furthermore, lung cancer screening trial participants 
have previously displayed gaps in essential knowledge, suggesting that the goal of informed choice 
in lung cancer screening may be difficult to achieve4. Quantitative research suggests screening 
uptake may be related to demographic factors, health status and attendance at previous screening 
tests3, 5, 6. The acceptability of a screening method is also a recurring factor in decisions to attend2. 
 
Lung cancer screening differs from other cancer screening because it targets a higher risk subgroup 
of the population characterised predominantly by smoking status. Barriers to uptake of lung cancer 
screening may include the absence of symptoms, lack of knowledge about the test and stigma 
associated with lung cancer4, 7, 8. Smokers may be more likely to perceive early detection and 
intervention to be of limited use9. It is important to develop an in depth understanding of the reasons 
some people decide not to have the EarlyCDT-Lung test in order to promote future uptake in those 
most at risk of lung cancer. 
 
Objectives: 
1. To explore decisions to not respond to ECLS Study invitations, reasons for not responding 
and the perceived barriers to attending for the ECLS Study visit. 
2. To assess non-responders’ understanding and knowledge of the information communicated 
to them about the EarlyCDT-Lung test. 
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3. To identify theory-based methods which could increase recruitment in a future trial or 
screening programme for early lung cancer detection. 
 
Sub-study two: How do participant s perceive the EarlyCDT-lung test and what do they understand 
about their test results? (Laura Bedford & Gozde Ozakinci) 
 
As the EarlyCDT-lung test is a different type of screening test for lung cancer it is important to 
examine participant s’ beliefs and expectations about the test. Qualitative research has highlighted 
different aspects of screening tests that individuals can hold beliefs about, for example, beliefs about 
the accuracy (sensitivity) of the test, the nature of the test, risks and side effects associated with the 
test, and type of result obtained using the test. Together, each of these beliefs can make up an 
individual’s overall perception of a screening test. Relatively limited research to date has found that 
screening test beliefs are one of several factors that can influence screening uptake8 and predict 
emotional and behavioural responses to screening test results10-12. As there is currently no method 
to quantitatively assess screening test beliefs, qualitative work in this area will be valuable as it will 
inform the development of a measure to capture participant s’ beliefs about screening tests. 
Furthermore, findings will inform how information on the EarlyCDT-lung test is presented to 
participant s.  
A participant’s understanding of their test result also has the potential to influence psychological 
outcomes following screening. For example, research has shown that a lack of understanding of the 
correct meaning of a positive screening test result can predict emotional distress following receipt of 
screening test results13, 14. Misunderstanding of a negative or normal screening test result has been 
found to lead to false reassurance, where an individual incorrectly understands a negative screening 
test result to mean that they are at no risk of developing the condition being screened for15, 16. In 
addition to understanding of test results, dissatisfaction with information provided on test results has 
also been found to predict adverse emotional outcomes, such as high levels of anxiety and worry15-
17. It is therefore important to explore what participant s understand about their EarlyCDT-lung test 
result and identify what information they need about their result as this will help to inform future 
communication of EarlyCDT-lung test results. Furthermore, the majority of work exploring 
understanding of screening test results and satisfaction with test result information has used 
quantitative methodology, so it would be valuable to conduct qualitative research in this area so that 
these factors can be explored in more depth.  
Objectives: 
1. To examine participants’ understanding of, and satisfaction with, the information they 
received about the test 
2. To explore participants’ beliefs about the EarlyCDT-lung test  
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3. To examine participants’ understanding of their test result 
4. To find out how satisfied participants were with the information provided on their test result. 
 
Sub-study three - An examination of changes in smoking behaviour following EarlyCDT-Lung testing 
(Ben Young) 
 
Smokers who attend lung cancer screening may be more motivated to stop smoking than other 
smokers18-20 and they may experience a 'teachable moment' for smoking cessation, a brief period in 
which motivation to stop smoking is enhanced21. However, evidence of changes in smoking 
behaviour in lung cancer screening participant s is inconclusive and long term changes in smoking 
prevalence in screened groups have not generally been observed22, 23. Increased cessation rates 
have been observed in participants receiving abnormal results21, 24. The ECLS Study will measure 
smoking behaviour and attitudes to smoking in a sample of participants over 12 months and this 
sub-study aims to provide an in depth exploration of those individuals’ experiences in relation to 
smoking during the study. 
Perceived barriers to smoking cessation can include current smoking behaviour, motivation to quit, 
past quit attempts, preferences for cessation support and fear of withdrawal symptoms, or of being 
judged or failing25, 26. Facilitators to cessation can include concerns about health, cost and the views 
of others27, as well as support services which are perceived to be personalised, accessible and 
effective25. The implementation of smoking cessation interventions as part of lung cancer screening 
programmes is being advocated28, creating a need for an evidence based approach to the integration 
of cessation interventions in such programmes. An exploration of the perceived barriers and 
facilitators to smoking behaviour change in ECLS Study participants can inform the development of 
relevant and acceptable cessation support in the lung cancer screening context. 
Objectives: 
8. To identify and explore decisions made regarding smoking cessation, reasons for those decisions 
and perceived barriers and facilitators to smoking cessation in screened ECLS Study 
participants. 
9. To compare differences in thoughts and experiences regarding smoking cessation between: 
a. Those who are successful in stopping smoking (i.e. reporting a change in smoking status 
from smoker to non-smoker), those who are unsuccessful (i.e. reporting a cessation attempt 
but no change in smoking status) and those who do not attempt to stop smoking (i.e. reporting 
no cessation attempt). 
b. Those who receive a positive lung cancer screening test result and those who receive a 
negative result. 
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1. Study management 
The studies will be conducted by Laura Bedford and Ben Young (PhD students) under the 
supervision of academic supervisors Kavita Vedhara (Professor of Health Psychology), Denise 
Kendrick (Professor of Primary Care Research) and John Robertson (Professor of Surgery), three 
ECLS study Principal Investigators based at the University of Nottingham, a research partner. In 
addition, Roshan das Nair (Consultant Clinical Psychologist and Honorary Associate Professor) will 
assist. Dr Gozde Ozakinci (University of St Andrews) will conduct analysis of Sub-study 2 data.  
2. Duration 
Sub-studies will take place between September 2013 – September 2015. 
3. Selection of participants 
Sub-study one – Investigating the experiences of individuals who choose not to have the 
EarlyCDT-Lung test (Ben Young) 
One recruitment strategy for the main ECLS study is identifying potential participants via SPCRN 
from primary care. Each GP list is screened by the GP to ensure eligibility and suitability. Invitation 
letters are sent via the Health Informatics Centre. These individual’s details are not know to the study 
team. Individuals who respond positively either by returning the reply slip or calling/emailing the 
study team directly will be registered on the Recruitment Tracker. The recruitment tracker is held 
within the HIC safehaven and ensures participant confidentiality and data security as per HIC 
information governance Standard Operating Procedures. The contact details of these individuals are 
released by HIC to the study team to allow further contact. Invited individuals who respond indicating 
they would like no further contact are registered on the recruitment tracker as a negative response. 
The specific details of these individuals are not visible to the study team, merely documented as a 
number of negative responses. The group which responded neither positively nor negatively are 
termed non-responders. This group can often be over 80% of the invited population. As per the study 
protocol these individuals will be sent a reminder letter/postcard.  
Participants unable to speak English will not be eligible for any of the three sub-studies as they 
involve with telephone or face to face interview. A surrogate marker for sub-studies 2 & 3 will be 
eligibility into the main ECLS study. For sub-study 1, eligibility will be assessed at the beginning of 
the telephone interview.  
For sub-study 1, eligible participants will be those within the non-responder group and who would 
have been eligible for the main ELCS study had they responded and can confirm they remember 
receiving the invitation and that they intentionally did not respond. 
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Non-responders will be identified periodically and sampled purposively from both the Glasgow and 
Dundee areas as recruitment to ECLS Study progresses. Consent will be obtained to participant in 
sub-study 1.  
Participants in the main ECLS study are invited to give consent to be contact for further contact. Only 
those participants who have given permission will be contacted with regard to sub-studies 2 & 3. 
Participants who have withdrawn from the main study or have received a diagnosis of lung cancer 
will not be eligible for sub-studies 2 &3.  
For all sub-studies one reminder will be sent. If the invited participant does not reply to either the 
initial invitation or the reminder they will not be contacted again for the sub-study participation.  
Sub-study 2: How do participants perceive the EarlyCDT-lung test and what do they 
understand about their test results? (Laura Bedford and Gozde Ozakinci) 
Eligible participants will be: 
• Willing and able to give informed consent for participation in the study 
• In the EarlyCDT-negative group or the EarlyCDT-positive group 
• Have received their screening test result within the past eight weeks.  
 
The aim is to recruit a diverse sample. This can be achieved through a maximum variation sampling 
strategy, which is recommended for qualitative studies.29 A sample obtained using maximum 
variation is not a representative sample but a purposive sample recruited to tap a variety of different 
views on a subject. This requires a strategy for sampling people who are different on a wide range 
of demographics. In this study, age, gender, ethnicity, level of deprivation (from the Scottish Index 
of Multiple Deprivation) and education level will be considered as variation factors. Roughly equal 
numbers of participants from Glasgow and Dundee will be recruited. Maximum variation sampling is 
an iterative process, whereby the first few participants sampled will direct who is sampled next.30  
 
It is expected that the final sample will consist of 30 participants, 15 from the EarlyCDT-positive 
group and 15 from the EarlyCDT-negative group. It is expected that saturation will be achieved with 
this sample; however, up to two participants from each group may be further recruited if saturation 
is not achieved. Both groups of participants will be recruited at the same rate. The sampling of 
participants will be dictated by the overall number required for this study. As previously stated, it is 
anticipated that 15 participants will be sampled per group over the 10-month study period. Therefore, 
approximately six participants will be approached per month per group with the aim of recruiting two 
participants from each group (33% response rate). A review will be carried out after two months of 
recruitment, and if response rates are low, then the number of participants approached each month 
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will be increased. The order of selecting participants will be based on maximum variation as 
described above.   
Sub-study 3 - An examination of changes in smoking behaviour following EarlyCDT-Lung 
testing (Ben Young) 
Eligible participants will have been: i) allocated to the ECLS Study screened group; ii) selected for 
follow up questionnaires; iii) have been a self-reported smoker at baseline. Participants reporting 
either successful or unsuccessful cessation attempts, or no attempt, will be sampled from groups 
receiving a positive test result and a negative test result, making six distinct groups for this sub-
study. 
• A smoker at baseline will be defined as a ‘YES’ response to the question: “Have you smoked 
any cigarettes or tobacco in the last seven days/week?” 
• A cessation attempt will be identified as a ‘YES’ response to the question at 3 months: “In the 
LAST 2 MONTHS have you tried to stop smoking?” 
• A successful cessation attempt will be defined as a smoker at baseline and a ‘NO’ response 
to the following question at 3 months: “Have you smoked any cigarettes or tobacco in the last 
seven days/week?” 
Individuals will be periodically sampled from participants in the RCT and approached in advance of 
planned researcher visits to Scotland. They will be sampled in a stratified quota manner with the 
objective of 15 negative test and 15 positive test participants and the aim of a 5-5-5 smoking 
behaviour split in each group. It is anticipated that 150 individuals will be approached with a 
recruitment rate of 20%, however the number of people sampled will be adjusted depending on 
response rates, the number of participants becoming eligible in each group and the available time in 
the relevant researcher visit to Scotland. 
4. Participant recruitment 
Sub-study 1 
Eligible participants will be mailed an invitation letter, information sheet and consent and contact 
forms requesting a contact telephone number and convenient times to call, to be returned in a 
prepaid envelope. This process will be carried out via HIC as the contact details of ECLS study non-
responders are not known to the study team. The replies will be returned to HIC and any positive 
responses will be uploaded onto the recruitment tracker. The researcher’s telephone number and 
ECLS study team details will be provided for any queries. If a participant’s telephone number is 
available, a follow up call will be made by the researcher to confirm receipt of the mailing and answer 
any questions. If there is no answer, a voicemail message may be left or one further call attempt 
made at a different time. 
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On receipt of a completed consent form and contact form participants will be telephoned by the 
researcher at a time they have indicated as being convenient. Verbal consent will be confirmed at 
the beginning of the call. Eligibility for the study will be confirmed and any questions from the 
participant will be answered. Should an individual indicate that they now wish to take part in the 
ELCS Study following contact regarding the sub-study, they will become ineligible for the sub-study 
and they will instead be telephoned by the ECLS Study research team as described in the main 
protocol. 
Sub-studies 2 & 3 
The researcher will send potential participants an invitation letter and a participant information sheet. 
The invitation letter will include a seven-day response deadline to ensure that the interview will take 
place as soon as possible of receipt of test result. Potential participants will be invited to indicate 
their interest in the research by completing a short form and posting it back to the researcher in the 
freepost envelope provided, or contacting the researcher by e-mail or phone. Once a response is 
received from a participant, the researcher will contact the participant by phone to arrange a date 
and time for their interview. During this phone call, the researcher will explain the details of the study 
and answer any questions that the participant has concerning study participation. An appointment 
letter or e-mail will be sent to the participant to confirm the date and time of their interview. The day 
before the interview, the participant will be contacted by phone, text, or e-mail as a reminder. If the 
participant is unable to attend the interview, but would still like to take part, then another interview 
will be arranged. 
[Please note: in order to maximise comprehension of study materials, readability of all participant 
documents has been tested using a readability programme. The participant information sheet layout 
and format was informed by the results of a study that applied the user testing method to improve 
the readability of a participant information sheet31. The participant information sheet (PIS) for study 
two was also piloted with three participants who matched those who will be eligible for recruitment 
to the trial.] 
5. Procedure 
5.1. Obtaining informed consent 
Sub-study 1. Potential participants will be sent PIS and informed consent form (ICF) with their letter 
of invitation. Contact numbers are given to contact the study team to answer any questions they may 
have. They are invited to send their reply and completed consent form in the prepaid envelope (to 
HIC). A copy of the ICF be kept by the participant and the original filed the study ISF. Prior to the 
telephone interview they will be asked to confirm their verbal consent. One consent form will be kept 
by the participant and the other kept by the researcher and filed in the ISF. 
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Sub-studies 2&3.  At the start of each face-to face interview, participants will be provided with a 
copy of the PIS and informed consent form. They will be asked if they have any further questions 
concerning their involvement in the study and asked to sign the ICF.  If the interview is to be 
conducted by telephone, the ICF will have been sent in advance of the interview and the participant 
will be asked to return to the study team using the prepaid envelope. Prior to conducting the 
telephone interview verbal consent will be confirmed. The process for obtaining consent will be in 
accordance with the REC guidance and Good Clinical Practice (GCP). Two consent forms will be 
signed and dated by the participant and the researcher. A copy of the ICF be kept by the participant 
and the original filed the study ISF.  
5.2. Interview procedure 
It is estimated that each interview will take no more than an hour. All interview questions have been 
structured around the aims of each sub-study (see interview schedules below).  
Sub-study one 
Participants will take part in a semi-structured interview by telephone which will be digitally recorded. 
There is a precedent for using this method for the study of non-responders to cancer screening trials 
in previous research in the UK8, 32, 33. It is anticipated telephone interviews will be more acceptable 
and convenient than face-to-face interviews in a population of non-responders and this method has 
been used successfully in similar studies8, 32. An initial interview schedule can be found in the 
appendices and these questions will be developed further by the findings of additional pilot work and 
a qualitative meta-synthesis currently being undertaken. Approximately 20 interviews will be 
conducted, however recruitment will continue until no new themes emerge from the interviews. 
Sub-studies two and three 
The participant will be interviewed in a one-to-one semi-structured interview at their local facility 
(CRC/CRF, GP practice) or if required their home. They can also take part in the interview over the 
phone. The interview will be conducted in a location where it cannot be overheard. Only the 
researcher and the participant will be present at the interview, however, the participant will have the 
option to have someone with them if they would prefer. If the participant would prefer a home visit, 
where possible a study nurse will also attend but will not present at the interview unless invited by 
the participant. All interviews will be carried out by the researcher who will adhere to local policies of 
research fieldwork. Participants will be offered taxi transport or travel expenses to attend face-to-
face interviews.  
5.3. Incentives 
Participants in all three sub-studies will be given a £5 gift voucher for use in a range of stores to 
thank them for their time. If they request it, participants will receive a lay summary of the findings of 
the study when it is complete. 
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5.4. Withdrawal from each sub-study 
Participants may be withdrawn from each study either at their own request or at the discretion of the 
researcher. The participants will be made aware that they do not have to give a reason for 
withdrawing from the study and withdrawing will not affect their future care. Participants will be asked 
if any information collected prior to withdrawal be kept for future analysis. 
6. Analysis 
Interviews for all three sub-studies will be audio recorded, transcribed verbatim and analysed using 
thematic analysis. The process of thematic analysis will be informed by the following phases outlined 
by Braun and Clarke34 in their step-by-step guide to doing thematic analysis:  
1) Familiarising oneself with the data (i.e., transcribing and re-reading the data),  
2) Generation of codes (i.e., developing codes that identify key features of the data. This will be done 
using NVivo software),  
3) Searching for themes (i.e., sorting the codes into themes and gathering all the data relevant to 
each theme. Consideration will be given to how codes can be combined to form an overall theme) 
4) Reviewing of themes (i.e., checking the extracts for each theme, ensuring that they form a clear 
pattern, and developing a thematic map), and  
5) Defining and naming themes. 
An initial analysis of the data will be conducted by both researchers [LB & BY]. They will discuss the 
results of each analysis and a final thematic framework will agreed upon. A third researcher [RdN] 
will review the framework and results of both analyses. This procedure will enable a validation of the 
themes and provide an in-depth interpretation of the data.  The 18 and 24 month psychological data 
will be analysed by the forth researcher [MC].7. Adverse events 
The occurrence of adverse events as a result of participation within these studies is not expected.  
However, the researchers are aware that certain questions will be of a sensitive nature, which 
participants might find distressing. Participants will be made aware that they do not have to answer 
all of the questions if they do not want to. The researchers will remind participants that they can 
withdraw from the study at any time without giving a reason. In the unlikely event the participant feels 
distressed by the interview; they will be signposted to local services for further support if required 
and to the ECLS study research team.  
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8. Records and record retention 
All data will be stored in compliance with the Data Protection Act 1998 and in accordance with 
University of Dundee, Health Informatics Standard operating Procedures and the Universities of 
Nottingham and St Andrews Code of Research Conduct and Research Ethics (non-identifiable study 
management information only, dates of interviews etc). The researchers [LB, BY, MC & GO] will be 
responsible for maintaining all documents concerning the study. The database will be stored on a 
University of Nottingham password protected computer in a locked office at Queens Medical Centre 
and will only be accessible by the research team and a University of St Andrews password protected 
computer in a locked office (e.g., the researchers and research supervisors).  
 
Each participant will be assigned a unique study identity code number for use on their interview 
transcript. Transcripts and signed consent forms will be treated as confidential documents and held 
securely in accordance with regulations. Each transcript document will be password protected and 
will be stored on a password protected file on University of Nottingham server. Only members of the 
research team (e.g., the researchers and the research supervisors) will have access to interview 
transcripts. Audio recordings will be stored on an audio recorder in a locked filing cabinet. Once 
audio recordings have been transcribed, the recording will be deleted off the audio recorder. Signed 
consent forms will be kept in the study ISF in a locked filing cabinet in a locked office at Queens 
Medical Centre. In line with the University of Nottingham Code of Research Conduct and Research 
Ethics, data will be stored for seven years from the date of any publication that is based upon them.  
9. Data protection 
All members of the research team will adhere to the Data Protection Act, 1998. Study documents 
will contain only the minimum required information for the purposes of the study.  
10. Publication and Dissemination 
The results of the sub-studies will be used for publications in peer reviewed scientific journals, 
conference presentations and a PhD thesis. Participants will not be identified in any publications. 
11. Funding source 
The sub-studies are funded by Oncimmune Ltd, University of Nottingham and the Dundee Cancer 
Centre. 
Sub-study 1: Telephone Interview Schedule 
Please note: This is an interview guide. The questions posed will relate to this guide, but the exact 
questions will be formulated based on the individual’s responses to previous questions during the interview 
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and on the basis of the preceding interviews with other participants. This iterative process is required when 
using qualitative methods to explore themes fully. 
It will have been established in the pre-interview screening call that the participant remembers receiving 
the ECLS Study invitation mailing and made a conscious decision to not respond to it. 
Preliminary data gathering tool 
At the start of the interview the researcher will ask the following structured questions as a preliminary data 
gathering tool. 
1. What is your age? 
2. Are you married/single/cohabiting? 
3. What is your current work situation? 
4. How would you describe your current health? Prompts: 
• Do you have any problems getting around? 
• Are you taking any medication? 
5. Have you ever been tested for any diseases, called a ‘screening test’? 
• For lung cancer? 
• For other cancers? 
• For other diseases? 
• If yes, why did you have the test(s)? 
• If no, why not? 
6. Are you a smoker? 
• If yes, how many cigarettes do you smoke per day on average and for how many years have you 
smoked? 
• If no, have you ever smoked? 
7. Do you have any family history of lung cancer? Or other cancers? 
• If yes, prompt to elaborate. 
Topic Guide for semi-structured interview 
Aim: To find out how the participant reacted to receiving the ECLS Study invitation letter/reminder 
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1. When people receive a letter like this they often have many different thoughts and feelings. Please 
describe your thoughts and feelings when you received the mailing? When you received the invitation 
mailing for the Early Lung Cancer Detection Study, please describe how you felt about it? 
Prompts: 
a. Thoughts and feelings might be about the mailing itself, the screening test, the research study, lung 
cancer, your health in general or other information you read in the mailing 
b. They might be positive or negative thoughts or feelings 
c. They might be prolonged or brief thoughts or feelings 
d. How did you feel when you received the mailing? Why did you feel like that? 
e. What thoughts did you have when you read the letter? How did those thoughts make you feel? 
f. How did you feel 5 minutes after reading the letter and leaflet? Were you still thinking about it? If 
so, what were you thinking? 
g. How did you feel 24 hours after reading the letter and leaflet? Were you still thinking about it? If 
so, what were you thinking? 
h. How much of the letter did you read? 
i. How much of the leaflet did you read? 
j. Where did you put them? 
k. Did you show them to anyone else? 
i. What did they say about them? 
ii. How did this influence you? 
l. Did you discuss them with anyone else? 
i. What did they say about it? 
ii. How did this influence you? 
m. Did you try to find out any more information about the study? 
n. At what point did you decide you wouldn’t respond to the letter? What were your thoughts and 
feelings at that stage? 
o. What were your reasons for not replying to the letter? 
i. Too busy/unable to attend/could not read the letter? 
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 ii. Worries about the test e.g. fear of needles? 
iii. Worries about lung cancer e.g. fear of the test being positive? 
iv. Invitation materials not good enough? 
v. Advice from others e.g. discussion with family or friends? 
vi. Previous experience of screening tests? 
vii. Taking part would not benefit me e.g. may have been in untested group? 
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Sub-study 2: Telephone Interview Schedule 
Aim: To explore understanding and knowledge of the information communicated in the ECLS Study 
invitation mailing 
2. The blood test offered to you is a new test. It can sometimes be difficult to understand what a test 
like this does and what the result means. It is important for us to see what people understood from the 
information they read. Please tell me everything you understand about the test you were offered. Tell me 
as much as you can and if you don’t know or you are unsure, it’s fine to say so. 
Prompts: 
a) What do you understand about what the test does? 
b) What do you understand about how the test is done? 
c) What do you understand about how good is the test at finding lung cancer? 
d) What do you understand about the risks of having the test? In other words, any bad things that 
could happen? 
e) What is your understanding of what it means if somebody gets a positive test result? 
 
Aim: To explore thoughts about how the ECLS Study invitation materials could be improved. 
3. If you were in charge of writing to people to ask them to have the test, what would you think was 
important to put in the letter and leaflet? What would you change about the way you were invited and the 
invitation letter? 
4. Is there anything else you would like to tell me about what we have talked about? 
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Sub-study 3: Telephone Interview Schedule  
Please note: This is an interview guide. The questions posed will relate to this guide, but the exact 
questions will be formulated based on the individual’s responses to previous questions during the 
interview and on the basis of the preceding interviews with other participants. This iterative process is 
required when using qualitative methods to explore themes fully. 
 
Aim: To explore changes in attitudes to smoking 
1) Before you joined the Early Lung Cancer Detection Study, how did you think and feel about 
smoking? 
2) Had you ever tried to stop smoking before you joined the study? If so, how did you find it? 
Prompts: 
a) How easy or difficult did you find it? 
b) Did you use a stop smoking support service or ask for any help to stop smoking? 
c) How long did you stop smoking for and how did you feel about that? 
3) How do you feel about smoking now? 
Prompt: 
a) If different from Q.1 – Why do you think your feelings have changed? 
 
Aim: To establish the decisions made regarding smoking cessation during the ECLS Study, the success 
of those decisions and explore the reasons for those decisions and the perceived barriers and 
facilitators to cessation. 
 
Questions are worded differently depending on whether the participant was successful at stopping 
smoking (‘Stopped’), unsuccessful at stopping smoking (‘Tried’) or made no attempt to stop smoking 
(‘No attempt’). 
4) Stopped: You told us you have stopped smoking since you had the lung blood test. Is this 
correct? 
Tried: You told us you have tried to stop smoking since you had the lung blood test but you didn’t 
manage to stop smoking. Is this correct? 
No attempt: Some smokers try to stop smoking and other people choose to carry on smoking without 
trying to stop. You told us you have not tried to stop smoking since you had the lung blood test and you 
are still a smoker. Is this correct? 
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a) If not correct, clarify the decisions made to stop smoking and the success of those decisions i.e. 
stopped/relapsed/tried but didn’t stop. 
5) Stopped & Tried: Can you tell me about your decision to try/stop smoking? 
Prompts: 
a) Which method(s) did you use to try to stop smoking? 
b) How easy or difficult was it for you to try to stop smoking after the lung cancer blood test? 
c) What do you feel helped you to try to stop smoking?  
d) Which things did you feel did not help you to try to stop smoking? 
No attempt: What thoughts and feelings did you have about smoking after your lung cancer blood test? 
Prompts: 
a) Did the lung cancer blood test change your thoughts and feelings about smoking? If so, how? 
b) We know that some people find that having a lung cancer blood test makes them want to stop 
smoking but other people find that it doesn’t. It is important for us to understand why this is. Based on 
your experience of having a lung cancer blood test, why do you think this is? 
 
Aim: To explore thoughts and feelings about smoking cessation advice for lung cancer screening 
patients. 
6) Imagine you are having a lung cancer blood test for the first time, but this time everybody who 
has the test is given special advice and support about stopping smoking. How would this make you feel 
about smoking? 
Prompts:  
a) Would it make you think or feel differently about having the lung cancer blood test if you knew 
this was going to happen? If so, how? 
b) Would it make you think or feel differently about stopping smoking? If so, how? 
c) Would it change how confident you felt about being able to stop smoking? If so, how? 
d) Would it change your plans to stop or carry on smoking? If so, how? 
e) Would it make you more likely or less likely to have a repeat lung cancer blood test in the future 
e.g. five years time? And why? 
7) What type of special advice & support would you find most helpful, if it was given to you during 
a visit for a lung cancer blood test? 
8) Is there anything else you would like to tell me about the things we have talked about? 
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Please note: This is an interview guide. The questions posed will relate to this guide but the exact 
questions will be formulated based on the individual’s responses to previous questions during the 
interview, and on the basis of the preceding interviews with other participants. This iterative process is 
required when using qualitative methods to explore themes fully.   
 
1. Since your lung cancer blood test, have you had any other tests for lung cancer? 
 
2. Before you had the lung cancer blood test, what were you told about it? 
 
3. How satisfied were you with the information you received about the test? 
 
4. Since you have had other tests for lung cancer, how has your understanding about this lung cancer 
blood test changed? (Question 4 is for participants in the EarlyCDT-positive group who have had further 
tests for lung cancer). 
 
5. If somebody asked you what having the lung cancer blood test was like, how would you describe it to 
them based on your experience?  
 
6. How do you think lung cancer is found in the blood? 
 
7. If somebody asked you to tell them about the letter you got about your lung cancer blood test result, 
how would you describe it to them? How satisfied were you with this letter, in terms of giving you the 
information you needed to understand the test results. (Question 7 is for participants in the EarlyCDT-
negative group) 
 
8. If somebody asked you to tell them about the appointment when you were given your lung cancer 
blood test result, how would you describe it to them based on your experience? (Question 8 is for 
participants in the EarlyCDT-positive group) 
 
9. Your lung cancer blood test result was negative. What does a negative blood test result mean to 
you? (Question 9 is for participants in the EarlyCDT-negative group) 
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10. Your lung cancer blood test result was positive. What does a positive blood test result mean to you? 
(Question 10 is for participants who received a positive test result but have not yet had further tests for 
lung cancer) 
 
11. Since you have had other tests for lung cancer, how have your thoughts about your lung cancer 
blood test result changed? (Question 11 is for participants who received a positive test result and have 
had further tests for lung cancer) 
 
End of interview 
 
• We have now come to the end of the interview. Before I switch off the recorder, is there 
anything else that you would like to tell me?  
 
General prompts to use throughout interview: 
 
- Can you please tell me more about that … 
- How has that changed … 
- Can you give me an example of … 
- What is your understanding of … 
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APPENDIX 3: ECLS STUDY: START RECRUITMENT 
SUBSTUDY (Version 1, 6/1/2014) 
 
MRC START in ECLS: What are the effects of a re-written and re-
designed Participant Information Sheet?  
 
NB: This sub-study was implemented when the recruitment target was 10,000 from NHS Tayside 
and NHS Glasgow. This study is now complete.  
1. Background 
In the UK, the NIHR vision sees ‘more patients and health professionals participating in health 
research’ [1]. Fundamental to health research is the testing of interventions through Randomised 
Controlled Trials (RCTs). Achieving high participation in RCTs has traditionally been difficult. 
Published data show that a minority of RCTs recruit successfully [2,3]. Recruitment problems 
reduce the total recruited sample (limiting internal validity), and the proportion of eligible 
participants who are recruited (limiting external validity). They can increase the cost of the study 
and delay the results. In extreme cases, poor recruitment can result in the cancellation of a trial. 
 
Clearly, there is a need to develop and test interventions to improve recruitment, and one method 
is to ‘nest’ trials of recruitment interventions in ongoing RCTs. Given the consensus among the 
research community concerning the challenge of recruitment, it is surprising that nested trials of 
recruitment interventions are so rare. Two recent reviews identified only 14 nested studies in real 
trials [4] and 27 overall [5]. Recruitment for science is not underpinned by a science of recruitment.  
 
The MRC START study is designed to develop the conceptual, methodological and logistical 
framework for nested studies, and to assess their feasibility. At the completion of MRC START, we 
will have rigorously tested two potential interventions for adoption in to routine practice (improved 
participant information sheets (PIS), and a multimedia decision aid), and provided the framework to 
make delivery of nested recruitment RCTs a routine activity. This will assist the rapid development 
of recruitment to meet policy goals [12].  
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The Early Cancer Detection Test – Lung Cancer Scotland (ECLS) is acting as a host trial to test an 
MRC START recruitment intervention. This protocol details the work that will be undertaken for the 
‘MRC START in ECLS’ sub-study. 
2. The intervention – Participant information sheets 
Research has reported patients’ rather patchy understanding at the end of a trial, such as one in 
five participants not knowing the name of the medicine being tested [6] and similar proportions not 
knowing that they could withdraw at any time [7]. These findings are confirmed by a systematic 
review of consent in cancer trials [8] in which aspects such as treatment risks and benefits and the 
right to withdraw consent, were found to be not well understood. The review concluded that 
“patients do not appear to be adequately informed” (p.304). A lack of participant knowledge might 
result from the difficulty in understanding complex information, such as randomisation [9], or 
because of the way the Participant Information Sheet (PIS) is written. The level of literacy required 
to understand a study PIS is often higher than that found within the general population [10], and 
poor information provision may particularly affect older or less educated patients [11].   
One promising approach to improving the quality of the written information provided is to develop 
the PIS through formal User Testing. In this process people in the target group for the trial read the 
PIS and are then asked to find and show an understanding of key information contained in the 
sheet. Any identified problems are rectified by the use of clear writing and by changing the way the 
PIS is laid out and designed. Further User Testing then tests whether the changes have led to 
improvements to the way the PIS performs. Three small, recent studies suggest that a combination 
of re-writing, design and testing results in a PIS that works much better to inform potential trial 
participants and which they prefer [13, 14, 15]. These studies have involved hypothetical settings, 
with participants being asked to imagine themselves being recruited to a trial, and what remains 
unknown is the effect of such changes to the PIS in actual trials. In particular, does an improved 
PIS impact on either of the quality of informed consent and the rate of recruitment? 
3. Host study details 
The ECLS trial will evaluate a new test (Early CDT) for lung cancer as part of a potential Scottish 
lung cancer screening program. The ECLS Trial needs to recruit at least 10,000 participants, 
chiefly from around Glasgow and Dundee.  A key recruitment route will be through postal invitation, 
which opens up the possibility of using the trial to test MRC START user tested patient information. 
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The trial is being managed by Tayside Clinical Trials Unit (TCTU) and the trial management team 
at TCTU has developed a PIS presented in booklet form and referred to in this trial as a participant 
information brochure PIB.  Recruitment consists of the following steps: 
1. Potential participants are identified by SPCRN staff from practice lists.  
2. Potential participants are sent a GP letter of invitation and a PIB 
3. Those responding positively to the invitation (via reply slip, text, email or phone) are then 
screened for eligibility for the study. Those eligible and consenting are recruited. 
 
ECLS, along with the TCTU PIB, has received ethical approval from the East of Scotland Research 
Ethics Service REC 1, reference 13/ES/0024.   
A revised PIB and GP covering letter will be developed by the MRC START team (Dr Peter Knapp) 
through User Testing. The content of the original PIB will be retained but it will be re-written and re-
designed based on the outcomes of the User Testing process.  
Potential participants to the ECLS trial will be randomised to receive either the original or the user-
tested PIB and GP invitation letter. It would be useful to know if the revised PIB and covering letter 
impact on rate of recruitment in comparison with the original PIB. A nested RCT would be the best 
approach to evaluate its effects.  
4. Research Objectives 
1. To measure differences in those expressing an interest in participating in the ECLS study 
as a result of receiving a participant information brochure and covering letter 
2. To establish if the number of patients recruited in to ECLS is improved by the use of a 
participant information brochure and covering letter developed through User Testing, 
compared to a routine participant information sheet. 
5. Method 
5.1 Design 
The proposed study will use an RCT design. Patients identified from GP lists will be randomly 
allocated to one of two conditions:  
a) Control PIB: the original ECLS participant information brochure and covering letter (approved in 
13/ES/0024 on 16/4/2013);  
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b) Intervention PIB: the user tested participant information brochure and covering letter (approved 
on [Date] by EoSREC REC 1).  
5.2 Inclusion / exclusion criteria 
All individuals approached by the ECLS host trial are eligible for this nested recruitment 
intervention study. 
5.3 Recruitment and Randomisation 
SPCRN will search practice lists for patients eligible for invitation to participate in the ECLS study. 
Potential participants identified from GP lists as eligible will be randomly allocated to receive the 
control or intervention PIB and covering letter in a 1:1 ratio.  The randomisation will use a list of 
random numbers from http://www.random.org/sequences/ with management of random allocation 
being done by SPCRN staff.   
Each potential participant will be allocated a cohort number (from the central patient management 
system). 
Potential participants can express and interest in the ECLS study in a number of ways: 
• By returning a reply paid slip to the central patient management system who notify the 
research team 
• By email to the research team 
• By text (to the research team) 
• By phone to the research team 
In each instance the patient cohort number will be recorded.  
Anonymised data on numbers of respondents and PIS version will be sent to the MRC START 
team. 
5.4 Control 
The control PIS is not a plain text document but is formatted in a more attractive way.  It was not, 
however, developed in a systematic way but relies on the experience of TCTU staff. One of the 
MRC START investigators, Shaun Treweek did proof-read the content of the control PIS in his 
former roles as Assistant Director of TCTU and co-investigator on ECLS.  None of the other MRC 
START investigators were involved in the development of the original PIS. This PIS is 32 pages in 
length and was approved by The East of Scotland Research Ethics Committee REC1 on 16th April 
2013, reference 13/ES/0024, as part of the application to conduct the ECLS study. 
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5.5 Intervention 
The revised PIS will contain the same content as the original version but will differ in the way that 
the information is laid out, written and presented. It will be developed through User Testing with 
members of the public selected to reflect the target patients for the PIB, who will read and then be 
asked to find and show an understanding of key facts contained in the PIB. The testing will be 
undertaken in several rounds: the first round testing the original PIB; then several rounds with 
different iterations of the revised PIB until we were confident that the PIB could perform well to 
inform potential trial participants. 
5.6 Outcome measures 
The primary outcome will be the number of patients recruited to the ECLS trial from each of the 
PIB arms.  
Secondary outcomes will be:  
1. The proportion of patients expressing an interest in participating in the ECLS study in 
response to each version of the PIB and covering letter 
2. The proportion of recruited patients who complete the ECLS screening process from 
each of the PIB arms. 
6. Statistical considerations 
6.1 Sample size 
MRC START in ECLS is powered to detect a significant improvement in recruitment rate, defined 
as an absolute increase of five per cent above baseline.  Baseline response rates for the first five 
ECLS practices are around 20% (2/12/2013).  Ineligibility, difficulties contacting people etc reduces 
the 20% response rate to a recruitment rate of around 14%.  The recruitment rate is the key rate 
for the MRC START project.  A range of samples sizes at 80% power and alpha 0.05 for a 5% 
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Response rate (%)  Recruitment (%) 
TCTU PIB START PIB 
Sample size 
(per arm) TCTU PIB START PIB 
Sample size 
(per arm) 
17 22 1970 (985) 11 16 1466 (733) 
20 25 2188 (1094) 14 19 1728 (864) 
23 28 2384 (1192) 17 22 1970 (985) 
 
Based on this table, we will have a sample size of 2000 invitations.  
6.2 Analysis 
Anonymised and aggregated recruitment data (ie. the number of potential participants sent each 
PIB and covering letter,  the numbers expressing an interest in participation, recruited to ECLS and 
completing the screening from each group) from ECLS will be sent to the MRC START team in 
accordance with the MRC START data sharing agreement (see Section 12). 
The proportion of participants who express an interest in the study, who are recruited in to the 
study and who complete the screening process will be calculated for the two groups (control and 
intervention PIB). The difference between the two proportions will be calculated along with the 
corresponding 95% confidence interval.  
 
Results from this trial will ultimately be combined in a meta-analysis with response rate data from 
other host trials participating in the MRC START programme. 
7. Ethical issues 
Patients will not have the opportunity to give informed consent to enter into the nested recruitment 
study. This has been approved by NRES Committee Yorkshire and the Humber – South Yorkshire 
(REC Reference 11/YH/0271) on the basis that the nested study is not withholding information – 
just changing the way it is presented. 
The nested study (MRC START in ECLS) will be registered by the ECLS trial as a sub-study on 
Clinicaltrials.gov 
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8. Financial and Insurance Issues 
The user testing for the nested trial is funded as part of MRC START which is sponsored by the 
University of Manchester. It forms a sub-study to the ECLS study, which is co-sponsored by the 
University of Dundee and Tayside Health Board. Normal NHS indemnity procedures will apply. 
9. Project Timetable 
Date  Action 
Jun 2013 Documentation for the nested study agreed & signed off 
Jun/July 2013 User Testing of original PIB and development and testing of revised PIB 
Jan 2014 Submission to REC of application for substantive amendment  
Feb/Mar 2014 Recruitment to the nested trial begins 
May/Jun 2014 Recruitment to the nested trial ends  
Jun/Jul 2014 Data cleaning and submission of data set to MRC START team 
Jul 2014 Collation of results and analysis, begin write up of trial level paper 
 
10. Dissemination of research 
The results of this nested sub-study will be published in a peer-reviewed journal to further improve 
the evidence base regarding effective recruitment strategies in trials. This publication will be led by 
the ECLS team. In addition the data will be included in a meta analysis of all studies recruited to 
the MRC START programme led by the MRC START team. Dissemination of research findings will 
be conducted in line with the MRC START authorship arrangements (see Section 13). 
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12. MRC START Data Sharing Agreement 
 
MRC START Data sharing agreement 
This document specifies the data management and data sharing agreement between the MRC START study and 
the ECLS study.  
In this document, the ‘START research team’ refers to researchers named on the protocol. ‘START 
collaborators’ refers to those providing ‘host’ trials for the study.  
MRC START roles and responsibilities 
ECLS team agrees to: 
(a) Randomly allocate a proportion of patients participating in ECLS to receive either the standard 
participant information brochure or the user tested patient information brochure. Both baseline 
response rates and baseline recruitment are uncertain at this point. A range of samples sizes at 80% 
power and alpha 0.05 for a 5% minimum important difference between the Tayside Clinical Trials Unit 
(TCTU) PIB and the MRC START PIB have been calculated and the final sample size for the MRC 
START sub-study will be determined by the response rate achieved in the early stages of the ECLS 
recruitment as per the MRC START in ECLS protocol. 
(b) Randomise patients to either the recruitment intervention using random number generation within the 
SQL software used for the ECLS patient management system. 
(c) Collect data on the numbers of patients approached using each recruitment method, and data on the 
numbers recruited to the trial, and the number retained at each follow up point as follows: 
a. Expressing interest (responding to either PIB) 
b. Attending screening 
c. Being consented in to the trial 
d. Completing the trial 
(d) Provide collected data in an anonymised form (labelled data set in SPSS or a data base suitable for 
import to SPSS) to the START research team for analysis by [target date for data collection tbc] 
(e) Not introduce the recruitment intervention in a non-randomised fashion during MRC START 
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(f) Seek permission from the MRC START research team to introduce them after the end of the MRC 
START study period. 
It is possible that host trials may wish to withdraw from MRC START before the end of the study. In this case, 
data collected up to that point would still be provided to the MRC START research team. 
Data Protection and publication issues in the START study 
The University of Manchester has strict guidelines for data storage, access to study data and adherence to the 
principles of data protection (including the Data Protection Act 1998). The link to relevant information is: 
http://www.staffnet.manchester.ac.uk/services/records-management/data-protection/data-protection-guidance/ 
Data Transfer Policy 
Datasets will be accepted from MRC START collaborators in electronic format (the University of Manchester 
can translate datasets in various formats through Stat Transfer). In addition, MRC START collaborators will 
provide written details of the coding of variables in the dataset to allow consistent analysis (see study protocol).  
All datasets will be anonymised by MRC START collaborators before transfer to the University of Manchester, 
removing all identifiable patient information such as names and addresses. Data may be encrypted before 
transmission to ensure security.  
Data storage 
Datasets from MRC START collaborators will be transferred to a combined database on a secure server at the 
Health Sciences Research Group, University of Manchester. All data received will be treated in the strictest 
confidence. Analysis of the data will take place by Professor Peter Bower and Professor Sandra Eldridge. 
Professor Bower will act as custodian for the combined dataset. The combined dataset will be stored by the 




The NIHR School for Primary Care Research (http://www.haps.bham.ac.uk/primarycare/nspcr/index.shtml) 
comprises the leading academic centres for primary care research in England, with a focus on research to 
improve everyday practice in primary care. The MRC START research project is led by the Centre for Primary 
Care, Institute of Population Health, the University of Manchester (http://www.population-
health.manchester.ac.uk/research/primarycare/)  
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13 MRC START Authorship Arrangements 
 
 
MRC START publications & authorship arrangements  
MRC START has the potential to generate a large number of publishable datasets, which will include 
nested trials of MRC START interventions run in single trials (‘single datasets’), and the combined 
datasets of MRC START interventions run in multiple trials (‘combined datasets’).   
This document describes the ground rules for publishing and authorship for applicants and researchers 
on the MRC START grant (‘START research team’) and researchers providing ‘host’ trials for the study 
(‘START collaborators’). 
Core Principles 
The core principle governing authorship are:  clear communication; no surprises; no waiting to publish; 
and access to an independent adviser. 
Ground rules: 
1. All publications arising from the ‘combined datasets’ will include the START research team and 
representatives from START collaborators (normally host trial PI).  
a) Where START collaborators request more than one representative, nominations for 
authorship will be discussed among the START research team.  
b) Requirements for authorship are those of the International Committee of Medical 
Journal Editors (http://www.icmje.org/).  
c) If author numbers become excessive, papers may be authored under a collaborative 
name or a combination of named authors (START research team) and a group 
collaborative name (START collaborators) 
(http://www.councilscienceeditors.org/i4a/pages/index.cfm?pageid=3373).  
2. The START research team are keen to encourage publication from single datasets where 
possible. 
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a) Publication of the final MRC START data takes precedence – we cannot delay 
publication, for example, to allow single datasets to be published first. 
b) We would expect that START collaborators would look for opportunities to involve 
members of the START research team as authors in publications arising from individual 
datasets, either as individuals or under a collective name.  
c) The START research team will be able to provide materials for papers on the 
development of the interventions, as well as general background and criteria for 
reporting standards in nested trials developed as part for the MRC START project. 
3. All other publications arising from MRC START (ie not based on the combined datasets) 
remain in the authorship of the START research team 
4. START collaborators need to sign up to the MRC START authorship arrangements. 
5. We will appoint an independent adviser to whom the START research team or START 
collaborators can go for advice or independent arbitration in the event of a disagreement about 
authorship. 
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APPENDIX 4: Sub Study 5: University Of Glasgow Mrc Phd 
Studentship.  
Exploring public perceptions of lung cancer screening  
Researcher: Hannah Scobie 
Supervisors: Dr Katie Robb, Dr Sara MacDonald, Professor Sally Wyke, Dr Stephen Harrow. 
University of Glasgow 
Funder: Medical Research Council 
1. Introduction 
1.1 Rationale 
Lung cancer kills more people than any other cancer, with approximately 5,000 people dying 
from lung cancer every year in Scotland. This is often because there are few symptoms until 
the cancer is at an advanced stage when the chance of cure is low. Lung screening offers 
the potential to detect lung cancers at an earlier stage when they are easier to treat. A recent 
trial in the US found that lung cancer mortality decreased by 20% among those receiving 
low dose computed tomography screening (Aberle, Adams, Berg, Black, Clapp & 
Fagerstrom, 2011). However, the benefits of cancer screening are only realised if people 
are willing to participate. Cancer screening participation rates remain suboptimal (Audit 
Scotland, 2012), and may be particularly challenging in the case of lung screening. Smokers 
are disproportionately represented among people living in more deprived areas who also 
have lower uptake of other cancer screening programmes (Scottish Household Survey, 
2013). This means that the potential lung screening target population could be particularly 
hard-to-reach.   
1.2 Proposed research 
The proposed research consists of two further sub-studies within the Early Cancer detection 
test – Lung cancer Scotland (ECLS) Trial.  The first sub-study will qualitatively investigate 
why individuals decided not to take part in the ECLS Trial, after showing initial interest. This 
study (Study 1) will involve interviewing ECLS Trial ‘non-attenders’ – those who initially 
expressed an interest in having the test, were appointed to be screened, but later decided 
not to participate. It is intended that up to a total of 20 men and women non-attenders in the 
ECLS trial will be interviewed. The sample will be drawn from the NHS Greater Glasgow 
and Clyde and NHS Lanarkshire Health Boards. 
The second proposed sub-study (Study 2) will be a quantitative analysis of ECLS Trial 
attenders examining potential demographic and psychosocial differences by recruitment 
type. Participants in the ECLS Trial were recruited by two strategies: i) those who were 
invited to take part via their General Practice (GP) or; ii) those who ‘self-selected’ after 
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seeing community advertisement/media releases or responded as a result of word of mouth. 
This study will examine potential differences in the demographic characteristics, beliefs 
about lung cancer and lung cancer screening, subjective health and risk perceptions among 
these two groups.  
The proposed studies will complement the embedded psychological sub-studies currently 
being conducted by researchers at the University of Nottingham including: emotional and 
behavioural responses following screening; exploring why people declined to participate; 
understanding of screening results; and smoking cessation in participants of the lung 
screening Trial.  The proposed work therefore adds two new aspects to the ECLS Trial 
research by considering; i) why people change their mind about participating in the Trial; 
and ii) exploring any potential differences between participants recruited through GPs and 
‘self-selecters’.   
2. STUDY 1 
2.1 Background & Literature Review 
While it is noted that participating in a screening Trial is not the same as participating in a 
screening programme, it is useful to draw from the literature on cancer screening 
programme participation in helping to understand screening behavior.  When participants 
make an appointment for cancer screening, it suggests they are motivated and intend to go 
to the screening appointment. However, this intention to attend does not always translate 
into action (i.e. attending the appointment) and ‘did not attend’ (DNA) and cancellations are 
frequent outcomes at screening clinics (Sheeran, 2002). Within the psychological literature. 
Orbell & Sheeran (1998) used the term inclined abstainers. To describe people with positive 
intentions who fail to act. 
In the context of the present study, participants who initially make an appointment (positive 
intention), but go on to cancel or do not attend their appointment would be considered to be 
inclined abstainers. It is this group who are the primary interest of Study 1.  
Among the small number of studies on psychosocial barriers to lung cancer screening, 
cancer fatalism appears to play a significant role in uptake. A qualitative study in England 
exploring attitudes towards participation in lung cancer screening found themes of fatalism, 
worry, and avoidance in those who declined to be screened (Patel, Akporobora, 
Chinyanganya, Hackshaw, Seale, Spiro, & Griffiths, 2012).  This conclusion was also 
supported by a quantitative study in the US, where participants who had fatalistic beliefs 
about lung cancer were less likely to undergo screening (Jonnalagadda, Bergamo, Lin, 
Lurslurchachai, Diefenbach, Smith, Nelson & Wisnivesky, 2012). Other barriers to lung 
cancer screening included: denial of risk, shame about smoking, fears about screening and 
embarrassment (Walton, McNeil, Stevens, Murray, Lewis, Aitken & Garrett, 2013). 
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Understanding the socio-demographic characteristics of attenders and non-attenders of 
cancer screening is crucial to ensure the introduction of a screening programme does not 
exacerbate health inequalities. For example, those from more deprived groups may be less 
likely to attend cancer screening (Weller & Campbell, 2009; Moser, Patnick & Beral (2009), 
but have a higher risk of cancer due to e.g. smoking, unhealthy diet, sedentary lifestyle. 
Other socio-demographic characteristics that may play a role in cancer screening 
attendance include age and gender.  
2.2 Potential Risks & Benefits 
Risks - This study is low risk, however there are a few areas to consider as potentially 
problematic.  Study 1 (invitation Strategy 2) will involve writing to potential participants in 
some cases 6 months or more after they did not attend their appointment.  It is possible 
that individual circumstances may have changed within this time. In some circumstances it 
is possible participants may have passed away or become unwell.  As a result, Health 
Informatics (HIC) University of Dundee will check against the patients CHI number through 
NHS health records to see if participants are still alive. In addition, the Study 1, Strategy 2 
invitation letter will include the sentence:  ‘We apologise if this letter arrives at a particularly 
difficult time for you.’ 
Another potential area of risk could be the topic of the study. We are discussing a health 
issue and cancer in particular, which might upset some participants. This will be avoided by 
reminding the participant that they are under no obligation to answer all of the questions and 
may stop the discussion at any point. Moreover, the interview will be flexible enough to allow 
participants to introduce information that they feel comfortable with. If the participant appears 
hesitant or in doubt about responding, the interviewer will give them some time to proceed, 
alter the question or move on.  Finally, we will provide the telephone number and email 
address of the researcher at the end of the interview in case participants wish to talk about 
any of the issues raised in the interview. If necessary the researcher will refer participants 
to one of the project supervisors to provided further information or support.  If required, the 
supervisor will provide details for professional organisations for people who feel they need 
to discuss issues further. 
Benefits –There are few potential benefits to research participants although in the past some 
participants in similar studies have reported enjoying the opportunity to take part in research. 
Those who participate in the interviews will be offered a £20 voucher as a token of 
appreciation for their participation (Appendix A). Participants will be required to sign for the 
voucher received at the end of the interview. If the participant wishes to withdraw from the 
interview at any point during the interview, the participant will still receive the voucher. 
2.3 Aim 
The aim of Study 1 is to explore the beliefs and perceptions about lung cancer and lung 
screening among people who initially expressed an interest in screening, were appointed to 
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be screened, but who later cancelled or did not attend their appointment, and in some cases 
did not attend a reappointment. 
Methodology  
2.4 Inclusion Criteria 
Participants are required to have been invited and subsequently been eligible to participate 
in the ECLS Trial. Further, participants will have shown initial interest in the study, but at a 
later time, declined to participate. See Table 1 for further details. 
2.5 Exclusion Criteria 
Participants who were invited to take part in the ECLS trial, and completed the study. Also, 
inability to speak, read or write English. The study involves understanding a Participant 
Information Sheet, completing a consent form and taking part in an interview in English. 
People who are unable to speak, read or write English will therefore be excluded most likely 
because they will not have responded to the initial invite to take part in the Trial.  See Table 
1 for further details. 
Table 1: Study 1 Inclusion / Exclusion Criteria 
Inclusion Exclusion 
Invited to take part in the ECLS trial Inability to speak, read or write English 
Eligible to take part in ECLS trial on 
reassessment 
Individuals who contacted the team for 
information, but did not make an 
appointment 
Participants who made an appointment, 
but subsequently cancelled or DNA 
Individuals whose eligibility to take part 
in the ECLS trial was not established 
 
Participants who cancelled or DNA, but 
rescheduled another appointment for a 
later date and attended. 
 
2.6 Study Design 
Interviews will be conducted face-to-face in the participants’ own homes or at the University 
of Glasgow, or over the telephone, whichever is most convenient to the participant. 
Participants’ travel expenses will be reimbursed if they choose to come to the University of 
Glasgow. It is recognised that the researcher will be working alone. As a result, the 
University of Glasgow’s policy on lone working will be followed to ensure the safety of the 
researcher and participant. 
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Participants will receive the Participant Information Leaflet and informed consent form with 
their letter of invitation by post before the interview is conducted. Contact numbers are given 
to contact the study team to answer any questions they may have. In the case of telephone 
interviews being the preferred interview format, participants are invited to send their reply 
and completed consent form in the prepaid envelope. Prior to the telephone interview they 
will be asked to confirm their verbal consent.  Participants will be offered the opportunity to 
ask any questions about the study before informed consent is taken by the researcher. The 
researcher will seek consent in the first instance. Interviews will last approximately 1 hour 
and will be based on a topic guide (Appendix B) developed from the existing screening 
literature with a particular focus on barriers to cancer screening. To avoid post-hoc 
rationalisations of their screening behaviour we will ask participants to discuss their general 
views on screening first before moving on to their personal experience. With the permission 
of the interviewee, interviews will be audio-recorded and transcribed verbatim. If the 
participant does not consent to be recorded, the participant can continue with the interview 
with the researcher taking detailed notes instead. Data from interviews will be anonymised 
during the transcription process. Thereafter paper copies of the transcripts will be stored in 
locked filing cabinets at General Practice & Primary Care, University of Glasgow. Interview 
transcripts will be assigned unique identifiers and any quotations that may be used with 
publications or reports will use the unique identifier. As such individual participants will not 
be identified.  
2.7 Researcher Effects 
Researcher effects will be kept to a minimum by using a topic guide to ensure participants 
are asked the same questions.  However, due to the nature of qualitative research, 
supplementary questions may vary depending on the responses of the participants. 
2.8 Duration of Participation 
Participants will be asked to take part in one qualitative interview lasting approximately one 
hour. The research team will not contact the participant again, although study results will be 
disseminated to the individual following completion of the study if requested. If participant 
request the study results, their name and address will be noted. Participants requesting the 
results will be mailed a summary of the main findings. The study results will also be 
disseminated through the normal academic channels, including, publications and 
conference presentations. 
2.9 Criteria for Discontinuation 
Study 1 involves a one off interview and this will be the only contact with the research team. 
If informed consent is taken at the time of interview and the participant completes the 
interview, the research team will have no further contact with the research participant. If a 
participant decides part way through the interview to withdraw from this study the data 
collected would be retained if permission is given. If no permission is given, the data will be 
withdrawn. 
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If participants make an appointment with the researcher, and cancel or DNA the researcher 
will attempt to make contact again. Appointments will be rearranged up to three times. If a 
participant is unable to make the interview after the third attempt of rearranging an 
appointment they will be removed from the invitation list. 
2.10 Procedure for collecting data 
This will be a difficult group to engage, as a result, three recruitment strategies will be 
used:  
1a. It is normal practice that the ECLS study team call participants the day before their 
appointment as a reminder in an attempt to reduce the number of DNAs. If during this call a 
potential participant states they wish to withdraw from the Trial the study team will ask the 
participant if they would be interested in taking part in a research project for people who 
decide not to attend their appointment. If participants express an interest they will be asked 
if they agree for a member of the research team to contact them directly to provide more 
information about the research. The participant will be reassured if they wish to decline and 
no further contact will be made by the research team.  
1b. Within the ECLS Trial protocol, if a participant DNA, the study team will call the 
participant to offer a new appointment time.  If during this call the participant states they wish 
to withdraw from the Trial, the study team will ask the participant if they would be interested 
in taking part in a research project and the procedure would be as described in 1a.   
2) We will retrospectively identify and contact people who booked an appointment, accepted 
an appointment, but cancelled or DNA initially within the previous 12  months (i.e. 1 year 
from the commencement of the sub-study). If insufficient participants respond, we will 
contact people from the beginning of the Trial in Glasgow.  Participants will be identified 
from the Patient Management System used by the ECLS Trial. Eligible participants will be 
identified by the researcher, searching the additional text related to each case for key words 
such as, ‘cancelled’, ‘did not attend’ or ‘DNA’. Once participants have been identified, the 
Health Informatics Centre (HIC at Dundee University) will extract the names and addresses 
of those eligible. 
Participants will be contacted by post after they have been identified as a suitable candidate 
via HIC.  Invitation letters will be sent out via a mail merge at HIC and those identified by 
HIC as having died will be excluded. Participants will be given a reply slip to return if they 
would like the researcher to contact them. Alternatively they can contact the researcher by 
telephone or email. The researcher will not know the identity of the participant until the reply 
slip stating that they wish to participate is returned. 
2.11 Data Protection 
When potential participants express an interest, contact details will be stored in a locked 
filing cabinet at the University of Glasgow.  Consent forms will similarly be stored in locked 
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filing cabinets. Data from interviews will be digitally recorded and recordings will be uploaded 
to password protected university computers.  The recordings will be assigned a unique ID 
number rather than the participant name. Thereafter paper copies of transcripts will also be 
stored in locked filing cabinets at the University of Glasgow. Any direct quotations that may 
be used with publications or reports will use the unique identifier. As such individual 
participants will not be identified. Data will be retained for 10 years after the study is 
completed.  
Statistical Considerations 
2.12 Sample Size 
We will undertake interviews with a sample of approximately 20 ECLS Trial non-attenders. 
Based on previous literature, this is the likely number required to reach 'saturation' in terms 
of identification of new themes/ideas/issues. Based on previous experience, in order to 
obtain a sample of 20 participants, around 400 people may need to be contacted although 
this may be less depending on the success of Strategies 1a and b. The study aims to 
interview a mix of males and females.  If possible a sampling frame will be used so the 
balance of gender reflects the ratio of men to women among the DNA group overall.  
However, we anticipate that it will be challenging to obtain 20 participants so this may not 
be possible.  
2.13 Method of Analysis  
The data will be analysed using the `framework approach´, a type of thematic analysis. 
Thematic analysis is a method for identifying, analysing, and reporting recurring patterns 
within data, which can then be reported in a detailed way.  The demographic characteristics 
of the participants including age, gender and Scottish Index of Multiple Deprivation score 
will also be described.  
3. STUDY 2 
3.1 Background & literature review 
The ECLS trial recruits participants in two distinct ways: i) invitation via GP or; ii) through 
community advertisement/ media releases/word of mouth and website review. As a result, 
it may be possible that there are sociodemographic and psychosocial differences between 
the participants who were invited by their GP and those who self-selected to participate. 
Previous research in lung cancer screening indicates that there are significant differences 
between participants who are invited to take part, and those who self-select. Participants in 
the US National Lung Screening Trial, who were recruited by the media, appeared to be 
younger, higher educated and less likely to be current smokers (NLST, 2010). Similarly, in 
the Dutch–Belgian Lung Cancer Screening Trial (NELSON trial), respondents to the initial 
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invitation were somewhat younger, and less likely to be current smokers (van der Aalst et 
al., 2012).  
Similar results can also be found outside lung cancer screening trials. In the Oslo Health 
Study, respondents to community and media advertisement were associated with older 
age, higher education levels, being mar
Selmer, Bjertness & Thelle, 2004). A secondary analysis of the Malmo Diet and Cancer 
of community invitations and personal invitations, Manjer et al. (2002) found that 
community respondents were older, and more often females, than participants recruited 
using personal invitations. Furthermore, participants recruited through community 
advertisement had a comparably more favourable situation with regard to 
sociodemographic and lifestyle factors. They also had a lower frequency of prevalent 
disease, lower incidence of cancer and lower mortality (Manjer, Elmsta, Janzon&Berglund, 
2002).   
 
The present ECLS study will examine potential differences between the two invitation 
groups of the ECLS trial. This will assist with the future development of more efficient 
invitation strategies that will target the most high risk groups.  
3.2 Aim 
The primary aim of Study 2 is to explore if there are any sociodemographic or psychosocial 
differences as assessed by a baseline questionnaire between participants of the ECLS 
study who were invited by GP or self-selected through community advertising. 
Methodology 
3.3 Inclusion Criteria 
In order to be included within the statistical analyses, participants are required to have taken 
part in the ECLS trial, and completed the baseline study questionnaire.   
3.4 Exclusion Criteria 
Participants who took part in the ECLS trial, but did not complete the study questionnaire 
will be excluded from the analysis. 
3.5 Procedure for identifying participants 
Participants will be identified from the patient management system (PMS) used by the ECLS 
trial. Eligible participants for the analyses will be identified by their invitation type group (GP 
or self-select). Once cases have been identified, the anonymised data required including 
demographic characteristics (age, gender, Scottish Index of Multiple Deprivation) and the 
responses to the psychosocial questionnaire will be extracted from OpenClinica.  Data will 
be extracted using participants’ cohort ID. 
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3.6 Study Design 
The required anonymized data will be extracted from study data base; Open Clinica in order 
to complete the analysis. Data will be analysed at the University of Glasgow. The data will 
be transferred and stored as per the Data Sharing Agreement. The data will be analysed 
using Microsoft Excel 2010 and IBM SPSS version 21, provided by the University of 
Glasgow. 
Statistical Considerations 
3.7 Sample Size 
This sub study will analyse the data from all attenders of the ECLS Trial. 
3.8 Method of Analysis 
Statistical analysis will be conducted using IBM SPSS. Participants’ base-line data will be 
compared for the two groups of interest – GP invitation and self-selected. This will include 
demographic characteristics, beliefs about lung cancer and lung cancer screening, 
perception of general health and risk perception obtained from the baseline questionnaire.  
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Appendix 4A: ECLS Non-Attenders Interview Schedule 
(version 1, May 2015) 
 
Study Title: Understanding why people who are initially interested in lung screening 
fail to participate. 
1) General views about cancer screening 
What do they think about it, what do they feel about it 
How do they think people make decisions about whether to do screening –
‘know’ as soon as invited/think it over/don’t know  
2) Beliefs about cancer in general and lung cancer 
Are they aware of spouse/family/friends taking part in screening? 
What comes to mind when you think about: 
i. Cancer? 
ii. Lung cancer? 
 
Following elicitation of participants’ beliefs about, ask how fearful participants are of 
cancer in general and lung cancer and whether they believe they (lung or other 
types) can be successfully treated (if these have not come up in response to the 
first questions). 
3) Understanding of the lung screening test 
What comes to mind when you think about lung cancer screening? 
Following the elicitation of image, ask them to explain how they would explain this  
image and why they had it.  
 
What is their understanding of what the test involves?  
What is their understanding of the purpose of the test – detection/prevention? 
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4) Personal decision about lung cancer screening participation (show example 
invitation letters and leaflets to prompt memory) 
Do they remember receiving an invitation for the screening test? 
As best they can remember, when invitation letter arrived in the post how did they 
think, how did they feel? 
How did they decide what to do next?  (e.g. Knew right away what they’d 
do/thought it over/don’t know/remember) 
What did they do next?  (e.g. Acted immediately, acted after a reminder, forgot, 
changed mind, didn’t get round to it.....) 
Did other things happening in life at the time influence decision?   
 
What did they think when decided not to attend the lung screening appointment?  
How did they feel about it?  Were other things happening in their life that influenced 
their decision?  
5) Feelings of risk lung cancer 
What do they feel about their chances of getting lung cancer?  Do they feel equally 
at risk/not at risk/higher risk for lung cancer compared to other types of cancer? Do 
they feel their chances of getting lung cancer is the same or different for other types 
of cancer? Why?  
Who do they think would be at high risk of getting lung cancer and why? 
Conclusion 
Thank participant for time 
Is there anything else you would like to add that we might have missed out? 
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Appendix 5. Sub-Study 6: Is there a difference in the emotional, cognitive and behavioural 
response to a positive earlyCDT test if pulmonary nodules are present on a chest 
computed tomography compared to a normal chest computed tomography?  
 
Researchers  
Dr. Marcia Clark (Primary Care, University of Nottingham) 
Prof. Denise Kendrick (Primary Care, University of Nottingham) 
Prof. Kavita Vedhara (Primary Care, University of Nottingham) 
Background:  
In the United States, it is estimated that every year hundreds of thousands of pulmonary 
nodules are detected following computed tomography (CT) examination of the chest [1].  
With the increasing use of CT scanning for high risk individuals, the often incidental finding 
of pulmonary nodules is only going to rise.  Indeed, it is thought that pulmonary nodules are 
detected in 20-50 % of individuals who undergo CT screening [2].  In the United States, the 
National Lung Screening Trial showed that the incidence of pulmonary nodules was 25.9 % 
in participants with a pack year history of at least 30 years [3].  Whilst the vast majority of 
pulmonary nodules are benign, the National Lung Screening Research Team found that in 
1.1 % of cases they were cancerous [3].   
 
The Early Cancer Detection Test - Lung Cancer Scotland Study (ECLS study), is currently 
assessing the effectiveness of using a blood test, which detects autoantibodies to tumour 
antigens (EarlyCDT-Lung test), in high risk individuals.  Those with a positive EarlyCDT-
Lung test undergo 6-monthly serial CT scans of their chest.  Since it is only those with a 
positive test that have a subsequent CT scan, this test will potentially reduce the number of 
high risk individuals who undergo CT scanning.  Despite this it is probable that a significant 
number of individuals will be found have to incidental pulmonary nodules following their CT 
scan.   
 
Previous studies, although limited, have found that a diagnosis of pulmonary nodules can 
have a negative impact [4-7].  Slatore and colleagues assessed the psychosocial effect that 
an incidental finding of pulmonary nodules had on a group of veterans from Portland, Oregon 
[4, 5].  They employed qualitative interview methods and found that the presence of 
pulmonary nodules was associated with distress [4, 5].  Although this distress decreased 
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with time, some veterans were noted to have increased levels at the time of their follow-up 
CT scans (1 and 2 years after their original diagnosis) [4, 5].  Their findings are supported 
by work completed by Weiner, who found through the use of focus groups (participants were 
undergoing pulmonary nodule surveillance with a median time since diagnosis of 10 
months), that a diagnosis of pulmonary nodules results in frustration and fear [7].  The 
participants’ fear was related to their perceived risk of cancer and whilst in some this fear 
diminished with time, there were participants (particularly those with a family history of 
cancer) who continued to experience a negative emotional response [7].  
 
To the investigators best knowledge, there have not been any studies investigating the 
emotional, cognitive and behavioural effect of a diagnosis of pulmonary nodules following a 
CT scan within a United Kingdom population.  In addition, the majority of studies are 
qualitative in nature.  This study aims to address this knowledge gap through the use of 
validated quantitative health outcome measures.  Based on previous studies, the 
investigators hypothesise that participants of the ECLS study who are diagnosed with 
pulmonary nodules, will have adverse emotional, cognitive and behavioural responses 
compared to those who have a normal CT scan.        
 
Objective: 
To determine whether the short and long term emotional, cognitive and behavioural 
response to having a positive early CDT test differs between participants diagnosed with 
pulmonary nodules on their chest CT and those that have a normal chest CT. 
 
Methods: 
Participants and Procedure 
Study participants will be taken from the EarlyCDT-positive group who participated in the 
emotional and behavioural outcomes study and completed the baseline questionnaire and 
at least one follow-up questionnaire at one, three or six months post recruitment.  It is 
estimated that approximately 150 participants in this group have had a chest CT that shows 
the presence of pulmonary nodules that are 8 mm or less in diameter (coded 1b on the 
ECLS Radiology Schema).  A comparison group will comprise the remaining participants in 
the EarlyCDT-positive group with a normal chest CT (coded 1a on the ECLS Radiology 
Schema).  Data collected from the questionnaire study will be compared between the 
pulmonary nodule and normal chest CT groups at baseline, 1, 3 and 6 months.  The 
emotional outcomes of interest will be EQ5D, positive and negative affect schedule 
(PANAS), health anxiety subscale of health orientation scale (HOS), lung cancer worry scale 
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(LCWS) and impact of events scale.  The revised illness perception questionnaire - lung 
cancer (IPQ-LC) and lung cancer risk perception will be used to determine the cognitive 
response.  Differences in behavioural response will be assessed using smoking behaviour 
and health utilisation data.  
 
Analysis 
Continuous data will be described using means and standard deviations or medians and 
interquartile ranges, depending on the distribution.  Box and whisker plots will also be used 
to graphically display the differences between the pulmonary nodule and normal chest CT 
groups.  Histograms will be used to illustrate discrete data.   
 
Baseline characteristics of participants with and without nodules will be compared using 2-
sample t-tests or Mann Whitney U tests as appropriate for continuous data and chi-squared 
tests for categorical data.  Outcomes at 1, 3 and 6 months will be compared between 
participants with and without nodules using multilevel linear (for continuous outcomes) or 
logistic (for binary outcomes) regression.  Two-level models will be used with observations 
at level one and participants at level two.  Analyses will:  
(a)  Adjust for baseline values of outcome variables.  
(b)  Adjust for baseline values of outcome variables, plus variables used in the 
minimisation for the ECLS trial (age, sex, smoking history, socio-economic status and 
practice).  If appropriate, practice will be adjusted for as a random effect rather than 
as a fixed effect. 
(c) Adjust for baseline values of outcome variables, plus minimisation variables, plus a 
prior defined confounder (educational level, family history of lung cancer, taking 
antidepressants) and variable imbalances at baseline. 
All data will be stored in compliance with the Data Protection Act 1998 and in accordance 
with University of Dundee, Health Informatics and TCTU Standard Operating Procedures 
and the University of Nottingham Code of Research Conduct and Research Ethics (non-
identifiable study management information only, dates of interviews etc.). The researchers 
will be responsible for maintaining all documents concerning the study. The extracted data 
will be stored on a University of Nottingham on a password protected computer in a locked 
office at Queens Medical Centre and will only be accessible by the research team (e.g., the 
researchers and research supervisors).  
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Each participant will be assigned a unique study identity code number for use on their 
interview transcript. Transcripts and signed consent forms will be treated as confidential 
documents and held securely in accordance with regulations. Each transcript document will 
be password protected and will be stored on a password protected file on University of 
Nottingham server. Only members of the research team (e.g., the researchers and the 
research supervisors) will have access to interview transcripts. Audio recordings will be 
stored on an audio recorder in a locked filing cabinet. Once audio recordings have been 
transcribed, the recording will be deleted off the audio recorder. Signed consent forms will 
be kept in the study ISF in a locked filing cabinet in a locked office at Queens Medical Centre. 
In line with the University of Nottingham Code of Research Conduct and Research Ethics, 
data will be stored for seven years from the date of any publication that is based upon them.  
Data protection 
All members of the research team will adhere to the Data Protection Act, 1998. Study 
documents will contain only the minimum required information for the purposes of the study. 
The results of this study will be disseminated at conferences and published in peer-reviewed 
journals.  A summary of our findings and recommendations will be produced for 
dissemination to clinicians, professional bodies and the UK National Screening Committee.   
A plain English summary of our findings will be published on the ECLS study website for 
participants to access.  This will also be made available to relevant lung cancer charities.          
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Background: 
Pulmonary nodules are widely defined as round lesions within the lung that are less than 3 
cm in diameter and entirely surrounded by normal lung tissue [1, 2].  It is estimated in the 
United States, that every year at least 150,000 individuals with pulmonary nodules are 
detected following computed tomography (CT) examination of the chest [3].  Pulmonary 
nodules are found in 20-50 % of high risk individuals who undergo CT screening [1].  It is 
anticipated that the UK incidence of pulmonary nodules is going to increase in light of the 
possibility of lung cancer screening for high risk individuals.   
 
The Early Cancer Detection Test - Lung Cancer Scotland Study (ECLS study), is currently 
assessing the effectiveness of using a blood test (EarlyCDT-Lung test), which detects 
autoantibodies to tumour antigens in high risk individuals.  Those with a positive EarlyCDT-
Lung test will then undergo 6-monthly serial CT scans of their chest for two years.  The 
resultant CT scans are reviewed and coded according to the ECLS Radiology Schema.  
Participants of the study who are found to have pulmonary nodules less than 8 mm in 
diameter (coded 1b) are sent a letter informing them of this result and are advised to contact 
the study team should they wish to discuss their result further.     
 
Previous studies, although limited, have found that a diagnosis of pulmonary nodules can 
have a negative impact, causing distress, frustration, fear and reduced health-related quality 
of life [4-7].  A systematic review by Hagerty showed that amongst cancer patients the 
manner and quality in which their diagnoses are communicated impacts on the patient’s 
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subsequent emotional and behavioural response [8].  For physicians, communicating an 
incidental finding of pulmonary nodules to individuals can also be challenging. This is 
especially in light of the fact that a study by Golden and colleagues found that primary care 
physicians in America felt that they did not have adequate information from their respiratory 
colleagues to communicate the incidental finding effectively to their patients [9].  It has been 
shown for breast cancer screening that women who receive their results by letter have a 
lower level of understanding and satisfaction than those who receive their result in person 
or over the telephone [10].  Despite this, screening results of screening programmes (e.g. 
breast, cervical, colorectal cancer screening) in the United Kingdom are communicated in 
writing in a manner similar to the ECLS study.  It is therefore imperative that the results letter 
sent provides adequate information in order to minimise any negative impact that a 
diagnosis of pulmonary nodules could potentially have.              
 
The aim of the study is to explore the ECLS study participant response following receipt of 
a letter informing them that their CT scan showed a pulmonary nodule.  The letter currently 
used in the trial is based on that used in routine clinical care.  It is important to explore 
patient’s experiences following receipt of the letter to inform any roll out of lung cancer 
screening as a national programme.  Through the use of focus groups the existing letter will 
be reviewed and, if deemed appropriate, modifications will be made with a view to improving 
how these test results are communicated.  
 
Objectives: 
1) Develop an understanding of the current participant experience following receipt of 
the letter informing them that they have a diagnosis of pulmonary nodules.  This will 
be achieved by answering the following questions: 
a. What was the participant’s emotional response on receipt of the letter? 
b. What was the participant’s initial and subsequent behavioural response to 
receipt of the letter? 
c. What is the participant’s understanding of pulmonary nodules and their 
relationship to lung cancer? 
2) How can the provision of information following a diagnosis of pulmonary nodules be 
optimised? 
3) What is the participant response to the modified information letter?  
 
Methods: 
The objectives of this study will be achieved through the use of four different focus groups.  
Groups 1 and 2 will focus on the current experiences of the ECLS trial participants and will 
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seek to address objectives 1 and 2.  Groups 3 and 4 will seek to address the third objective.  
Each focus group will have a maximum of 8 participants; this number has been chosen to 
balance the ability of managing the group with the production of high quality data [11].  It is 
anticipated through the use of focus groups that data will be generated that reflects a variety 
of opinions, whilst respecting what could potentially be a sensitive topic [12, 13].   
  
Focus Group Participants 
Eligible participants will be: 
 Recruited to the ECLS trial and given consent to be contacted for future research. 
 In the EarlyCDT-positive group and have been informed by letter that they have lung 
nodules on their study CT.  A range of participants will be selected with different times 
since diagnosis of their lung nodules. 
 Able and willing to give informed consent for participation in the study. 
 
Focus Group Recruitment 
It is intended that a diverse range of participants are recruited with different demographic 
backgrounds in order to obtain a good variation of views and experiences.  Maximum 
variation sampling will therefore be employed with the demographics of the participants in 
focus group 1 analysed prior to recruiting the second.  This process will be repeated for 
focus groups 3 and 4.  The demographic factors considered relevant to this study include 
age, gender, smoking history, GP practice location, level of deprivation (from the Scottish 
Index of Multiple Deprivation), educational level and time since diagnosis of a pulmonary 
nodule. 
 
Participants that fit the eligibility criteria will be identified from the ECLS study databases 
(baseline questionnaire and CT result).  Letters will be sent to eligible participants who have 
previously agreed to be contacted for future research, with a participant information leaflet, 
consent form and a response slip indicating their interest and availability for participating in 
the study.  On receipt of their response slip a researcher will contact the participant by 
telephone, and describe the study to them, answer any questions they may have and ask if 
they are still happy to participate in the study.  If they are, they will be advised of the date, 
time and venue of the focus group.  In addition, they will be asked demographic information 
including their marital status, work situation and smoking history.  Non-responders will be 
sent a reminder letter 14 days after the initial letter.  Further letters will be sent to potential 
participants until an adequate number have been recruited.  Participants will be reminded of 
the focus group one day prior to the date by a phone call from a researcher.   
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Focus Group Logistics 
There will be four focus groups in total.  Focus groups 1 and 3 will be conducted in Glasgow.  
Focus groups 2 and 4 will be conducted in Dundee.  Glasgow and Dundee have been 
chosen as the ECLS study recruited participants from these two locations.  It is anticipated 
that community venues will be used, with each focus group being facilitated by two 
researchers; one will act as the moderator facilitating the group and the other as observer 
taking notes.  Refreshments will be provided. 
 
Procedure 
Prior to the focus groups commencing, written informed consent will be obtained from each 
participant.  A copy will be sent to the participant after the event, a copy to their GP (with 
consent) and one filed in the ISF. They will be advised that the session will be audio 
recorded, with a verbatim transcript generated of the discussion held, which will be 
anonymised.  The basis of each focus group will be centred on the relevant objectives as 
outlined above and structured according to the focus group guide (see below).  At the end 
of each of the focus groups participants will offered reasonable travel expenses and issued 
as per local policy and procedure and be given a £5 voucher to thank them for their 
contribution. They will also be advised that on their request they can be sent a plain English 
summary of the findings of the study which will be documented at time of consent. At any 
stage of the study participants can request to be withdrawn.  Participants do not need to 
give a reason for this and doing so will not impact on their future care.  They will be informed 
that they can withdraw their data up to 24 hours after the focus group.  After this time, the 
data will have been transcribed and anonymised and therefore, cannot be withdrawn. 
 
It is anticipated that participation in the focus groups will not result in the occurrence of any 
form of adverse events.  However, the researchers are aware that discussion during the 
focus group may be sensitive and potentially distressing.  Should any undue distress occur, 
participants will be supported should they wish to withdraw from the focus group and study.  
They will be advised to seek help from the Principal Investigator, Research Nurse at their 
site or consult with their general practitioner.  
Study documentation and digital audio recorders will be security stored in a lockable 
box/brief case after each focus group prior to transportation and secure storage at the 
University of Nottingham.  
Analysis 
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Each of the focus groups will be recorded using audio equipment, transcribed verbatim and 
analysed using the framework method.  This involves the researchers familiarising 
themselves with the transcription, coding the data, developing a working analytical 
framework, applying this framework and charting the data into the framework matrix [14].  
The information obtained from focus groups 1 and 2 will be used to optimise the participant 
information following a pulmonary nodule diagnosis, with further refinements made following 
focus groups 3 and 4.  Although direct quotes and extracts from the focus groups may be 
presented in the research outputs, they will be anonymised to ensure that participants 
cannot be identified through the data.  Participants will be assigned pseudonyms to protect 
their identities.  
All data will be stored in compliance with the Data Protection Act 1998 and in accordance 
the University of Nottingham Code of Research Conduct and Research Ethics (non-
identifiable study management information only, dates of interviews etc.). The researchers 
will be responsible for maintaining all documents concerning the study. The data will be 
stored on a University of Nottingham on a password protected computer in a locked office 
at Queens Medical Centre and will only be accessible by the research team (e.g., the 
researchers and research supervisors).  
 
Each participant will be assigned a unique study identity code number for use on their 
interview transcript. Transcripts and signed consent forms will be treated as confidential 
documents and held securely in accordance with regulations. Each transcript document will 
be password protected and will be stored on a password protected file on University of 
Nottingham server. Only members of the research team (e.g., the researchers and the 
research supervisors) will have access to interview transcripts. Audio recordings will be 
stored on an audio recorder in a locked filing cabinet. Once audio recordings have been 
transcribed, the recording will be deleted off the audio recorder. Signed consent forms will 
be kept in the study ISF in a locked filing cabinet in a locked office at Queens Medical Centre. 
In line with the University of Nottingham Code of Research Conduct and Research Ethics, 
data will be stored for seven years from the date of any publication that is based upon them.  
 
The results of this study will be disseminated at conferences and published in peer-reviewed 
journals.  A summary of our findings and recommendations will be produced for 
dissemination to clinicians, professional bodies and the UK National Screening Committee.   
A plain English summary of our findings will be published on the ECLS study website for 
participants to access.  This will also be made available to relevant lung cancer charities.          
 
Alternative Data Collection 
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Should it prove too difficult to organise the focus groups as outlined above, semi-structured 
interviews will be used as an alternative means of data collection.  There will be two different 
interview types.  The first will cover the first and second objectives.  The second will cover 
the third objective.  Participants for the interview covering the third objective (what is the 
participants’ response to the modified information letter?) will be sent the modified letter at 
least one week prior to the interview, to allow time for reading the modified letter.  Questions 
asked in the interview will be the same as those within the focus group guide.  Participants 
will be recruited using the same criteria as that for the focus groups.  Written consent will be 
obtained, with the interviews held face-to-face or over the telephone dependent upon 
participant preference.  Where interviews are conducted by telephone consent forms will be 
posted to potential participants and interviews will only be conducted once completed forms 
have been returned.  The interview will be audio recorded, with a verbatim transcript 
generated of the discussion held, which will be anonymised.  Data will be analysed as 
described above for the focus groups.  Interviews will be continued until data saturation is 
reached.     
Focus Group/Interview Guides: 
The questions within this guide are designed to act as a participant prompt and as a means 
of steering participant discussion in order to achieve the objectives of the study.  They are 
intended to facilitate discussion and debate amongst participants, rather than a question 
and answer session between participant and facilitator. 
 
Prior to commencement of all the focus groups participants will complete both consent and 
demographic forms.  Before starting the recording equipment ground rules will be 
established, including the need for confidentiality amongst participants.  Each focus group 
will start with an introduction advising the participants that it is their thoughts and opinions 
that are being sought and that there are no right or wrong answers. 
 
Focus Groups 1 and 2 
Following the general introduction the participants will be provided with a copy of the ECLS 
trial pulmonary results letter. 
1) Participant feelings on receipt of the pulmonary nodule results letter 
 What happened when you first received the letter? 
 What was your initial reaction to the letter? 
 What was your understanding of what the letter was trying to inform you of? 
 What was your understanding of the future plan following diagnosis of a 
nodule? 
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 How did you feel about finding out this result in the form of a letter? 
2) Participant response following receipt of the pulmonary nodule results letter 
 Did you seek any advice or further information after you received the letter?  If 
so how did you do this?  
 How do you now feel about having a nodule within your lungs? 
 How have your feelings about the nodule changed since you received the 
letter? 
 How often do you think about your lung nodule? 
 What do you find most difficult about living with a lung nodule? 
 Has the finding of a nodule within your lungs changed your lifestyle?  Ask 
specifically about smoking behaviour if not discussed. 
3) Understanding of pulmonary nodules 
 What do you think a lung nodule is? 
 How likely do you think it is that the nodule will become cancer?  
 How often and for how long do you think you will be followed up for as a result 
of having a lung nodule? 
 Do you think that your nodule is causing you to have symptoms?  If so which 
ones?    
 If you wanted to explain the presence of nodules in your lungs to your family 
or friends, what would you say to them?  
4) Improvement to information provision 
At this stage participants will be given a short explanation of lung nodules. 
 Do you think that the results letter could be improved? If so how? Consider 
including a definition of a lung nodule, images, the risk of lung cancer, details 
of a follow-up plan and symptoms that should trigger a visit to their GP. 
 Knowing what you know now, are there things it would have been helpful to 
know at the time you were told you had a lung nodule? 
 What would be your preferred method of receiving news that you had a lung 
nodule?  Why would you prefer that method? Consider the provision of results 
in person, over the telephone, a link to online information or a link to a 
YouTube video of a physician explaining a diagnosis of lung nodules. 
 
Focus Groups 3 and 4 
Participants will be given copies of both the original nodule result letter and the modified 
nodule result letter and information. 
1) Response to modified information provision 
 How would your initial feelings differ if you were to receive the modified letter? 
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 How would this letter change what you did after being told you had a lung 
nodule?  How might it affect you looking for information elsewhere?  How might 
it affect where you looked for information.  How might it affect the sort of 
information you looked for? (e.g. about what lung nodules are , risk of cancer, 
follow-up scans, affect of lifestyle on reducing the chance on progressing to 
cancer). 
 Has your understanding of lung nodules changed since reading the modified 
letter? 
 How does the modified nodule result letter compare to the original letter? 
 Are there any other ways the letter could be improved? 
 
All focus groups will close by asking whether there is anything else that the participants 
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